



Universitat Autònoma de Barcelona

**Unitat d'Antropologia Biològica
Departament de Biologia Animal Biologia Vegetal i
Ecologia**

Freqüència i Patró de l'Heteroplàsmia Mitochondrial Humana

Amanda Ramos Reche

Tesi Doctoral

2012

Treball finançat pel Ministeri d'Educació i Ciència
(Projecte: CGL2006-07374, CGL2008-03408-E i
CGL2009-08205)

Freqüència i Patró de l'Heteroplàsmia Mitochondrial Humana

Memòria presentada per Amanda Ramos Reche per a optar al títol de Doctor en Biologia, programa de doctorat en Biodiversitat del Departament de Biologia Animal, Biologia Vegetal i Ecologia de la Universitat Autònoma de Barcelona, dirigida per les professores:

- Dra. M^a Pilar Aluja Paris, Professora Titular de la Unitat d'Antropologia Biològica del Departament de Biologia Animal, Biologia Vegetal i Ecologia de la Universitat Autònoma de Barcelona.
- Dra. Cristina Pereira Santos, Professora Lector de la Unitat d'Antropologia Biològica del Departament de Biologia Animal, Biologia Vegetal i Ecologia de la Universitat Autònoma de Barcelona.

Dra. M^a Pilar Aluja Paris

Dra. Cristina Pereira Santos

Amanda Ramos Reche

*I wanted to change the world.
But I have found that the only thing one
can be sure of changing is oneself.*

Aldous Huxley

*“Te recuerdo Amanda,
la calle mojada,
corriendo a la fábrica
donde trabajaba Manuel.
La sonrisa ancha, la lluvia en el pelo,
no importaba nada, ibas a encontrarte con él,
con él, con él, con él, con él.*

*Son cinco minutos.
La vida es eterna en cinco minutos.
Suena la sirena de vuelta al trabajo,
y tú caminando, lo iluminas todo.
Los cinco minutos te hacen florecer*

*Que partió a la sierra.
Que nunca hizo daño. Que partió a la sierra,
y en cinco minutos quedó destrozado.
Suena la sirena, de vuelta al trabajo.
Muchos no volvieron, tampoco Manuel”*

Víctor Jara.

*A mi padre, por haber creído en mí, siempre,
A tu, Pere, pel teu suport i ajuda incondicionals*

RESUM

La investigació desenvolupada en la present Tesi està enfocada a l'estudi de l'heteroplàsmia mitocondrial humana. Els treballs d'heteroplàsmia mitocondrial que s'han publicat fins al moment d'inici de la Tesi s'han centrat en la regió no codificant del DNA mitocondrial (DNAm_t) i no hi ha cap estudi on s'utilitzin seqüències completes de DNAm_t. Per detectar correctament l'heteroplàsmia mitocondrial, cal tenir en compte la presència dels anomenats NUMTs (insercions nuclears d'origen mitocondrial). A causa de l'elevada similitud entre NUMTs i DNAm_t, una co-amplificació entre ells podria comprometre la veracitat dels resultats. Actualment, no existeix en la bibliografia cap treball on s'utilitzin *primers* que evitin la co-amplificació amb NUMTs. D'altra banda, les bases de dades de NUMTs descrites fins el moment presenten una gran discrepància en el nombre total de NUMTs i han estat realitzades amb una versió antiga de l'esborrany del genoma humà.

Els objectius de la Tesi són els següents: 1) establir una metodologia adequada per a la correcta amplificació i seqüenciació del genoma mitocondrial humà que eviti la co-amplificació amb

NUMTs; 2) realitzar una exhaustiva compilació de les insercions nuclears d'origen mitocondrial basada en la darrera versió de l'esborrany del genoma humà (GRCh37); 3) avaluar l'impacte de la contaminació per NUMTs en estudis de càncer com un exemple d'aplicació de la base de dades descrita; 4) determinar la freqüència i el patró de l'heteroplàsmia en la totalitat del genoma mitocondrial; i 5) comparar el patró mutacional de l'heteroplàsmia mitocondrial amb l'observat a nivell poblacional.

La metodologia així com la presentació dels resultats i la discussió s'han organitzat en 3 capítols dirigits a respondre els diversos objectius. En el primer capítol s'ha dut a terme el disseny i la validació d'un conjunt de *primers* que permet l'amplificació i seqüenciació completa de genoma mitocondrial. A més, aquests *primers* estan dissenyats de manera que eviten la co-amplificació amb DNA nuclear (DNAn). Finalment, i com a conseqüència de l'actualització de l'esborrany del genoma humà, s'han re-avaluat aquests *primers*, havent-se de redissenyar una de les parelles. En el segon capítol es presenta la compilació de les 755 insercions nuclears d'origen mitocondrial realitzada tenint en compte el darrer esborrany del genoma humà GRCh37. En aquesta base de dades, es presenten per primera vegada les posicions no idèntiques entre el DNAm i el DNAn. Aquestes posicions han estat la base per l'aplicació de l'exemple que s'ha realitzat en estudis de càncer, avaluant així l'impacte de la contaminació per NUMTs. En el tercer i darrer capítol es presenta l'estudi exhaustiu sobre la freqüència i patró de l'heteroplàsmia mitocondrial humana mitjançant la seqüenciació completa del genoma mitocondrial de 101 individus.

Alhora aquesta informació s'ha utilitzat per realitzar una comparativa amb l'espectre mutacional a nivell poblacional.

Aquest és el primer treball on es descriuen per primera vegada un conjunt d'eines essencials pel correcte estudi de l'heteroplàsmia mitocondrial humana: es presenta un conjunt de *primers* que permeten amplificar i seqüenciar selectivament la totalitat del genoma mitocondrial i s'ha generat una base de dades d'insercions nuclears d'origen mitocondrial basada en el nou esborrany del genoma humà GRCh37, reportant alhora les posicions no-idèntiques entre el DNAm i els NUMTs.

És la primera vegada on s'analitza la freqüència i el patró de l'heteroplàsmia mitocondrial humana en individus sans. El 62.37% de la població presenta heteroplàsmia mitocondrial (de longitud i/o puntual) i un 24.75% d'individus presenta heteroplàsmia puntual, posant de manifest l'elevada freqüència d'heteroplàsmia mitocondrial a nivell poblacional. La distribució de l'heteroplàsmia mitocondrial comprèn tot el genoma mitocondrial, localitzant-se tant en posicions definides com a *hotspot* com en posicions altament estables i conservades. Comparant el patró mutacional de l'heteroplàsmia amb el descrit a nivell poblacional, sembla haver-hi un excés d'heteroplàsmia puntual localitzada en posicions que presenten zero *hits* en la filogènia. L'excés de transicions detectat en l'espectre mutacional de l'heteroplàsmia, en comparació amb el descrit a nivell poblacional, implica que determinades forces evolutives com la deriva o la selecció han hagut d'actuar perquè finalment siguin eliminades. En aquest context, les heteroplàsmies puntuals localitzades en posicions estables podrien tenir un gran

impacte en la supervivència de la pròpia mitocòndria, suggerint que la selecció purificadora hauria d'estar actuant per prevenir la seva fixació en els individus.

Aquest és el primer treball on s'analitza la freqüència i el patró de l'heteroplàsmia mitocondrial humana en individus sans. Tenint en compte l'elevada quantitat de dades que es presenta unit a la poca informació prèvia disponible, aquest treball proporciona una nova perspectiva per a l'estudi de les malalties associades al DNAm així com en treballs a nivell poblacional, evolutiu i forense.

ABSTRACT

The investigation developed in this thesis is focused on the study of human mitochondrial heteroplasmy. Until the beginning of the present thesis, the heteroplasmy works published have been focused on the analysis of non-coding region, and no studies on determining the levels of heteroplasmy using complete mitochondrial DNA (mtDNA) sequences has been published. To properly detect the mitochondrial heteroplasmy, the presence of NUMTs (nuclear insertions of mitochondrial origin) has to be taken into account. Due to similarity between NUMTs and mtDNA, a co-amplification between them could compromise the veracity of the sequence results. Currently, the published primers to amplify the whole mtDNA do not prevent the co-amplification with NUMTs. Moreover, the NUMT databases described until now show discrepancies in the total number of NUMTs and all of them have been carried out with an older version of the Human Genome Reference Sequence.

The main goals of the thesis are: 1) to establish an appropriate methodology for the correct amplification and sequencing of the human mitochondrial genome that avoid the co-amplification with

NUMTs; 2) to perform an exhaustive compilation of nuclear insertions of mitochondrial origin based on latest version of the Human Genome Reference Sequence (GRCh37); 3) to evaluate the impact of NUMTs contamination on cancer studies as an application example of the described database; 4) to determine the frequency and pattern of heteroplasmy in the whole mitochondrial genome; and 5) to compare the heteroplasmic mutational spectrum with the observed at population level in the whole mtDNA.

The methodology used, the presentation of results and the discussion are organized into 3 chapters directed to answer the objectives. In the first chapter, the design and validation of the set of primers that allows a selective amplification and sequencing of complete mitochondrial genome has been performed. Moreover, these primers have been designed to avoid co-amplification with nuclear DNA (DNAn). Finally, and as a result of the updated Human Genome Reference Sequence, primer pairs have been re-evaluated and one of them had to be redesigned. The second chapter presents the compilation of the 755 nuclear insertions of mitochondrial origin performed with the last Human Genome Reference Sequence GRCh37. In this database, we present for the first time the non-identical positions between DNAm_t and DNAn. These positions have been the basis for the evaluation of the impact of NUMTs contamination on cancer studies in the application example. In the third and final chapter is presented an exhaustive study of the frequency and pattern of the human mitochondrial heteroplasmy using the complete sequencing of the mitochondrial genome of 101

individuals. Moreover, this information has been used to perform a comparison with the mutational spectrum at the population level.

This is the first study that describes essential tools for the correct study of the human mitochondrial heteroplasmy: a set of primers that can selectively amplify and sequence the entire mitochondrial genome and a database of nuclear insertions of mitochondrial origin based on the last Human Genome Reference Sequence GRCh37, reporting the non-identical positions between mtDNA and NUMTs.

For the first time the analysis of the frequency and pattern of the human mitochondrial heteroplasmy in healthy individuals is reported. The results show that the 62.37% of the individuals are heteroplasmic (length and/or point) and 24.75% of individuals presented point heteroplasmy, highlighting the high frequency of mitochondrial heteroplasmy at population level. The distribution of mitochondrial heteroplasmy covers the whole mitochondrial genome, finding them in hotpots as well as in highly stable and conserved positions. Comparing the presented results with the mutational spectrum at population level, it seems that there is an excess of point heteroplasmy located in positions that have zero hits in the mitochondrial phylogeny. The excess of transitions detected in the heteroplasmic mutational spectrum, in comparison with the described at the population level, implies that some evolutionary forces may be acting to finally remove them. In fact, highly stable heteroplasmic positions could have a greater impact in the viability of mitochondrial survival, suggesting that purifying selection must be operating to prevent their fixation within individuals.

This is the first study that analyses the frequency of heteroplasmy in healthy population, carrying out an evolutionary evaluation of the detected changes. This work provides a new perspective which would be important for medical, evolutionary, and forensic proposes.

ÍNDEX

	Pàgina
PRÒLEG	1
1. INTRODUCCIÓ	5
1.1 CARACTERÍSTIQUES DEL DNA MITOCONDRIAL HUMÀ	7
1.1.1 Elevat nombre de còpies	13
1.1.2 Herència materna	13
1.1.3 Pèrdua de recombinació	15
1.1.4 Taxa de mutació	17
1.2 ORIGEN EVOLUTIU DE LA MITOCÒNDRIA	21
1.2.1 Insercions nuclears d'origen mitocondrial (NUMTs)	24
1.3 HETEROPLÀSMIA MITOCONDRIAL	29
1.3.1 Metodologies aplicades a l'estudi de l'heteroplàsmia mitocondrial	35
2. JUSTIFICACIÓ DEL TREBALL I OBJECTIUS	41
2.1 JUSTIFICACIÓ DEL TREBALL	43
2.2 OBJECTIUS	47
3. METODOLOGIA, RESULTATS I DISCUSSIÓ	49
3.1 CAPÍTOL 1: Primer design and validation for mtDNA amplification and sequencing	51

3.1.1 Materials and methods	55
<i>Primer design and validation</i>	55
<i>Total DNA extraction, amplification and sequencing of the entire mtDNA</i>	56
<i>Cloning</i>	57
3.1.2 Results	58
<i>Primer design and validation</i>	58
<i>PCR and sequencing primers to mtDNA analysis</i>	61
3.1.3 Discussion	65
3.1.3.1 Human mtDNA complete amplification and sequencing: a new validated primer set that prevents NUMTs co-amplification	65
3.1.3.2 Validated primer set that prevents nuclear DNA sequences of mitochondrial origin co-amplification: a revision based on the new human genome reference sequence (GRCh37)	67
3.2 CAPÍTULO 2: Updating of NUMTs database and usefulness in cancer studies	71
3.2.1 Materials and methods	75
<i>Updating of insertions of mitochondrial origin database</i>	75
<i>Applications to Cancer</i>	76
3.2.2 Results	78
<i>Database of nDNA sequences of mitochondrial origin based on the GRCh37 Human Genome Reference Sequence</i>	78
<i>Applications to cancer</i>	87
3.2.3 Discussion	90

3.3 CAPÍTOL 3: Frequency and pattern of human	
mitochondrial heteroplasmy	95
3.3.1 Materials and methods	97
<i>Samples and DNA Extraction</i>	97
<i>MtDNA Analysis</i>	98
<i>Detection and Authentication of Heteroplasmy</i>	98
<i>Data analysis</i>	100
3.3.2 Results	104
<i>Frequency and type of heteroplasmy</i>	104
<i>Pattern and distribution of point heteroplasmy along the</i>	
<i>mtDNA genome</i>	107
<i>Stability of point heteroplasmic positions</i>	111
3.3.3 Discussion	119
<i>Frequency and type of heteroplasmy</i>	119
<i>Pattern and stability of point heteroplasmic positions along</i>	
<i>the mtDNA genome</i>	123
4. DISCUSSIÓ GENERAL	129
<i>Disseny i validació de primers per a l'amplificació i</i>	
<i>seqüenciació del DNAm</i>	131
<i>Actualització de la base de dades de NUMTs i aplicació en</i>	
<i>estudis de càncer</i>	134
<i>Freqüència i patró de l'heteroplàsmia mitocondrial humana</i>	138
5. CONCLUSIONS	147
6. BIBLIOGRAFIA	153
7. ANNEX	183
7.1 Annex I	185
7.2 Annex II	271

PRÒLEG

El present estudi pretén ampliar significativament la informació que es té actualment de l'heteroplàsmia mitocondrial humana, aportant informació desconeguda fins el moment, que podrà aplicar-se en camps de la investigació tan diversos com l'evolutiu, el poblacional, així com els estudis forenses i genètics.

Actualment, hi ha una gran varietat de treballs sobre l'estudi del DNA mitocondrial (DNAMt), tant per la seva relació amb malalties com en la caracterització d'individus sans. Pel que fa als estudis poblacionals, la majoria dels treballs publicats fins el moment s'han centrat en la regió no codificant del genoma mitocondrial, que comprèn només el 7% del genoma mitocondrial. Val a dir que, el ràpid desenvolupament de les tècniques de seqüenciació automàtica ha permès ampliar aquests estudis a la resta del genoma mitocondrial. No obstant, pel que fa a l'estudi de l'heteroplàsmia mitocondrial, en el moment d'inici de la present Tesi Doctoral, no hi havia cap treball publicat centrat en l'anàlisi de l'heteroplàsmia que utilitzés seqüències completes de DNAMt.

Per identificar correctament l'heteroplàsmia mitocondrial, cal tenir en compte la presència dels anomenats NUMTs (insercions nuclears d'origen mitocondrial), ja que l'elevada similitud entre NUMTs i DNAMt, pot induir una co-amplificació entre ells i comprometre la correcta identificació de l'heteroplàsmia mitocondrial. Fins a la realització d'aquesta Tesi, no s'ha publicat cap treball on tots els *primers* utilitzats evitessin la co-amplificació entre el DNAMt i els NUMTs. Tanmateix, actualment existeixen diverses bases de dades de NUMTs, però totes elles s'han realitzat amb una versió antiga de l'esborrany del genoma humà.

La present Tesi Doctoral aborda aquestes mancances i s'inicia amb una introducció on es destaquen les principals característiques del DNAMt; es detalla l'origen evolutiu de la mitocòndria i es descriuen les característiques de les insercions nuclears d'origen mitocondrial; i finalment es fa una exhaustiva descripció de l'heteroplàsmia mitocondrial, recopilant els tipus de treballs duts a terme fins ara, així com les metodologies que s'han d'aplicar per la correcta detecció i interpretació d'aquesta. A continuació, s'exposa la justificació del treball i s'estableixen els objectius principals de la Tesi Doctoral. La metodologia, els resultats i la discussió s'estructuren en tres capítols adreçats a respondre als diferents objectius plantejats. Aquest capítols estan escrits en anglès per facilitar la difusió de la Tesi. En el primer capítol es descriu el disseny i validació d'un nou set de *primers* per a l'amplificació i seqüenciació completa del DNAMt humà, evitant alhora la co-amplificació amb NUMTs; així com la revisió d'aquest set de *primers* degut a l'actualització del nou esborrany del genoma humà

(GRCh37). El segon capítol presenta una nova base de dades d'insercions nuclears d'origen mitocondrial basada en darrer esborrany del genoma humà (GRCh37) i la seva aplicació en estudis de càncer. En el darrer capítol es descriu l'estudi de la freqüència i el patró de l'heteroplàsmia mitocondrial humana. Seguidament s'exposa la discussió general, organitzada en funció dels objectius plantejats i, finalment, es presenten les conclusions de la Tesi Doctoral.

1. INTRODUCCIÓ



“ All these mitochondrial DNAs stem from one woman who is postulated to have lived about 200,000 years ago, probably in Africa.”

Rebecca Cann, Mark Stoneking & Allan Wilson

1.1 CARACTERÍSTIQUES DEL DNA MITOCONDRIAL HUMÀ

El DNA mitocondrial (DNAm_t) humà és una molècula circular de 16569 parells de bases (pb) de longitud. És un genoma de doble cadena, amb una cadena pesada H (*Heavy Strand*), rica en guanina i una cadena lleugera L (*Light Strand*) rica en citosina.

Aquest genoma es troba a les mitocòndries, els òrgans responsables de la respiració cel·lular, que generen la major part dels subministraments d'adenosina trifosfat (ATP) que necessita la cèl·lula.

Una revisió de Cowdry (1918), citat per Lehninger (1965), conté més d'un dotzena de termes per referir-se a les estructures que ara es coneixen com a mitocòndries: lefaroplast, condricont,

condriòmits, condrioplasts, condriosomes, condriosferes, fila, grànuls fucsinoflics, Korner, Fadenkörper, mitogel, cossos parabasals, vermícules, sarcosomes, cossos intersticials, plasmosomes, plastocondris i bioblasts, entre d'altres. Més tard, l'any 1948, amb el estudis de Hogeboon, Schneider i Palade, i gràcies a la utilització del microscopi electrònic, es confirmà que les mitocòndries presenten dues membranes: una membrana externa llisa i una membrana interna plegada formant les crestes mitocondrials (Hogeboon et al. 1948). Així s'establí definitivament la mitocòndria com el lloc on es duu a terme la respiració cel·lular.

El nombre de mitocòndries per cèl·lula és un paràmetre que sembla variar significativament d'un tipus de cèl·lula a un altre, sobretot per la importància de la biogènesi mitocondrial en el context de la diferenciació i especialització cel·lulars. Estimacions a partir de seccions seriades de cèl·lules donen valors d'entre uns pocs centenars fins a milers per cèl·lula, per exemple, unes 800 mitocòndries en el cas dels hepatòcits. S'estima que l'òocit humà conté més de 100.000 mitocòndries, mentre que els espermatozoides en tenen relativament poques (tot i que aquestes poden ser excepcionalment grans) (Scheffler 2008).

Cada mitocòndria pot presentar múltiples còpies de DNAm, de manera que cada cèl·lula pot contenir-ne milers. El primer informe definitiu que afirmava la presència de DNA en aquest orgànul va aparèixer l'any 1960, però es considerava tan especialitzat i excepcional que la troballa no va ser generalitzada a totes les mitocòndries (Steinert and Steinert 1960).

Donada la reduïda mida del genoma mitocondrial, és evident que només un nombre limitat de gens hi podrien ser presents. Durant les tres darreres dècades, centenars de genomes mitocondrials d'animals, plantes i fongs s'han caracteritzat i fins i tot seqüenciat genèticament. La primera seqüenciació completa d'aquest genoma va ser la dels éssers humans (Anderson et al. 1981), i poc després va completar-se la seqüència bovina (Anderson et al. 1982).

L'estimació que es va realitzar sobre el nombre de polipèptids diferents en cada mitocòndria va situar-se per sobre dels mil (Schatz 1995), però les anàlisis proteòmiques més recents han identificat entre 500 i 800 proteïnes (Da Cruz et al. 2005; Forner et al. 2006; Gabaldon and Huynen 2004; Johnson et al. 2007; Prokisch et al. 2006; Vo and Palsson 2007). Això vol dir que, uns 1000 gens nuclears contribueixen a la biogènesi i funció de les mitocòndries. Molts d'ells són coneguts, però encara n'hi ha que no s'han identificat i caracteritzat.

El DNAm de dels metazous codifica per dos RNAs ribosomals (rRNA) (12S i 16S), 22 RNAs de transferència (tRNAs) (amb excepcions en algunes espècies), tres gens de les subunitats del citocrom oxidasa (COXI-COXIII), el gen del citocrom b (Cyt B), set gens de les subunitats del NAD deshidrogenasa (N1-N6, N4L), dos gens de les subunitats del ATPasa (6 i 8) i el gen del citocrom b (Scheffler 2008) (Figura 1).

El DNAm també inclou una regió no codificant o D-loop que conté l'origen de replicació de la cadena pesada i les regions promotores de la transcripció en direccions oposades. Per aquestes

raons, es coneix com a “regió control”. La seva longitud és de 1122 pb en humans i, degut a la seva identitat funcional, aquesta regió no està ben conservada entre espècies, sent polimòrfica fins i tot dins d'una sola espècie com en els éssers humans. Tot i així, en la regió control hi ha petites zones funcionalment significatives i segments conservats. Podríem establir doncs, que la regió del D-loop és funcionalment conservada en tots els vertebrats, però les seqüències de nucleòtids que la componen no ho són (Scheffler 2008).




Figura 1. Representació esquemàtica del genoma mitocondrial humà amb les seves regions funcionals: els dos rRNAs (12S i 16S), tres gens de les subunitats del citocrom oxidasa (COXI-COXIII), set gens de les subunitats del NAD deshidrogenasa (N1-N6, N4L), dos gens de les subunitats de l'ATPasa (6 i 8), el gen del citocrom b, 22 tRNAs (amb el codi estàndard de lletra única), dos orígens de replicació de les cadenes lleugera i pesada (O_H i O_L), els promotors de la transcripció tant de la cadena pesada com de la lleugera (HSP i LSP) i la regió control. Figura adaptada de DiMauro i Schon (2008).

L'any 1987, Cann, Stoneking i Wilson (Cann et al. 1987) van publicar un treball sobre l'anàlisi del DNAmT mitjançant fragments de restricció de 147 individus provinents de cinc poblacions geogràficament espaiades (34 asiàtics, 21 aborígens australians, 26 aborígens de Nova Guinea, 46 caucàsics i 20 africans). L'impacte científic d'aquest treball va ser enorme. L'aplicació de mètodes de genètica molecular en l'estudi de l'evolució de primats i humans, amb especial atenció al DNAmT, ja havia estat suggerida per Brown (1981), i diverses publicacions de Brown, Wilson i els seus col·legues l'havien precedit a la publicació de referència del 1987 (Brown et al. 1982; Cann et al. 1982; Cann et al. 1984). No obstant això, el gran nombre de persones representades en aquest estudi va permetre obtenir proves convinents de la força potencial d'aquest enfocament en el tractament de preguntes sobre l'evolució humana, sobre els orígens dels éssers humans moderns i sobre els patrons migratoris dels nostres avantpassats (Cann et al. 1987).

En les últimes dues dècades s'han dut a terme anàlisis per enzims de restricció abastament refinats, s'ha aplicat la reacció en cadena de la polimerasa (PCR), s'han seqüenciat regions concretes i, fins i tot s'han analitzat seqüències de DNAmT humà de les zones més remotes del globus. Darrerament, degut a la introducció de les tècniques de seqüenciació d'última generació (plataformes 454 de Roche o Illumina de Solexa, entre d'altres) s'estan realitzant seqüenciacions massives en una gran diversitat de treballs que ampliaran enormement el volum de seqüències completes de DNAmT per a la seva utilització en futurs estudis [per exemple Ansorge (2009), Briggs et al. (2009) i Metzker et al. (2010)].

El DNAm_t ha estat la regió més estudiada dels genomes eucariotes i ha tingut un paper fonamental en el desenvolupament de l'estudi de les poblacions i la genètica evolutiva (Awise 1991; Awise et al. 1987; Brown 1985; Harrison 1989; Moritz et al. 1987; Rand 1994). Durant la primera dècada dels estudis, en el camp de la biologia evolutiva, va assumir-se que el DNAm_t actuava de manera neutra com a marcador genètic. Més recentment, ha anat creixent l'interès de com la selecció podria estar actuant en el DNAm_t, i dos enfocaments diferents s'han postulat per abordar aquesta qüestió. Anàlisis directes, mitjançant l'estudi de diferents poblacions, han intentat identificar els efectes de la *fitness* o supervivència en els diferents haplotips (Clark and Lyckegaard 1988; Fos et al. 1990; Garcia-Martinez et al. 1998; Hutter and Rand 1995; Kambhampati et al. 1992; Kilpatrick and Rand 1995; MacRae and Anderson 1988; Nigro and Prout 1990). D'altra banda, s'han buscat evidències de selecció en el DNAm_t realitzant anàlisis estadístiques de models neutres d'evolució molecular basant-se en seqüències de DNA de poblacions naturals (Ballard 2000; Ballard and Kreitman 1994; Blouin 2000; Excoffier 1990; Nachman 1998; Nachman et al. 1994; Nachman et al. 1996; Quesada et al. 1999; Rand et al. 1994; Rand and Kann 1996; Rand and Kann 1998; Rand et al. 2000; Templeton 1996; Weinreich and Rand 2000; Whittam et al. 1986; Wise et al. 1998). Tots dos enfocaments han identificat una evolució del DNAm_t no neutre, implicant l'actuació de la selecció a nivell individual. No obstant això, un augment ràpid de la literatura sobre biologia cel·lular i genètica molecular ha demostrat la importància de la selecció i la deriva genètica dins i entre citoplasmes com a mecanisme primari, afectant a l'expressió fenotípica de les mutacions

en el DNAm (Pereira et al. 2009; Ruiz-Pesini et al. 2004; Ruiz-Pesini and Wallace 2006).

L'ús generalitzat d'aquest genoma es deu a les característiques úniques del DNAm, que el fan especialment susceptible als estudis evolutius. Aquestes característiques inclouen un alt nombre de còpies, l'herència materna, la manca de recombinació i una taxa de mutació més alta que la que es troba en el DNA nuclear (DNAn).

1.1.1 Elevat nombre de còpies

El DNAm és present en un gran nombre de còpies en les cèl·lules humanes. La mitjana de cèl·lules somàtiques només té dues còpies d'un determinat gen o segment de DNAn, però centenars de milers de còpies de DNAm (Robin and Wong 1988). Aquesta propietat, juntament amb el fet de localitzar-se fora del nucli, fa que sigui més fàcil d'obtenir, sent la molècula escollida per a l'anàlisi en estudis de DNA antic i per certes aplicacions forenses. Però a la vegada, aquesta propietat també complica la genètica de poblacions del DNAm perquè hi ha diferents nivells en els quals les poblacions de molècules de DNAm poden ser definides -dins del mitocondri, dins d'una cèl·lula, dins d'un determinat teixit, dins d'un individu, i dins d'un grup de persones (la tradicional definició d'una població).

1.1.2 Herència materna

Encara que l'herència paterna del DNAm es produeix en múscols (Zouros et al. 1992), i s'ha observat tant de manera inter

com intraespecífica en *Drosophila*, ratolins, i híbrids d'aus (Gyllensten et al. 1991; Kaneda et al. 1995; Kondo et al. 1990; Kvist et al. 2003), des de fa anys, l'herència estrictament materna del DNAm_t humà ha estat considerada com un dogma indestructible (Stoneking 1993; Stoneking and Soodyall 1996; Wallace et al. 1999). Aquesta herència uniparental és un dels grans avantatges del DNAm_t, ja que permet als investigadors traçar llinatges relacionats a través del temps, destacant l'ascendència materna d'una població, sense els efectes de confusió de l'herència biparental i la recombinació inherent al DNAn. No obstant però, l'any 2002 va fer-se públic l'informe d'un home amb intolerància severa a l'exercici, on el DNAm_t del teixit muscular era predominantment d'origen patern, fet que va provocar certs dubtes sobre la validesa de la hipòtesi de l'estricta herència materna del DNAm_t (Schwartz and Vissing 2002). Això provocà que s'alcessin veus advertint sobre la prudència a l'hora de fer inferències sobre les poblacions humanes i de la història basada en el supòsit ara qüestionable de l'herència estrictament materna (Bromham et al. 2003). Investigacions posteriors amb un major nombre de pacients amb miopaties mitocondrials no han reportat més casos d'herència paterna (Filosto et al. 2003; Schwartz and Vissing 2004; Taylor et al. 2003). Es coneix des de fa anys, que les mitocondries de l'esperma són selectivament destruïdes a l'oòcit (Manfredi et al. 1997; Shitara et al. 1998), i s'ha demostrat que el DNAm_t patern és destruït en els oòcits per ubiquitinització (Sutovsky et al. 1999; Sutovsky et al. 2000). Per tant, sembla molt probable que el cas d'herència paterna del DNAm_t fos conseqüència d'una ruptura en el reconeixement normal i eliminació de les molècules d'aquest DNAm_t patern. D'altra banda,

milers de comparacions mare-fill no han demostrat cap indicati de contribució paterna (Giles et al. 1980; Howell et al. 2003; Jazin et al. 1998; Santos et al. 2008b; Santos et al. 2005b). Per tant, a l'actualitat, l'herència materna del DNAm en els éssers humans encara es pot considerar com la norma general (Schwartz and Vissing 2003). Aquesta característica d'herència uniparental fa que tots els individus pertanyents a un mateix llinatge comparteixin una mateixa seqüència, el que confereix la possibilitat d'estudiar llinatges al llarg del temps, esclariant els ancestres materns de les poblacions (Pakendorf and Stoneking 2005).

1.1.3 Pèrdua de recombinació

Un altre principi de l'Antropologia Molecular, que es va veure sacsejat fa uns anys, és que el DNAm no recombina. Això va ser considerat com un fet establert (Stoneking 1993; Stoneking and Soodyall 1996; Wallace et al. 1999) fins els anys 1999-2000, quan quatre publicacions reportaren evidències de recombinació en el DNAm humà (Awadalla et al. 1999; Awadalla et al. 2000; Eyre-Walker et al. 1999; Hagelberg et al. 1999). Tres d'aquests estudis es van basar en anàlisis filogenètiques i estadístiques mitjançant seqüències de DNAm. Els autors van demostrar l'evidència de recombinació amb l'argument d'un excés de llocs homoplàsics observats en els arbres filogenètics (Eyre-Walker et al. 1999), i la correlació del desequilibri de lligament amb la distància a través del genoma mitocondrial (Awadalla et al. 1999; Awadalla et al. 2000). El quart estudi va afirmar tenir proves directes de recombinació en el DNAm d'individus de la Melanèsia (Hagelberg et al. 1999). No obstant això, posteriorment es va demostrar que els estudis

filogenètics i/o estadístics havien utilitzat dades errònies i/o mètodes estadístics qüestionables (Arctander 1999; Jorde and Bamshad 2000; Kumar et al. 2000; Macaulay et al. 1999; Merriweather and Kaestle 1999; Parsons and Irwin 2000), i el treball de Hagelberg et al. (1999) va haver-se de retractar (Hagelberg et al. 2000). Tres estudis sobre la correlació del desequilibri de lligament i la distància en grans conjunts de dades de seqüències completes de DNAm_t (Elson et al. 2001; Ingman et al. 2000; Piganeau and Eyre-Walker 2004) no van trobar evidències de recombinació, encara que, de nou, va detectar-se un excés de posicions homoplàsiques (Piganeau and Eyre-Walker 2004) - això però, s'atribueix generalment a l'heterogènia taxa de mutació del DNAm_t humà (Excoffier and Yang 1999; Howell and Smejkal 2000; Stoneking 2000). Fins el moment però, només ha estat publicat un cas de recombinació en el DNAm_t humà en la única persona coneguda que conté tant DNAm_t d'origen matern com patern (Kraytsberg et al. 2004; Schwartz and Vissing 2002). En aquest cas, la recombinació entre el DNAm_t matern i patern es va produir en aproximadament el 0,7% del total de DNAm_t en el teixit muscular del pacient. Aquesta troballa posa de manifest que la recombinació és possible, ja que les mitocòndries posseeixen una recombinasa funcional (Thyagarajan et al. 1996).

No obstant això, recentment s'ha demostrat que la fusió entre mitocòndries d'una mateixa cèl·lula proporcionaria protecció enfront a mutacions en el DNAm_t mitjançant l'intercanvi genètic, fet que permetria als genomes mitocondrials amb diferents mutacions complementar-se entre ells, compensant així la càrrega mutacional (Nakada et al. 2001; Nakada et al. 2009). Això podria donar-se fins i tot dins d'una sola mitocòndria, sempre i quan fos entre nucleoides i

no entre molècules de DNAmT en el sí del mateix nucleoide, fet que limitaria la recombinació (Chen et al. 2010; Gilkerson et al. 2008). A més, les fuites de DNAmT patern són un fenomen molt rar, per tant la recombinació no sembla ser un procés fonamental (Hagelberg 2003; Slate and Gemmell 2004) - en absència de molècules de DNA en heteroplàsmia, els esdeveniments de recombinació es traduirien en DNAs mitocondrials que no diferirien dels originals.

1.1.4 Taxa de mutació

Per lògica es pot pensar que com més importància té el contingut genètic més lentament hauria d'actuar un canvi evolutiu, però tot i que la majoria del DNAmT conté gens indispensables per a la vida cel·lular, la taxa de mutació d'aquest genoma se situa per sobre de la dels gens nuclears en diversos ordres de magnitud (Nachman et al. 1996; Schriner et al. 2000).

La proximitat als efectes mutagènics dels radicals oxigènics generats per la fosforilació oxidativa i el fet de que aquest genoma no està associat a histones que podrien protegir-lo, són explicacions per aquest augment de la pressió mutagènica en el DNAmT (Gray et al. 1999; Shigenaga et al. 1994). De totes maneres, aquesta elevada taxa de mutació proporciona una considerable variació a nivell poblacional, ja que podria permetre a alguns individus sobreviure a sobtats canvis ambientals. Per tant, l'elevada taxa de mutació que es dona en la línia germinal del DNAmT dels mamífers podria representar un compromís entre la generació de suficient variació adaptativa per a poder augmentar la probabilitat de que les espècies sobrevisquin a un canvi ambiental catastròfic, *versus* la supressió de la taxa de mutació del DNAmT suficientment com per a garantir que

l'acumulació de mutacions perjudicials al llarg dels llinatges materns no condueix a l'extinció com a resultat del trinquet de Muller (Wallace 2007).

Tot i existir una gran controvèrsia pel que fa a l'acceptació d'una taxa de mutació que pugui ser utilitzada en diferents camps d'investigació, una estimació d'aquesta seria $0,017 \times 10^{-6}$ substitucions/posició/any pel que fa a tot el genoma, exceptuant la regió de control (Ingman et al. 2000). En les dues regions hipervariables (HVRI i HVRII) de la regió no codificant, la taxa és encara major, tot i que saber quant major és, és una qüestió que encara genera discrepàncies.

Aquesta gran controvèrsia pel que fa a la taxa de mutació del mtDNA, és deguda en gran mesura, al procediment que es realitza per calcular-la. Existeixen dues vessants clarament diferenciades: els mètodes basats en comparacions filogenètiques, ja estiguin fonamentades en comparacions interespecífiques o intraespecífiques, que donen estimacions de 0.0250-0.1770 substitucions/posició/milió d'anys pel que fa a la regió control, i els mètodes empírics d'observació directa de les mutacions del DNAmT en famílies o llargs llinatges, on es consideren totes les substitucions, que donen estimacions de 0.3791-1.7957 substitucions/posició/milió d'anys [per revisió veure Santos et al. (2005a; 2008b)]. Aquesta última sembla ser una taxa significativament més elevada que les obtingudes filogenèticament. A l'actualitat existeix un debat pel que fa a la incògnita de com la taxa reflecteix el "veritable" estat de coses, i com s'utilitza en estudis poblacionals (Heyer et al. 2001; Howell and Mackey 1997; Howell et al. 2003; Jazin et al. 1998; Macaulay et al. 1997; Paabo 1996; Parsons et al. 1997;

Sigurgardottir et al. 2000). Una bona reflexió al respecte és la suggerida per Santos et al (2008b; 2005b) que proposa una sèrie de factors a tenir en compte i que eliminen les discrepàncies, si s'apliquen les correccions necessàries, com per exemple la taxa d'heteroplàsmia (0.4332 substitucions/posició/milió d'anys).

*“The first cell fusion, precursor of fertilization,
may have been the result of cannibalism: a microorganism ate
another without digesting.”*

Lynn Margulis

1.2 ORIGEN EVOLUTIU DE LA MITOCÒNDRIA

Poc després d'extreure, per primera vegada, mitocòndries de cèl·lules d'organismes superiors, fa uns 120 anys, ja es va expressar d'una forma més o menys explícita la idea de que estaven relacionades d'alguna manera amb els bacteris (Margulis 1981). Llavors, els pensaments sobre l'origen de les mitocòndries i els cloroplasts varen culminar en una declaració extremista de la Teoria Endosimbiòtica que deia: "la 'cèl·lula' eucariota són múltiples 'cèl·lules' procariotes" (Taylor 1974), i Lynn Margulis es va convertir en una divulgadora particularment eloqüent i contundent sobre les idees de la simbiosi en l'evolució cel·lular eucariota.

Formalment, és necessari almenys tenir en compte dues hipòtesis alternatives sobre l'origen evolutiu de les mitocòndries. Una d'elles proposa que les mitocòndries provenen de l'interior d'una

cèl·lula mitjançant un procés de compartimentació intracel·lular i especialització funcional. Quan es va descobrir el DNA en aquests orgànuls, calia afegir que la informació genètica d'un genoma nuclear s'havia distribuït entre aquests dos compartiments. La segona hipòtesi suggereix que les mitocondries es van originar a partir d'una relació simbiòtica entre una proto-cèl·lula eucariota i un organisme procariota primitiu capaç de dur a terme la fosforilació oxidativa. Només la segona hipòtesi s'està considerant seriosament a l'actualitat (Scheffler 2008).

Una revisió crítica dels arguments a favor i en contra sobre la hipòtesi endosimbiont publicada per Gray i Doolittle l'any 1982 (Gray and Doolittle 1982) va fer un intent per definir el tipus de dades que provaven aquesta hipòtesi, i va concloure que "un origen endosimbiont dels mitocondris és més complex i molt menys creïble" que el cas d'un origen dels cloroplasts (plastidis) a partir d'eubacteris fotosintètics (cianobacteris). Durant la dècada de 1980 van començar a compilar-se una gran quantitat de dades addicionals que eren revisades periòdicament per Gray i altres, culminant l'any 1992 en una revisió exhaustiva i avaluada (Gray 1992). L'autor va arribar a la conclusió que re-avaluar hipòtesis alternatives no tenia sentit en vista de l'enorme quantitat de proves a favor de la hipòtesi endosimbiont.

El DNAmt codifica per proteïnes molt específiques i úniques, tot i que és evident que és un genoma massa petit per codificar la informació suficient perquè un organisme visqui per si sol. La pèrdua d'informació genètica de les mitocondries primordials es va veure compensat per les funcions codificades pel nucli, però en aquest

moment s'hauria de distingir entre dues possibilitats. Una d'òbvia és que els gens proto-mitocondrials van ser transferits al nucli, havent-hi una evidència convincent de que aquests esdeveniments s'havien produït. També hauria de ser obvi però, que la simbiosi implica que els bacteris destinats a convertir-se en mitocondria van haver d'envair una cèl·lula hoste, un proto-eucariota, que abans d'aquest esdeveniment evolutiu era igualment capaç d'una existència independent. La distinció entre les dues cèl·lules des de la visió més simple, és que el proto-eucariota ja tenia el seu DNA compartimentat en un nucli amb una membrana nuclear, mentre que el proto-mitocondri s'assemblava a un bacteri sense nucli. Tots dos havien de ser capaços de replicar i transcriure el seu DNA, així com de sintetitzar proteïnes i diversos lípids per a formar la membrana. El cicle de Krebs també l'haurien de poder fer totes dues. Per tant, l'associació inicial entre aquestes dues cèl·lules havia de conduir a una considerable i redundat informació genètica. Els gens redundants en la mitocondria podrien simplement haver-se perdut, d'altres van ser transferits al nucli i només un nombre molt petit va romandre a la mitocondria (Kleine et al. 2009).

Hi ha però, un límit establert en la reducció d'aquest genoma mitocondrial (Palmer 1997)? Està força acceptat que els pèptids que resten codificats en el genoma mitocondrial són extremadament hidrofòbics i no poden ser importats mitjançant la maquinària de translocació mitocondrial. D'altra banda, dos pèptids d'ancoratge hidrofòbic del complex II són codificats per gens nuclears en la majoria dels organismes examinats fins al moment. Els arguments teòrics s'han remès a la predicció que el genoma mitocondrial, en

última instància, necessita retenir només dos gens que codifiquen pèptids, a més dels RNAr i els RNAt (Claros 1995; Claros et al. 1995; Popot and de Vitry 1990). Els dos gens assenyalats són el Cyt B i el COXI, que codifiquen per pèptids amb més de tres o quatre segments transmembrana hidrofòbics. Alguns descobriments proporcionen evidències convincentes de que la pèrdua completa dels gens funcionals del genoma mitocondrial va ocórrer, de fet, abans de l'emergència dels animals, fa aproximadament 1000 milions d'anys (Palmer 1997). Una de les idees emergents és que la mitocondria endosimbiont original va evolucionar de forma independent en les diverses espècies que habiten en aquests entorns, del que en resultà una col·lecció de variants d'òrgans morfològica, genètica i funcionalment heterogènia, incloent mitocondries aeròbiques, anaeròbiques, hidrogenosomes i mitosomes (Van der Giezen and Tovar 2005).

1.2.1 Insercions nuclears d'origen mitocondrial (NUMTs)

Tot i que hi ha evidències de que la transferència de material genètic funcional de les mitocondries al nucli ha finalitzat, la transferència de DNA organular no funcional al nucli és un procés que continua actiu (Hazkani-Covo and Graur 2007; Hazkani-Covo et al. 2010; Ricchetti et al. 2004) i que té com a resultat la formació de pseudogens coneguts com a NUMTs o NUPTs, depenent de si tenen un origen mitocondrial o cloroplastídic (Leister 2005) (Figura 2).




Figura 2. Visió esquemàtica dels diferents tipus de transferència de DNA intercompartimental. (a) Orgànul-nucli; (b) cloroplast→mitocondri; (c) nucli→mitocondri. Figura adaptada de Leister et al (2005).

Fins al moment, tots els NUMTs estudiats en mamífers han perdut la seva funció. Probablement a causa de les diferències entre els codis genètics nuclear i mitocondrial, aquestes insercions van passar immediatament a ser no funcionals quan van arribar al nucli (Hazkani-Covo et al. 2003).

Diversos estudis han demostrat que els NUMTs són similars però no idèntics a les seves contraparts en el DNAm; varien en grandària i es poden repetir en tàndem (Tourmen et al. 2002). A més, els NUMTs es caracteritzen per la seva heterogeneïtat estructural i la desigual distribució en els cromosomes (Bensasson et al. 2001;

Tourmen et al. 2002). Alguns d'aquests NUMTs s'han integrat recentment al genoma nuclear mantenint la seva estructura. D'altres però, es van inserir fa molt temps i, posteriorment a la inserció, han patit processos com ara duplicacions, delecions, inversions o desplaçaments dins de la seqüència nuclear (Tourmen et al. 2002).

L'explicació més parsimoniosa que explica l'origen dels NUMTs és la reparació dels trencaments de doble cadena (DSBR) pel mecanisme d'unió d'extremes no homòlegs (NHEJ) (Hazkani-Covo and Covo 2008). Durant aquest procés de reparació, una seqüència de DNAm_t serveix de pegat i preserva el DNAn de la pèrdua de nucleòtids. D'aquesta manera, el NUMT previndria la formació de delecions cromosòmiques (Hazkani-Covo and Covo 2008).

S'han descrit NUMTs en més de 80 espècies i el nombre d'aquestes seqüències és diferent entre elles (Bensasson et al. 2001; Hazkani-Covo and Graur 2007). Richly i Leister (2004) suggereixen que l'abundància variable dels NUMTs entre les espècies pot ser la causa de les diferències en la freqüència de la transferència de DNAm_t al nucli o les distintes taxes de pèrdua de NUMTs. No obstant això, l'estimació del contingut i abundància de NUMTs encara continua incompleta (Bensasson et al. 2001).

L'anàlisi de NUMTs ha permès estudiar diversos mecanismes d'integració del DNAm_t al nucli, així com conèixer les forces evolutives que actuen sobre les seqüències no codificants (Kleine et al. 2009). Aquest procés evolutiu ha estat àmpliament estudiat

mitjançant comparacions paràlogues dins dels genomes (Hazkani-Covo et al. 2003; Mourier et al. 2001; Woischnik and Moraes 2002).

Els NUMTs es classifiquen com ortòlegs, quan deriven d'un procés d'especiació i estan presents en el mateix locus al genoma de diferents espècies. Així doncs, podem considerar els NUMTs com fòssils moleculars que ens aporten informació sobre l'estat ancestral del DNAm, alhora que ens permet arrelar els arbres filogenètics recents dins d'una mateixa espècie sense necessitat d'utilitzar una espècie *outgroup*. Si profunditzem en aquest ús dels NUMTs, podem comprendre fenòmens poblacionals i establir històries evolutives de les poblacions d'una mateixa espècie (Ricchetti et al. 2004; Thalmann et al. 2005). La taxa en que ocorren les insercions de NUMTs, la seva ortologia i l'estudi dels processos post-insercionals que pateixen, es perfilen com una bona eina per l'estudi filogenètic de les espècies (Hazkani-Covo and Graur 2007; Jensen-Seaman et al. 2009) i de fet, s'han construït filogènies de primats a partir de l'estudi dels NUMTs amb eines bioinformàtiques, concordants amb les consensuades fins al moment (Hazkani-Covo 2009). D'altra banda, els NUMTs poden classificar-se com a no-ortolòlegs quan deriven d'un procés de duplicació i estan presents en un sol genoma. En aquest cas, es classifiquen en insercions, delecions parcials o totals i en duplicacions en tàndem (Hazkani-Covo and Graur 2007). En aquest context, es coneix que la duplicació de NUMTs ja establerts en el genoma nuclear, és un procés que contribueix a un augment substancial en el nombre d'insercions (Richly and Leister 2004).

Diversos estudis publicats fins ara, mostren discrepàncies significatives en el nombre total de NUMTs presents en el genoma humà. Aquest nombre oscil·la entre 190 (Lascaro et al. 2008) i 1105 (Tourmen et al. 2002), havent treballs que reporten 206 insercions (Richly and Leister 2004), 211 (Ricchetti et al. 2004), 247 (Mishmar et al. 2004), 296 (Mourier et al. 2001), 452 (Hazkani-Covo and Graur 2007), 585 (Simone et al. 2011), 612 (Woischnik and Moraes 2002) i 871 (Hazkani-Covo et al. 2010). D'acord amb Lascaro et al. (2008), les principals causes per explicar aquest desacord són el criteri propi de cada investigador en la utilització dels mètodes bioinformàtics i l'aplicació a genomes nuclears que encara no estan acoblats correctament. D'altra banda, hi ha molts estudis que no tenen en compte els possibles efectes dels processos post-insercionals de les duplicacions en el genoma nuclear (Hazkani-Covo et al. 2003). A més, les recopilacions i bases de dades existents no estan actualitzades, ja que s'han dut a terme amb una versió antiga del genoma humà enlloc de l'actual versió (GRCh37).

“It is quite likely that all of us harbour more than one mtDNA type among the trillions and trillions of mtDNA genomes in our bodies”

Brigitte Pakendorf & Mark Stoneking.

1.3 HETEROPLÀSMIA MITOCONDRIAL

Les múltiples còpies del genoma mitocondrial dins d'un individu no han de ser necessàriament idèntiques; l'existència de diferents tipus de DNAm_t dins d'una mateixa mitocòndria, cèl·lula o individu es coneix com a heteroplàsmia (Figura 3).




Figura 3. Representació esquemàtica dels diferents nivells on pot observar-se l'heteroplàsmia mitocondrial

Existeixen dos tipus d'heteroplàsmia mitocondrial:

- Heteroplàsmia puntual: s'estableix quan unes còpies de DNAmT pateixen una substitució (Figura 4a).
- Heteroplàsmia de longitud, s'estableix quan unes còpies de DNAmT pateixen una inserció o deleció (Figura 4b). Aquesta acostuma a produir-se en zones repetitives com les regions de poliC del D-loop: la regió compresa entre les posicions 16184-16193 de la HVRI i 303-315 de la HVRII.




Figura 4. Electroferograma corresponent a la seqüència d'una regió del DNAmT. **a)** Heteroplàsmia puntual donada per una substitució C/T. **b)** Heteroplàsmia de longitud en una poliC de la HVRII situada entre les posicions 303-309.

L'estudi de l'heteroplàsmia mitocondrial humana es remunta als anys 80 i va ser identificada per primera vegada en estudis genètics sobre malalties mitocondrials, on es van observar nivells variables de deleccions (Holt et al. 1988) o mutacions (Wallace et al.

1988) en els pacients afectats. No obstant això, l'heteroplàsmia no és necessàriament un estat relacionat amb patologies. Bendall et al. (1996) va suggerir que la freqüència de l'heteroplàsmia mitocondrial és superior a la detectada fins el moment i que no s'havien pogut detectar abans degut, probablement, a dificultats metodològiques. Per tant, la freqüència observada dependrà de com es mesura.

Les estimacions inicials sobre la freqüència d'heteroplàsmia puntual detectaven nivells mínims o nuls d'heteroplàsmia, degut a que els mètodes emprats eren poc sensibles. Una de les estimacions més actuals considera que aproximadament un 24% de la població té més d'un tipus de DNAm present, amb una freqüència d'almenys un 0.08% (Li et al. 2010), i de fet és molt probable que tothom albergui més d'un tipus de DNAm entre els trilions i trilions de genomes mitocondrials que tenim al nostre cos (Pakendorf and Stoneking 2005). No obstant això, l'homogeneïtat total del DNAm entre individus indica que una restricció en el nombre de molècules de DNAm, o "coll d'ampolla", està darrere d'aquest procés: un nombre molt petit de molècules de DNAm, o fins i tot una sola molècula, podria servir de model en la replicació per a formar part dels oòcits dels qual es transmet el DNAm a la descendència (Clayton 1996; Chinnery 2002; Poulton 1995). Diferents autors estan d'acord en que, ja sigui per deriva genètica o per un complex procés de tria, és possible explicar fàcilment la ràpida segregació dels genomes mitocondrials; el veritable enigma resideix en l'estabilitat que tenen certes heteroplàsmies observades en alguns arbres genealògics (Lightowers et al. 1997; Santos et al. 2005b). Una dona amb una fracció relativament petita de DNAm mutat pot tenir descendència amb una proporció significativament més alta d'aquest DNAm

mutat, si aquest és aleatòriament amplificat. No obstant això, l'heteroplàsmia hauria de ser reduïda en la majoria dels seus descendents.

Actualment però, no està del tot clar en quin moment del desenvolupament es dona aquesta reducció dràstica de material genètic mitocondrial. Estudis recents han postulat que el coll d'ampolla es produeix durant el desenvolupament embrionari com a conseqüència d'una dràstica reducció del contingut de mtDNAs a les cèl·lules germinals (Jansen and de Boer 1998; Krakauer and Mira 1999), mentre que altres estudis proposen que el coll d'ampolla és el resultat de la replicació d'una subpoblació de mtDNAs durant la maduració de l'òocit a nivell postnatal i que, per tant, el coll d'ampolla es dona sense una reducció del contingut de molècules de mtDNA a les cèl·lules germinals (Cao et al. 2010; Wai et al. 2008). S'han dut a terme estimacions de la mida del coll d'ampolla (Bendall et al. 1996; Howell et al. 1992; Marchington et al. 1998) utilitzant diferents models de selecció. Aplicant el model de selecció única descrit per Bendall et al. (1996), en parelles de bessons, han estimat una mida del coll d'ampolla de 3 a 30 unitats de segregació. Marchington et al. (1998), utilitzant oòcits han obtingut una estimació similar de 1 a 31 unitats de segregació. D'altra banda, estudis de segregació de l'heteroplàsmia mitocondrial quantifiquen, a través de les generacions, de l'ordre de només 10 unitats de segregació per individu (Bendall et al. 1996; Brown et al. 2001; Poulton and Marchington 2002).

Actualment existeixen un nombre important de treballs centrats en l'observació de les variacions heteroplàsmiques en

poblacions sense malaltia mitocondrial evident (Calloway et al. 2000; He et al. 2010; Irwin et al. 2009; Kirches et al. 2001; Santos et al. 2008c). En general, aquests estudis s'han centrat en l'anàlisi de la regió de control, zona que només cobreix el 7% del DNAm total. Aquests treballs detecten elevades freqüències pel que fa a heteroplàsmia de longitud (aproximadament un 70%) i al voltant d'un 4% en quant a la freqüència d'heteroplàsmia puntual. Els escassos estudis en els que s'han analitzat regions de la porció codificant del DNAm en individus sans mostra que l'heteroplàsmia mitocondrial és més freqüent a la regió de control (Jazin et al. 1996; Li et al. 2010; Santos et al. 2008b).

S'ha observat que els nivells d'heteroplàsmia varien entre els teixits (Bendall et al. 1997; Calloway et al. 2000; Goto et al. 2011; Grzybowski et al. 2003; He et al. 2010). En aquests treballs s'ha posat de manifest que, teixits com el muscular o l'epiteli bucal presenten freqüències més elevades d'heteroplàsmia respecte altres teixits com el sanguini. També s'ha detectat que la freqüència observada a les arrels dels cabells és molt variable, podent presentar tant els nivells mínims com els més elevats d'heteroplàsmia que pot tenir un mateix individu. D'altra banda, la freqüència d'heteroplàsmia també pot variar entre poblacions (Irwin et al. 2009). Al treball de Irwin et al. (2009) es destaquen, d'entre les poblacions estudiades, les poblacions de Jordània (9.5% en sang) i Vietnam (15.5% en epiteli bucal) com les que presenten freqüències més elevades d'heteroplàsmia, mentre que les de Nairobi (1% en sang) i Kazakhstan (4.3%, en epiteli bucal) són les que tenen freqüències més baixes.

Si enfoquem l'heteroplàsmia mitocondrial com una etapa intermèdia entre la generació de mutacions i la fixació d'aquestes en un individu o una cèl·lula, aquesta representa un pas obligatori en l'evolució del DNAm (Rand 2001). Per tant, l'heteroplàsmia mitocondrial és una eina potencial per a l'estudi del patró de mutació, el possible paper de la selecció i, fins i tot, de l'existència de la recombinació del mtDNA (Zsurka et al. 2005).

“There's about 1,000 times more mitochondrial DNA than nuclear DNA in our cells, so it's much easier to pick up”

Chris Stringer

1.3.1 Metodologies aplicades a l'estudi de l'heteroplàsmia mitocondrial

La detecció de l'heteroplàsmia mitocondrial ha evolucionat significativament des de la seva primera troballa, cap als volts dels anys 80. De fet, és la millora en les tècniques el que ha permès aprofundir més i millor en seu estudi. A banda d'intentar millorar el nivell de detecció, les tècniques per observar-la són molt variades i sovint depenen del tipus d'estudi que es pretengui realitzar.

S'ha dut a terme un recull de les publicacions relacionades amb la detecció de l'heteroplàsmia puntual des de l'any 2004 fins a l'actualitat. Aquesta revisió inclou 24 estudis poblacionals (Afonso Costa et al. 2010; Bai and Wong 2004; Ballana et al. 2008; Biggin et al. 2005; Cassandrini et al. 2006; Chong et al. 2005; De Camargo et al. 2011; Irwin et al. 2009; Jacobs et al. 2007; Lo et al. 2005; Lutz-Bonengel et al. 2008; Meierhofer et al. 2005; Nakahara et al. 2008;

Paneto et al. 2010; Picornell et al. 2006; Poe et al. 2007; Rose et al. 2010; Santos et al. 2008b; Singh et al. 2006; Sondheimer et al. 2011; Theves et al. 2006; Wang and Boles 2006; White et al. 2005; Zsurka et al. 2005) i 43 estudis realitzats amb mostres patològiques (Abnet et al. 2004; Alston et al. 2010; Ambrosini-Spaltro et al. 2010; Betts et al. 2006; Bi et al. 2010; Bidooki et al. 2004; Brinckmann et al. 2007; Canter et al. 2005; Cardaioli et al. 2008; Coskun et al. 2004; D'Aurelio et al. 2010; Debray et al. 2007; Dobrowolski et al. 2009; Fendt et al. 2011; Frederiksen et al. 2009; Gambello et al. 2006; Genasetti et al. 2007; Gigarel et al. 2005; He et al. 2010; Jacobs et al. 2005; Jakupciak et al. 2008; Kaare et al. 2009; Kaplanova et al. 2004; Karppa et al. 2004; Kloss-Brandstatter et al. 2010; Laloi-Michelin et al. 2009; Leshinsky-Silver et al. 2005; Li et al. 2005; Lindberg et al. 2008; Lu et al. 2009; Marchington et al. 2011; Meierhofer et al. 2006; Monnot et al. 2011; Phasukkijwatana et al. 2006; Sarzi et al. 2007; Suen et al. 2010; Tan et al. 2008; Uusimaa et al. 2007; Whittaker et al. 2007; Wong et al. 2004; Zaragoza et al. 2010; Zhadanov et al. 2007; Zsurka et al. 2011).

Aquest recull ha evidenciat que la tècnica més habitual per determinar els nivells d'heteroplàsmia és la seqüenciació automàtica basada en el mètode Sanger. D'aquesta manera, un 41,18% dels estudis poblacionals s'han realitzat mitjançant la seqüenciació automàtica (Afonso Costa et al. 2010; Biggin et al. 2005; Cassandrini et al. 2006; Chong et al. 2005; De Camargo et al. 2011; Irwin et al. 2009; Jacobs et al. 2007; Lo et al. 2005; Nakahara et al. 2008; Paneto et al. 2010; Picornell et al. 2006; Santos et al. 2008b; Theves et al. 2006; Wang and Boles 2006), havent-se observat una

frequència similar (40,32%) en els estudis centrats en malalties (Abnet et al. 2004; Ambrosini-Spaltro et al. 2010; Bi et al. 2010; Bidooki et al. 2004; Brinckmann et al. 2007; Cardaioli et al. 2008; D'Aurelio et al. 2010; Fendt et al. 2011; Gigarel et al. 2005; He et al. 2010; Jacobs et al. 2005; Jakupciak et al. 2008; Kloss-Brandstatter et al. 2010; Laloi-Michelin et al. 2009; Leshinsky-Silver et al. 2005; Li et al. 2005; Lu et al. 2009; Marchington et al. 2011; Meierhofer et al. 2006; Monnot et al. 2011; Sarzi et al. 2007; Tan et al. 2008; Zaragoza et al. 2010; Zhadanov et al. 2007; Zsurka et al. 2011).

La segona tècnica més emprada en els estudis poblacionals (17,65%), és la cromatografia líquida d'alta resolució (DHPLC) (Ballana et al. 2008; Biggin et al. 2005; Jacobs et al. 2007; Lo et al. 2005; Meierhofer et al. 2005; Rose et al. 2010). Per contra, en els estudis de malalties (Brandstatter and Parson 2003; Kaare et al. 2009; Meierhofer et al. 2006), aquesta tècnica es fa servir només en un 3,23% dels casos. Alternativament, el segon mètode més utilitzat en els estudis de malalties és el de PCR-RFLP (Alston et al. 2010; Betts et al. 2006; Brinckmann et al. 2007; Canter et al. 2005; Cardaioli et al. 2008; Coskun et al. 2004; D'Aurelio et al. 2010; Debray et al. 2007; Genasetti et al. 2007; Kaplanova et al. 2004; Karppa et al. 2004; Lindberg et al. 2008; Phasukkijwatana et al. 2006; Sarzi et al. 2007; Suen et al. 2010; Uusimaa et al. 2007; Whittaker et al. 2007; Wong et al. 2004; Zhadanov et al. 2007; Zsurka et al. 2011), amb una freqüència d'un 32,26%, aplicant-se tan sols en un 14,71% dels estudis poblacionals (Bai and Wong 2004; Meierhofer et al. 2005; Singh et al. 2006; White et al. 2005; Zsurka et al. 2005).

Les tècniques de seqüenciació de nova generació, com les plataformes 454 (Roche), Illumina (Solexa) i Life (APG), s'utilitzen tant en estudis poblacionals (14,71%) (Ballana et al. 2008; Biggin et al. 2005; Lutz-Bonengel et al. 2008; Sondheimer et al. 2011; White et al. 2005) com en estudis de malalties (6,45%) (Alston et al. 2010; Brinckmann et al. 2007; He et al. 2010; Zaragoza et al. 2010).

Finalment, un 11,76% i un 17,74% respecte als estudis poblacionals (Bai and Wong 2004; Cassandrini et al. 2006; Poe et al. 2007; Theves et al. 2006) i de malalties respectivament (Bi et al. 2010; Dobrowolski et al. 2009; Frederiksen et al. 2009; Gambello et al. 2006; Genasetti et al. 2007; Jacobs et al. 2005; Jakupciak et al. 2008; Laloi-Michelin et al. 2009; Li et al. 2005; Tan et al. 2008; Wong et al. 2004), apliquen tecnologies diferents i més específiques. L'electroforesi temporal per gradient de temperatura (TTGE), el *melting* d'alta resolució (HRM) i el sistema d'amplificació refractari de mutació (ARMS), són alguns dels mètodes utilitzats als estudis de malalties. Pel que fa als estudis poblacionals, s'usen altres tècniques com la detecció a temps real de la fluorescència, la hibridació per Southern blot i LATE-PCR de molècula única.

Al voltant dels anys 80, alguns autors van concloure que la seqüenciació automàtica (Maxam and Gilbert 1977; Sanger and Coulson 1975; Smith et al. 1985; Smith et al. 1986) era capaç de detectar clarament el doble pic d'una heteroplàsmia puntual on la variant minoritària fos $\geq 20\%$, però donava senyals ambigües i/o indetectables a nivells inferiors al 5-10% (Bai and Wong 2004; Irwin et al. 2009; Tang and Huang 2010). Malgrat això, s'ha demostrat clarament que una heteroplàsmia on la variant minoritària sigui del

5% pot ser observada per seqüenciació automàtica si es segueixen estrictes protocols de validació i autenticació d'aquestes (Santos et al. 2008b). Aquests protocols estan bastats en un criteri molt exigent d'acceptació de seqüències vàlides (amb un nul soroll de fons) i d'un seriat de repeticions independents, utilitzant *primers* de seqüenciació en ambdós sentits (directe i revers), diferents productes de PCR i fins i tot diferents extractes de DNA.

Segons Grzybowski et al. (2000), l'ús de diferents tècniques d'amplificació pot donar diferències en la quantificació dels nivells d'heteroplàsmia. No obstant això, aquests resultats no van poder ser reproduïts en un altre estudi (Brandstatter and Parson 2003). De la mateixa manera, en un estudi recent, l'ús de la seqüenciació de la cadena lleugera (L) dona millors resultats en quant a qualitat de la seqüència que no pas si es seqüencia la cadena pesada (H) (Brandstatter and Parson 2003).

D'altra banda, la presència de NUMTs porta a replantejar els estudis de DNAm. Degut a l'elevada similitud amb el DNAm, els NUMTs són una font de contaminació en els treballs de DNAm basats en la seva amplificació per PCR (Parr et al. 2006b; Yao et al. 2008b). Tot i que aquest problema ha estat silenciats amb l'argument de l'elevat nombre de còpies del DNAm, respecte el locus corresponent al DNAn, la precaució ha de ser-hi present (Parfait et al. 1998), ja que la co-amplificació amb un NUMT donarà problemes en la interpretació de les seqüències i, sobretot, en la interpretació de l'heteroplàsmia mitocondrial (Parr et al. 2006a; Parr et al. 2006b). En un estudi de Parr et al. (2006b), on utilitzà cèl·lules $\rho 0$ (absència de mitocondries), va suggerir que un dels factors més importants que

determina si un NUMT serà co-amplificat amb el DNAmT és la regió de DNAmT que es pretén amplificar així com el número de còpies del NUMT. A més, les mostres de DNA antic o qualsevol teixit amb un baix nombre de còpies de DNAmT, tant en teixit sa com en mostres patològiques (per exemple mostres tumorals) també semblen ser factors importants que determinarien la possibilitat de co-amplificació (Goios et al. 2008; Parr et al. 2006b). Goios et al. (2008) va postular que en seqüenciacions estàndards de mostres utilitzades per a la caracterització poblacional, en la que la detecció d'heteroplàsmia mitocondrial no constituïa una prioritat, la co-amplificació de NUMTs no constitueix un problema real, ja que el contingut de DNAmT en aquestes mostres és molt superior al contingut de DNAn. Però Yao et al. (2008b) i Parr et al. (2006b) van demostrar que la co-amplificació de NUMTs pot donar-se fins i tot quan s'utilitzen mostres amb una qualitat i quantitat de DNA estàndard. A l'estudi de Parr et al. (2006b) es demostra aquesta problemàtica amb la seqüenciació de 46 fragments de DNA paràlegs que representen tot el genoma mitocondrial i Hirano et al. (1997) assenyalaren que una heteroplasmia aparent en un malalt d'Alzheimer era en realitat el resultat d'una co-amplificació amb DNAn.

2. JUSTIFICACIÓ DEL TREBALL I OBJECTIUS



2.1 JUSTIFICACIÓ DEL TREBALL

El DNAm_t humà segueix sent un dels DNAs més estudiats. Els atributs distintius, en contrast amb el genoma nuclear, com ara la seva abundància en les cèl·lules humanes, l'herència materna i l'elevada taxa de mutació, fan d'aquesta molècula una atractiva font d'informació per a estudis evolutius i de genètica de poblacions. Una altra característica del genoma mitocondrial és la presència de més d'un tipus de DNAm_t en una mateixa mitocòndria, cèl·lula o individu, particularitat anomenada heteroplàsmia mitocondrial. Actualment, hi ha una gran varietat de treballs centrats en l'estudi de l'heteroplàsmia mitocondrial, tant per la seva relació amb malalties com estudis amb individus sans. Aquests últims s'han centrat en l'estudi de la regió no codificant del genoma mitocondrial, que representa només el 7% del seu genoma. Tot i així, pel que fa a l'anàlisi de l'heteroplàsmia en la totalitat del genoma mitocondrial, en el moment d'inici de la present Tesi Doctoral, no hi havia cap treball publicat enfocat en aquest tema on s'utilitzessin seqüències completes de DNAm_t. Recentment però, s'ha publicat un treball on s'analitza l'heteroplàsmia mitocondrial mitjançant seqüències completes de DNAm_t, tot i que el propòsit se centra en l'aplicació de

la plataforma de seqüenciació massiva Illumina (Solexa) (Li et al. 2010).

Un estudi exhaustiu de les posicions heteroplàsmiques ens ajudarà a entendre millor quina és la dinàmica i quines forces estan intervenint en l'evolució del genoma mitocondrial. La comprensió de les bases de l'heteroplàsmia mitocondrial, aportarà una valuosa informació en una gran diversitat de camps d'investigació com l'evolutiu, el poblacional, el forense i el de la genètica.

Per treballar amb el DNAmT i, més encara, si es pretén estudiar l'heteroplàsmia mitocondrial, cal tenir en compte la presència dels anomenats NUMTs. A causa de l'elevada similitud entre NUMTs i DNAmT, una co-amplificació entre ells podria comprometre la veracitat dels resultats. Actualment, no existeix en la bibliografia cap treball on tots els *primers* utilitzats evitin la co-amplificació amb NUMTs. És per això que, dur a terme una bona estratègia per evitar-ne aquesta co-amplificació, és de vital importància.

Degut a la possibilitat de co-amplificació amb el DNAmT, seria molt útil disposar d'una base de dades de totes les insercions d'origen mitocondrial. Actualment existeixen diverses bases de dades de NUMTs, però entre elles presenten una gran discrepància en el nombre total de NUMTs. A més, totes elles es troben desactualitzades ja que s'han realitzat amb una versió antiga de l'esborrany del genoma humà i no amb la darrera versió (GRCh37). Això comporta la necessitat de generar una nova base de dades basada en el nou esborrany del genoma humà. Aquesta pràctica eina permetrà poder validar mutacions del DNAmT, així com l'elaboració

d'unes estratègies adequades per a la realització d'estudis evolutius, filogeogràfics i, fins i tot, epidemiològics.

2.2 OBJECTIUS

El propòsit general d'aquest estudi és determinar la freqüència i el patró de l'heteroplàsmia en la totalitat del genoma mitocondrial humà. Per fer-ho, es plantegen els següents objectius:

- 1. Establir una metodologia adequada per a l'amplificació i seqüenciació del genoma mitocondrial humà que permeti la correcta interpretació de l'heteroplàsmia tant en mostres d'individus sans com amb patologies.**
- 2. Realitzar una exhaustiva compilació de les insercions nuclears d'origen mitocondrial basada en la darrera versió de l'esborrany del genoma humà (GRCh37).**
- 3. Avaluar l'impacte de la contaminació per NUMTs en estudis de càncer com un exemple d'aplicació de la base de dades descrita.**
- 4. Determinar la freqüència i el patró de l'heteroplàsmia en la totalitat del genoma mitocondrial a nivell poblacional.**
- 5. Comparar el patró mutacional de l'heteroplàsmia mitocondrial amb l'observat a nivell poblacional.**

3. METODOLOGIA, RESULTATS I DISCUSSIÓ



3.1 Capítol 1: *Primer design and validation for mtDNA amplification and sequencing*



The described methodology as well as the results of the primer design are detailed below and in the following publications (Annex II):

Ramos, A; Santos, C; Alvarez, L; Nogués, R; Aluja, MP. Human mitochondrial DNA complete amplification and sequencing: a new validated primer set that prevents nuclear DNA sequences of mitochondrial origin co-amplification. Electrophoresis. 2009 May; 30(9):1587-1593.

Ramos, A; Santos, C; Barbena, E; Mateiu, L; Alvarez, L; Nogues, R; Aluja MP. Validated primer set that prevents nuclear DNA sequences of mitochondrial origin coamplification: A revision based on the New Human Genome Reference (GRCh37). Electrophoresis. 2011 Mar;32(6-7):782-3.

3.1.1 Materials and methods

Primer design and validation

In order to analyze the whole mitochondrial genome, primers previously published (Torrioni et al. 2001) were tested and new ones were designed. The primer design was performed using the Lasergene 7.2 software, from the DNASTAR package, following the general criteria of primers design (Roche 2006) . Particular attention was devoted to adjust, as much as possible, the melting temperatures (T_m) of all the primer pairs.

To discard co-amplifications of nDNA and mtDNA, PCR primers were submitted to the Basic Local Alignment Search Tool (BLAST) available in the National Center for Biotechnology Information (<http://www.ncbi.nlm.nih.gov/> BLAST/) (Altschul et al. 1990). BLAST finds regions of local similarity between sequences comparing nucleotide sequences with sequence databases and calculating the statistical significance of matches. In this work, the specific tool Basic BLAST, optimized for highly similar sequences (Megablast), was performed using the Reference genomic sequence

data base for Homo sapiens (refseq_genomic: Genomic sequences from National Center for Biotechnology Information Reference Sequence Project). A primer pair was discarded if both primers showed similarity (expected number of chance matches in a random model – E-value – lower than 1) inside the same chromosome region.

After BLAST validation, primers were further tested in PCR experiments employing total DNA standard samples (see next section) and nDNA obtained from sperm cells. The nDNA isolation was performed by sperm differential lyses using the QIAmp DNA Investigator Kit (Qiagen) according to the manufacturer's specifications. To guarantee the complete mtDNA elimination, the initial washing step mentioned in QIAmp DNA Investigator Kit manual was repeated at least four times. Moreover, to ensure the integrity of nDNA, Y-chromosome STRs were amplified using AmpFISTR® Y-filer™ PCR kit (Applied Biosystems), under conditions recommended by the manufacturer and all the markers were correctly amplified.

Total DNA extraction, amplification and sequencing of the entire mtDNA

Total DNA from blood samples was extracted using JETQUICK Blood DNA Spin Kit (Genomed) and isoamlic phenol-chloroform (Sambrook 2001).

Optimized primers and PCR conditions for the mtDNA amplification are reported in Table 1. The PCR mix for each sample consisted of 50 pmol of each primer, 200 mM of each dNTP, 2mM of MgCl₂, 10NH₄-based reaction buffer, 1 U of *Taq* DNA polymerase, and 30 ng of DNA in a final volume of 50 mL. The PCRs were performed in a G-Storm GS1 thermocycler and the amplification program consisted of an initial denaturation step of 5 min, followed by 35 cycles of PCR (1 min at 94°C, 40 s at annealing temperature (Ta) and 2.5 min at 72°C), and a final extension step of 5 min at 72°C. The PCR amplification results were visualized by electrophoresis in agarose gels (2%).

PCR products were purified using the JETQUICK PCR Purification Spin Kit (Genomed) and the mtDNA was fully sequenced in both strands using 62 primers (Table 2). Sequence reactions were carried out using the sequencing kit BigDye Terminator v.3 (Applied Biosystems) according to the manufacturer's specifications and were run in an ABI 3130XL sequencer (Servei de Genòmica, Universitat Autònoma de Barcelona).

Cloning

PCR products that, in the optimization process, show consistently more than a one size product were cloned into the pCR®4-TOPO® vector, using the TOPO TA Cloning® Kit for Sequencing (Invitrogen). Ten clones were sequenced using the previously explained methodology.

3.1.2 Results

Primer design and validation

From the primers reported in the literature for the complete mtDNA amplification, we evaluated the 11 primer pairs published by Torroni et al. (2001) since, compared with other works, the authors define a small number of fragments [see Table 2 in Torroni et al. (2001)]. These primers were tested using BLAST. After this analysis, four pairs of primers that show high similarity with nuclear regions were rejected.

The BLAST analysis allows detecting two major problematic regions for primer design. The first one, located between 3914 and 9074 mtDNA positions, presents a 98% similarity with a region within chromosome 1 (see BLAST results on Table I.1.1(1) of Annex I); the second one encompasses the region located between 9582 and 14479 mtDNA positions and it shows a 88% similarity with a region within chromosome 5 (see BLAST results on Table I.1.1 (2) of Annex I). For these regions new primers were designed and verified until the selective amplification of mtDNA was obtained. The 3914–9074 region (Figure 5) was split into two fragments (fragments 4 and 5 in Figure 5); For each primer pair, one

of the primers was designed outside the 3914–9074 region, preventing the amplification of the similar region of chromosome 1. For the 9582–14479 region (Figure 5), minimum of four fragments with 2000 bp were necessary to completely amplify it. Thus, the previous strategy could only be applied for flanking fragments (fragments 6 and 9 in Figure 5), and the primers used to amplify the two fragments that were placed completely within the region (fragments 7 and 8 in Figure 5) were designed in low-sequence similarity regions.




Figure 5. - Schematic representation of mtDNA. The nine overlapping fragments defined to PCR amplify the complete mtDNA genome are represented as well as the two nuclear regions with high similarity with mtDNA

After BLAST validation, PCR optimization was performed using three samples of total DNA extracted using JETQUICK Blood DNA Spin Kit (Genomed). Surprisingly, the outcome of the amplifications of fragments between positions 12012–13828 and 3798–6739 resulted in more than one PCR product. However, a new amplification with a different sample isolated with isoamiliic phenol-chloroform (Sambrook 2001) was carried out and only one PCR fragment (with the expected size) was obtained (Figure 6). These results allow to hypothesize that: (i) the observed additional bands correspond to deletions in mtDNA; (ii) the amplification of an NUMT not detected by BLAST analysis; (iii) the extraction method influences the DNA quality and by consequence the PCR performance and specificity, resulting in unspecific amplification of nuclear or mtDNA. To test these hypotheses the fragment 12012–13828 was cloned into the pCR®4- TOPO® vector, using the TOPO TA Cloning® Kit for Sequencing (Invitrogen) and ten clones were sequenced. The resulting sequences were tested with BLAST showing a complete similarity with mtDNA. A careful analysis reveals that the PCR forward primer hybridized with two close regions of mtDNA: the target region and another one that present several differences with the primer. Therefore, the amplification result is an artifact that can be attributed to the poor quality of DNA. For this reason, the forward primer was redesigned and tested again as previously described.




Figure 6- Gel electrophoresis showing amplification results between positions 12012-13828 using blood samples extracted with different methods. a) JETQUICK Blood DNA Spin Kit (Genomed); b) isoamiliic phenol-chloroform. M: Size marker.

Finally, to discard co-amplifications of nDNA and mtDNA, which could not be deduced by BLAST analysis, PCR amplifications were performed using isolated nDNA obtained from sperm cells. The PCR primers were tested and no positive amplifications were observed.

PCR and sequencing primers to mtDNA analysis

For these primers, validated as previously explained, melting temperatures were adjusted as much as possible and the annealing temperatures were obtained by a PCR gradient being selected the highest temperature that shows positive amplification. In Table 1

PCR primers and annealing and melting temperatures to amplify the nine overlapping fragments that cover the entire mtDNA (Figure 5) are reported. Some of the primers were previously published by Torroni et al. (2001) and the remaining ones were designed for this study.

Since the size of fragments is of ~2000 bp, internal primers were designed to fully sequence both strands of each fragment. In Table 2 the sequence of the primers to sequence each fragment in both stands are shown. All the primers were tested to sequence three samples and a good efficiency of sequencing was obtained.

Table 1- Validated primers to amplify the complete mtDNA in 9 overlapping fragments. Melting temperatures (T_m) and annealing temperature (T_a) for each pair of primers are also presented.

Fragment	Fragment length	Name	Sequence (5' → 3')	Primer pair length (pb)	T _a	T _m
1	1822	14898for 151rev	tagccatgcactactaccaga ggatgaggcaggaatcaaagac	22	60	60.3
2	1758	16488for ^a 1676rev ^a	ctgtatccgacatctggctct gtttagctcagagcggtaagt	22	60	60.3
3	2543	1404for ^a 3947rev	acttaagggcgaagggtgatt tcgatgttgaagcctgagacta	22	57	58.4
4	3005	3734for 6739rev	aagtcaccctagccatcattcta gatatcatagctcagaccataacc	23	61	58.9
5	2709	6511for 9220rev	ctgctggcatcactataactacta gattggggggtcattatgtgttg	23	58	58.9
6	1738	8910for ^a 10648rev	cttaccacaaggcacacctaca ggcacaatattgctaagagggg	22	61	60.3
7	1866	10360for 12226rev	gtctggcctatgagtgactaca cagttctgtgagctttctcgg	22	61	60.3
8	1853	11977for 13830rev	ctccctctacatattaccacaac aagtcctaggaagtgacagcga	24 23	63	59.3 60.6
9	1872	13477for ^a 15349rev ^a	gcaggaatacctttcctcacag gtgcaagaataggaggtggagt	22	63	60.3

^a Oligonucleotides from Torroni et al. (2001)

Table 2- Primers designed to sequencing the whole mtDNA after PCR amplification in nine overlapping fragments.

Fragment	Name / Sequence (5'→3')			
1	14898for	15416for	15966for	
	tagccatgcactactaccaga	tacacaatcaaagacgccctc	agtccttaactccaccattag	
	151rev	16281rev	15825rev	
2	ggatgaggcaggaatcaaagac	ggtggtatcctagtggtgag	gtgaagtatagtagcggatgct	
	16488for	411for	909for	
	ctgtatccgacatctggttct	cggtatgcactttaacagtc	gattaaccaagtcaatagaa	
3	1677rev	1159rev	638rev	
	gtttagctcagagcggcaagt	taagctgtggctcgtagtgt	ggtgatgtgagcccgtctaaa	
	1404for	2028for	2646for	3239for
4	acttaaggctcaaggtggatt	gatagaatcttagtcaact	ggttcagctgtcttacttt	
	3947rev	3382rev	gcagagccccggaatcgcata	
	tcgatgtgaacctgagacta	ttcgttcggttaagcattagga	taatcgagtttgtagttaa	
5	3734for	4346for	4896for	
	aagtcaacctagccatattcta	gaaccatccctgagaatcca	taccaaatctctccctcacta	
	6739rev	6154rev	5571rev	
6	gatacatagctcagaccatacc	ggaactagtcagttgccaaag	aagtattgcaacttactgagg	
	6511for	7111for	7713for	
	ctgctggcatcactataacta	acaccctagaccaaacctacg	tctaacactcacaacaaaac	
7	9220rev	8600rev	8000rev	
	gattgtgggtcattatgtgtg	agaatgatcagtactcggcg	caactgcaaggagtcgcaggt	
	8910for	9393for	9874for	
8	ctfaccacaaggcacactaca	cgagaaaacacataccaaggc	taatatttcactttacatcca	
	10648rev	10154rev	9647rev	
	ggcacaatattgctaagaggg	ttctatgtagccgttgagttg	agctcaggtgattgatactcc	
9	10360for	10892for	11461for	
	gtctggcctatgagtactaca	atcaacaacaacctatttagc	actctaaaactaggcggcta	
	12226rev	11673rev	11163rev	
10	cagttctgtgagctttctcgg	gtttgatgagaatggctgtt	cgggtgatgatgccaaggtg	
	11977for	12500for	12988for	
	ctccctctacatattaccacaac	tgtcctagaccaagaagtta	ctagcagcagcaggcaaatca	
11	13830rev	13297rev	12763rev	
	aagtcctaggaagtgcacagcga	ggtgatcccattgtaacta	cgatgaacagttggaataggt	
	13477for	13950for	14440for	
12	gcaggaaataccttctcacag	ctatctagccttcttacag	atactcctcaatgcccacgc	
	15349rev	14838rev	14325rev	
	gtgcaagaataggaggtggagt	catcatcggagatgtggat	aactttaatagtgtaggaagc	

3.1.3 Discussion

3.1.3.1 Human mtDNA complete amplification and sequencing: a new validated primer set that prevents NUMTs co-amplification

The PCR amplification and sequencing of mtDNA is routinely used in many research fields; however, the interpretation of results, particularly of mtDNA heteroplasmy, could be complicated by the co-amplification of NUMTs (Parr et al. 2006b; Yao et al. 2008a). Therefore, an effort to design PCR primers that selectively amplify mtDNA must be performed. In this work we report a set of primers to amplify the whole mtDNA that were validated using the BLAST analysis and by the performance of PCR amplifications using nDNA isolated from sperm cells.

The BLAST search allowed the identification of two problematic regions in primer design (region 3914–9074 of the mtDNA present in chromosome 1 and region 9582–14479 present in chromosome 5). Region 3914–9074 was previously reported (Lascaro et al. 2008) as presenting a high sequence similarity with a region within chromosome 1, a result that is in accordance with our

results. However, the presence of an NUMT in chromosome 5, which shows a high identity with the 9582–14479 region of the mtDNA, was not reported in previous studies; accordingly, this region could represent a non-reported NUMT and this deserves further investigation.

According to Goios et al. (2008) the amplification of NUMTs can only be obtained when mtDNA is almost completely removed from the samples, such as those resulting from preferential semen lyses. Thus, to test the proposed set of primers for the selective amplification of mtDNA, we used a sperm sample that was submitted to DNA extraction using four steps of preferential lyses and for which Y-STRs were successfully amplified and no signs of amplification with the designed primers were detected. This result indicates that the proposed primers specifically amplify mtDNA and we can ensure that no NUMTs will be amplified if this set of nine pair primers is used.

The primers proposed amplification regions of about 2000 bp of mtDNA. As a consequence, in some samples (such as ancient and forensic ones) it would be almost impossible to obtain PCR amplifications with this set of primers. To overcome this problem, we suggest that additional primers within each fragment could be designed using a similar strategy to that applied for fragment 9582–14479, that is, locating primers in regions that show low similarity with nDNA.

3.1.3.2 Validated primer set that prevents nuclear DNA sequences of mitochondrial origin co-amplification: a revision based on the new human genome reference sequence (GRCh37)

The *in silico* primer validation presented in the present chapter and in the publication by Ramos et al. (2009) was performed using the human reference sequence hg18. However, a new human reference sequence -GRCh37- was recently (February 2009) generated by the Genome Reference Consortium. In order to guarantee the selective mtDNA amplification of presented primers, a new *in silico* validation using the new human reference sequence GRCh37 was performed.

Accordingly to the latest human reference sequence update, one of the most problematic NUMTs for the primer design appears to be larger than earlier reported. This nuclear sequence is located in chromosome 1 and presents a 98% of similarity with one third of the mtDNA. This redefined NUMT (detailed and described on table I.1.2 of Annex I) lays between positions 564461 and 570304 (in relation to the *Homo sapiens* chromosome 1, GRCh37 primary reference assembly - NC_000001), and presents a 98% similarity with the region 3911-9755 of human mtDNA (Andrews et al. 1999).

The new *in silico* analysis revealed that one of the nine previously described primer pairs, specifically the one designed to amplify the 2709 bp region of the mtDNA, located between positions 6511 and 9220 [fragment 5 in table 1 and reported by Ramos et al. (2009)], lays on the redefined similar region. Thus, an accidental co-amplification of mtDNA and nDNA could occur. The described NUMT appears to be Human specific since it is present in *Homo sapiens* but it is not present in other primates (see alignment results on table I.1.3 of Annex I). To date, its variability (presence/absence) in human population is unknown, and we cannot discard the possibility of nDNA co-amplification at least in some individuals. For this reason, a new design, description and *in silico* validation [according to the methods previously presented and reported by Ramos et al. (2009)] of the fragment 5 primer pair is presented.

The size of the redefined chromosome 1 NUMT does not allow locating a primer out of this region following a normal PCR amplification strategy. Consequently, a new approach to primer design was undertaken: (i) primers were relocated to areas with low degree of similarity with chromosome 1 and (ii) the 3' end of each primer were located in mismatch positions relatively to chromosome 1 sequence. Therefore, the possibility of co-amplification of nDNA and mtDNA is reduced. Optimized primer pair and PCR conditions for this concrete region of mtDNA are reported in Table 3. Internal sequence primers previously reported [table 2 and presented by Ramos et al. (2009)] are not affected and can still be used to sequence this region.

Table 3. New validated primer pair to amplify the mtDNA region affected by the new updated NUMT is reported. Melting temperatures (T_m) are also presented. In bold show the primer base located in position 3' that differs from the sequence of chromosome 1.

Fragment	Fragment length	Name	Sequence (5'-3')	Primers pair length (bp)	T _m
5	2664	6520for 9184rev	tcactatactactaacagacc gc gtagaggcttactagaagt gtg	23 22	58.9 58.4

In conclusion, we report a set of primers that guarantee the selective amplification and sequencing of the whole mtDNA in nine overlapping fragments. These primers could be a useful tool in future projects that deal with mtDNA complete sequencing since they represent the first published set of primers tested for the non-amplification of nDNA and therefore suitable for the screening of mtDNA heteroplasmy in both standard and pathological samples.

3.2 Capítol 2: *Updating of NUMTs database and usefulness in cancer studies*



The described methodology as well as the reported database and their application in cancer studies are detailed below and in the following publication (Annex II):

Ramos, A; Barbena, E; Matieu, L; González, MM; Mairal, Q; Lima, M; Montiel, R; Aluja, MP; Santos, C. Nuclear insertions of mitochondrial origin: database updating and usefulness in cancer studies. Mitochondrion. 2011 Nov;11(6):946-53.

3.2.1 Materials and methods

Updating of insertions of mitochondrial origin database

NUMTs detection was performed *in silico*; the new version of the human genome draft (GRCh37) and the criteria for NUMTs detection proposed by Hazkani-Covo and Graur (2007) were used. The Basic Local Alignment Search Tool (BLAST), available from the NCBI (National Center for Biotechnology Information: <http://www.ncbi.nlm.nih.gov/BLAST/>) (Altschul et al. 1990), was used to identify regions of similarity between mitochondrial and nuclear genomes. The Human mtDNA Reference Sequence (NC_012920) was compared against the human RefSeq Genomic database at NCBI. The similar nucleotide sequences were found using the RemoteBlast package in Bioperl bundle (Stajich et al. 2002) with the parameters set to restrict the search to human organism and the E-value of 10^{-3} (Hazkani-Covo and Graur 2007). Moreover, regions with less than 20bp were excluded. The BLAST report contains the basic information for each hit and the lists of the identical positions in the high scoring alignment pairs, both in the query and in the hit sequence. An *in-house* Perl script was written to

further process this information. For each alignment pair, the array of sites listed in the query range was compared against the identical sites found. The same was carried out for positions in the hit range, and finally the sites of interest, namely the non-identical nucleotides, were extracted.

BLAST results were manually inspected to select only the hits obtained for the GRCh37 primary reference assembly and no post-insertional processes were taken into account.

Applications to Cancer

MtDNA mutations previously described in cancer samples, and classified as having zero hits in the mtDNA phylogeny (that are therefore not polymorphic in human populations) by Santos et al. (2008a) were used to evaluate the impact of NUMT contamination in cancer studies. First, mutations compiled by Santos et al. (2008a) were re-evaluated using the updated mtDNA phylogeny - mit. Tree build 8 - (Van Oven and Kayser 2009) and mutations that had one or more hits in the new phylogeny were not considered for subsequent analysis.

Mutations detected in cancer, with no hits in the mtDNA phylogeny, were then searched in the database of non-identical positions between the paralogous sequences. Furthermore, for those studies in which mutations coincided with non-identical positions between the paralogous sequences, an *in silico* validation of primers used in each study was performed. In brief, the PCR primers were

submitted to BLAST. The specific Basic BLAST tool, optimized for highly similar sequences (Megablast), was performed using the Reference Genomic Sequence database for *Homo sapiens* (refseq_genomic: Genomic sequences from National Center for Biotechnology Information Reference Sequence Project). If both primers showed similarity (expected number of chance matches in a random model –E-value– lower than 1) inside the same chromosome region they were selected as being susceptible to co-amplify mtDNA and nDNA.

3.2.2 Results

Database of nDNA sequences of mitochondrial origin based on the GRCh37 Human Genome Reference Sequence

The NUMT database based on the GRCh37 Human Genome Reference Sequence is reported in reported in Table I.2.1 (Annex I).

Seven hundred and fifty-five insertions were found to be spread throughout the entire genome. For each insertion the following information is reported: location at the chromosome; length of the chromosome; access number; score and the E-value of the match; fraction and the percentage identity; number of gaps; total length of match (alignment mtDNA/nDNA); the effective length in nDNA and in the mtDNA; the number of identical positions; the region in the mtDNA and nDNA; and finally, matrix of the identical and non-identical positions in mtDNA and nDNA (Figure 7).

Table 4. Number and length of insertions and their percentages for each chromosome. Length of each chromosome and their percentage are also reported.

Chromosome	Length chromosome (% in relation to the entire genome)	Number of insertions (% in relation to the total number of insertions)	Length of insertions (% in relation to the total length of insertions)
1	249250621 (8.05%)	51 (6.75%)	44798 (8.17%)
2	243199373 (7.86%)	106 (14.04%)	5268 (0.96%)
3	198022430 (6.40%)	44 (5.83%)	97489 (17.78%)
4	191154276 (6.17%)	41 (5.43%)	35103 (6.40%)
5	180915260 (5.84%)	35 (4.64%)	33053 (6.03%)
6	171115067 (5.53%)	31 (4.11%)	11738 (2.14%)
7	159138663 (5.14%)	43 (5.70%)	36328 (6.63%)
8	146364022 (4.73%)	47 (6.23%)	36917 (6.73%)
9	141213431 (4.56%)	34 (4.50%)	28498 (5.20%)
10	135534747 (4.38%)	35 (4.64%)	20926 (3.82%)
11	135006516 (4.36%)	31 (4.10%)	26640 (4.86%)
12	133851895 (4.32%)	42 (5.56%)	8264 (1.51%)
13	115169878 (3.72%)	22 (2.91%)	10691 (1.95%)
14	107349540 (3.47%)	9 (1.19%)	8899 (1.62%)
15	102531392 (3.31%)	14 (1.85%)	9395 (1.71%)
16	90354753 (2.92%)	15 (1.99%)	15965 (2.91%)
17	81195210 (2.62%)	23 (3.05%)	21990 (4.01%)
18	78077248 (2.52%)	6 (0.79%)	1334 (0.24%)
19	59128983 (1.91%)	20 (2.65%)	9318 (1.70%)
20	63025520 (2.04%)	9 (1.19%)	7471 (1.36%)
21	48129895 (1.55%)	18 (2.38%)	6753 (1.23%)
22	51304566 (1.66%)	17 (2.25%)	23544 (4.29%)
X	155270560 (5.02%)	50 (6.62%)	38843 (7.08%)
Y	59373566 (1.92%)	12 (1.59%)	9025 (1.65%)
Total	3095677412 (100%)	755 (100%)	548250 (100%)




Figure 8. Frequency and size (bp) of insertions for each chromosome.

There is a positive correlation between the number of insertions and chromosome size (Spearman correlation: 0.822 $p < 0.001$) (Figure 9a). Chromosome 2, the second largest chromosome in relation to the entire genome (7.86%), appears as an outlier. It encompasses 106 insertions (representing 14.04% of total number of insertions), nearly double the number of insertions that would be expected (Figure 9a).





Figure 9. Correlation between chromosome length and number of insertions (figure 9a), and correlation between chromosome and insertion length (figure 9b). Coefficient of determination (Sq r linear) for the two correlations is shown.

The correlation between the size of insertions and their representation on each chromosome is also positive and significant (Spearman correlation: 0.587 $p=0.003$). However, two outliers, chromosome 2 and 3, were identified (Figure 9b). As before, chromosome 2 is an outlier containing the highest number of insertions. But the length of insertions is quite short, covering only 0.96% of the total length of insertions (Table 4). On the contrary, chromosome 3, which is also one of the largest (6.40% in relation to the entire genome) with a relatively high frequency of insertion (representing 5.83% of total number of insertion), presents the highest total length of insertions (17.78%). In both analyses, chromosome 2 appears as an outlier. This would suggest a differential evolution of this chromosome, a hypothesis that deserves further investigation (Figure 9b).

The mean percentage of identity between nuclear insertions and mtDNA sequence is 79.2%, ranging from 63.5% to 100%. When the analysis of identity is performed for each chromosome (Table 5), the similarity between inserted mitochondrial sequences and the original mitochondrial sequences presents almost the same pattern in all chromosomes, with a mean percentage of identity of ~80% along the chromosomes.

Table 5. Percentage identity for all chromosomes.

Chromosome	1	2	3	4	5	6	7	8	9	10	11	12	13
Mean	78.76	80.20	79.42	81.24	82.02	80.77	77.67	77.88	78.22	78.31	78.27	83.40	80.61
Median	75.73	78.93	79.80	80.43	80.73	81.74	75.83	76.32	77.30	76.98	75.76	88	80.72
Minimum	64.71	65.04	68.14	68.71	66.35	64.69	68.46	67.77	68.02	69.08	66.46	67.79	65.41
Maximum	100	98.48	97.44	96.77	97.67	93.33	97.09	98.81	90.20	92	98.61	98.88	99.22
Percentiles	25	71.43	74.58	73.16	76.19	76.47	77.78	72.22	72.37	73.97	74.14	74.44	77.58
	50	75.73	78.93	79.80	80.43	80.73	81.74	75.83	76.32	77.30	76.98	75.76	88
	75	84.03	85.47	83.56	84.86	88.36	85	82.02	82.35	80.71	82.08	81.67	88
Chromosome	14	15	16	17	18	19	20	21	22	X	Y		
Mean	80.40	79.23	77.37	81.69	84.61	72.92	81.43	75.82	75.74	76.05	79.00		
Median	79.13	77.65	76.72	80.41	83.96	69.65	77.88	74.05	72.16	73.83	74.57		
Minimum	73.55	71.83	68.26	68.54	74.08	63.50	69.49	65.59	65.67	64.82	70.15		
Maximum	93.07	95.35	85.45	97.06	95.57	86.59	100	98.75	100	96.30	100		
Percentiles	25	74.75	75.15	73.53	77.06	75.89	67.43	72.40	69.09	69.32	69.78	71.38	
	50	79.13	77.65	76.72	80.41	83.96	69.65	77.88	74.04	72.16	73.83	74.57	
	75	86.02	83.37	81.73	83.42	94.08	79.04	94.10	79.71	80.31	80.95	82.35	

The relationship between the size of the insertion and the percentage identity is shown in Table 6. Concerning the size of insertions, it appears that most refer to small insertions (Table 6 and Figure 8) of less than 500 bp. Only 12.85% of the insertions have more than 1500 bp. The smallest insertions found are 39 bp long and are located on chromosomes 1 and 3. On the other hand, the largest insertion (14,836 bp) is located on chromosome 4 (Table I.2.1, Annex D).

Table 6. Frequency and identity of insertions in relation to the size of insertion (bp).

Size (bp)	Identity		Total	Percentage
	≥80%	<80%		
<500	276	245	521	69.00
[500-1500[21	116	137	18.15
[1500-2500[5	43	48	6.36
[2500-4000[3	21	24	3.18
≥4000	4	21	25	3.31
Total	309	446	755	100

About half of the small insertions have a percentage identity higher than 80% of the mitochondrial sequence (Table 6). As the size of the insertion increases, however, the proportion of insertions with a percentage identity equal to or higher than 80% decreases. There are 33 paralogous sequences with more than 500 bp, which present a similarity equal to or higher than 80% (Table 7). These sequences would represent the most problematic, in terms of mtDNA/nDNA co-amplification.

Table 7. Paralogous sequences with more than 500 bp and that present a similarity equal or higher than 80%.

Chromosome	% identity	nDNA length	mtDNA length	mtDNA region	nDNA region
1	98.53	5844	5845	3911-9755	564461-570304
1	84.03	517	521	987-1507	142792601-142793117
1	83.87	518	521	987-1507	143243224-143243741
1	83.78	515	519	987-1505	143344679-143345193
2	84.03	516	521	987-1507	95564754-95565269
2	83.95	728	729	6270-6998	50815826-50816553
2	81.78	1350	1349	4854-6202	156119971-156121320
3	95.39	1323	1323	1396-2718	96336032-96337354
3	83.31	623	623	7151-7773	120440870-120441492
3	80.38	1621	1622	1418-3039	40293638-40295258
5	95.05	2114	2121	577-2697	79945841-79947954
5	94.06	5219	5219	10269-15487	134258999-134264217
5	88.36	9108	9067	6117-15183	99381642-99390749
5	87.24	3463	3463	12662-16124	93903161-93906623
5	84.54	962	961	577-1537	123096499-123097460
6	90.70	527	527	2408-2934	62284008-62284534
7	83.66	2514	2517	577-3093	142373012-142375525
7	81.27	562	561	2740-3300	141504769-141505330
9	83.85	2517	2517	577-3093	33656612-33659128
10	84.62	533	533	8281-8813	101817140-101817672
11	94.24	2394	2396	577-2972	10529434-10531827
11	81.68	560	568	596-1163	87524440-87524999
14	93.07	1021	1024	5583-6606	32953304-32954324
17	96.17	653	653	6818-7470	51183094-51183746
17	83.42	10477	10536	577-11112	22021365-22031841
17	81.73	621	619	2656-3274	19504577-19505197
17	80.57	1514	1521	577-2097	19501874-19503387
17	80.41	2206	2205	14365-16569	22018521-22020726
17	80.24	575	582	2084-2665	19503699-19504273
21	83.78	515	519	987-1505	9735524-9736038
X	93.68	554	554	10606-11159	125606714-125607267
X	93.07	749	750	6553-7302	125605687-125606435
Y	83.08	517	521	987-1507	13290151-13290667

Applications to cancer

From the 271 mtDNA mutations previously described in cancer samples, and classified as having zero hits in the mtDNA phylogeny by Santos et al. (2008a), 15 have one or more hits in the current phylogeny by van Oven and Kayser (2009) (mit. Tree build 8). From the 256 positions with zero hits in the current mtDNA phylogeny (Table I.2.2 of Annex I), 220 could represent changes in one or more nuclear insertions of mtDNA (Table I.2.3 of Annex I includes the 220 positions and their matches in non-identical positions in the insertions and the paralogous mtDNA sequences), since they are non-identical between mtDNA and nDNA. Accordingly at that point, only 36 positions can be considered as authentic mtDNA mutations, since they were not found as non-identical in any of the nuclear insertions reported in our study (positions signalled with * in Table I.2.2 of Annex I).

The 220 positions that can represent false mtDNA mutations correspond to a total of 592 mutations described in the cancer studies, revised in Santos et al. (2008a). Of these, 186 mutations were once observed in different types of cancer and/or studies (Table I.2.2 of Annex I and references therein). The mutations that occur

more than once are mostly reported in the study of ovarian cancer by Aikhionbare et al. (2007). In this work, the D-loop and part of the coding region of mtDNA were characterized in 102 samples. The PCR reactions were performed with two primer pairs; after primer BLAST validation, the primer pair that amplifies the region located between positions 16453-16569 and 1-1693 reveals no risk of co-amplification. The *in silico* validation of the other primer pair, located between positions 7392 and 8921, reveals a risk of co-amplification between mtDNA and the region of chromosome 1 located between positions 46578 and 48102. However, in the NUMTs that can potentially be amplified by this primer set, the mtDNA mutations described by Aikhionbare et al. (2007) were not reported as non-identical positions in our NUMT database (Table I.2.3 of Annex I).

With regard the remaining studies, in five we were unable to assess their primers (Liu et al. 2001; Lorenc et al. 2003; Parr et al. 2006a; Petros et al. 2005; Zhou et al. 2007), since PCR primers were not reported in the original manuscripts, and after requesting them from the authors no response was obtained.

In the study by Allegra et al. (2006), the primer pair which amplifies the 10688-11500 mtDNA region also co-amplifies nDNA; specifically, it amplifies the region 99385306-99386137 on chromosome 5. Moreover, position 11203, reported as a mitochondrial mutation by Allegra et al. (2006), was reported as a non-identical position between mtDNA and the NUMT located on chromosome 5 in the region 99381642-99390749 (position signalled with † in Table I.2.3 of Annex I).

In ten different studies (Aikhionbare et al. 2007; Allegra et al. 2006; Fliss et al. 2000; Gasparre et al. 2007; Hervouet and Godinot 2006; Jin et al. 2007; Lièvre et al. 2005; Mithani et al. 2007; Polyak et al. 1998; Tan et al. 2006) the primer *in silico* validation also revealed a risk of co-amplification between mtDNA and nDNA. The twenty-seven positions described by the authors as mtDNA mutations, however, are not reported as non-identical position between mtDNA and the nuclear regions that might potentially be co-amplified.

Finally, 123 positions described in 15 studies (Aikhionbare et al. 2007; Fliss et al. 2000; Gasparre et al. 2007; Habano et al. 1999; Hervouet and Godinot 2006; Jin et al. 2007; Jones et al. 2001; Kassauei et al. 2006; Lièvre et al. 2005; Mithani et al. 2007; Nagy et al. 2003; Parrella et al. 2001; Polyak et al. 1998; Tan et al. 2006; Tzen et al. 2007) are more likely to be authentic, since the primers used to amplify the regions that encompass such mutations did not suggest the possibility of nDNA co-amplification (positions signalled with ** in Table I.2.2 of Annex I).

3.2.3 Discussion

In population and clinical genetics, as well as in the design of evolutionary, phylogenetic and epidemiological studies, it is important to have a complete overview of the total number of NUMTs, their location and variation. In this study, a NUMT database obtained using the latest version of the Human Genome – GRCh37 draft is reported. This is, to our knowledge, the first database that is based on this latest version of the human genome. Moreover, it is also the first where the non-identical positions between mtDNA and nDNA are listed for each NUMT.

In this study, 755 nuclear insertions of mtDNA origin were reported. A comparison of the total number of NUMTs in previously published works clearly shows significant discrepancies. The number of reported NUMTs ranges from 190 (Lascaro et al. 2008) to 1105 (Tourmen et al. 2002), with reports of 206 (Richly and Leister 2004), 211 (Ricchetti et al. 2004), 247 (Mishmar et al. 2004), 452 (Hazkani-Covo and Graur 2007), 612 (Woischnik and Moraes 2002) and 871 (Hazkani-Covo et al. 2010) insertions. The reasons for such discrepancies have been discussed by others previously (Lascaro et al. 2008). According to Lascaro et al. (2008), the incautious usage of

bioinformatics methods and the application of methods to an as yet not correctly assembled nuclear genome, are the main factors underlying the disagreement observed between studies. In this sense, the Human mtDNA Reference Sequence (NC_012920) was compared against the human RefSeq Genomic database at NCBI, using the RemoteBlast package in Bioperl bundle (Stajich et al. 2002) with the parameters set to restrict the search to the human organism and the E-value of 10^{-3} . Moreover, regions with less than 20 bp were excluded and only hits in the most recent version of the Human genome draft - GRCh37 primary reference assembly were considered.

Another factor that can induce differences in the number of reported insertions is whether or not the post-insertional processes were evaluated in order to differentiate original insertions from those that result from processes that alter the initially inserted sequence. In this study, post-insertional processes were not considered, since we aimed to obtain an accurate database with all the nuclear insertions and their specific variation (relatively to human mtDNA).

In accordance to other authors [for a review see Hazkani-Covo et al. (2010)], the reported frequency of insertions, as well as their length and distribution along the genome is variable. Most insertions have less than 500bp. This agrees with the most parsimonious explanation for the origin of NUMT which assumes that mtDNA would be used as a “patch” in the double-strand break repair from non-homologous end joining repair mechanism (Hazkani-Covo and Covo 2008; Hazkani-Covo et al. 2010; Leister 2005).

As previously mentioned, due to the similarity with mtDNA, NUMTs are a potential source of contamination in mtDNA studies based on PCR amplification (Parr et al. 2006b; Yao et al. 2008b). In this context, large insertions with a high percentage of identity with mtDNA would be particularly problematic. In fact, one of these insertions, located on chromosome 1, was previously reported to be a source of several errors and misinterpretations (Yao et al. 2008b). We characterized the 33 large insertions (with more than 500 bp) that present a percentage identity greater than 80%. Its size makes it difficult to perform primer designs to prevent co-amplification between nuclear insertions and mtDNA [chapter 1 of the present thesis, Ramos et al. (2009) and Ramos et al. (2011b)].

This study reports for the first time all identical and non-identical positions between the NUMTs and the GRCh37 version of the nuclear genome and the mtDNA Reference Sequence. This information can be used as a tool in the authentication of mtDNA mutations reported in different fields. Notwithstanding, it is worth mentioning that, in this compilation, the variation of NUMTs was not considered since no studies of NUMT sequence variation had yet been performed to date. Moreover, the mtDNA variation was only taken into account for human mtDNA, although the original insertion could in fact represent mtDNA sequence from very different species.

The described NUMT database was used as a tool to assess the impact of NUMT contamination on cancer studies. Several authors detected innumerable deficiencies in the medical literature related to the analysis and interpretation of mtDNA data [Salas et al. (2005), Yao et al. (2004) among others]. Concerning cancer studies, Salas et

al. (2005) showed the consequences of poor experimental design, both in the misinterpretation of the role of mtDNA in the complex tumoral process, as well as in the comparison of results. Also, Yao et al. (2004) showed that researchers may still ignore the possibility of a NUMT contribution when a seemingly novel mtDNA sequence is encountered. Using the NUMT database, we evaluated 256 mtDNA positions that were previously reported to be mutated in cancer samples and that present zero hits in the updated mtDNA phylogeny (Van Oven and Kayser 2009). From those positions, 220 (identified in 21 studies) could represent changes in one or more nuclear insertions of mtDNA since they are non-identical between mtDNA and nDNA. Thus, we raise the hypothesis that these changes could represent nuclear variations instead of mtDNA variation. To test this hypothesis, we further validated *in silico* the primer pairs used in several original studies if they were accessible in the publication or if they were provided by the authors after request. After primer *in silico* validation, from a total of 16 works for which primers were available, only six studies (Habano et al. 1999; Jones et al. 2001; Kassaei et al. 2006; Nagy et al. 2003; Parrella et al. 2001; Tzen et al. 2007) did not evidence the possibility of nDNA co-amplification. In the remaining studies (Table I.2.3 of Annex I and references therein), some of the positions reported are located in regions that could be the result of co-amplification. However, with the exception of position 11203 reported by Allegra et al. (2006), these positions are not reported as non-identical between the potentially co-amplified mtDNA and nDNA regions. Even so, we must take into account the fact that the variability of NUMTs is unknown, and that the non-identical positions database was generated using the mtDNA

and nDNA Reference Sequences. Thus, the differences between mtDNA and nDNA reported in our database are surely underestimated and the above mentioned positions could be non-authentic mtDNA mutations. On the other hand, it is possible that these changes actually represent authentic mtDNA mutations; however, this hypothesis seems extremely difficult to test.

Using cancer studies as an example application, we aimed to highlight the applicability of the described NUMT database as a new tool to validate *in silico* mtDNA mutations described in different contexts; it is clear that there is a need to follow standardized protocols that avoid co-amplification between mitochondrial and nuclear paralogous sequences. Moreover, and due to the amount of information provided for each nuclear insertion, this database could be applied as a tool to design evolutionary, phylogenetic and epidemiological studies.

To our knowledge, this is the first work to report the non-identical positions between the mtDNA and nDNA. These positions are the basis for the application to cancer studies reported in this work, and knowledge of their distribution is useful for the authentication of mtDNA mutations reported in different kinds of study, especially those occurring in heteroplasmy.

3.3 Capítol 3:
*Frequency and pattern of human
mitochondrial heteroplasmy*



3.3.1 Materials and methods

Samples and DNA Extraction

From two hundred and fourteen samples collected and analysed by Alvarez et al. (2010), a total of one hundred and one were used in the present study. Alvarez et al. (2010) characterized the genetic structure of a Northwest Iberia population using the mtDNA variation. The authors sequenced the HVRI of mtDNA and analysed phylogenetically informative coding region polymorphisms in order to assign each sample to a mtDNA haplogroup. To the present study, the selection of samples encompasses an equal representation of both sex and a mtDNA haplogroup distribution similar to that of an European population. All of the samples were from maternally unrelated Spanish individuals sampled in regional health centres. For all voluntary donors, appropriate informed consent and the birth places of all their known maternal ancestors up to the third generation were obtained under strictly confidential circumstances.

Total DNA from blood and mouth scrap samples was extracted using JETQUICK Blood DNA Spin Kit (Genomed, Löhne, Germany) according to the manufacturer's specifications.

MtDNA Analysis

The whole mitochondrial genome was amplified for all samples using a set of 9 primers pairs that prevents NUMTs co-amplification [chapter 1 of the present thesis, Ramos et al. (2009) and Ramos et al. (2011b)] PCR was performed as described in chapter 1 of the present thesis and by Ramos et al. (2009; 2011b). PCR products were purified using the JETQUICK PCR Purification Spin Kit (Genomed, Löhne, Germany).

All samples were fully sequenced using 32 internal primers in forward direction as well as 32 primers in reverse direction [chapter 1 of the present thesis, Ramos et al. (2009) and Ramos et al. (2011b)]. Sequence reactions were carried out using the sequencing kit Big Dye Terminator v.3 (Applied Biosystems, Foster City, USA) according to the manufacturer's specifications. Purification of DNA sequencing reactions was carried out with BigDye XTerminator® Purification Kit (Applied Biosystems, Foster City, USA) and sequences were run in an ABI Prism 3100 sequencer (Servei de Genòmica, Universitat Autònoma de Barcelona).

Detection and Authentication of Heteroplasmy

Sequences obtained were analysed using the Sequencing Analysis 5.2.0 software (Applied Biosystems, Foster City, USA), considering a value of 2% in the Mixed Base Identification option. Moreover, all sequences were visually verified and compared with others from the same run in order to detect the presence of

heteroplasmy. Only sequences with a good intensity and with background almost imperceptible were used.

Sequences were subsequently compiled and aligned in relation to the revised Cambridge Reference Sequence (CRS) (Andrews et al. 1999), using SeqScape software (Applied Biosystems, Foster City, USA).

Levels of heteroplasmy were determined as described in Santos et al. (2005b) using the height of the peaks in the electropherograms. About 6 sequences of every point heteroplasmy detected were used to calculate the average of heteroplasmy levels.

The authentication of mtDNA heteroplasmy was performed following a strategy similar to that used by Santos et al. (Santos et al. 2005b; Santos et al. 2008c), following the three main steps:

1. DNA extraction, PCR amplification, and sequencing of total mitochondrial genome were carried out; if necessary, the amplification and sequencing process was repeated to ensure sequences with a good intensity and with almost imperceptible backgrounds.
2. Individuals that appeared to present heteroplasmy in step 1 were confirmed by a second PCR amplification and sequencing.
3. To authenticate results, an independent DNA extraction, PCR amplification, and sequencing were subsequently performed for all individuals showing heteroplasmy in step 2.

Data analysis

Statistical analyses

In order to increase the total number of point heteroplasmies analysed and to perform a more robust heteroplasmy study, results published by Li et al. (2010) were also pooled with our data.

The point heteroplasmy frequencies detected both in the present study and that reported by Li et al. (2010) were determined by counting and the Bayesian 0.95 credible region (95% CR) was calculated using the SAMPLING software (V. Macaulay, personal communication).

To know if the distribution of point heteroplasmy across the mtDNA genome shows differences, a proportion test was calculated using the OpenStat version 2008. To test if there is a relation between haplogroup and the presence of point heteroplasmy, Fisher exact test was performed using the Struc program by Genepop 3.3 (Raymond and Rousset 2001). The remaining statistical tests were performed using the program SPSS ver. 15.0.1 software (SPSS 1989-2006).

Hits in the phylogeny, Population database and Conservation index (CI)

The number of hits in the phylogeny or number of occurrences was compiled from the updated mtDNA phylogeny – mit. Tree build 8 – (Van Oven and Kayser 2009) and from Soares et al. (2009).

Using the number of occurrences for each mutation reported by Soares et al. (2009), the probability of mutation was calculated as: number of hits/total number of hits. A mtDNA position was considered as a hotspot if it presents a probability of mutation ten times higher than the mean value of the probability of mutation.

In order to calculate the frequency of each variant for a particular nucleotide position, a population database of 3880 mtDNA complete sequences available from mtDNA phylogeny –mit. Tree build 8 – (Van Oven and Kayser 2009) was created. The database is in SPSS format (SPSS 1989-2006), and each mtDNA position represents a variable that allows calculate the frequency of nucleotides for each mtDNA position.

Nucleotide and amino acid conservation index (CI) were estimated for all heteroplasmic point positions calculating the percentage of variation between reference sequences of different species of the reign of metazoa. A total of 1491 nucleotid sequences and 1628 amino acid sequences were used respectively for nucleotides and amino acid CI (for specific list of species and accession number see Table I.3.1 of Annex I). Sequences were aligned using clustal W (Thompson et al. 1994) and formatting for further frequency analyses in SPSS software (SPSS 1989-2006).

Due to the difficulty to obtain a good alignment for the D-loop, an independent alignment was performed using 48 mitochondrial reference sequences of primates.

Structure prediction

To know if any implication of mitochondrial point heteroplasmy exists in the secondary structure of tRNAs and rRNA or in the protein interactions of mitochondrial genes, an analysis of structure prediction was performed.

The secondary structure prediction were developed using the RNAfold web server. Base-pair probabilities and positional entropy of any tRNA predicted structures were used to estimate the implication in the molecule. Human reference tRNA models were compiled (Putz et al. 2007), whereas rRNA models were not available. In order to know if rRNA heteroplasmic positions are located in stem or loop regions, additional analysis with software mtDNA-GeneSyn version 1.0 (Pereira et al. 2009) was performed.

The implications in the tertiary structures of proteins were performed using available crystal structures. After BLAST search, only bovine crystal structures of mitochondrial complex bc1 and IV were actually available (Iwata et al. 1998; Tsukihara et al. 1996).

The human sequence of COXI, COXII and COXIII (complex IV) and CYB (bc1 complex) were used as templates to search for the highest E-value pdb using BlastP analysis (Altschul et al. 1997). The resulting codes of bovine structures (pdb 1occ and 1bgy for complex IV and bc1, respectively) were then used in MODELLER (Sali and Blundell 1993) in order to build human structural models. The accuracy of the predicted 3D human models was estimated using three model quality: Verify 3D, SOLVX and ANOLEA (Holm and Sander 1992; Luthy et al. 1992; Melo and Feytmans 1998) .

All residue-residue bonds were calculated using Pymol software and all the structures were visualized using the same software.

3.3.2 Results

Frequency and type of heteroplasmy

From 101 complete mtDNA genome sequences, an exhaustive analysis of frequency and pattern of heteroplasmy was performed. The complete mutation report of all individuals is available on Table I.3.2 in Annex I.

For analysed samples, 63 individuals (62.37%) presented point and/or length heteroplasmy, and the remaining 37.63% were fully homoplasmic (Table 8). The 24.75% of the individuals present point heteroplasmy. There were found 4 individuals with more than one point heteroplasmy (Table 8). Twenty-eight different positions were involved; with the exception of positions 152 and 16189 that appeared to be heteroplasmic in two individuals, each position is heteroplasmic in a single individual.

The frequency of heteroplasmy did not present significant differences between sexes ($\chi^2=0.601$, $df=1$ $p=0.438$). Moreover, the haplogroup distribution of the heteroplasmic samples is similar to that of the original sample (Fisher exact test $p=0.8091$).

Concerning length heteroplasmy, a 48.51% of the individuals were heteroplasmic. In this case, 33 individuals presented only one length heteroplasmy and the remaining carried more than one length and/or one point heteroplasmy (Table 8).

Table 8. Classification of the analysed individuals depending on the heteroplasmic presence (PH: point heteroplasmy, LH: length heteroplasmy, CI: confidence interval).

Classification	Number of individuals	Frequency (95% CI)
Homoplasmy	38	37.63 (28.8-47.4)
Heteroplasmy	63	62.37 (52.6-71.2)
1 PH	12	11.88 (7-19.6)
1 LH	33	32.67 (24.3-42.3)
>1 PH	2	1.98 (0.6-6.9)
>1 LH	5	4.95 (2.2-11.1)
One or more PH+LH	11	10.89 (6.2-18.5)
Total PH	25	24.75 (17.4-34)
Total LH	49	48.51 (39-58.2)
Total	101	

In table 9 the regions of the mtDNA genome showing length heteroplasmy are presented. The highest frequency of length heteroplasmy was located in the poly(C) tract of HVRII. The poly(C) tract of HVRI, and the poly(C) tract of HVRIII located between positions 568-573 of the mtDNA present a frequency of 9.1%. A 5.45% of individuals showed length heteroplasmy in poly (AC) between positions 514-525 of the HVRIII region. Finally, three individuals present length heteroplasmy in different regions of mtDNA: between positions 8272-8278, 956-965 and in position 8289 (Table 9).

Table 9. Distribution of length heteroplasmy along the mtDNA genome.

Length heteroplasmy region	Number of heteroplasmies	Frequency (95% CI)
HVRI poly(C) (16189-16193)	5	9.1 (4-19.6)
HVRII poly(C) (303-309)	39	70.9 (57.8-81.2)
HVRIII		
poly(C) (514-525)	3	5.4 (2-14.9)
poly(AC) (568-573)	5	9.1 (4-19.6)
Coding region		
956-965	1	1.8 (0.4-9.6)
8272-8278	1	1.8 (0.4-9.6)
8289	1	1.8 (0.4-9.6)
Total	55	

Pattern and distribution of point heteroplasmy along the mtDNA genome

A total of 30 point heteroplasmic positions were confirmed in our study. To obtain a more accurate pattern of point heteroplasmy, results published by Li et al. (2010) were pooled together with our data (for a detailed list of positions see table I.3.3 in Annex I).

The distribution of point heteroplasmy observed along the mitochondrial genome is showed in table 10, both for the present study and for the study of Li et al. (2010). As it can be observed, the distribution of heteroplasmy across the mtDNA genome is similar in both studies.

Combining the information of both studies, the prevalent region of mtDNA that presents point heteroplasmy was the control region, with a frequency of 31.34% of the total of detected heteroplasmies (Table 10). The remaining 68.66% were located in tRNA (7.46%) and rRNA (5.97%), and coding positions for the respiratory chain of mtDNA (55.22%) (Table 10).

In order to know if point heteroplasmy followed a differential distribution along mitochondrial genome, tests for difference between two independent proportions were performed. Statistical significant differences (after Bonferroni correction) were observed between control and coding region, being the control region the most frequent location of mtDNA heteroplasmy ($z=-4.319$, $p<0.0001$). Also, statistical differences were observed between RNA regions (rRNA and tRNA) and protein coding genes presenting heteroplasmy (complex I, III, IV and V) ($z=-5.838$, $p<0.0001$) as

well as between complex I and the rest of others complex, being the complex I the most common region in the protein coding genes zone (Complex I vs. Complex IV: $z=-3.622$, $p=0.0001$; Complex I vs. Complex III and Complex I vs. Complex V: $z=-3.896$, $p<0.0001$).

From 46 point heteroplasmies located in 45 different positions of the coding region, 37 of them were located in protein coding genes: 21 were located in positions that encode for different subunits of the NADH dehydrogenase (56.75%); 6 point heteroplasmic positions were in the cytochrome c oxidase subunits I, II and III (16.21%); 5 point heteroplasmic positions were in the ATP synthase F0 subunit 6 (13.51%); and the remaining 5 were located in the cytochrome B (13.51%) (Table 10).

Table 10. Distribution of point heteroplasmy along the mtDNA genome in the present study and reported by Li et al. (2010).

mtDNA region	Present study		Li et al. (2010)		Pooled Data	
	Number of heteroplasmies	Frequency (95% CI)	Number of heteroplasmies	Frequency (95% CI)	Number of heteroplasmies	Frequency (95% CI)
D-loop	8	26.7 (14.2-44.6)	13	35.14 (21.8-51.4)	21	31.34 (21.5-43.3)
HVRI	3	10 (3.6-25.8)	5	13.51 (6-28.1)	8	11.93 (6.2-21.9)
HVRII	5	16.7 (7.5-33.7)	8	21.63 (11.4-37.3)	13	19.40 (11.7-30.5)
Coding region	22	73.3 (55.4-85.8)	24	64.86 (48.6-78.2)	46	68.66 (56.7-78.5)
tRNA	4	13.3 (5.5-29.8)	1	2.7 (0.6-13.8)	5	7.46 (3.3-16.3)
rRNA	2	6.7 (2-21.4)	2	5.4 (1.7-17.7)	4	5.97 (2.4-14.4)
Complex I	7	23.3 (3.4-13.6)	14	37.8 (24-54)	21	31.34 (21.5-43.3)
Complex III	2	6.7 (2-21.4)	3	8.1 (2.9-21.4)	5	7.46 (3.3-16.3)
Complex IV	4	13.3 (55.4-85.8)	2	5.4 (1.7-17.7)	6	8.95 (4.2-18.2)
Complex V	3	10 (3.6-25.8)	2	5.4 (1.7-17.7)	5	7.46 (3.3-16.3)
Total	30		37		67	

These 37 point heteroplasmies placed in protein coding genes are located in 36 different positions and 16 of them represent nonsynonymous mutations (43.24% of frequency), giving a nonsynonymous:synonymous ratio of 1:3 (Table 11).

Concerning the kind of mutation, 34 of point mutations detected in heteroplasmy were purine transitions and 29 were pyrimidine transitions, only 4 transversions were found. The transition:transversion and purine:pyrimidine ratios are also presented in table 11.

Table 11. Comparison of results obtained in present study with heteroplasmy detected by Santos et al. (2008c) and with the whole mtDNA genome mutational spectrum at population level (Pereira et al. 2009).

Type of mutation	Heteroplasmy in present study ^a	Heteroplasmy in D-loop ^b	Mutational spectrum at population level ^c
Transition:Transversion			
Whole mtDNA genome	15.75:1	-	7.5:1
Control Region	21:0	57.5:1	20.8:1
Purine:Pyrimidine			
Whole mtDNA genome	1.17:1	-	1.28:1
Control Region	1:3.2	1:2.93	1:1.7
Nonsynonymous:Synonymous	1:3	-	1:1.97

^a Pooled data from present work and from Li et al. (2010).

^b Santos et al. (2008c).

^c Computed using data of mtDNA mutation fixed at the individual level and polymorphic at population level, by Pereira et al. (2009).

Stability of point heteroplasmic positions

For the 67 point heteroplasmy found in pooled data, and located in 61 different positions of mtDNA genome, several analyses were performed to know the impact of mutation in the involved positions. The number of hits in the mtDNA phylogeny, the probability of mutation, the frequency in the population database, and the conservation index (CI) both at nucleotide and at amino acid level, were calculated (Table I.3.3 in Annex I).

A total of 21 point heteroplasmy were located in 16 different positions of the non-coding region (Figure 10 and Table I.3.3 in Annex I). These heteroplasmic positions have typical characteristics of non-stable position: high number of hits in the phylogeny, high frequency representation of the minority variant in database population and low percentages of conservation index (Table I.3.3 in Annex I).

Concerning coding region, 9 point heteroplasmy (in 9 positions) were located in stem regions of mitochondrial rRNA and tRNA (Table 10). From that, 2 heteroplasmic positions (1552 and 3014) are related to a high stability and conservation. These positions do not have any hit in mtDNA phylogeny, present a null representation of minority variant on database population and have a nucleotide CI over 70% (Figure 10 and Table I.3.3 in Annex I).

Thirty seven point heteroplasmy were located in 36 different positions of protein coding genes (Figure 10 and Table I.3.3 in Annex I). There are a total of 11 point heteroplasmy located in 11 stable positions (3532, 6054, 7697, 7754, 8603, 9029, 11253, 13604,

14561, 14770 and 15046). All these 11 positions present a maximum of 2 hits in the phylogeny, a minimum of 99.6% of representation in database population concerning to the majority variant and a minimum nucleotide CI of 77.25%. Moreover, nine of stable positions represent nonsynonymous mutations (3532, 8603, 6054, 7697, 7754, 9029, 11253, 13604 and 14561). From the total of 11 point heteroplasmies, six of them can be considered as highly stable positions (6054, 7697, 7754, 9029, 13604, and 15046). Besides the characteristics mentioned above (low number of hits, low representation in database population and low CI at nucleotide level), these positions present $CI \geq 92.9\%$ at amino acid level (Table I.3.3 in Annex I).




Figure 10. Schematic information of point heteroplasmies analysed in present study and reported by Li et al. (2010). Information about distribution along the mtDNA genome, kind of mutation (synonymous/nonsynonymous), stability^a of positions and implication in secondary and tertiary structure is reported (PH:point heteroplasmy, *S*:synonymous, *NS*:nonsynonymous).

^aDefined by: distribution in database population, number of hits in the phylogeny and nucleotide and amino acid conservation index.

In table 12 the distribution of point heteroplasmy and the number of hits in the phylogeny, considering the stability of positions, is presented. Taking the distribution of mutations at the population level, as the expected mutation distribution, there is an excess of point heteroplasmy located in positions that present 0 hits in the phylogeny. The frequency of point heteroplasmy located in no hotspot positions with a probability of mutation lower than the mean seems to be quite different compared to mutations at the population level. On the other hand, the proportion of heteroplasmy in hotspots is similar to the observed at population level.

Table 12. Distribution of point heteroplasmy and of hits in the phylogeny considering the stability of position (Mean value of the probability of mutation^a = 6.034×10^{-5}). *N*: total number.

mtDNA positions	Point heteroplasmy		Hits in the phylogeny ^c	
	N	Frequency (95% IC)	N	Frequency (95% IC)
0 Hits	13	19.40 (11.7-30.5)	0	0 (0.00-0.00)
Hotspot ^b	29	43.28 (32.1-55.2)	4089	38.29 (37.8-38.7)
No hotspot \geq mean	8	11.94 (6.5-21.9)	2872	26.89 (26.1-27.7)
No hotspot $<$ mean	17	25.37 (16.5-37)	3719	34.82 (33.9-35.7)

^a Probability of mutation: number of hits/total number of hits.

^b Hotspot: probability of mutation ten times higher than the mean value.

^c Soares et al. (2009).

In order to know the impact of mutation in the stability of secondary and tertiary conformation of tRNA, rRNA and proteins encoded by mtDNA, a prediction of different structures with the wildtype and mutant variant were performed and afterwards are presented those that imply changes in secondary or tertiary structures (Figure I.3.1 of Annex I).

In the case of tRNAs, it seems that point heteroplasmic position 15908 located in threonine tRNA implies a reduction in the number of residue-residue bond that evolve one of the stems of this tRNA (Figure 11). Moreover, this position presents two hits in the phylogeny, a representation of minor variant of 0.1% in population database and a CI of 17.78%, representing a stable position. Concerning rRNA, half of positions located in 12S and 16S are in stem regions, and the rest of them in loops. The heteroplasmy located in 1552 position imply a reduction in the stability of bonds of this stem region. Moreover, entropy information of bonds in this position is reduced (Figure 12).




Figure 11. Secondary structure prediction of threonine tRNA. Implication of point heteroplasmic position 15908. The structure below is colored by base-pairing probabilities, for unpaired regions the colour denotes the probability of being unpaired. Structure drawing encoding positional entropy is also reported.




Figure 12. Secondary structure prediction of 12S RNA. Implication of point heteroplasmic position 3014. Detailed view of wildtype and mutated position is shown. The structure below is colored by base-pairing probabilities, for unpaired regions the colour denotes the probability of being unpaired. Structure drawing encoding positional entropy is reported in Figure I.3.1 in Annex I. (WT:wildtype, Mut:mutated).

Concerning the implications in the tertiary structures of proteins, only information of complex IV and bc1 was available. Four nonsynonymous heteroplasmic positions (6052, 7697, 7754 and 15314) were located in these regions (Figure I.3.1 in Annex D). It seems that heteroplasmic position 7754, which implies an amino acid substitution (Asp57Asn) in COXII region, has some implication in the interactions between amino acids in tertiary structure. The mutated amino acid is located in the centre of an α -helix and the

substitution of an acidic by a polar amino acid implies the loss of interactions with the neighbours amino acid 56S and 58A (Figure 13). Moreover, as reported above, the heteroplasmic position 7754 is one of the most conserved and stable positions (Table I.3.3 in Annex I).




Figure 13. Three-dimensional model of human COXII complex. Implication of amino acid substitution Asp57Asn due to a point heteroplasmic position 7754. Detailed view of wildtype (Asp) and mutated (Asn) is also showed.

3.3.3 Discussion

Frequency and type of heteroplasmy

The frequency of heteroplasmy at the population level has been estimated for the hypervariable regions of mtDNA (De Camargo et al. 2011; Irwin et al. 2009; Santos et al. 2008c) and at the moment only exists one previous study that use deep sequencing of the complete mitochondrial genomes to analyse mtDNA heteroplasmy (Li et al. 2010).

In the present study, 62.37% of individuals are heteroplasmic at the population level. The 48.51% of analysed individuals presented length heteroplasmy and 24.75% of individuals carry out point heteroplasmy. The frequency of length heteroplasmy obtained in the control region [4.95% for HVRI (95% CI, 2.2-11.1%) and 38.61% for HVRII (95% CI, 29.7-48.4%)] was significantly lower than that reported by Santos et al. (2008c) [17.145% for HVRI (95% CI, 12.3-22.93%) and 64.76% for HVRII (95% CI, 57.89-71.21%)]. These differences could not be due to methodological approaches since both studies were performed using the same methodology and analytic conditions. It is possible that the differences could be related to the population origin of analysed samples since other authors

reported differences in point heteroplasmy frequencies in different populations (Irwin et al. 2009).

Concerning the frequency of individuals with point heteroplasmy in the control region, our results [7.9% (95% CI, 4.1-14.9%)] are slightly higher than those reported by Santos et al. (2008c) [3.81% (95% CI, 1.66-7.37%)] however differences are not significant. For the total mtDNA genome, comparing our results of point heteroplasmy frequency [24.75% (95% CI, 17.4-34%)] to those reported by Li et al. (2010) [24.42% (95% CI, 17.9-32.5%)] no differences were observed. Our results put in evidence the high frequency of heteroplasmy at the population level. Taking into account the high frequency of heteroplasmy and the high level of individuals that present more than one heteroplasmy, it appears that mitochondrial recombination could be a source of new mtDNA variants, increasing thus the variability in the mitochondrial genome at individual level and ultimately, at population level. On the other hand, recombination could avoid the accumulation of deleterious mutations along maternal lineages preventing their extinction as a result of Muller's ratchet (Wallace 2007).

Different technologies have been used for heteroplasmy detection. The majority of work published so far used the automated sequencing, the same method used in the present study. On the other hand, next-generation sequencing has been used by Li et al. (2010). Although the sequencing method is different, both studies report similar point heteroplasmy frequencies and similar distribution of point heteroplasmy across the mtDNA genome. In the present study, special attention was taken to avoid co-amplification between

mtDNA and nDNA, as well as to use an efficient protocol to validate point heteroplasmy. In spite of it, and in accordance with others (Santos et al. 2008c), our study demonstrates that heteroplasmy levels of 5% can be detected with confidence using the automated sequencing system if a good sequencing strategy and an accurate procedure of heteroplasmy validation are used. And comparing our results to those reported by Li et al. (2010), the methodology used in the present study could be as precise as massive sequencing.

No significant results have been found in the relation between sex or haplogroup and the distribution of point heteroplasmy in human populations, a result similar to that obtained by Camargo et al. (2011). These results suggest that evolutionary forces that control the levels of heteroplasmy act independently from sex and mtDNA haplogroups.

Several investigations have noted an association between increases in human mitochondrial heteroplasmy and aging. This includes pathogenic heteroplasmies (Cortopassi et al. 1992) but also seemingly benign deletions or polymorphic variants (Calloway et al. 2000; Da Costa et al. 2007; Michikawa et al. 1999; Wang et al. 2001). Some studies have suggested that some heteroplasmies may play a role in longevity (Rose et al. 2007; Salvioli et al. 2008). In our study a total of 30 point heteroplasmies have been detected in blood samples of 101 individuals. The age of these individuals ranges between 9 and 92 years, with an average age of 58.9 years. The average age of heteroplasmic individuals (58.6 years) and non heteroplasmic individuals (59 years) did not present significant

differences. Thus, it seems that our data do not show any relation between mitochondrial heteroplasmy and aging.

The heteroplasmic state of an individual could have arisen either via transmission from the mother (i.e., through the germline) or via a new somatic mutation occurring within the individual. In order to know the origin of point heteroplasmy detected in present study, further analyses were performed. Mouth scrap samples of the detected heteroplasmic individuals were used as a reference of another tissue with different embryonic origin (blood as a reference tissue of mesodermic origin and mouth scrap of ectodermic origin). From the 24 available epithelial samples, 21 presented once again the point heteroplasmy, whereas only 3 did not show any signal of mix variant. The presence of heteroplasmy in more than one tissue with different blastodermic origin indicates that probably this heteroplasmy is germinal. Thus, 87.5% of the point heteroplasmy detected in the present study are germinal and only 12.5% are somatic. Our data are in accordance with that reported by Santos et al. (2005b). In that work, the authors confirmed the point heteroplasmic origin by the analysis of the mother and other relatives of the heteroplasmic individuals and a frequency of 61.6% germinal heteroplasmy was reported. The low representation of somatic point heteroplasmy in our data may have biased the detection of a possible relation between heteroplasmy and aging previously presented. In fact, the age average of individuals presenting somatic heteroplasmy (72.2 years) is higher than the reported for the individuals presenting germinal heteroplasmy (56.8 years). These observations put forward that most of heteroplasmy are germinal and only a small fraction are somatic. Notwithstanding, somatic

heteroplasmy appears to be related to aging/longevity since these heteroplasmy appear in older individuals. On the other hand, the high levels of germinal point heteroplasmy would imply that individuals carried out a mutational background that would increase the risk or protect from mitochondrial related pathologies. Moreover, this genetic variation would be selected for the sequence evolution, implicating the final fixation or loss of a specific mtDNA variant.

Pattern and stability of point heteroplasmic positions along the mtDNA genome

Concerning the kind of mutations detected, the 94% of point heteroplasmy involved transitional variants, yielding a transition:transversion ratio of 15.75:1 (Table 11). This high representation of transitions are in accordance to the mutational spectrum at population level reported by Pereira et al. (2009) (ratio 7.5:1). However, in the present study there are twice more transitions in heteroplasmy than at the population level, a similar result to that obtained for D-loop in previous studies (Pereira et al. 2009). These provide evidences of an excess of transitions (or deficit of transversions) in the mutational spectrum in heteroplasmy.

A frequency of 64% of point mutations detected in heteroplasmy in the whole mitochondrial genome involved purines, representing a ratio purine:pyrimidine of 1.17:1, according well with the ratio 1.28:1 at population level (Pereira et al. 2009). Classifying the reported results by coding and non-coding region and according with others (Irwin et al. 2009; Pereira et al. 2009; Santos et al.

2008c), high proportion of mutations involving pyrimidines (76.2%) was obtained for the control region, both considering mutations in heteroplasmy and at the population level (Table 11). This differential result between mitochondrial regions could not be due to a differential base composition, since there is a similar ratio 1:1.31 of purine:pyrimidine in both regions, and the causes of such difference deserves further investigations.

As previously reported, mutations are the root cause of heteroplasmy and also provide the basis for sequence evolution, so it is reasonable to expect a correlation between sites that experience high rates of heteroplasmy and those that evolve quickly within populations (Irwin et al. 2009). However, it seems that a different pattern is established for point heteroplasmy, since there is an excess of point heteroplasmies located in positions that present 0 hits in the phylogeny.

A total of 16 different point heteroplasmies has been detected in nonsynonymous positions, representing a ratio nonsynonymous:synonymous of 1:3. These results are in accordance with values reported by others at the population level (ratio 1:1.97) (Pereira et al. 2009). Pereira et al. (2009) found high levels of nonsynonymous polymorphisms in ATP6 and ATP8 regions of mtDNA and low levels in COXI, ND4 and ND5 regions. In the present work, the distribution between regions is different, probably due to the low number of nonsynonymous positions detected. The same authors show that the group of neutral amino acid V, I, A, M, T present the higher proportion of all possible changes observed in human population. Our data show that from the 16 nonsynonymous

heteroplasmic positions, 7 of these are located in amino acid of the reported group, and also all of them imply an amino acid change with the same polarity/acidity (neutral to neutral), suggesting that the new residue could maintain the interactions with the other residues in order to preserve the tertiary structure of the protein.

Concerning tRNAs, one of the most conserved positions where heteroplasmy was found is the 15908. This change implies a reduction in the stability of the molecule due to a length reduction of one of the stems of the threonine tRNA. There has been reported that some polymorphisms in the human population are located in positions identified as 100% and >90% conserved in mammalian tRNAs (Kivisild et al. 2006). Moreover, Pereira et al. (2009) and according to Kivisild et al (2006), found the threonine as the tRNA with the highest amount of polymorphisms. Along with the point heteroplasmic position 15908 there are three more heteroplasms located in other tRNAs, all of them found in stem regions. These results are in contrast with Pereira et al. (2009) that found a ratio of stem:loop of 0.99, according to the principal function of stem regions in the maintenance of the secondary structure.

Eleven point heteroplasms detected in protein coding genes are located in stable positions (3532, 6054, 7697, 7754, 8603, 9029, 11253, 13604, 14561, 14770 and 15046), presenting a representation in mtDNA phylogeny near zero, low or null levels of minor variant in population database and high levels of CI. Moreover, from those heteroplasmic positions located in complexes for which the mitochondrial crystal structures are known, the 7754 position, which implicates an amino acid substitution Asp70Asn, have a direct

implication in the tertiary structure of COXII, implying the loss of interactions with nearby amino acids.

In the present study, two heteroplasmies located in stable positions (7679 and 11253) have been related to mitochondrial pathologies. The point heteroplasmy located in 7697 position and its amino acid change implication (valine to isoleucine) have been reported as a genetic factor that indicate a susceptibility to Hypertrophic cardiomyopathy (HCM) in Chinese Han ethnic population (Wei et al. 2009). Moreover, the point heteroplasmy located in 11253 position (amino acid change isoleucine to threonine) has been related to have a direct implication on Leber's hereditary optic neuropathy (LHON) (Fauser et al. 2002; Leo-Kottler et al. 2002). Although the mutant variant frequency of this individual is relatively high (76%), in the majority of LHON patients and family members, the pathogenic mtDNA mutation is homoplasmic; thus, at this stage the mutation observed in this individuals does not have phenotypic implications (Howell et al. 2000; Smith et al. 1993).

Taking up the previously mentioned about the excess of transitions in the mutational spectrum in heteroplasmy, it seems that some evolutionary force may be acting to lower these at population level. Most probably these mutations will be finally eliminated by genetic drift or by selection. In fact, all of the point heteroplasmies located in stable positions could have a greater impact in the viability of mitochondria survival, suggesting that purifying selection must be operating on some heteroplasmies to prevent their fixation within individuals. Although purifying selection has been proposed by others (Elson et al. 2004; Rand 2001; Ruiz-Pesini and Wallace 2006;

Santos et al. 2008c), no previous evidence involving heteroplasmy has been found, but in accordance with Li et al (2010), actually there are not enough heteroplasmic studies to reflect the purifying selection actuation.

This is the first study that analyses the frequency of heteroplasmy in healthy population, carrying out an evolutionary evaluation of the detected changes. This work provides a new perspective which would be important for medical, evolutionary, and forensic proposes.

4. DISCUSSIÓ GENERAL



Disseny i validació de primers per a l'amplificació i seqüenciació del DNAm

L'amplificació i seqüenciació del DNAm s'utilitza rutinàriament en una gran diversitat d'estudis. Tot i així, la interpretació dels resultats, sobretot pel que fa a l'estudi de l'heteroplàsmia mitocondrial, es pot complicar per la possibilitat de co-amplificar DNAm i DNAn (Parr et al. 2006b; Yao et al. 2008b). Per aquest motiu, i donat que no existeixen a la bibliografia *primers* que permetin amplificar la totalitat del genoma mitocondrial, evitant alhora l'amplificació de NUMTs, la primera tasca duta a terme va ser dissenyar i validar uns *primers* que permetessin amplificar el genoma mitocondrial, a la vegada que evitaven la possible co-amplificació amb NUMTs.

El disseny de *primers* es va fer tenint en compte l'esborrany hg18 del genoma humà, el més actual en l'inici de la Tesi. Durant el disseny de les parelles de *primers* es van detectar dues regions del DNAn de gran mida i altament similars amb el DNAm. Aquestes regions es localitzen al cromosoma 1 (regió 3914–9074 del DNAm) i al cromosoma 5 (regió 9582–14479 del DNAm). La regió que se situa al cromosoma 1 ja havia estat descrita anteriorment (Lascaro et

al. 2008) com una regió nuclear altament similar al DNAm_t. Però pel que fa a la regió que es localitza al cromosoma 5, aquesta no ha estat reportada amb anterioritat, podent representar una inserció nuclear d'origen mitocondrial no descrita en treballs anteriors sobre NUMTs. De fet, aquesta seqüència s'ha pogut identificar i caracteritzar en el moment en que es va dur a terme la compilació de NUMTs.

La validació dels *primers* d'amplificació dibuixats, mitjançant una mostra d'esperma sotmesa a una lisi preferencial, ha permès demostrar que les nou parelles de *primers* dissenyades amplifiquen específicament DNAm_t i no permeten la co-amplificació amb DNAn.

Donat que no hi havia *primers* descrits a la bibliografia que permetessin una amplificació selectiva del DNAm_t, evitant alhora possibles co-amplificacions entre el DNAm_t i el DNAn, aquest treball va publicar-se a inicis de l'any 2009 (Ramos et al. 2009). Els *primers* presentats poden ser una eina molt útil per a qualsevol projecte on calgui realitzar una amplificació i seqüenciació completa del DNAm_t, sent molt adient per al *screening* de l'heteroplàsmia mitocondrial tant en mostres d'individus sans com malalts, així com en determinacions forenses. D'altra banda, l'estricta metodologia emprada per dissenyar-los i validar-los pot ser utilitzada com a referència per a qualsevol estudi de DNAm_t que requereixi un disseny de *primers*.

Com s'ha dit anteriorment, aquests *primers* [capítol 1 de la present Tesi i Ramos et al. (2009)] van ser validats *in silico*

(mitjançant BLAST) utilitzant la seqüència de referència hg18, però al febrer de 2009, va generar-se un nou esborrany del genoma humà GRCh37. Com a conseqüència, s'han hagut de validar, *in silico*, novament els *primers*, utilitzant aquesta vegada la nova seqüència de referència del genoma humà GRCh37.

D'acord amb l'actualització de l'esborrany del genoma humà, un dels NUMTs més problemàtics (situat al cromosoma 1) sembla ser més gran del que s'havia descrit. Amb l'antiga referència del genoma humà aquest NUMT tenia un 98% de similitud amb la regió del DNAm_t compresa entre les posicions 3914–9074, però degut a l'actualització, aquesta regió s'amplia en més de 700 pb (regió 3911-9755 del DNAm_t), conservant la mateixa similitud (Andrews et al. 1999). Aquesta modificació provoca que un dels *primers* dissenyats (situat entre les posicions 6511-9220 del DNAm_t) perdi la capacitat d'amplificació exclusiva del DNAm_t i per tant, possibiliti la co-amplificació amb el DNAn.

L'estudi d'aquest NUMT ha permès identificar-lo com un NUMT específic d'espècie, ja que no el comparteixen la resta de primats. Malauradament però, no es coneix encara la variabilitat (presència/absència) que pot tenir un NUMT a la població humana i per tant, no es pot descartar la possible co-amplificació entre el DNAm_t i DNAn. Per aquest motiu s'ha redissenyat una de les parelles de *primers*. Degut a la gran mida del NUMT, aquesta parella de *primers* s'ha hagut de localitzar en una zona de baixa similitud entre el DNAm_t i el DNAn, col·locant l'extrem 3' de cadascun dels *primers* en una posició no idèntica entre el DNAm_t i el DNAn.

Aquesta actualització va publicar-se l'any 2011 (Ramos et al. 2011b).

Actualització de la base de dades de NUMTs i aplicació en estudis de càncer

Els NUMTs poden ser una eina molt útil en estudis evolutius i de poblacions. D'altra banda, degut a l'elevada similitud amb el DNAm, els NUMTs poden ser una font de contaminació en estudis basats en l'amplificació per PCR del DNAm. Per tant, conèixer de primera mà el nombre total d'aquestes insercions, la seva localització i variació és important per a dur a terme un bon disseny de qualsevol tipus d'estudi, ja sigui filogenètic, epidemiològic, evolutiu, poblacional o clínic. Actualment però, tot i existir una gran quantitat de bases de dades que recullen aquesta informació referent als NUMTs, totes elles s'han realitzat mitjanant una versió desactualitzada del genoma humà de referència. Per aquests motius, un dels objectius de la present Tesi, ha estat realitzar una exhaustiva compilació de les insercions nuclears d'origen mitocondrial basada en la darrera versió de l'esborrany del genoma humà (GRCh37). El treball resultant s'ha publicat recentment a la revista *Mitochondrion* (Ramos et al. 2011a).

En aquesta base de dades es presenten 755 insercions. Si comparem el número total de NUMTs amb els reportats en estudis publicats prèviament, aquest nombre pot variar des de 190 (Lascaro et al. 2008) a 1105 (Tourmen et al. 2002), amb publicacions que reporten 206 insercions (Richly and Leister 2004), 211 (Ricchetti et

al. 2004), 247 (Mishmar et al. 2004), 452 (Hazkani-Covo and Graur 2007), 585 (Simone et al. 2011), 612 (Woischnik and Moraes 2002) i 871 (Hazkani-Covo et al. 2010).

D'acord amb Lascaro et al. (2008), els motius principals d'aquestes discrepàncies són la disparitat que hi ha en els mètodes bioinformàtics utilitzats, així com en els paràmetres tinguts o no en compte i a l'aplicació de genomes nuclears que encara no estan acoblats correctament.

Un altre factor que pot induir diferències en el nombre total de NUMTs és el fet de considerar, o no, els processos post-insercionals que pot patir una inserció. Aquest factor pot servir per saber si un NUMT representa una inserció original o si és el resultat d'un procés que ha alterat la seqüència inicial com ara la duplicació. En la base de dades que es presenta en aquesta Tesi, i a fi de poder obtenir una base de dades que contingués totes les insercions nuclears, així com la seva pròpia variabilitat relativa al DNAmT, els processos post-insercionals no s'han tingut en compte.

La freqüència de les insercions presentades, així com la seva mida i distribució al llarg del genoma, és variable, destacant el fet que la majoria d'aquestes insercions són menors de 500 pb. Aquests resultats estan d'acord amb altres autors (Hazkani-Covo et al. 2010) i amb l'explicació més parsimoniosa sobre l'origen del NUMTs, que assumeix que el DNAmT podria ser utilitzat com a pegat en la reparació dels trencament de doble cadena (DSBR) pel mecanisme d'unió d'extrem no homòlegs (NHEJ) (Hazkani-Covo and Covo 2008).

D'altra banda, i per primera vegada, juntament amb la base de dades d'insercions nuclears, es presenten les posicions no idèntiques entre NUMTs (mitjançant el darrer esborrany del genoma humà GRCh37) i la seqüència de referència del DNAm. Aquesta informació pot ser molt útil per autenticar mutacions del DNAm que han estat publicades en diferents àrees d'estudi. Cal mencionar però, que en aquest recull no s'ha tingut en compte la variació de presència/absència que pot tenir un NUMT en la població. A més, pel que fa a la variació del DNAm, només s'ha tingut present a nivell humà, però una inserció original podria representar la seqüència d'un DNAm d'una espècie molt diferent.

Com un exemple d'aplicació d'aquesta base de dades, s'ha avaluat l'impacte de la contaminació per NUMTs en estudis de càncer. Aquest fet és degut a l'elevada similitud que tenen els NUMTs amb el DNAm, sent una font de contaminació en els treballs de DNAm basats en la seva amplificació per PCR (Parr et al. 2006b; Yao et al. 2008b). De fet, actualment estan publicats un seguit d'estudis que posen de manifest innumerables deficiències en la literatura mèdica relacionada amb la interpretació de les dades en anàlisis del DNAm [Salas et al. (2005), Yao et al. (2004), entre d'altres]. Aquests treballs demostren les conseqüències que pot tenir un pobre disseny experimental i el desconeixement de l'existència dels NUMTs com a possible font de contaminació.

De les 256 posicions del DNAm avaluades, que han estat prèviament reportades com a mutacions relacionades amb càncer i que no apareixen com a polimòrfiques a l'espècie humana, 220 poden representar canvis en una o més insercions nuclears, ja que

estan localitzades en posicions no idèntiques entre el DNAm i DNAn. Després de dur a terme la validació *in silico* dels primers utilitzats en els diferents estudis de càncer (primers disponibles en 16 estudis d'un total de 21 treballs analitzats), només en 6 treballs (Habano et al. 1999; Jones et al. 2001; Kassaei et al. 2006; Nagy et al. 2003; Parrella et al. 2001; Tzen et al. 2007) no es van observar evidències de possibles co-amplificacions. De tota manera, amb l'excepció de la posició 11203 descrita per Allegra et al. (2006), la resta de posicions no estan reportades com a posicions no idèntiques entre el DNAm i el DNAn, en les insercions que podrien ser potencialment co-amplificades.

Utilitzant els estudis de càncer com a exemple, s'ha evidenciat l'aplicabilitat de la base de dades de NUMTs com una nova eina per validar *in silico* les mutacions de DNAm descrites en diferents contextos. D'altra banda, l'exemple posa de manifest la necessitat d'estandarditzar protocols que evitin la co-amplificació de DNAm i DNAn.

Tenir a l'abast una base de dades de NUMTs, així com dur a terme un correcte disseny de primers com el que s'ha descrit en aquesta Tesi són dues eines a tenir en compte en el moment d'iniciar un treball centrat en el DNAm, ja que proporcionen una font d'informació molt útil. Existeix la possibilitat però, que no es pugui evitar la co-amplificació, com és el cas dels estudis de DNA antic o forenses on la mida dels fragments amplificats no permet situar els primers fora de les regions conflictives entre DNAm i DNAn. En aquests casos seria important tenir com a mínim constància de les posicions no idèntiques que es presenten a la base de dades de

NUMTs i així poder controlar la possible contaminació en el moment d'interpretar els resultats.

Freqüència i patró de l'heteroplàsmia mitocondrial humana

L'estudi de l'heteroplàsmia mitocondrial s'ha realitzat utilitzant els *primers* dissenyats en la present Tesi per amplificar i seqüenciar el genoma mitocondrial de 101 individus. L'estudi posterior de l'heteroplàsmia mitocondrial a permès reafirmar l'amplificació selectiva del DNAm, ja que no s'ha detectat co-amplificació entre DNAm i DNAn en cap de les mostres.

La freqüència d'heteroplàsmia a nivell poblacional ha estat estimada en diverses ocasions pel que fa a la regió control del DNAm (De Camargo et al. 2011; Irwin et al. 2009; Santos et al. 2008c), actualment però, només existeix un estudi que ho realitzi per tot el genoma mitocondrial (Li et al. 2010).

La metodologia utilitzada per dur a terme l'estudi de l'heteroplàsmia mitocondrial humana ha estat la seqüenciació automàtica, sent la tècnica més utilitzada en la gran majoria de treballs centrats aquest tema. En comparació amb la tècnica de seqüenciació massiva aplicada per Li et al. (2010) i donat que tots dos treballs reporten freqüències similars d'heteroplàsmia puntual, s'ha fet palès que les dues metodologies presenten una sensibilitat similar. Val a dir que això ha estat gràcies a l'exhaustiu disseny de *primers* així com a l'aplicació d'un eficient protocol de validació de l'heteroplàsmia puntual. Conforme això i d'acord amb Santos et al.

(2008c), el present estudi demostra la possibilitat de detectar amb seguretat les heteroplàsmies puntuals amb un nivell d'un 5%.

En el present estudi s'ha determinat que un 62.37% de la població presenta heteroplàsmia mitocondrial, concretament, s'han detectat un 58.51% d'individus amb heteroplàsmia de longitud i un 24.75% amb heteroplàsmia puntual. Aquests resultats posen de manifest l'elevada freqüència d'heteroplàsmia mitocondrial a nivell poblacional. Tenint en compte aquesta elevada freqüència i l'elevat nombre d'individus que presenten més d'una heteroplàsmia mitocondrial, sembla ser que la recombinació mitocondrial podria actuar com a font generadora de noves variants de DNAm, augmentant així la variabilitat en el genoma mitocondrial a nivell individual i en última instància, a nivell poblacional. D'altra banda, la recombinació podria impedir l'acumulació de mutacions perjudicials al llarg dels llinatges materns, prevenint-ne l'extinció com a resultat del trinquet de Muller (Wallace 2007).

Pel que fa a la relació entre el sexe o l'haplogrup de l'individu i l'heteroplàsmia mitocondrial en població humana, no s'han trobat resultats significatius. Aquests resultats estan d'acord amb altres autors (De Camargo et al. 2011), suggerint que les forces evolutives que controlen els nivells d'heteroplàsmia actuen independentment del sexe i de l'haplogrup mitocondrial.

Un seguit de treballs han detectat una associació entre l'augment d'heteroplàsmies mitocondrials i l'edat (Calloway et al. 2000; Cortopassi et al. 1992; Da Costa et al. 2007; Michikawa et al. 1999; Wang et al. 2001). D'altres, han suggerit que certes heteroplàsmies podrien jugar un paper fonamental en la longevitat

(Rose et al. 2007; Salvioli et al. 2008). L'edat dels individus analitzats en el present estudi varia entre 9 i 92 anys, amb una mitjana d'edat de 58.9 anys. La mitjana d'edat dels individus que tenen heteroplàsmia mitocondrial (58.6 anys) i dels que no en presenten (59 anys) no té diferències significatives. Per tant, els nostres resultats no semblen mostrar cap relació entre la presència d'heteroplàsmia i l'edat.

L'heteroplàsmia mitocondrial d'un individu pot tenir origen matern (i per tant, venir a través de la línia germinal) o pot resultar de l'aparició de mutacions somàtiques que es donen en el sí de l'individu. Per conèixer quin és l'origen de les heteroplàsmies puntuals detectades en el present estudi, van realitzar-se anàlisis posteriors dels individus que presentaven heteroplàsmia mitocondrial. Es van utilitzar mostres de raspap bucal d'aquests individus com a referència d'un teixit amb diferent origen embrionari (la sang seria el teixit de referència d'origen mesodèrmic i l'epiteli bucal seria el d'origen ectodèrmic). De les 24 mostres de raspap bucal disponible, 21 van presentar de nou l'heteroplàsmia puntual detectada prèviament en sang, i només en 3 no hi va haver senyal d'una mescla de variants. La presència d'una heteroplàsmia mitocondrial en més d'una fulla blastodèrmica indicaria que l'origen d'aquesta heteroplàsmia és probablement germinal. D'aquesta manera, el 87.5% de les heteroplàsmies puntuals analitzades tindrien un origen germinal, mentre que només un 12.5% serien somàtiques. Aquesta elevada freqüència d'heteroplàsmies d'origen germinal ja ha estat reportada per altres autors (Santos et al. 2005b), mitjançant l'anàlisi de la mare i altres familiars de l'individu heteroplàsmic.

La baixa representació d'heteroplàsmies d'origen somàtic, podria esbiaixar la possible relació entre l'heteroplàsmia i l'edat. De fet, la mitjana d'edat dels individus que presenten heteroplàsmia d'origen somàtic (72.2 anys) és força superior a la dels individus amb heteroplàsmia germinal (56.8 anys), la qual cosa podria relacionar l'heteroplàsmia somàtica amb processos d'envelliment i/o longevitat.

Aquestes observacions posen de manifest que la majoria de les heteroplàsmies mitocondrials són germinals i només una petita fracció són somàtiques. L'elevat nivell d'heteroplàsmia germinal, implica que els individus porten un *background* mutacional, que podria augmentar el risc, o protegir-los, enfront a patologies relacionades amb disfunció mitocondrial.

El 94% de les heteroplàsmies mitocondrials detectades en el genoma mitocondrial comprometen transicions, donant una raó transició:transversió de 15.75:1. Aquesta elevada representació està en consonància amb el que es presenta a nivell poblacional, reportat per Pereira et al. (2009) (ratio 7.5:1). Val a dir, que les freqüències en heteroplàsmia doblen a les que es presenten a nivell poblacional, evidenciant un excés de transicions (o dèficit de transversions) en l'espectre mutacional de l'heteroplàsmia.

D'altra banda, el 64% de les heteroplàsmies detectades impliquen canvis purínics, representant una raó purina:pirimidina de 1.17:1, molt en consonància amb la raó de 1.28:1 reportada a nivell poblacional (Pereira et al. 2009). Si només tenim en compte els resultats obtinguts pel que fa la regió control, i d'acord amb altres autors (Irwin et al. 2009; Pereira et al. 2009; Santos et al. 2008c), es

detecten elevades freqüències de pirimidines (76.2% present treball). Cal destacar que la composició nucleotídica és la mateixa en tot el genoma mitocondrial (raó purina:pirimidina 1.31:1), per tant, la diferent composició de bases entre regions del DNAm no podria ser la causa d'aquesta inversió que es detecta tant en l'espectre mutacional de l'heteroplàsmia com a nivell poblacional, per tant, les causes d'aquesta diferència haurien de ser investigades en futurs estudis.

Les mutacions són la causa fonamental de l'heteroplàsmia alhora que proporcionen la base per l'evolució del genoma, per tant és raonable esperar una correlació entre les posicions que experimenten elevades taxes d'heteroplàsmia amb aquelles que evolucionen amb rapidesa dintre de les poblacions (Irwin et al. 2009). De tota manera, sembla que hi ha un patró diferencial per a l'heteroplàsmia puntual, ja que s'ha detectat un excés d'aquestes en posicions que presenten zero *hits* a la filogènia.

S'han detectat un total de 16 heteroplàsmies puntuals en posicions no sinònimes, representant una raó no-sinònim:sinònim de 1:2.2. Aquests resultats estan d'acord amb altres descrits a nivell poblacional (raó de 1:1.97) (Pereira et al. 2009). Pereira et al. (2009), reporta que els nivells més elevats de mutacions no sinònimes es troben en les regions ATP6 i ATP8 del DNAm i els més baixos en les regions del COXI, ND4 i ND5. Respecte això, en el present treball no es detecta la mateixa distribució, probablement degut al baix nombre de posicions no sinònimes analitzades. Així, caldria ampliar el nombre d'estudis d'heteroplàsmia de tot el genoma. Aquests mateixos autors mostren que els aminoàcids neutres V, I, A,

M i T manifesten les proporcions més elevades pel que fa les mutacions no sinònimes. En els nostres resultats, de les 16 posicions heteroplàsmiques no sinònimes que s'han detectat, 7 d'elles estan localitzades en el grup d'aquests aminoàcids; a més, totes impliquen un canvi aminoacídic amb una polaritat similar (neutre a neutre), suggerint que el nou residu aminoacídic podria seguir mantenint les interaccions amb els aminoàcids veïns per preservar l'estructura terciària de la proteïna.

Respecte dels tRNAs, una de les posicions més conservades on s'ha detectat heteroplàsmia, és a la posició 15908. Aquest canvi provoca una reducció en l'estabilitat de l'estructura secundària del tRNA de la treonina degut a una disminució en la mida d'un dels braços. Alguns estudis han descrit que certs polimorfismes de la població humana es localitzen en posicions altament conservades dels tRNAs (Kivisild et al. 2006). Tanmateix, Periera et al. (2009) i d'acord amb Kivisild et al. (2006), troben que el tRNA de la treonina és un dels que conté major nombre de polimorfismes. A més de l'heteroplàsmia puntal 15908, s'han detectat 3 posicions heteroplàsmiques més situades en altres tRNAs, totes ells localitzades en les braços dels tRNAs. Aquests resultats difereixen dels detectats a nivell poblacional, on es troba una raó, pel que fa a la localització en el tRNA, braç-bucle de 0.99 (Pereira et al. 2009), alhora que contrasta amb la funció principal dels braços dels tRNAs de mantenir l'estructura secundària.

S'han detectat un total d'onze heteroplàsmies puntuals localitzades en posicions estables de gens que codifiquen per proteïnes (3532, 6054, 7697, 7754, 8603, 9029, 11253, 13604,

14561, 14770 i 15046). Aquestes posicions tenen entre dos i zero *hits* a la filogènia, presenten freqüències nul·les o quasi nul·les a la població pel que fa a la variant minoritària, així com uns índex de conservació molt elevats. A més, d'aquelles posicions heteroplàsmiques localitzades en complexos mitocondrials pels quals ha estat descrita la seva estructura cristal·lina, la posició 7754, que implica una substitució Asp70Asn, té una implicació directa en l'estructura terciària del complex COXII, provocant la pèrdua de les interaccions amb els aminoàcids propers.

Dues d'aquestes posicions heteroplàsmiques estables (7679 i 11253) estan relacionades amb patologies mitocondrials. La posició heteroplàsmica 7697 i el conseqüent canvi aminoacídic (valina a isoleucina) ha estat reportat com un factor genètic indicatiu de successibilitat a cardiomiopatia hipertròfica (HCM) (Wei et al. 2009). Pel que fa a l'heteroplàsmia puntual localitzada a la posició 11253 (canvi aminoacídic isoleucina a treonina), s'ha relacionat directament amb neuropatia òptica hereditària de Leber (LHON) (Fauser et al. 2002; Leo-Kottler et al. 2002).

Recuperant l'anteriorment exposat pel que fa a l'excés de transicions en l'espectre mutacional de l'heteroplàsmia, sembla ser que les forces evolutives podrien estar actuant per disminuir aquests nivells a nivell poblacional. El més probable és que aquestes mutacions siguin finalment eliminades per deriva genètica o per selecció. De fet, les heteroplàsmies puntuals detectades en aquest treball en posicions estables, podrien tenir un gran impacte en la supervivència de la mitocòndria, suggerint que la selecció

purificadora deu estar actuant per prevenir la fixació de mutacions perjudicials en els individus.

Aquest és el primer estudi on s'analitza la freqüència i el patró de l'heteroplàsmia mitocondrial humana en individus sans. Tenint en compte l'elevada quantitat de dades que es presenta, unit a la poca informació prèvia disponible, aquest treball proporciona una nova perspectiva per a l'estudi de les malalties associades al DNAm, així com en treballs a nivell poblacional, evolutiu i forense.

5. CONCLUSIONS



CONCLUSIONS DE LA TESI

1. S'han dissenyat, validat i descrit per primera vegada un conjunt de *primers* que permeten amplificar i seqüenciar selectivament la totalitat del genoma mitocondrial. Aquesta metodologia pot ser utilitzada com a referència per al correcte disseny de *primers*.
2. La publicació del nou genoma humà de referència GRCh37 ha provocat el redisseny i validació d'una de les parelles de *primers* per poder seguir garantint l'amplificació selectiva de DNAm_t; posant de manifest la necessitat de realitzar una actualització tant de les bases de dades de NUMTs com dels *primers* dissenyats per amplificar selectivament DNAm_t.
3. S'ha generat, per primera vegada, una base de dades d'insercions nuclears d'origen mitocondrial basada en el nou esborrany del genoma humà GRCh37. Tenint en compte la quantitat d'informació aportada per a cada

inserció nuclear, la base de dades pot ser usada per al disseny d'estudis evolutius, filogenètics i epidemiològics.

4. És el primer treball en que es reporten les posicions no-identiques entre el DNAmT i els NUMTs. El coneixement de la distribució d'aquestes posicions és una eina útil per autenticar mutacions del DNAmT presentades en diferents tipus d'estudis, sobretot aquelles detectades en heteroplàsmia.
5. Utilitzant els estudis de càncer com a exemple, s'ha evidenciat l'aplicabilitat de la base de dades de NUMTs com una nova eina per validar *in silico* les mutacions de DNAmT descrites en diferents contextos. També es posa de manifest la necessitat d'estandarditzar protocols que evitin la co-amplificació entre DNAmT i DNAn, com per exemple el disseny de *primers* que es presenta en aquesta Tesi.
6. L'estudi de l'heteroplàsmia mitocondrial realitzat revela que un 62.37% de la població presenta heteroplàsmia mitocondrial (de longitud i/o puntual) i un 24.75% d'individus presenta heteroplàsmia puntual, posant de manifest l'elevada freqüència d'heteroplàsmia mitocondrial a nivell poblacional.
7. La comparació dels resultats obtinguts amb els descrits per Li et. al (2010) apunta que les dues metodologies utilitzades en la seqüenciació completa del DNAmT,

presenten una sensibilitat similar. A més, el present estudi demostra la possibilitat de detectar amb seguretat les heteroplàsmies puntuals amb un nivell d'un 5%.

8. La gran majoria de les heteroplàsmies puntuals tenen un origen germinal i només una petita fracció té un origen somàtic. Les heteroplàsmies d'origen somàtic semblen tenir una certa relació amb l'envelliment i/o la longevitat, ja que les presenten els individus d'edat avançada.
9. L'elevada freqüència d'heteroplàsmies d'origen germinal implica que els individus porten un *background* mutacional que augmentaria el risc o protegiria enfront a patologies relacionades amb disfunció mitocondrial.
10. La distribució de l'heteroplàsmia mitocondrial comprèn tot el genoma mitocondrial, localitzant-se tant en posicions definides com a *hotspot* com en posicions altament estables i conservades. Comparant el patró mutacional de l'heteroplàsmia amb el descrit a nivell poblacional, sembla haver-hi un excés d'heteroplàsmia puntual localitzada en posicions que presenten zero *hits* en la filogènia.
11. L'excés de transicions detectat en l'espectre mutacional de l'heteroplàsmia, en comparació amb el descrit a nivell poblacional, implica que determinades forces evolutives, com la deriva o la selecció, han hagut d'actuar perquè finalment siguin eliminades. En aquest context, les

heteroplàsmies puntuals localitzades en posicions estables podrien tenir un gran impacte en la supervivència de la pròpia mitocondria, suggerint que la selecció purificadora hauria d'estar actuant per prevenir la seva fixació en els individus.

12. Aquest és el primer treball on s'analitza la freqüència i el patró de l'heteroplàsmia mitocondrial humana en individus sans. Tenint en compte l'elevada quantitat de dades que es presenta, unit a la poca informació prèvia disponible, aquest treball proporciona una nova perspectiva per a l'estudi de les malalties associades al DNAm, així com en treballs a nivell poblacional, evolutiu i forense.

6. BIBLIOGRAFIA



- Abnet CC, Huppi K, Carrera A, Armistead D, McKenney K, Hu N, Tang ZZ, Taylor PR, Dawsey SM (2004) Control region mutations and the 'common deletion' are frequent in the mitochondrial DNA of patients with esophageal squamous cell carcinoma. *BMC Cancer* 4:30
- Afonso Costa H, Carvalho M, Lopes V, Balsa F, Bento AM, Serra A, Andrade L, Anjos MJ, Vide MC, Pantoja S, Vieira DN, Corte-Real F (2010) Mitochondrial DNA sequence analysis of a native Bolivian population. *J Forensic Leg Med* 17:247
- Aikhionbare FO, Mehrabi S, Kumaresan K, Zavareh M, Olatinwo M, Odunsi K, Partridge E (2007) Mitochondrial DNA sequence variants in epithelial ovarian tumor subtypes and stages. *J Carcinog* 6:1
- Alston CL, Lowe J, Turnbull DM, Maddison P, Taylor RW (2010) A novel mitochondrial tRNAGlu (MTTE) gene mutation causing chronic progressive external ophthalmoplegia at low levels of heteroplasmy in muscle. *J Neurol Sci* 298:140
- Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ (1990) Basic local alignment search tool. *J Mol Biol* 215:403
- Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, Miller W, Lipman DJ (1997) Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. *Nucleic Acids Res* 25:3389
- Alvarez L, Santos C, Ramos A, Pratdesaba R, Francalacci P, Aluja MP (2010) Mitochondrial DNA patterns in the Iberian Northern plateau: population dynamics and substructure of the Zamora province. *Am J Phys Anthropol* 142:531
- Allegra E, Garozzo A, Lombardo N, De Clemente M, Carey TE (2006) Mutations and polymorphisms in mitochondrial DNA in head and neck cancer cell lines. *Acta Otorhinolaryngol Ital* 26:185
- Ambrosini-Spaltro A, Morandi L, Spagnolo DV, Cavazza A, Brisigotti M, Damiani S, Jain S, Eusebi V (2010) Nasal seromucinous hamartoma (microglandular adenosis of the nose): a morphological and molecular study of five cases. *Virchows Arch* 457:727
- Anderson S, Bankier AT, Barrell BG, de Bruijn MH, Coulson AR, Drouin J, Eperon IC, Nierlich DP, Roe BA, Sanger F, Schreier PH, Smith AJ, Staden R, Young IG (1981)

- Sequence and organization of the human mitochondrial genome. *Nature* 290:457
- Anderson S, de Bruijn MH, Coulson AR, Eperon IC, Sanger F, Young IG (1982) Complete sequence of bovine mitochondrial DNA. Conserved features of the mammalian mitochondrial genome. *J Mol Biol* 156:683
- Andrews RM, Kubacka I, Chinnery PF, Lightowlers RN, Turnbull DM, Howell N (1999) Reanalysis and revision of the Cambridge reference sequence for human mitochondrial DNA. *Nat Genet* 23:147
- Ansorge WJ (2009) Next-generation DNA sequencing techniques. *N Biotechnol* 25:195
- Arctander P (1999) Mitochondrial recombination? *Science* 284:2090
- Avise JC (1991) Ten unorthodox perspectives on evolution prompted by comparative population genetic findings on mitochondrial DNA. *Annu Rev Genet* 25:45
- Avise JC, Arnold J, Ball RM, Bermingham E, Lamb T, Neigel JE, Reeb CA, Saunders NC (1987) Intraspecific phylogeography - the mitochondrial DNA bridge between population genetics and systematics. *Ann Rev Ecol Syst* 18:489
- Awadalla P, Eyre-Walker A, Smith JM (1999) Linkage disequilibrium and recombination in hominid mitochondrial DNA. *Science* 286:2524
- Awadalla P, Eyre-Walker A, Smith JM (2000) Questioning evidence for recombination in human mitochondrial DNA. *Science* 288:1931a
- Bai RK, Wong LJ (2004) Detection and quantification of heteroplasmic mutant mitochondrial DNA by real-time amplification refractory mutation system quantitative PCR analysis: a single-step approach. *Clin Chem* 50:996
- Ballana E, Govea N, de Cid R, Garcia C, Arribas C, Rosell J, Estivill X (2008) Detection of unrecognized low-level mtDNA heteroplasmy may explain the variable phenotypic expressivity of apparently homoplasmic mtDNA mutations. *Hum Mutat* 29:248
- Ballard JW (2000) Comparative genomics of mitochondrial DNA in members of the *Drosophila melanogaster* subgroup. *J Mol Evol* 51:48
- Ballard JW, Kreitman M (1994) Unraveling selection in the mitochondrial genome of *Drosophila*. *Genetics* 138:757

- Bendall KE, Macaulay VA, Baker JR, Sykes BC (1996) Heteroplasmic point mutations in the human mtDNA control region. *Am J Hum Genet* 59:1276
- Bendall KE, Macaulay VA, Sykes BC (1997) Variable levels of a heteroplasmic point mutation in individual hair roots. *Am J Hum Genet* 61:1303
- Bensasson D, Zhang D, Hartl DL, Hewitt GM (2001) Mitochondrial pseudogenes: evolution's misplaced witnesses. *Trends Ecol Evol* 16:314
- Betts J, Jaros E, Perry RH, Schaefer AM, Taylor RW, Abdel-All Z, Lightowlers RN, Turnbull DM (2006) Molecular neuropathology of MELAS: level of heteroplasmy in individual neurones and evidence of extensive vascular involvement. *Neuropathol Appl Neurobiol* 32:359
- Bi R, Zhang AM, Yu D, Chen D, Yao YG (2010) Screening the three LHON primary mutations in the general Chinese population by using an optimized multiplex allele-specific PCR. *Clin Chim Acta* 411:1671
- Bidooki S, Jackson MJ, Johnson MA, Chrzanowska-Lightowlers ZM, Taylor RW, Venables G, Lightowlers RN, Turnbull DM, Bindoff LA (2004) Sporadic mitochondrial myopathy due to a new mutation in the mitochondrial tRNASer(UCN) gene. *Neuromuscul Disord* 14:417
- Biggin A, Henke R, Bennetts B, Thorburn DR, Christodoulou J (2005) Mutation screening of the mitochondrial genome using denaturing high-performance liquid chromatography. *Mol Genet Metab* 84:61
- Blouin MS (2000) Neutrality tests on mtDNA: unusual results from nematodes. *J Hered* 91:156
- Brandstatter A, Parson W (2003) Mitochondrial DNA heteroplasmy or artefacts--a matter of the amplification strategy? *Int J Legal Med* 117:180
- Briggs AW, Good JM, Green RE, Krause J, Maricic T, Stenzel U, Lalueza-Fox C, Rudan P, Brajkovic D, Kucan Z, Gusic I, Schmitz R, Doronichev VB, Golovanova LV, de la Rasilla M, Fordea J, Rosas A, Paabo S (2009) Targeted retrieval and analysis of five Neandertal mtDNA genomes. *Science* 325:318
- Brinckmann A, Ruther K, Williamson K, Lorenz B, Lucke B, Nurnberg P, Trijbels F, Janssen A, Schuelke M (2007) De novo double mutation in PAX6 and mtDNA tRNA(Lys)

- associated with atypical aniridia and mitochondrial disease. *J Mol Med (Berl)* 85:163
- Bromham L, Eyre-Walker A, Smith NH, Smith JM (2003) Mitochondrial Steve: paternal inheritance of mitochondria in humans. *Trends Ecol Evol* 18:2
- Brown DT, Samuels DC, Michael EM, Turnbull DM, Chinnery PF (2001) Random genetic drift determines the level of mutant mtDNA in human primary oocytes. *Am J Hum Genet* 68:533
- Brown WM (1981) Mechanisms of evolution in animal mitochondrial DNA. *Ann N Y Acad Sci* 361:119
- Brown WM (1985) The mitochondrial genome of animals. In: R.J. eM (ed) *Molecular evolutionary genetics*, (Plenum, New York), pp. 95-130
- Brown WM, Prager EM, Wang A, Wilson AC (1982) Mitochondrial DNA sequences of primates: tempo and mode of evolution. *J Mol Evol* 18:225
- Calloway CD, Reynolds RL, Herrin GL, Jr., Anderson WW (2000) The frequency of heteroplasmy in the HVII region of mtDNA differs across tissue types and increases with age. *Am J Hum Genet* 66:1384
- Cann RL, Brown WM, Wilson AC (1982) Evolution of human mitochondrial DNA: a preliminary report. *Prog Clin Biol Res* 103 Pt A:157
- Cann RL, Brown WM, Wilson AC (1984) Polymorphic sites and the mechanism of evolution in human mitochondrial DNA. *Genetics* 106:479
- Cann RL, Stoneking M, Wilson AC (1987) Mitochondrial DNA and human evolution. *Nature* 325:31
- Canter JA, Eshaghian A, Fessel J, Summar ML, Roberts LJ, Morrow JD, Sligh JE, Haines JL (2005) Degree of heteroplasmy reflects oxidant damage in a large family with the mitochondrial DNA A8344G mutation. *Free Radic Biol Med* 38:678
- Cao Y, Ma Y, Zhang Y, Li Y, Fang F, Wang S, Bu D, Xu Y, Pei P, Li L, Xiao Y, Wu H, Yang Y, Zou L, Qi Y (2010) Detection of eight frequently encountered point mutations in mitochondria in Chinese patients suggestive of mitochondrial encephalomyopathies. *Mitochondrion* 10:330
- Cardaioli E, Da Pozzo P, Malfatti E, Gallus GN, Rubegni A, Malandrini A, Gaudiano C, Guidi L, Serni G, Berti G, Dotti MT, Federico A (2008) Chronic progressive external

- ophthalmoplegia: a new heteroplasmic tRNA(Leu(CUN)) mutation of mitochondrial DNA. *J Neurol Sci* 272:106
- Cassandrini D, Calevo MG, Tessa A, Manfredi G, Fattori F, Meschini MC, Carozzo R, Tonoli E, Pedemonte M, Minetti C, Zara F, Santorelli FM, Bruno C (2006) A new method for analysis of mitochondrial DNA point mutations and assess levels of heteroplasmy. *Biochem Biophys Res Commun* 342:387
- Clark AG, Lyckegaard EM (1988) Natural selection with nuclear and cytoplasmic transmission. III. Joint analysis of segregation and mtDNA in *Drosophila melanogaster*. *Genetics* 118:471
- Claros MG (1995) MitoProt, a Macintosh application for studying mitochondrial proteins. *Comput Appl Biosci* 11:441
- Claros MG, Perea J, Shu Y, Samatey FA, Popot JL, Jacq C (1995) Limitations to in vivo import of hydrophobic proteins into yeast mitochondria. The case of a cytoplasmically synthesized apocytochrome b. *Eur J Biochem* 228:762
- Clayton DA (1996) Mitochondrial DNA gets the drift. *Nat Genet* 14:123
- Cortopassi GA, Shibata D, Soong NW, Arnheim N (1992) A pattern of accumulation of a somatic deletion of mitochondrial DNA in aging human tissues. *Proc Natl Acad Sci U S A* 89:7370
- Coskun PE, Beal MF, Wallace DC (2004) Alzheimer's brains harbor somatic mtDNA control-region mutations that suppress mitochondrial transcription and replication. *PNAS* 101:10726
- Chen H, Vermulst M, Wang YE, Chomyn A, Prolla TA, McCaffery JM, Chan DC (2010) Mitochondrial fusion is required for mtDNA stability in skeletal muscle and tolerance of mtDNA mutations. *Cell* 141:280
- Chinnery PF (2002) Inheritance of mitochondrial disorders. *Mitochondrion* 2:149
- Chong MD, Calloway CD, Klein SB, Orrego C, Buoncristiani MR (2005) Optimization of a duplex amplification and sequencing strategy for the HVI/HVII regions of human mitochondrial DNA for forensic casework. *Forensic Sci Int* 154:137
- D'Aurelio M, Vives-Bauza C, Davidson MM, Manfredi G (2010) Mitochondrial DNA background modifies the bioenergetics of NARP/MILS ATP6 mutant cells. *Hum Mol Genet* 19:374
- Da Costa CK, Kiyomoto BH, Schmidt B, Oliveira AS, Gabbai AA, Tengan CH (2007) Age-related mitochondrial DNA point

- mutations in patients with mitochondrial myopathy. *J Neurol Sci* 263:139
- Da Cruz S, Parone PA, Martinou JC (2005) Building the mitochondrial proteome. *Expert Rev Proteomics* 2:541
- De Camargo MA, Paneto GG, de Mello AC, Martins JA, Barcellos W, Cicarelli RM (2011) No relationship found between point heteroplasmy in mitochondrial DNA control region and age range, sex and haplogroup in human hairs. *Mol Biol Rep* 38:1219
- Debray FG, Lambert M, Lortie A, Vanasse M, Mitchell GA (2007) Long-term outcome of Leigh syndrome caused by the NARP-T8993C mtDNA mutation. *Am J Med Genet A* 143A:2046
- DiMauro S, Schon EA (2008) Mitochondrial disorders in the nervous system. *Annu Rev Neurosci* 31:91
- Dobrowolski SF, Hendrickx AT, Van den Bosch BJ, Smeets HJ, Gray J, Miller T, Sears M (2009) Identifying sequence variants in the human mitochondrial genome using high-resolution melt (HRM) profiling. *Hum Mutat* 30:891
- Elson JL, Andrews RM, Chinnery PF, Lightowlers RN, Turnbull DM, Howell N (2001) Analysis of European mtDNAs for recombination. *Am J Hum Genet* 68:145
- Elson JL, Turnbull DM, Howell N (2004) Comparative genomics and the evolution of human mitochondrial DNA: assessing the effects of selection. *Am J Hum Genet* 74:229
- Excoffier L (1990) Evolution of human mitochondrial DNA: evidence for departure from a pure neutral model of populations at equilibrium. *J Mol Evol* 30:125
- Excoffier L, Yang Z (1999) Substitution rate variation among sites in mitochondrial hypervariable region I of humans and chimpanzees. *Mol Biol Evol* 16:1357
- Eyre-Walker A, Smith NH, Smith JM (1999) How clonal are human mitochondria? *Proc Biol Sci* 266:477
- Fausser S, Lubrichs J, Besch D, Leo-Kottler B (2002) Sequence analysis of the complete mitochondrial genome in patients with Leber's hereditary optic neuropathy lacking the three most common pathogenic DNA mutations. *Biochem Biophys Res Commun* 295:342
- Fendt L, Niederstatter H, Huber G, Zelger B, Dunser M, Seifarth C, Rock A, Schafer G, Klocker H, Parson W (2011) Accumulation of mutations over the entire mitochondrial

- genome of breast cancer cells obtained by tissue microdissection. *Breast Cancer Res Treat* 128:327
- Filosto M, Mancuso M, Vives-Bauza C, Vila MR, Shanske S, Hirano M, Andreu AL, DiMauro S (2003) Lack of paternal inheritance of muscle mitochondrial DNA in sporadic mitochondrial myopathies. *Ann Neurol* 54:524
- Fliss MS, Usadel H, Caballero OL, Wu L, Buta MR, Eleff SM, Jen J, Sidransky D (2000) Facile detection of mitochondrial DNA mutations in tumors and bodily fluids. *Science* 287:2017
- Forner F, Foster LJ, Campanaro S, Valle G, Mann M (2006) Quantitative proteomic comparison of rat mitochondria from muscle, heart, and liver. *Mol Cell Proteomics* 5:608
- Fos M, Dominguez MA, Latorre A, Moya A (1990) Mitochondrial DNA evolution in experimental populations of *Drosophila subobscura*. *Proc Natl Acad Sci U S A* 87:4198
- Frederiksen AL, Jeppesen TD, Vissing J, Schwartz M, Kyvik KO, Schmitz O, Poulsen PL, Andersen PH (2009) High prevalence of impaired glucose homeostasis and myopathy in asymptomatic and oligosymptomatic 3243A>G mitochondrial DNA mutation-positive subjects. *J Clin Endocrinol Metab* 94:2872
- Gabaldon T, Huynen MA (2004) Shaping the mitochondrial proteome. *Biochim Biophys Acta* 1659:212
- Gambello MJ, Bai RK, Chen TJ, Dimachkie M, Wong LJ (2006) Exercise intolerance associated with a novel 8300T > C mutation in mitochondrial transfer RNAlys. *Muscle Nerve* 34:437
- Garcia-Martinez J, Castro JA, Ramon M, Latorre A, Moya A (1998) Mitochondrial DNA haplotype frequencies in natural and experimental populations of *Drosophila subobscura*. *Genetics* 149:1377
- Gasparre G, Porcelli AM, Bonora E, Pennisi LF, Toller M, Iommarini L, Ghelli A, Moretti M, Betts CM, Martinelli GN, Ceroni AR, Curcio F, Carelli V, Rugolo M, Tallini G, Romeo G (2007) Disruptive mitochondrial DNA mutations in complex I subunits are markers of oncocytic phenotype in thyroid tumors. *Proc Natl Acad Sci U S A* 104:9001
- Genasetti A, Valentino ML, Carelli V, Vigetti D, Viola M, Karousou EG, Melzi d'Eril GV, De Luca G, Passi A, Pallotti F (2007) Assessing heteroplasmic load in Leber's hereditary optic neuropathy mutation 3460G->A/MT-ND1 with a real-time PCR quantitative approach. *J Mol Diagn* 9:538

- Gigarel N, Ray PF, Burlet P, Frydman N, Royer G, Lebon S, Bonnefont JP, Frydman R, Munnich A, Steffann J (2005) Single cell quantification of the 8993T>G NARP mitochondrial DNA mutation by fluorescent PCR. *Mol Genet Metab* 84:289
- Giles RE, Blanc H, Cann HM, Wallace DC (1980) Maternal inheritance of human mitochondrial DNA. *Proc Natl Acad Sci U S A* 77:6715
- Gilkerson RW, Schon EA, Hernandez E, Davidson MM (2008) Mitochondrial nucleoids maintain genetic autonomy but allow for functional complementation. *J Cell Biol* 181:1117
- Goios A, Prieto L, Amorim A, Pereira L (2008) Specificity of mtDNA-directed PCR-influence of NUClear MTDNA insertion (NUMT) contamination in routine samples and techniques. *Int J Legal Med* 122:341
- Goto H, Dickins B, Afgan E, Paul IM, Taylor J, Makova KD, Nekrutenko A (2011) Dynamics of mitochondrial heteroplasmy in three families investigated via a repeatable re-sequencing study. *Genome Biol* 12:R59
- Gray MW (1992) The endosymbiont hypothesis revisited. *Int Rev Cytol* 141:233
- Gray MW, Burger G, Lang BF (1999) Mitochondrial evolution. *Science* 283:1476
- Gray MW, Doolittle WF (1982) Has the endosymbiont hypothesis been proven? *Microbiol Rev* 46:1
- Grzybowski T (2000) Extremely high levels of human mitochondrial DNA heteroplasmy in single hair roots. *Electrophoresis* 21:548
- Grzybowski T, Malyarchuk BA, Czarny J, Miscicka-Sliwka D, Kotzbach R (2003) High levels of mitochondrial DNA heteroplasmy in single hair roots: reanalysis and revision. *Electrophoresis* 24:1159
- Gyllensten U, Wharton D, Josefsson A, Wilson AC (1991) Paternal inheritance of mitochondrial DNA in mice. *Nature* 352:255
- Habano W, Sugai T, Yoshida T, Nakamura S (1999) Mitochondrial gene mutation, but not large-scale deletion, is a feature of colorectal carcinomas with mitochondrial microsatellite instability. *Int J Cancer* 83:625
- Hagelberg E (2003) Recombination or mutation rate heterogeneity? Implications for Mitochondrial Eve. *Trends Genet* 19:84
- Hagelberg E, Goldman N, Lio P, Whelan S, Schiefenovel W, Clegg JB, Bowden DK (1999) Evidence for mitochondrial DNA

- recombination in a human population of island Melanesia. *Proc Biol Sci* 266:485
- Hagelberg E, Goldman N, Lio P, Whelan S, Schiefenhover W, Clegg JB, Bowden DK (2000) Evidence for mitochondrial DNA recombination in a human population of island Melanesia: correction. *Proc Biological Sci* 267:1595
- Harrison RG (1989) Animal mitochondrial DNA as a genetic marker in population and evolutionary biology. *Trends Ecol Evol* 4:6
- Hazkani-Covo E (2009) Mitochondrial insertions into primate nuclear genomes suggest the use of numts as a tool for phylogeny. *Mol Biol Evol* 26:2175
- Hazkani-Covo E, Covo S (2008) Numt-mediated double-strand break repair mitigates deletions during primate genome evolution. *PLoS Genet* 4:e1000237
- Hazkani-Covo E, Graur D (2007) A Comparative Analysis of numt Evolution in Human and Chimpanzee. *Mol. Biol. Evol.* 24:13
- Hazkani-Covo E, Sorek R, Graur D (2003) Evolutionary dynamics of large numts in the human genome: rarity of independent insertions and abundance of post-insertion duplications. *J Mol Evol* 56:169
- Hazkani-Covo E, Zeller RM, Martin W (2010) Molecular poltergeists: mitochondrial DNA copies (numts) in sequenced nuclear genomes. *PLoS Genet* 6:e1000834
- He Y, Wu J, Dressman DC, Iacobuzio-Donahue C, Markowitz SD, Velculescu VE, Diaz LA, Jr., Kinzler KW, Vogelstein B, Papadopoulos N (2010) Heteroplasmic mitochondrial DNA mutations in normal and tumour cells. *Nature* 464:610
- Hervouet E, Godinot C (2006) Mitochondrial disorders in renal tumors. *Mitochondrion* 6:105
- Heyer E, Zietkiewicz E, Rochowski A, Yotova V, Puymirat J, Labuda D (2001) Phylogenetic and familial estimates of mitochondrial substitution rates: study of control region mutations in deep-rooting pedigrees. *Am J Hum Genet* 69:1113
- Hirano M, Shtilbans A, Mayeux R, Davidson MM, DiMauro S, Knowles JA, Schon EA (1997) Apparent mtDNA heteroplasmy in Alzheimer's disease patients and in normals due to PCR amplification of nucleus-embedded mtDNA pseudogenes. *Proc Natl Acad Sci U S A* 94:14894

- Hogeboon GH, Schneider WC, Palade GE (1948) Cytochemical studies of mammalian tissues; isolation of intact mitochondria from rat liver; some biochemical properties of mitochondria and submicroscopic particulate material. *J Biol Chem* 172:619
- Holm L, Sander C (1992) Evaluation of protein models by atomic solvation preference. *J Mol Biol* 225:93
- Holt IJ, Harding AE, Morgan-Hughes JA (1988) Deletions of muscle mitochondrial DNA in patients with mitochondrial myopathies. *Nature* 331:717
- Howell N, Ghosh SS, Fahy E, Bindoff LA (2000) Longitudinal analysis of the segregation of mtDNA mutations in heteroplasmic individuals. *J Neurol Sci* 172:1
- Howell N, Halvorson S, Kubacka I, McCullough DA, Bindoff LA, Turnbull DM (1992) Mitochondrial gene segregation in mammals: is the bottleneck always narrow? *Hum Genet* 90:117
- Howell N, Mackey D (1997) mtDNA mutation rates - No need to panic - Reply. *Am J Hum Genet* 61:986
- Howell N, Smejkal CB (2000) Persistent heteroplasmy of a mutation in the human mtDNA control region: hypermutation as an apparent consequence of simple-repeat expansion/contraction. *Am J Hum Genet* 66:1589
- Howell N, Smejkal CB, Mackey DA, Chinnery PF, Turnbull DM, Herrnstadt C (2003) The pedigree rate of sequence divergence in the human mitochondrial genome: there is a difference between phylogenetic and pedigree rates. *Am J Hum Genet* 72:659
- Hutter CM, Rand DM (1995) Competition between mitochondrial haplotypes in distinct nuclear genetic environments: *Drosophila pseudoobscura* vs. *D. persimilis*. *Genetics* 140:537
- Ingman M, Kaessmann H, Paabo S, Gyllensten U (2000) Mitochondrial genome variation and the origin of modern humans. *Nature* 408:708
- Irwin JA, Saunier JL, Niederstatter H, Strouss KM, Sturk KA, Diegoli TM, Brandstatter A, Parson W, Parsons TJ (2009) Investigation of heteroplasmy in the human mitochondrial DNA control region: a synthesis of observations from more than 5000 global population samples. *J Mol Evol* 68:516
- Iwata S, Lee JW, Okada K, Lee JK, Iwata M, Rasmussen B, Link TA, Ramaswamy S, Jap BK (1998) Complete structure of

- the 11-subunit bovine mitochondrial cytochrome bc1 complex. *Science* 281:64
- Jacobs HT, Hutchin TP, Kappi T, Gillies G, Minkkinen K, Walker J, Thompson K, Rovio AT, Carella M, Melchionda S, Zelante L, Gasparini P, Pyykko I, Shah ZH, Zeviani M, Mueller RF (2005) Mitochondrial DNA mutations in patients with postlingual, nonsyndromic hearing impairment. *Eur J Hum Genet* 13:26
- Jacobs L, Gerards M, Chinnery P, Dumoulin J, de Coo I, Geraedts J, Smeets H (2007) mtDNA point mutations are present at various levels of heteroplasmy in human oocytes. *Mol Hum Reprod* 13:149
- Jakupciak JP, Maragh S, Markowitz ME, Greenberg AK, Hoque MO, Maitra A, Barker PE, Wagner PD, Rom WN, Srivastava S, Sidransky D, O'Connell CD (2008) Performance of mitochondrial DNA mutations detecting early stage cancer. *BMC Cancer* 8:285
- Jansen RP, de Boer K (1998) The bottleneck: mitochondrial imperatives in oogenesis and ovarian follicular fate. *Mol Cell Endocrinol* 145:81
- Jazin E, Soodyall H, Jalonen P, Lindholm E, Stoneking M, Gyllensten U (1998) Mitochondrial mutation rate revisited: hot spots and polymorphism. *Nat Genet* 18:109
- Jazin EE, Cavelier L, Eriksson I, Orelund L, Gyllensten U (1996) Human brain contains high levels of heteroplasmy in the noncoding regions of mitochondrial DNA. *Proc Natl Acad Sci U S A* 93:12382
- Jensen-Seaman MI, Wildschutte JH, Soto-Calderón ID, Anthony NM (2009) A Comparative Approach Shows Differences in Patterns of Numt Insertion During Hominoid Evolution. *J Mol Evol* 68
- Jin X, Zhang J, Gao Y, Ding K, Wang N, Zhou D, Jen J, Cheng S (2007) Relationship between mitochondrial DNA mutations and clinical characteristics in human lung cancer. *Mitochondrion* 7:347
- Johnson DT, Harris RA, Blair PV, Balaban RS (2007) Functional consequences of mitochondrial proteome heterogeneity. *Am J Physiol Cell Physiol* 292:C698
- Jones JB, Song JJ, Hempfen PM, Parmigiani G, Hruban RH, Kern SE (2001) Detection of mitochondrial DNA mutations in pancreatic cancer offers a "mass"-ive advantage over detection of nuclear DNA mutations. *Cancer Res* 61:1299

- Jorde LB, Bamshad M (2000) Questioning evidence for recombination in human mitochondrial DNA. *Science* 288:1931
- Kaare M, Gotz A, Ulander VM, Ariansen S, Kaaja R, Suomalainen A, Aittomaki K (2009) Do mitochondrial mutations cause recurrent miscarriage? *Mol Hum Reprod* 15:295
- Kambhampati S, Rai KS, Verleye DM (1992) Frequencies of mitochondrial DNA haplotypes in laboratory cage populations of the mosquito, *Aedes albopictus*. *Genetics* 132:205
- Kaneda H, Hayashi J, Takahama S, Taya C, Lindahl KF, Yonekawa H (1995) Elimination of paternal mitochondrial DNA in intraspecific crosses during early mouse embryogenesis. *Proc Natl Acad Sci U S A* 92:4542
- Kaplanova V, Zeman J, Hansikova H, Cerna L, Houstkova H, Misovicova N, Houstek J (2004) Segregation pattern and biochemical effect of the G3460A mtDNA mutation in 27 members of LHON family. *J Neurol Sci* 223:149
- Karppa M, Mahjneh I, Karttunen A, Tolonen U, Majamaa K (2004) Muscle computed tomography patterns in patients with the mitochondrial DNA mutation 3243A>G. *J Neurol* 251:556
- Kassauei K, Habbe N, Mullendore ME, Karikari CA, Maitra A, Feldmann G (2006) Mitochondrial DNA mutations in pancreatic cancer. *Int J Gastrointest Cancer* 37:57
- Kilpatrick ST, Rand DM (1995) Conditional hitchhiking of mitochondrial DNA: frequency shifts of *Drosophila melanogaster* mtDNA variants depend on nuclear genetic background. *Genetics* 141:1113
- Kirches E, Michael M, Warich-Kirches M, Schneider T, Weis S, Krause G, Mawrin C, Dietzmann K (2001) Heterogeneous tissue distribution of a mitochondrial DNA polymorphism in heteroplasmic subjects without mitochondrial disorders. *J Med Genet* 38:312
- Kivisild T, Shen P, Wall DP, Do B, Sung R, Davis K, Passarino G, Underhill PA, Scharfe C, Torroni A, Scozzari R, Modiano D, Coppa A, de Knijff P, Feldman M, Cavalli-Sforza LL, Oefner PJ (2006) The role of selection in the evolution of human mitochondrial genomes. *Genetics* 172:373
- Kleine T, Maier UG, Leister D (2009) DNA transfer from organelles to the nucleus: the idiosyncratic genetics of endosymbiosis. *Annu Rev Plant Biol* 60:115

- Kloss-Brandstatter A, Schafer G, Erhart G, Huttenhofer A, Coassin S, Seifarth C, Summerer M, Bektic J, Klocker H, Kronenberg F (2010) Somatic mutations throughout the entire mitochondrial genome are associated with elevated PSA levels in prostate cancer patients. *Am J Hum Genet* 87:802
- Kondo R, Satta Y, Matsuura ET, Ishiwa H, Takahata N, Chigusa SI (1990) Incomplete maternal transmission of mitochondrial DNA in *Drosophila*. *Genetics* 126:657
- Krakauer DC, Mira A (1999) Mitochondria and germ-cell death. *Nature* 400:125
- Kraytsberg Y, Schwartz M, Brown TA, Ebraldise K, Kunz WS, Clayton DA, Vissing J, Khrapko K (2004) Recombination of human mitochondrial DNA. *Science* 304:981
- Kumar S, Hedrick P, Dowling T, Stoneking M (2000) Questioning evidence for recombination in human mitochondrial DNA. *Science* 288:1931
- Kvist L, Martens J, Nazarenko AA, Orell M (2003) Paternal leakage of mitochondrial DNA in the great tit (*Parus major*). *Mol Biol Evol* 20:243
- Laloi-Michelin M, Meas T, Ambonville C, Bellanne-Chantelot C, Beaufils S, Massin P, Vialettes B, Gin H, Timsit J, Bauduceau B, Bernard L, Bertin E, Blickle JF, Cahen-Varsaux J, Cailleba A, Casanova S, Cathebras P, Charpentier G, Chedin P, Crea T, Delemer B, Dubois-Laforgue D, Duchemin F, Ducluzeau PH, Bouhanick B, Dusselier L, Gabreau T, Grimaldi A, Guerci B, Jacquin V, Kaloustian E, Larger E, Leclaire-Collet A, Lorenzini F, Louis J, Mausset J, Murat A, Nadler-Fluteau S, Olivier F, Paquis-Flucklinger V, Paris-Bockel D, Raynaud I, Reznik Y, Riveline JP, Schneebeli S, Sonnet E, Sola-Gazagnes A, Thomas JL, Trabulsi B, Virally M, Guillausseau PJ (2009) The clinical variability of maternally inherited diabetes and deafness is associated with the degree of heteroplasmy in blood leukocytes. *J Clin Endocrinol Metab* 94:3025
- Lascaro D, Castellana S, Gasparre G, Romeo G, Saccone C, Attimonelli M (2008) The RHNumtS compilation: features and bioinformatics approaches to locate and quantify Human NumtS. *BMC Genomics* 9:267
- Lehninger (1965) *The Mitochondrion — Molecular Basis of Structure and Function*. W. A. Benjamin, New York

- Leister D (2005) Origin, evolution and genetic effects of nuclear insertions of organelle DNA. *Trends Genet* 21:655
- Leo-Kottler B, Lubrichs J, Besch D, Christ-Adler M, Fauser S (2002) Leber's hereditary optic neuropathy: clinical and molecular genetic results in a patient with a point mutation at np T11253C (isoleucine to threonine) in the ND4 gene and spontaneous recovery. *Graefes Arch Clin Exp Ophthalmol* 240:758
- Leshinsky-Silver E, Lev D, Tzofi-Berman Z, Cohen S, Saada A, Yanoov-Sharav M, Gilad E, Lerman-Sagie T (2005) Fulminant neurological deterioration in a neonate with Leigh syndrome due to a maternally transmitted missense mutation in the mitochondrial ND3 gene. *Biochem Biophys Res Commun* 334:582
- Li M, Schonberg A, Schaefer M, Schroeder R, Nasidze I, Stoneking M (2010) Detecting heteroplasmy from high-throughput sequencing of complete human mitochondrial DNA genomes. *Am J Hum Genet* 87:237
- Li R, Ishikawa K, Deng JH, Heman-Ackah S, Tamagawa Y, Yang L, Bai Y, Ichimura K, Guan MX (2005) Maternally inherited nonsyndromic hearing loss is associated with the T7511C mutation in the mitochondrial tRNASerUCN gene in a Japanese family. *Biochem Biophys Res Commun* 328:32
- Lièvre A, Chapusot C, Bouvier AM, Zinzindohoue F, Piard F, Roignot P, Arnould L, Beaune P, Faivre J, Laurent-Puig P (2005) Clinical value of mitochondrial mutations in colorectal cancer. *J Clin Oncol* 23:3517
- Lightowlers RN, Chinnery PF, Turnbull DM, Howell N (1997) Mammalian mitochondrial genetics: heredity, heteroplasmy and disease. *Trends Genet* 13:450
- Lindberg C, Moslemi AR, Oldfors A (2008) MELAS syndrome in a patient with a point mutation in MTT51. *Acta Neurol Scand* 117:128
- Liu VW, Shi HH, Cheung AN, Chiu PM, Leung TW, Nagley P, Wong LC, Ngan HY (2001) High incidence of somatic mitochondrial DNA mutations in human ovarian carcinomas. *Cancer Res* 61:5998
- Lo MC, Lee HM, Lin MW, Tzen CY (2005) Analysis of heteroplasmy in hypervariable region II of mitochondrial DNA in maternally related individuals. *Ann N Y Acad Sci* 1042:130

- Lorenc A, Bryk J, Golik P, Kupryjanczyk J, Ostrowski J, Pronicki M, Semczuk A, Szolkowska M, Bartnik E (2003) Homoplasmic MELAS A3243G mtDNA mutation in a colon cancer sample. *Mitochondrion* 3:119
- Lu SY, Nishio S, Tsukada K, Oguchi T, Kobayashi K, Abe S, Usami S (2009) Factors that affect hearing level in individuals with the mitochondrial 1555A.G mutation. *Clin Genet* 75:480
- Luthy R, Bowie JU, Eisenberg D (1992) Assessment of protein models with three-dimensional profiles. *Nature* 356:83
- Lutz-Bonengel S, Sanger T, Parson W, Muller H, Ellwart JW, Follo M, Bonengel B, Niederstatter H, Heinrich M, Schmidt U (2008) Single lymphocytes from two healthy individuals with mitochondrial point heteroplasmy are mainly homoplasmic. *Int J Legal Med* 122:189
- Macaulay V, Richards M, Sykes B (1999) Mitochondrial DNA recombination--no need to panic. *Proc Biol Sci* 266:2037
- Macaulay VA, Richards MB, Forster P, Bendall KE, Watson E, Sykes B, Bandelt HJ (1997) mtDNA mutation rates--no need to panic. *Am J Hum Genet* 61:983
- MacRae AF, Anderson WW (1988) Evidence for non-neutrality of mitochondrial DNA haplotypes in *Drosophila pseudoobscura*. *Genetics* 120:485
- Manfredi G, Thyagarajan D, Papadopoulou LC, Pallotti F, Schon EA (1997) The fate of human sperm-derived mtDNA in somatic cells. *Am J Hum Genet* 61:953
- Marchington D, Malik S, Banerjee A, Turner K, Samuels D, Macaulay V, Oakeshott P, Fratter C, Kennedy S, Poulton J (2011) Information for genetic management of mtDNA disease: sampling pathogenic mtDNA mutants in the human germline and in placenta. *J Med Genet* 47:257
- Marchington DR, Macaulay V, Hartshorne GM, Barlow D, Poulton J (1998) Evidence from human oocytes for a genetic bottleneck in an mtDNA disease. *Am J Hum Genet* 63:769
- Margulis L (1981) *Symbiosis in Cell Evolution: Life and its Environment on the Early Earth*. San Francisco: W. H. Freeman and Co.
- Maxam AM, Gilbert W (1977) A new method for sequencing DNA. *PNAS* 74:560
- Meierhofer D, Mayr JA, Ebner S, Sperl W, Kofler B (2005) Rapid screening of the entire mitochondrial DNA for low-level heteroplasmic mutations. *Mitochondrion* 5:282

- Meierhofer D, Mayr JA, Fink K, Schmeller N, Kofler B, Sperl W (2006) Mitochondrial DNA mutations in renal cell carcinomas revealed no general impact on energy metabolism. *Br J Cancer* 94:268
- Melo F, Feytmans E (1998) Assessing protein structures with a non-local atomic interaction energy. *J Mol Biol* 277:1141
- Merriweather DA, Kaestle FA (1999) Mitochondrial recombination? (continued). *Science* 285:837
- Metzker ML (2010) Sequencing technologies - the next generation. *Nat Rev Genet* 11:31
- Michikawa Y, Mazzucchelli F, Bresolin N, Scarlato G, Attardi G (1999) Aging-dependent large accumulation of point mutations in the human mtDNA control region for replication. *Science* 286:774
- Mishmar D, Ruiz-Pesini E, Brandon M, Wallace DC (2004) Mitochondrial DNA-like sequences in the nucleus (NUMTs): insights into our African origins and the mechanism of foreign DNA integration. *Hum Mutat* 23:125
- Mithani SK, Taube JM, Zhou S, Smith IM, Koch WM, Westra WH, Califano JA (2007) Mitochondrial mutations are a late event in the progression of head and neck squamous cell cancer. *Clin Cancer Res* 13:4331
- Monnot S, Gigarel N, Samuels DC, Burlet P, Hesters L, Frydman N, Frydman R, Kerbrat V, Funalot B, Martinovic J, Benachi A, Feingold J, Munnich A, Bonnefont JP, Steffann J (2011) Segregation of mtDNA throughout human embryofetal development: m.3243A>G as a model system. *Hum Mutat* 32:116
- Moritz C, Dowling TE, Brown WM (1987) Evolution of animal mitochondrial-DNA- relevance for population biology and systematics. *Ann Rev Ecol Sys* 18:269
- Mourier T, Hansen AJ, Willerslev E, Arctander P (2001) The Human Genome Project reveals a continuous transfer of large mitochondrial fragments to the nucleus. *Mol Biol Evol* 18:1833
- Nachman MW (1998) Deleterious mutations in animal mitochondrial DNA. *Genetica* 102-103:61
- Nachman MW, Boyer SN, Aquadro CF (1994) Nonneutral evolution at the mitochondrial NADH dehydrogenase subunit 3 gene in mice. *Proc Natl Acad Sci U S A* 91:6364

- Nachman MW, Brown WM, Stoneking M, Aquadro CF (1996) Nonneutral mitochondrial DNA variation in humans and chimpanzees. *Genetics* 142:953
- Nagy A, Wilhelm M, Kovacs G (2003) Mutations of mtDNA in renal cell tumours arising in end-stage renal disease. *J Pathol* 199:237
- Nakada K, Inoue K, Hayashi J (2001) Interaction theory of mammalian mitochondria. *Biochem Biophys Res Commun* 288:743
- Nakada K, Sato A, Hayashi J (2009) Mitochondrial functional complementation in mitochondrial DNA-based diseases. *Int J Biochem Cell Biol* 41:1907
- Nakahara H, Sekiguchi K, Imaizumi K, Mizuno N, Kasai K (2008) Heteroplasmies detected in an amplified mitochondrial DNA control region from a small amount of template. *J Forensic Sci* 53:306
- Nigro L, Prout T (1990) Is there selection on RFLP differences in mitochondrial DNA? *Genetics* 125:551
- Paabo S (1996) Mutational hot spots in the mitochondrial microcosm. *Am J Hum Genet* 59:493
- Pakendorf B, Stoneking M (2005) Mitochondrial DNA and human evolution. *Annu Rev Genomics Hum Genet* 6:165
- Palmer JD (1997) Organelle genomes: going, going, gone! *Science* 275:790
- Paneto GG, Longo LV, Martins JA, de Camargo MA, Costa JC, de Mello AC, Chen B, Oliveira RN, Hirata MH, Cicarelli RM (2010) Heteroplasmy in hair: study of mitochondrial DNA third hypervariable region in hair and blood samples. *J Forensic Sci* 55:715
- Parfait B, Rustin P, Munnich A, Rotig A (1998) Co-amplification of nuclear pseudogenes and assessment of heteroplasmy of mitochondrial DNA mutations. *Biochem Biophys Res Commun* 247:57
- Parr RL, Dakubo GD, Crandall KA, Maki J, Reguly B, Aguirre A, Wittcock R, Robinson K, Alexander JS, Birch-Machin MA, Abdel-Malak M, Froberg MK, Diamandis EP, Thayer RE (2006a) Somatic mitochondrial DNA mutations in prostate cancer and normal appearing adjacent glands in comparison to age-matched prostate samples without malignant histology. *J Mol Diagn* 8:312
- Parr RL, Maki J, Reguly B, Dakubo GD, Aguirre A, Wittcock R, Robinson K, Jakupciak JP, Thayer RE (2006b) The pseudo-

- mitochondrial genome influences mistakes in heteroplasmy interpretation. *BMC Genomics* 7:185
- Parrella P, Xiao Y, Fliss M, Sanchez-Cespedes M, Mazzarelli P, Rinaldi M, Nicol T, Gabrielson E, Cuomo C, Cohen D, Pandit S, Spencer M, Rabitti C, Fazio VM, Sidransky D (2001) Detection of mitochondrial DNA mutations in primary breast cancer and fine-needle aspirates. *Cancer Res* 61:7623
- Parsons TJ, Irwin JA (2000) Questioning evidence for recombination in human mitochondrial DNA. *Science* 288:1931
- Parsons TJ, Muniec DS, Sullivan K, Woodyatt N, Alliston-Greiner R, Wilson MR, Berry DL, Holland KA, Weedn VW, Gill P, Holland MM (1997) A high observed substitution rate in the human mitochondrial DNA control region. *Nat Genet* 15:363
- Pereira L, Freitas F, Fernandes V, Pereira JB, Costa MD, Costa S, Maximo V, Macaulay V, Rocha R, Samuels DC (2009) The diversity present in 5140 human mitochondrial genomes. *Am J Hum Genet* 84:628
- Petros JA, Baumann AK, Ruiz-Pesini E, Amin MB, Sun CQ, Hall J, Lim S, Issa MM, Flanders WD, Hosseini SH, Marshall FF, Wallace DC (2005) mtDNA mutations increase tumorigenicity in prostate cancer. *Proc Natl Acad Sci U S A* 102:719
- Phasukkijwatana N, Chuenkongkaew WL, Suphavitai R, Luangtrakool K, Kunhapan B, Lertrit P (2006) Transmission of heteroplasmic G11778A in extensive pedigrees of Thai Leber hereditary optic neuropathy. *J Hum Genet* 51:1110
- Picornell A, Gimenez P, Castro JA, Ramon MM (2006) Mitochondrial DNA sequence variation in Jewish populations. *Int J Legal Med* 120:271
- Piganeau G, Eyre-Walker A (2004) A reanalysis of the indirect evidence for recombination in human mitochondrial DNA. *Heredity (Edinb)* 92:282
- Poe BG, Navratil M, Arriaga EA (2007) Absolute quantitation of a heteroplasmic mitochondrial DNA deletion using a multiplex three-primer real-time PCR assay. *Anal Biochem* 362:193
- Polyak K, Li Y, Zhu H, Lengauer C, Willson JK, Markowitz SD, Trush MA, Kinzler KW, Vogelstein B (1998) Somatic mutations of the mitochondrial genome in human colorectal tumours. *Nat Genet* 20:291

- Popot JL, de Vitry C (1990) On the microassembly of integral membrane proteins. *Annu Rev Biophys Biophys Chem* 19:369
- Poulton J (1995) Transmission of mtDNA: cracks in the bottleneck. *Am J Hum Genet* 57:224
- Poulton J, Marchington DR (2002) Segregation of mitochondrial DNA (mtDNA) in human oocytes and in animal models of mtDNA disease: clinical implications. *Reproduction* 123:751
- Prokisch H, Andreoli C, Ahting U, Heiss K, Ruepp A, Scharfe C, Meitinger T (2006) MitoP2: the mitochondrial proteome database--now including mouse data. *Nucleic Acids Res* 34:D705
- Putz J, Dupuis B, Sissler M, Florentz C (2007) Mamit-tRNA, a database of mammalian mitochondrial tRNA primary and secondary structures. *RNA* 13:1184
- Quesada H, Wenne R, Skibinski DO (1999) Interspecies transfer of female mitochondrial DNA is coupled with role-reversals and departure from neutrality in the mussel *Mytilus trossulus*. *Mol Biol Evol* 16:655
- Ramos A, Barbena E, Mateiu L, Gonzalez MM, Mairal Q, Lima M, Montiel R, Aluja MP, Santos C (2011a) Nuclear insertions of mitochondrial origin: Database updating and usefulness in cancer studies. *Mitochondrion* 11:946
- Ramos A, Santos C, Alvarez L, Nogués R, Aluja MP (2009) Human Mitochondrial DNA complete amplification and sequencing: A new validated primer set that prevents nuclear DNA sequences of mitochondrial origin co-amplification. *Electrophoresis* 30:1
- Ramos A, Santos C, Barbena E, Mateiu L, Alvarez L, Nogues R, Aluja MP (2011b) Validated primer set that prevents nuclear DNA sequences of mitochondrial origin co-amplification: a revision based on the New Human Genome Reference Sequence (GRCh37). *Electrophoresis* 32:782
- Rand DM (1994) Thermal habit, metabolic rate and the evolution of mitochondrial DNA. *Trends Ecol Evol* 9:125
- Rand DM (2001) The units of selection on mitochondrial dna. *Annu. Rev. Ecol. Syst* 32:415
- Rand DM, Dorfsman M, Kann LM (1994) Neutral and non-neutral evolution of *Drosophila* mitochondrial DNA. *Genetics* 138:741

- Rand DM, Kann LM (1996) Excess amino acid polymorphism in mitochondrial DNA: contrasts among genes from *Drosophila*, mice, and humans. *Mol Biol Evol* 13:735
- Rand DM, Kann LM (1998) Mutation and selection at silent and replacement sites in the evolution of animal mitochondrial DNA. *Genetica* 102-3:393
- Rand DM, Weinreich DM, Cezairliyan BO (2000) Neutrality tests of conservative-radical amino acid changes in nuclear- and mitochondrially-encoded proteins. *Gene* 261:115
- Raymond M, Rousset F (2001) GENEPOP 3.3: population genetics software for exact tests and ecumenicism. , Institut des Sciences de l'Evolution. Université de Montpellier II, Montpellier, France
- Ricchetti M, Tekaia F, Dujon B (2004) Continued colonization of the human genome by mitochondrial DNA. *PLoS Biol* 2:E273
- Richly E, Leister D (2004) NUMTs in sequenced eukaryotic genomes. *Mol Biol Evol* 21:1081
- Robin ED, Wong R (1988) Mitochondrial DNA molecules and virtual number of mitochondria per cell in mammalian cells. *J Cell Physiol* 136:507
- Roche (2006) PCR Applications Manual. Roche Diagnostics GmbH, Mannheim
- Rose G, Passarino G, Scornaienchi V, Romeo G, Dato S, Bellizzi D, Mari V, Feraco E, Maletta R, Bruni A, Franceschi C, De Benedictis G (2007) The mitochondrial DNA control region shows genetically correlated levels of heteroplasmy in leukocytes of centenarians and their offspring. *BMC Genomics* 8:293
- Rose G, Romeo G, Dato S, Crocco P, Bruni AC, Hervonen A, Majamaa K, Sevini F, Franceschi C, Passarino G (2010) Somatic point mutations in mtDNA control region are influenced by genetic background and associated with healthy aging: a GEHA study. *PLoS One* 5:e13395
- Ruiz-Pesini E, Mishmar D, Brandon M, Procaccio V, Wallace DC (2004) Effects of purifying and adaptive selection on regional variation in human mtDNA. *Science* 303:223
- Ruiz-Pesini E, Wallace DC (2006) Evidence for adaptive selection acting on the tRNA and rRNA genes of human mitochondrial DNA. *Hum Mutat* 27:1072
- Salas A, Carracedo A, Macaulay V, Richards M, Bandelt HJ (2005) A practical guide to mitochondrial DNA error prevention in

- clinical, forensic, and population genetics. *Biochem Biophys Res Commun* 335:891
- Sali A, Blundell TL (1993) Comparative protein modelling by satisfaction of spatial restraints. *J Mol Biol* 234:779
- Salvioli S, Capri M, Santoro A, Raule N, Sevini F, Lukas S, Lanzarini C, Monti D, Passarino G, Rose G, De Benedictis G, Franceschi C (2008) The impact of mitochondrial DNA on human lifespan: a view from studies on centenarians. *Biotechnol J* 3:740
- Sambrook J (2001) *Molecular cloning : a laboratory manual* Cold Spring Harbor : Cold Spring Harbor Laboratory
- Sanger F, Coulson AR (1975) A rapid method for determining sequences in DNA by primed synthesis with DNA polymerase. *J Mol Biol* 94:441
- Santos C, Abade A, Cantons J, Mayer FM, Aluja MP, Lima M (2005a) Genetic structure of Flores island (Azores, Portugal) in the 19th century and in the present day: evidence from surname analysis. *Hum Biol* 77:317
- Santos C, Martinez M, Lima M, Hao YJ, Simoes N, Montiel R (2008a) Mitochondrial DNA mutations in cancer: a review. *Curr Top Med Chem* 8:1351
- Santos C, Montiel R, Arruda A, Alvarez L, Aluja MP, Lima M (2008b) Mutation patterns of mtDNA: empirical inferences for the coding region. *BMC Evol Biol* 8:167
- Santos C, Montiel R, Sierra B, Bettencourt C, Fernandez E, Alvarez L, Lima M, Abade A, Aluja MP (2005b) Understanding differences between phylogenetic and pedigree-derived mtDNA mutation rate: a model using families from the Azores Islands (Portugal). *Mol Biol Evol* 22:1490
- Santos C, Sierra B, Alvarez L, Ramos A, Fernandez E, Nogues R, Aluja MP (2008c) Frequency and pattern of heteroplasmy in the control region of human mitochondrial DNA. *J Mol Evol* 67:191
- Sarzi E, Brown MD, Lebon S, Chretien D, Munnich A, Rotig A, Procaccio V (2007) A novel recurrent mitochondrial DNA mutation in ND3 gene is associated with isolated complex I deficiency causing Leigh syndrome and dystonia. *Am J Med Genet A* 143:33
- Schatz G (1995) *Mitochondria: beyond oxidative phosphorylation*. *Biochim Biophys Acta* 1271:123
- Scheffler I (2008) *Mitochondria*. John Wiley & Sons

- Schriner SE, Ogburn CE, Smith AC, Newcomb TG, Ladiges WC, Dolle ME, Vijg J, Fukuchi K, Martin GM (2000) Levels of DNA damage are unaltered in mice overexpressing human catalase in nuclei. *Free Radic Biol Med* 29:664
- Schwartz M, Vissing J (2002) Paternal inheritance of mitochondrial DNA. *N Engl J Med* 347:576
- Schwartz M, Vissing J (2003) New patterns of inheritance in mitochondrial disease. *Biochem Biophys Res Commun* 310:247
- Schwartz M, Vissing J (2004) No evidence for paternal inheritance of mtDNA in patients with sporadic mtDNA mutations. *J Neurol Sci* 218:99
- Shigenaga MK, Hagen TM, Ames BN (1994) Oxidative damage and mitochondrial decay in aging. *Proc Natl Acad Sci U S A* 91:10771
- Shitara H, Hayashi JI, Takahama S, Kaneda H, Yonekawa H (1998) Maternal inheritance of mouse mtDNA in interspecific hybrids: segregation of the leaked paternal mtDNA followed by the prevention of subsequent paternal leakage. *Genetics* 148:851
- Sigurgardottir S, Helgason A, Gulcher JR, Stefansson K, Donnelly P (2000) The mutation rate in the human mtDNA control region. *Am J Hum Genet* 66:1599
- Simone D, Calabrese FM, Lang M, Gasparre G, Attimonelli M (2011) The reference human nuclear mitochondrial sequences compilation validated and implemented on the UCSC genome browser. *BMC Genomics* 12:517
- Singh R, Ellard S, Hattersley A, Harries LW (2006) Rapid and sensitive real-time polymerase chain reaction method for detection and quantification of 3243A>G mitochondrial point mutation. *J Mol Diagn* 8:225
- Slate J, Gemmell NJ (2004) Eve 'n' Steve: recombination of human mitochondrial DNA. *Trends Ecol Evol* 19:561
- Smith KH, Johns DR, Heher KL, Miller NR (1993) Heteroplasmy in Leber's hereditary optic neuropathy. *Arch Ophthalmol* 111:1486
- Smith LM, Fung S, Hunkapiller MW, Hunkapiller TJ, Hood LE (1985) The synthesis of oligonucleotides containing an aliphatic amino group at the 5' terminus: synthesis of fluorescent DNA primers for use in DNA sequence analysis. *Nucleic Acids Res* 13:2399

- Smith LM, Sanders JZ, Kaiser RJ, Hughes P, Dodd C, Connell CR, Heiner C, Kent SB, Hood LE (1986) Fluorescence detection in automated DNA sequence analysis. *Nature* 321:674
- Soares P, Ermini L, Thomson N, Mormina M, Rito T, Rohl A, Salas A, Oppenheimer S, Macaulay V, Richards MB (2009) Correcting for purifying selection: an improved human mitochondrial molecular clock. *Am J Hum Genet* 84:740
- Sondheimer N, Glatz CE, Tirone JE, Deardorff MA, Krieger AM, Hakonarson H (2011) Neutral mitochondrial heteroplasmy and the influence of aging. *Hum Mol Genet* 20:1653
- SPSS I (1989-2006) SPSS 15.0.1 for Windows. SPSS Inc., Chicago.
- Stajich J, Block D, Boulez K, Brenner S, Chervitz S, Dagdigian C, Fuellen G, Gilbert J, Korf I, Lapp H, Lehväslaiho H, Matsalla C, Mungall C, Osborne B, Pocock M, Schattner P, Senger M, Stein L, Stupka E, Wilkinson M, Birney E (2002) The BioPerl toolkit: Perl modules for the life sciences. *Genome Res.* 12:1611
- Steinert M, Steinert G (1960) Inhibition de la synthese de lacide desoxyribonucleique de trypanosoma-mega par luee a faible concentration. *Experimental Cell Research* 19:421
- Stoneking M (1993) DNA and recent human evolution. *Evol. Anthropol.* 2:60
- Stoneking M (2000) Hypervariable sites in the mtDNA control region are mutational hotspots. *Am J Hum Genet* 67:1029
- Stoneking M, Soodyall H (1996) Human evolution and the mitochondrial genome. *Curr Opin Genet Dev* 6:731
- Suen DF, Narendra DP, Tanaka A, Manfredi G, Youle RJ (2010) Parkin overexpression selects against a deleterious mtDNA mutation in heteroplasmic cybrid cells. *PNAS* 107:11835
- Sutovsky P, Moreno RD, Ramalho-Santos J, Dominko T, Simerly C, Schatten G (1999) Ubiquitin tag for sperm mitochondria. *Nature* 402:371
- Sutovsky P, Moreno RD, Ramalho-Santos J, Dominko T, Simerly C, Schatten G (2000) Ubiquitinated sperm mitochondria, selective proteolysis, and the regulation of mitochondrial inheritance in mammalian embryos. *Biol Reprod* 63:582
- Tan D, Goerlitz DS, Dumitrescu RG, Han D, Seillier-Moiseiwitsch F, Spernak SM, Orden RA, Chen J, Goldman R, Shields PG (2008) Associations between cigarette smoking and mitochondrial DNA abnormalities in buccal cells. *Carcinogenesis* 29:1170

- Tan DJ, Chang J, Liu LL, Bai RK, Wang YF, Yeh KT, Wong LJ (2006) Significance of somatic mutations and content alteration of mitochondrial DNA in esophageal cancer. *BMC Cancer* 6:93
- Tang S, Huang T (2010) Characterization of mitochondrial DNA heteroplasmy using a parallel sequencing system. *Biotechniques* 48:287
- Taylor FJR (1974) Implications and Extensions of the Serial Endosymbiosis Theory of the Origin of Eukaryotes. *Taxon* 23:229
- Taylor RW, McDonnell MT, Blakely EL, Chinnery PF, Taylor GA, Howell N, Zeviani M, Briem E, Carrara F, Turnbull DM (2003) Genotypes from patients indicate no paternal mitochondrial DNA contribution. *Ann Neurol* 54:521
- Templeton AR (1996) Contingency tests of neutrality using intra/interspecific gene trees: the rejection of neutrality for the evolution of the mitochondrial cytochrome oxidase II gene in the hominoid primates. *Genetics* 144:1263
- Thalmann O, Serre D, Hofreiter M, Lukas D, Eriksson J, Vigilant L (2005) Nuclear insertions help and hinder inference of the evolutionary history of gorilla mtDNA. *Mol Ecol* 14:179
- Theves C, Keyser-Tracqui C, Crubezy E, Salles JP, Ludes B, Telmon N (2006) Detection and quantification of the age-related point mutation A189G in the human mitochondrial DNA. *J Forensic Sci* 51:865
- Thompson JD, Higgins DG, Gibson TJ (1994) CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. *Nucleic Acids Res* 22:4673
- Thyagarajan B, Padua RA, Campbell C (1996) Mammalian mitochondria possess homologous DNA recombination activity. *J Biol Chem* 271:27536
- Torrioni A, Rengo C, Guida V, Cruciani F, Sellitto D, Coppa A, Calderon FL, Simionati B, Valle G, Richards M, Macaulay V, Scozzari R (2001) Do the four clades of the mtDNA haplogroup L2 evolve at different rates? *Am J Hum Genet* 69:1348
- Tourmen Y, Baris O, Dessen P, Jacques C, Malthiery Y, Reynier P (2002) Structure and chromosomal distribution of human mitochondrial pseudogenes. *Genomics* 80:71

- Tsukihara T, Aoyama H, Yamashita E, Tomizaki T, Yamaguchi H, Shinzawa-Itoh K, Nakashima R, Yaono R, Yoshikawa S (1996) The whole structure of the 13-subunit oxidized cytochrome c oxidase at 2.8 Å. *Science* 272:1136
- Tzen CY, Mau BL, Wu TY (2007) ND4 mutation in transitional cell carcinoma: Does mitochondrial mutation occur before tumorigenesis? *Mitochondrion* 7:273
- Uusimaa J, Moilanen JS, Vainionpää L, Tapanainen P, Lindholm P, Nuutinen M, Lopponen T, Maki-Torkko E, Rantala H, Majamaa K (2007) Prevalence, segregation, and phenotype of the mitochondrial DNA 3243A>G mutation in children. *Ann Neurol* 62:278
- Van der Giezen M, Tovar J (2005) Degenerate mitochondria. *EMBO Rep* 6:525
- Van Oven M, Kayser M (2009) Updated comprehensive phylogenetic tree of global human mitochondrial DNA variation. *Hum Mutat* 30:E386
- Vo TD, Palsson BO (2007) Building the power house: recent advances in mitochondrial studies through proteomics and systems biology. *Am J Physiol Cell Physiol* 292:C164
- Wai T, Teoli D, Shoubridge EA (2008) The mitochondrial DNA genetic bottleneck results from replication of a subpopulation of genomes. *Nat Genet* 40:1484
- Wallace DC (2007) Why do we still have a maternally inherited mitochondrial DNA? Insights from evolutionary medicine. *Annu Rev Biochem* 76:781
- Wallace DC, Brown MD, Lott MT (1999) Mitochondrial DNA variation in human evolution and disease. *Gene* 238:211
- Wallace DC, Zheng XX, Lott MT, Shoffner JM, Hodge JA, Kelley RI, Epstein CM, Hopkins LC (1988) Familial mitochondrial encephalomyopathy (MERRF): genetic, pathophysiological, and biochemical characterization of a mitochondrial DNA disease. *Cell* 55:601
- Wang Q, Boles RG (2006) Individual human hair mitochondrial DNA control region heteroplasmy proportions in mothers and children. *Mitochondrion* 6:37
- Wang Y, Michikawa Y, Mallidis C, Bai Y, Woodhouse L, Yarasheski KE, Miller CA, Askanas V, Engel WK, Bhasin S, Attardi G (2001) Muscle-specific mutations accumulate with aging in critical human mtDNA control sites for replication. *Proc Natl Acad Sci U S A* 98:4022

- Wei YL, Yu CA, Yang P, Li AL, Wen JY, Zhao SM, Liu HX, Ke YN, Campbell W, Zhang YG, Li XH, Liao WQ (2009) Novel mitochondrial DNA mutations associated with Chinese familial hypertrophic cardiomyopathy. *Clin Exp Pharmacol Physiol* 36:939
- Weinreich DM, Rand DM (2000) Contrasting patterns of nonneutral evolution in proteins encoded in nuclear and mitochondrial genomes. *Genetics* 156:385
- White HE, Durston VJ, Seller A, Fratter C, Harvey JF, Cross NC (2005) Accurate detection and quantitation of heteroplasmic mitochondrial point mutations by pyrosequencing. *Genet Test* 9:190
- Whittaker RG, Schaefer AM, McFarland R, Taylor RW, Walker M, Turnbull DM (2007) Prevalence and progression of diabetes in mitochondrial disease. *Diabetologia* 50:2085
- Whittam TS, Clark AG, Stoneking M, Cann RL, Wilson AC (1986) Allelic variation in human mitochondrial genes based on patterns of restriction site polymorphism. *Proc Natl Acad Sci U S A* 83:9611
- Wise CA, Sraml M, Easteal S (1998) Departure from neutrality at the mitochondrial NADH dehydrogenase subunit 2 gene in humans, but not in chimpanzees. *Genetics* 148:409
- Woischnik M, Moraes CT (2002) Pattern of organization of human mitochondrial pseudogenes in the nuclear genome. *Genome Res* 12:885
- Wong LJ, Wladyka C, Mardach-Verdon R (2004) A mitochondrial DNA mutation in a patient with an extensive family history of Duchenne muscular dystrophy. *Muscle Nerve* 30:118
- Yao J, Chang C, Salmi ML, Hung YS, Loraine A, Roux SJ (2008a) Genome-scale cluster analysis of replicated microarrays using shrinkage correlation coefficient. *BMC Bioinformatics* 9:288
- Yao YG, Bravi CM, Bandelt HJ (2004) A call for mtDNA data quality control in forensic science. *Forensic Sci Int* 141:1
- Yao YG, Kong QP, Salas A, Bandelt HJ (2008b) Pseudomitochondrial genome haunts disease studies. *J Med Genet* 45:769
- Zaragoza MV, Fass J, Diegoli M, Lin D, Arbustini E (2010) Mitochondrial DNA variant discovery and evaluation in human Cardiomyopathies through next-generation sequencing. *PLoS One* 5:e12295

- Zhadanov SI, Grechanina EY, Grechanina YB, Gusar VA, Fedoseeva NP, Lebon S, Munnich A, Schurr TG (2007) Fatal manifestation of a de novo ND5 mutation: Insights into the pathogenetic mechanisms of mtDNA ND5 gene defects. *Mitochondrion* 7:260
- Zhou S, Kachhap S, Sun W, Wu G, Chuang A, Poeta L, Grumbine L, Mithani SK, Chatterjee A, Koch W, Westra WH, Maitra A, Glazer C, Carducci M, Sidransky D, McFate T, Verma A, Califano JA (2007) Frequency and phenotypic implications of mitochondrial DNA mutations in human squamous cell cancers of the head and neck. *Proc Natl Acad Sci U S A* 104:7540
- Zouros E, Freeman KR, Ball AO, Pogson GH (1992) Direct evidence for extensive paternal mitochondrial DNA inheritance in the marine mussel *Mytilus*. *Nature* 359:412
- Zsurka G, Hampel KG, Nelson I, Jardel C, Mirandola SR, Sassen R, Kornblum C, Marcocelles P, Lavoue S, Lombes A, Kunz WS (2011) Severe epilepsy as the major symptom of new mutations in the mitochondrial tRNA(Phe) gene. *Neurology* 74:507
- Zsurka G, Kraytsberg Y, Kudina T, Kornblum C, Elger CE, Khrapko K, Kunz WS (2005) Recombination of mitochondrial DNA in skeletal muscle of individuals with multiple mitochondrial DNA heteroplasmy. *Nat Genet* 37:873

7. ANNEX

7.1 Annex 1



Els annexos d'aquesta Tesi estan organitzats segons el capítol on es citen, i es presenten de la següent manera:

Capítol 1: Disseny i validació de *primers* per a l'amplificació i seqüenciació del DNAm

Taula I.1.1. Resultat del BLAST de les regions del DNAm: **1)** 3914-9074; i **2)** 9582-14479.

Table I.1.2 Descripció detallada del NUMT actualitzat.

Table I.1.3 Alineament de la seqüència d'*Homo sapiens* amb cinc primats i el cavall.

Capítol 2: Actualització de la base de dades de NUMTs i aplicació en estudis de càncer

Taula I.2.1 Base de dades de NUMTs basada en el genoma humà de referència GRCh37.

Taula I.2.2 Posicions compilades de Santos et al. (2008) que segueixen tenint 0 hits a la filogènia actual (Van Oven et al. 2009) (mit. Tree build 8).

Taula 1.2.3 Posicions amb zero hits en la filogènia del DNAMt que coincideixen amb posicions no idèntiques entre el DNAMt i les insercions nuclears.

Aquesta informació es troba disponible en el CD adjunt dins de la carpeta anomenada “Annex I_Capítol 2” i dins l’arxiu Excel anomenat “Annex_Capítol 2”.

Capítol 3: Freqüència i patró de l’heteroplàsmia mitocondrial humana

Figura I.3.1 Implicació de l’heteroplàsmia puntual del DNAMt en l’estructura secundària dels tRNAs, rRNAs i en l’estructura terciària dels complexos COXI, COXII i CitB.

Taula I.3.1 Llistat dels números d’accés i les espècies utilitzades per calcular els índex de conservació a nivell nucleotídic i a nivell aminoacídic.


Aquesta informació es troba disponible en el CD adjunt dins de la carpeta anomenada “Annex I_Capítol 3” i dins l’arxiu Excel anomenat “Annex_Capítol 3”.

Taula I.3.2 Compilació de les mutacions presents en el genoma mitocondrial de 101 individus. Les heteroplàsmies puntuals i de longitud estan representades en negreta. El sexe i l'haplogrup de cada individu també es troba representat.

Taula I.3.3 Compilació dels resultats per a cada posició heteroplàsmica analitzada (localització, nom de la mostra, tipus d'heteroplàsmia, origen de l'heteroplàsmia, mitjana de l'alçada dels pics, distribució en la base de dades, número de hits en la filogènia del DNAm (PhyloTree.org) i la reportada per Soares et al. (2009), probabilitat de mutació i índex de conservació a nivell de nucleòtid i d'aminoàcid).

Table I.1.1

1) Blast result for 3914-9074 mtDNA region.

[ref|AC_000133.1|AC_000133](#)  Homo sapiens chromosome 1, alternate assembly (based on HuRef), whole genome shotgun sequence
Length=219475005

Max score: [9118](#)

Total score: 1.475e+04

[Query coverage](#): 68%

E value 0.00

[Max ident](#) 100%

Score = 9118 bits (4937), Expect = 0.0
Identities = 5087/5161 (98%), Gaps = 3/5161 (0%)
Strand=Plus/Plus

Query	3914	GGGAGTCCGAAGTCTCAGGCTTCAACATCGAATACGCCGAGGCCCTTCGCCCTAT	3973
Sbjct	719	GGGAGTCCGAAGTCTCAGGCTTCAACATCGAATACGCCGAGGCCCTTCGCCCTAT	778
Query	3974	TCTTCATAGCCGAATACACAAACATTATTATAATAAACACCCCTCACCCTACAATCTTCC	4033
Sbjct	779	TCTTCATAGCCGAATACACAAACATTATTATAATAAACACCCCTCACCCTACAATCTTCC	838

Query	4034	TAGGAACAACATATGACGCACTCTCCCCTGAACTCTACACAACATATTTTGTCCACCAAGA	4093
Sbjct	839	TAGGAACAACATATAACGCACTCTCCCCTGAACTCTACACAACATATTTTGTCCACCAAGA	898
Query	4094	CCCTACTTCTAACCTCCCTGTTCTTATGAATTCGAACAGCATAACCCCGATTCCGCTACG	4153
Sbjct	899	CCCTACTTCTGACCTCCCTGTTCTTATGAATTCGAACAGCATAACCCCGATTCCGCTACG	958
Query	4154	ACCAACTCATAACCTCCTATGAAAAAACTTCCTACCACTCACCTAGCATTACTTATAT	4213
Sbjct	959	ACCAACTCATAACCTCCTATGAAAAAACTTCCTACCACTCACCTAGCATTACTTATAT	1018
Query	4214	GATATGTCTCCATAACCCATTACAATCTCCAGCATTCCCCCTCAAACCTAAGAAATATGTC	4273
Sbjct	1019	GATATGTCTCCATAACCCATTACAATCTCCAGCATTCCCCCTCAAACCTAAGAAATATGTC	1078
Query	4274	TGATAAAAGAGTTACTTTGATAGAGTAAATAATAGGAGCTTAAACCCCTTATTTCTAGG	4333
Sbjct	1079	TGATAAAAGAGTTACTTTGATAGAGTAAATAATAGGAGTTAAATCCCTTATTTCTAGG	1138
Query	4334	ACTATGAGAATCGAACCCATCCCTGAGAATCCAAAATTCTCCGTGCCACCTATCACACC	4393
Sbjct	1139	ACTATGAGAATCGAACCCATCCCTGAGAATCCAAAATTCTCCGTGCCACCTATCACACC	1198
Query	4394	CATCCTAAAGTAAGGTCAGCTAAATAAGCTATCGGGCCCATAACCCGAAAATGTTGGTTA	4453
Sbjct	1199	CATCCTAAAGTAAGGTCAGCTAAATAAGCTATCGGGCCCATAACCCGAAAATGTTGGTTA	1258

Query	4454	TACCCTTCCCGTACTAATTAATCCCCTGGCCCAACCCGTCATCTACTCTACCATCTTTGC	4513
Sbjct	1259	TATCCTTCCCGTACTAATTAATCCCCTGGCCCAACCCGTCATCTACTCTACCATCTTTGC	1318
Query	4514	AGGCACACTCATCACAGCGCTAAGCTCGCACTGATTTTTTACCTGAGTAGGCCTAGAAAT	4573
Sbjct	1319	AGGCACACTCATCACAGCGCTAAGCTCGCACTGATTTTTTACCTGAGTAGGCCTAGAAAT	1378
Query	4574	AAACATGCTAGCTTTTATTCCAGTTCTAACCaaaaaaTAAACCCTCGTTCCACAGAAGC	4633
Sbjct	1379	AAACATGCTAGCTTTTATTCCAGTTCTAACCAAAAAAAAATAAACCCTCGTTCCACAGAAGC	1438
Query	4634	TGCCATCAAGTATTTCTCAGCAAGCAACCGCATCCATAATCCTTCTAATAGCTATCCT	4693
Sbjct	1439	TGCCATCAAGTATTTCTCAGCAAGCAACCGCATCCATAATCCTTCTAATAGCTATCCT	1498
Query	4694	CTTCAACAATATACTCTCCGGACAATGAACCATAACCAATACTACCAATCAATACTCATC	4753
Sbjct	1499	CTTCAACAATATACTCTCCGGACAATGAACCATAACCAATACTACCAATCAATACTCATC	1558
Query	4754	ATTAATAATCATAATAGCTATAGCAATAAAACTAGGAATAGCCCCCTTCACTTCTGAGT	4813
Sbjct	1559	ATTAATAATCATAATGGCTATAGCAATAAAACTAGGAATAGCCCCCTTCACTTCTGAGT	1618
Query	4814	CCCAGAGGTTACCCAAGGCACCCCTCTGACATCCGGCCTGCTTCTTCTCACATGACAAAA	4873
Sbjct	1619	CCCAGAGGTTACCCAAGGCACCCCTCTGACATCCGGCCTGCTCCTTCTCACATGACAAAA	1678

Query	4874	ACTAGCCCCCATCTCAATCATATACCAAATCTCTCCCTCACTAAACGTAAGCCTTCTCCT	4933
Sbjct	1679	ACTAGCCCCCATCTCAATCATATACCAAATTTCTCCCTCATTAAACGTAAGCCTTCTCCT	1738
Query	4934	CACTCTCTCAATCTTATCCATCATAGCAGGCAGTTGAGGTGGATTAAACCAAACCCAGCT	4993
Sbjct	1739	CACTCTTTCAATCTTATCCATCATGGCAGGCAGTTGAGGTGGATTAAACCAAACCCAACT	1798
Query	4994	ACGCAAAATCTTAGCATACTCCTCAATTACCCACATAGGATGAATAATAGCAGTTCTACC	5053
Sbjct	1799	ACGCAAAATCTTAGCATACTCCTCAATTACCCACATAGGATGAATAACAGCAGTTCTACC	1858
Query	5054	GTACAACCCTAACATAACCATTCTTAATTTAACTATTTATATTATCCCTAACTACTACCGC	5113
Sbjct	1859	GTACAACCCTAACATAACCATTCTTAATTTAACTATTTATATTATCCCTAACTACTACCGC	1918
Query	5114	ATTCCTACTACTCAACTTAAACTCCAGCACCACGACCCTACTACTATCTCGCACCTGAAA	5173
Sbjct	1919	ATTCCTACTACTCAACTTAAACTCCAGCACCACAACCCTACTACTATCTCGCACCTGAAA	1978
Query	5174	CAAGCTAACATGACTAACACCCTTAATTCCATCCACCCTCCTCTCCCTAGGAGGCCTGCC	5233
Sbjct	1979	CAAGCTAACATGACTAACACCCTTAATTCCATCCACCCTCCTCTCCCTAGGAGGCCTGCC	2038
Query	5234	CCCCTAACCGGCTTTTTGCCCAAATGGGCCATTATCGAAGAATTCACAAAAACAATAG	5293
Sbjct	2039	CCCCTAACCGGCTTTTTGCCCAAATGGGCCATTATCGAAGAATTCACAAAAACAATAG	2098

Query	5294	CCTCATCATCCCCACCATCATAGCCACCATCACCCCTCCTTAACCTCTACTTCTACCTACG	5353
Sbjct	2099	CCTCATCATCCCCACCATCATAGCCACCATCATCACCCCTCCTTAACCTCTACTTCTACCTGCG	2158
Query	5354	CCTAATCTACTCCACCTCAATCACACTACTCCCCATATCTAACAACGTAAAAATAAAATG	5413
Sbjct	2159	CCTAATCTACTCCACCTCAATCACACTACTCCCTATATCTAACAACGTAAAAATAAAATG	2218
Query	5414	ACAGTTTGAACATACAAAACCCACCCCATTCCTCCCACACTCATCGCCCTTACCACGCT	5473
Sbjct	2219	ACAGTTTGAACACACAAAACCCACCCCATTCCTCCCACACTCATCGCCCTTACCACACT	2278
Query	5474	ACTCCTACCTATCTCCCCTTTTATACTAATAATCTTATAGAAATTTAGGTTAAATACAGA	5533
Sbjct	2279	GCTCCTACCTATCTCCCCTTTTATGCTAATAATCTTATAGAAATTTAGGTTAAATACAGA	2338
Query	5534	CCAAGAGCCTTCAAAGCCCTCAGTAAGTTGCAATACTTAATTTCTGTAACAGCTAAGGAC	5593
Sbjct	2339	CCAAGAGCCTTCAAAGCCCTCAGTAAGTTGCAATACTTAATTTCTGCAACAGCTAAGGAC	2398
Query	5594	TGCAAAACCCCACTCTGCATCAACTGAACGCAAATCAGCCACTTTAATTAAGCTAAGCCC	5653
Sbjct	2399	TGCAAAACCCCACTCTGCATCAACTGAACGCAAATCAGCCACTTTAATTAAGCTAAGCCC	2458
Query	5654	TTACTAGACCAATGGGACTTAAACCCACAAACACTTAGTTAACAGCTAAGCACCCCTAATC	5713
Sbjct	2459	TTACTAGACCAATGGGACTTAAACCCACAAACACTTAGTTAACAGCTAAGCACCCCTAATC	2518

Query	5714	AACTGGCTTCAATCTACTTCTCCCGCCGCCGGGAAAAAAGGCGGGAGAAGCCCCGGCAGG	5773
Sbjct	2519	AACTGGCTTCAATCTACTTCTCCCGCCGCCGGGAAAAAAGGCGGGAGAAGCCCCGGCAGG	2578
Query	5774	TTTGAAGCTGCTTCTTCGAATTTGCAATTCAATATGAAAATCACCTCGGAGCTGGTAAAA	5833
Sbjct	2579	TTTGAAGCTGCTTCTTCGAATTTGCAATTCAATATGAAAATCACCTCAGAGCTGGTAAAA	2638
Query	5834	AGAGGCCTAACCCCTGTCTTTAGATTTACAGTCCAATGCTTCACTCAGCCATTTTACCTC	5893
Sbjct	2639	AGAGGCCTAACCCCTGTCTTTAGATTTACAGTCCAATGCTTCACTCAGCCATTTTACCTC	2698
Query	5894	ACCCCCACTGATGTTTCGCCGACCGTTGACTATTCTCTACAAACCACAAAGACATTGGAAC	5953
Sbjct	2699	ACCCCCACTGATGTTTCGCCGACCGTTGACTATTCTCTACAAACCACAAAGACATTGGAAC	2758
Query	5954	ACTATACCTATTATTTCGGCGCATGAGCTGGAGTCTTAGGCACAGCTCTAAGCCTCCTTAT	6013
Sbjct	2759	ACTATACCTATTATTTCGGCGCATGAGCTGGAGTCTTAGGCACAGCTCTAAGCCTCCTTAT	2818
Query	6014	TCGAGCCGAGCTGGGCCAGCCAGGCAACCTTCTAGGTAACGACCACATCTACAACGTTAT	6073
Sbjct	2819	TCGAGCCGAACTGGGCCAGCCAGGCAACCTTCTAGGTAACGACCACATCTACAACGTTAT	2878
Query	6074	CGTCACAGCCCATGCATTTGTAATAATCTTCTTCATAGTAATACCCATCATAATCGGAGG	6133
Sbjct	2879	CGTCACAGCCCATGCATTTGTAATAATCTTCTTCATAGTAATACCCATCATAATCGGAGG	2938

Query	6134	CTTTGGCAACTGACTAGTTCCCCTAATAATCGGTGCCCCGATATGGCGTTTCCC	6193
Sbjct	2939	CTTTGGCAACTGACTAGTTCCCCTAATAATCGGTGCCCCGATATGGCGTTTCCC	2998
Query	6194	AAACAACATAAGCTTCTGACTCTTACCTCCCTCTCTCCTACTCCTGCTCGCATCTGCTAT	6253
Sbjct	2999	AAACAACATAAGCTTCTGACTCTTACCCCCCTCTCTCCTACTCCTGCTTGCATCTGCTAT	3058
Query	6254	AGTGGAGGCCGGAGCAGGAACAGGTTGAACAGTCTACCCTCCCTTAGCAGGGA	6313
Sbjct	3059	AGTGGAGGCCGGCGCAGGAACAGGTTGAACAGTCTACCCTCCCTTGGCAGGGA	3118
Query	6314	CCACCCTGGAGCCTCCGTAGACCTAACCATCTTCTCCTTACACCTAGCAGGTGTCCTC	6373
Sbjct	3119	CCACCCTGGAGCCTCCGTAGACCTAACCATCTTCTCCTTACACCTAGCAGGTATCTCCTC	3178
Query	6374	TATCTTAGGGGCCATCAATTTTCATCACAACAATTATCAATATAAAAACCCCTGCCATAAC	6433
Sbjct	3179	TATCTTAGGAGCCATCAATTTTCATCACAACAATTATTAATATAAAAACCCCTGCCATAAC	3238
Query	6434	CCAATACCAAACGCCCTCTTCGTCTGATCCGTCCCTAATCACAGCAGTCCTACTTCTCCT	6493
Sbjct	3239	CCAATACCAAACGCCCTTTTCGTCTGATCCGTCCCTAATCACAGCAGTCCTACTTCTCCT	3298
Query	6494	ATCTCTCCCAGTCCTAGCTGCTGGCATCACTATACTACTAACAGACCGCAACCTCAACAC	6553
Sbjct	3299	ATCTCTCCCAGTCCTAGCCGCTGGCATCACTATACTACTAACAGACCGTAACCTCAACAC	3358

Query	6554	CACCTTCTTCGACCCCGCCGGAGGAGAGACCCCATTTCTATAACCAACACCTATTCTGATT	6613
Sbjct	3359	CACCTTCTTCGACCCAGCCGGAGGAGAGACCCCATTTCTATAACCAACACCTATTCTGATT	3418
Query	6614	TTTCGGTCACCCTGAAGTTTATATTCTTATCCTACCAGGCTTCGGAATAATCTCCCATAT	6673
Sbjct	3419	TTTCGGTCACCCTGAAGTTTATATTCTCATCCTACCAGGCTTCGGAATAATCTCCCATAT	3478
Query	6674	TGTAACCTACTACTCCGGaaaaaaGAACCATTTGGATACATAGGTATGGTCTGAGCTAT	6733
Sbjct	3479	TGTAACCTACTACTCCGGAAAAAAGAACCATTTGGATACATAGGTATGGTCTGAGCTAT	3538
Query	6734	GATATCAATTGGCTTCCCTAGGGTTTATCGTGTGAGCACACCATATATTTACAGTAGGAAT	6793
Sbjct	3539	GATATCAATTGGCTTCCCTAGGGTTTATCGTGTGAGCACACCATATATTTACAGTAGGAAT	3598
Query	6794	AGACGTAGACACACGAGCATATTTACCTCCGCTACCATAATCATCGCTATCCCCACCGG	6853
Sbjct	3599	AGACGTAGACACACGAGCATATTTACCTCCGCTACCATAATCATCGCTATCCCCACCGG	3658
Query	6854	CGTCAAAGTATTTAGCTGACTCGCCACACTCCACGGAAGCAATATGAAATGATCTGCTGC	6913
Sbjct	3659	CGTCAAAGTATTTAGCTGACTCGCCACACTCCACGGAAGCAATATGAAATGATCTGCTGC	3718
Query	6914	AGTGCTCTGAGCCCTAGGATTCATCTTTCTTTTCACCGTAGGTGGCCTGACTGGCATTGT	6973
Sbjct	3719	AGTGCTCTGAGCCCTAGGATTTATTTTTCTTTTCACCGTAGGTGGCCTGACTGGCATTGT	3778

Query	6974	ATTAGCAAACCTCATCACTAGACATCGTACTACACGACACGTACTACGTTGTAGCCCCTT	7033
Sbjct	3779	ATTAGCAAACCTCATCACTAGACATCGTACTACACGACACGTACTACGTTGTAGCCCCTT	3838
Query	7034	CCACTATGTCCTATCAATAGGAGCTGTATTTGCCATCATAGGAGGCTTCATTCCTGATT	7093
Sbjct	3839	CCACTATGTCCTATCAATAGGAGCTGTATTTGCCATCATAGGAGGCTTCATTCCTGATT	3898
Query	7094	TCCCCTATTCTCAGGCTACACCCTAGACCAAACCTACGCCAAAATCCATTTCACTATCAT	7153
Sbjct	3899	TCCCCTATTCTCAGGCTACACCCTAGACCAAACCTACGCCAAAATCCATTTGCTATCAT	3958
Query	7154	ATTCATCGGCGTAAATCTAACTTTCTTCCCACAACACTTTCTCGGCCTATCCGGAATGCC	7213
Sbjct	3959	ATTCATCGGCGTAAATCTAACTTTCTTCCCACAACACTTTCTCGGCCTATCCGGAATGCC	4018
Query	7214	CCGACGTTACTCGGACTACCCGATGCATACACCACATGAAACATCCTATCATCTGTAGG	7273
Sbjct	4019	CCGACGTTACTCGGACTATCCCGATGCATACACCACATGAAATATCCTATCATCTGTAGG	4078
Query	7274	CTCATTCAATTTCTCTAACAGCAGTAATATTAATAATTTTCATGATTTGAGAAGCCTTCGC	7333
Sbjct	4079	CTCATTCAATTTCTCTAACAGCAGTAATATTAATAATTTTCATAATTTGAGAAGCCTTCGC	4138
Query	7334	TTCGAAGCGAAAAGTCTTAATAGTAGAAGAACCCTCCATAAACCTGGAGTGACTATATGG	7393
Sbjct	4139	TTCGAAGCGAAAAGTCTTAATAGTAGAAGAACCCTCCATAAACCTGGAGTGACTATATGG	4198

Query	7394	ATGCCCCCACCCTACCACACATTTCGAAGAACCCGTATACATAAAAATCTAGACAAAAAAG	7453
Sbjct	4199	ATGCCCCCACCCTACCACACATTTCGAAGAACCCGTATACATAAAAATCTAGACAAAAAAG	4258
Query	7454	GAAGGAATCGAACCCCCAAAGCTGGTTTCAAGCCAACCCCATGGCCTCCATGACTTTTT	7513
Sbjct	4259	GAAGGAATCGAACCCCCAAAGCTGGTTTCAAGCCAACCCCATGGCCTCCATGACTTTTT	4318
Query	7514	CAAAAAGGTATTAGAAAAACCATTTTCATAACTTTGTCAAAGTTAAATTATAGGCTAAATC	7573
Sbjct	4319	CAAAAAGATATTAGAAAAACCATTTTCATAACTTTGTCAAAGTTAAATTATAGGCTAAATC	4378
Query	7574	CTATATATCTTAATGGCACATGCAGCGCAAGTAGGTCTACAAGACGCTACTTCCCCTATC	7633
Sbjct	4379	CTATATATCTTAATGGCACATGCAGCGCAAGTAGGTCTACAAGACGCTACTTCCCCTATC	4438
Query	7634	ATAGAAGAGCTTATCACCTTTTCATGATCACGCCCTCATAATCATTTTCCTTATCTGCTTC	7693
Sbjct	4439	ATAGAAGAGCTTATCATCTTTTCATGATCACGCCCTCATAATCATTTTCCTTATCTGCTTC	4498
Query	7694	CTAGTCCTGTATGCCCTTTTCCTAACACTCACAACAAAATAACTAATACTAACATCTCA	7753
Sbjct	4499	CTAGTCCTGTACGCCCTTTTCCTAACACTCACAACAAAATAACTAATACTAACATCTCA	4558
Query	7754	GACGCTCAGGAAATAGAAACCGTCTGAACTATCCTGCCC GCCATCATCCTAGTCCTCATC	7813
Sbjct	4559	GACGCTCAGGAAATAGAAACCGTCTGAACTATCCTGCCC GCCATCATCCTAGTCCTTATC	4618

Query	7814	GCCCTCCCATCCCTACGCATCCTTTACATAACAGACGAGGTCAACGATCCCTCCCTTACC	7873
Sbjct	4619	GCCCTCCCATCCCTACGCATCCTTTACATAACAGACGAGGTCAACGATCCCTCCCTTACC	4678
Query	7874	ATCAAATCAATTGGCCACCAATGGTACTGAACCTACGAGTACACCGACTACGGCGGACTA	7933
Sbjct	4679	ATCAAATCAATTGGCCATCAATGGTACTGAACCTACGAATACACCGACTACGGCGGACTA	4738
Query	7934	ATCTTCAACTCCTACATACTTCCCCATTATTCTAGAACCCAGGCGACCTGCGACTCCTT	7993
Sbjct	4739	ATCTTCAACTCCTACATACTTCCCCATTATTCTAGAACCCAGGCGACCTGCGACTCCTT	4798
Query	7994	GACGTTGACAATCGAGTAGTACTCCCGATTGAAGCCCCCATTCGTATAATAATTACATCA	8053
Sbjct	4799	GACGTTGACAATCGAGTAGTACTCCCGTTGAAGCCCCCATTCGTATAATAATTACATCA	4858
Query	8054	CAAGACGTCTTGCACTCATGAGCTGTCCCCACATTAGGCTTAAAAACAGATGCAATTCCC	8113
Sbjct	4859	CAAGACGTCTTACACTCATGAGCTGTCCCCACATTAGGCTTAAAAACAGATGCAATTCCC	4918
Query	8114	GGACGTCTAAACCAAACCACTTTACCGCTACACGACCGGGGTATACTACGGTCAATGC	8173
Sbjct	4919	GGACGTCTAAACCAAACCACTTTCACTGCTACACGACCGGGGTATACTACGGCCAATGC	4978
Query	8174	TCTGAAATCTGTGGAGCAAACCACAGTTTCATGCCCATCGTCCTAGAATTAATTCCCCTA	8233
Sbjct	4979	TCTGAAATCTGTGGAGCAAACCA--GTTTTATGCCCATCGTCCTAGAATTAATTCCCCTA	5036

Query	8234	AAAATCTTTGAAATAGGGCCCGTATTTACCTATAGCACCCCTCTACCCCTCTAGAGC	8293
Sbjct	5037	AAAATCTTTGAAATAGGGCCTGTATTTACCTATAGCACCCCTCTACCCCTCTAGAGC	5096
Query	8294	CCACTGTAAAGCTAACTTAGCATTAAACCTTTTAAAGTTAAAGATTAAGAGAACCAACACCT	8353
Sbjct	5097	CCACTGTAAAGCTAACTTAGCATTAAACCTTTTAAAGTTAAAGATTAAGAGAACCAACACCT	5156
Query	8354	CTTTACAGTGAAATGCCCAACTAAATACTACCGTATGGCCACCATAATTACCCCCATA	8413
Sbjct	5157	CTTTACAGTGAAATGCCCAACTAAATACTACCGTATGACCCACCATAATTACCCCCATA	5216
Query	8414	CTCCTTACACTATTCCCTCATCACCCAATAAAAAATATTAAACACAACTACCACCTACCT	8473
Sbjct	5217	CTCCTTACACTATTCCCTCATCACCCAATAAAAAATATTAAATACAAATTACCACCTACCT	5276
Query	8474	CCCTCACCAAAGCCCATaaaaataaaaaTTATAACAAACCCTGAGAACCAAAATGAACG	8533
Sbjct	5277	CCCTCACCAAAGCCCATAAAAAATAAAAACTATAACAAACCCTGAGAACCAAAATGAACG	5336
Query	8534	AAAATCTGTTTCGCTTCATTCATTGCCCCCACAATCCTAGGCCTACCCGCCGAGTACTGA	8593
Sbjct	5337	AAAATCTGTTCACTTCATTCATTGCCCCCACAATCCTAGGCCTACCCGCCGAGTACTGA	5396
Query	8594	TCATTCTATTTCCCCCTCTATTGATCCCCACCTCCAAATATCTCATCAACAACCGACTAA	8653
Sbjct	5397	TCATTCTATTTCCCCCTCTATTGATCCCCACCTCCAAATATCTCATCAACAACCGACTAA	5456

Query	9074	C	9074
Sbjct	5876	C	5876

2) Blast result for 9582-14479 mtDNA region.


Max score: [1.082e+04](#)

Total score: 3.019e+04

[Query coverage](#): 79%

E value 0.00

[Max ident](#) 100%

[ref|AC_000137.1|AC_000137](#)  Homo sapiens chromosome 5, alternate assembly (based on HuRef),
whole genome shotgun sequence
Length=175444460

Score = 5954 bits (3224), Expect = 0.0
Identities = 4360/4918 (88%), Gaps = 39/4918 (0%)
Strand=Plus/Minus

Query	9582	CCCCTAGAAGTCCCCTCTAAACACATCCGTATTACTCGCATCAGGAGTATCAATCACC	9641
Sbjct	94573924	CCCCCAGAAGTCCCCTTCTGAACACATCCGTACTACTCGCATCAGGAGTCTCAATCACT	94573865
Query	9642	TGAGCTCACCATAGTCTAATAGAAAACAACCGAAACCAAATAATTCAAGCACTGCTTATT	9701
Sbjct	94573864	TGAGCCCACCACAGCCTAATAGAAAATAATCGAAACCAAATAATTCAAGCGTTACTTATT	94573805

Query	9702	ACAATTTTACTGGGTCTCTATTTTACCCTCCTACAAGCCTCAGAGTACTTCGAGTCTCCC	9761
Sbjct	94573804	ACAATTTTACTAGGTGTTTACTTTACCCTCCTACAAGCCTCAGAGTATTTGAAACGCC	94573745
Query	9762	TTCACCAT-T-T-CCGACGGCATCTACGGCTCAACATTTTTTGTAGCCACAGGCTTCCAC	9818
Sbjct	94573744	TTTACCATCTCTGACGACGGCATCTATGGCTCAACATTTTTTGTAGCCACAGGCTTTCAC	94573685
Query	9819	GGACTTCACGTCATTATTGGCTCAACTTTCCTCACTATCTGCTTCATCCGCCAACTAATA	9878
Sbjct	94573684	GGACTCCACGTCATCATTGGATCAACTTTCCTCACTATTTGCCTCATCCGCCAACTAACA	94573625
Query	9879	TTTCACTTTACATCCAAACATCACTTTGGCTTCGAAGCCGCCCTGATACTGGCATT	9938
Sbjct	94573624	TTTCACTTTACATCTAAACATCACTTTCGGCTTTGAAGCCGCCCTGGTACTGACACTTC	94573565
Query	9939	GTAGATGTGGTTTGGACTATTTCTGTATGTCTCCATCTATTGATGAGGGTCTTACTCTTTT	9998
Sbjct	94573564	ATAGATGTAGTCTGACTATTTCTATACGTCTCAATCTACTGATGAGGATCTTACTCTTTT	94573505
Query	9999	AGTATAAATAGTACCGTTAACTTCCAATTAAGTATTTGACAACATTCAAAAAAGAGTA	10058
Sbjct	94573504	AGTATAAACAGTACCGTTAACTTCCAATTAAGTATTTGATGATATTCAAAAAAGAGTA	94573445
Query	10059	ATAAACTTCGCCTTAATTTAATAATCAACACCCTCCTAGCCTTACTACTAATAATTATT	10118
Sbjct	94573444	ATAAACTTCGCCTAATTCTAATAGTCAATACCCTCCTAGCCTACTATTAATAGTTATT	94573385

Query	10119	ACATTTTGGACTACCACAACCTCAACGGCTACATAGAAAAATCCACCCCTTACGAGTGCGGC	10178
Sbjct	94573384	ACATTCTGATTACCACAACCTCAACAGTTACATAGAAAAATCCAACCCCTTACGAATGTGGC	94573325
Query	10179	TTCGACCCTATATCCCCGCCCCGCGTCCCTTTCTCCATAAAAATTCTTCTTAGTAGCTATT	10238
Sbjct	94573324	TTCGACCCCTATTCCCCACCCGCATTCCTTTCTCCATGAAATTCTTCTTAGTAGCCATC	94573265
Query	10239	ACC-TTCTTATTATTTGATCTAGAAAATTGCCCTCCTTTTACCCCTACCATGAGCCCTACA	10297
Sbjct	94573264	ACCTTTC-TATTATTTGACCTAGAAAATTGCTCTCCTACTGCCCTTACCATGAGCCCTACA	94573206
Query	10298	AACAACCTAACCTGCCACTAATAGTTATGTCATCCCTCTTATTAATCATCATCCTAGCCCT	10357
Sbjct	94573205	AACAACCAACTTACCACTAACAGTCATATCATCCCTCTTATTAATCATTATCCTAACCCCT	94573146
Query	10358	AAGTCTGGCCTATGAGTGACT-ACAAAAAGGATTAGACTGAACCGAATTGGTATATAGTT	10416
Sbjct	94573145	AAGCCTAGCCTACGAATGA-TCACAAAAGGGATTAGACTGAGCCGAATTGGTACATAGTT	94573087
Query	10417	TAAACAAAACGAATGATTTTCGACTCATTAAATTATGATAATCATATTTACCAAATGCCCC	10476
Sbjct	94573086	TAAATAAAAACGAATGATTTTCGACTGATTAAATTATGATAGTCATATTTACCAAATGCCCC	94573027
Query	10477	TCATTTACATAAAATATTATACTAGCATTTACCATCTCACTTCTAGGAATACTAGTATATC	10536
Sbjct	94573026	TTATTTATATAAAATATTATACTAGCATTTACTATCTCACTTCTAGGAATATTAGTATACC	94572967

Query	10537	GCTCACACCTCATATCCTCCCTACTATGCCTAGAAAGGAATAATACTATCGCTGTTTCATTA	10596
Sbjct	94572966	GCTTACACCTGATATCCTCCCTACTATGTCTAGAAAGGAATAATATTGTCATTATTTATTA	94572907
Query	10597	TAGCTACTCTCATAACCCTCAACACCCACTCCCTCTTAGCCAATATTGTGCCTATTGCCA	10656
Sbjct	94572906	TGGCTACTCTCATAACCCTTAAACACCCACTCCCTCTTAGCCAACATCGTGCCTATCACCA	94572847
Query	10657	TACTAGTCTTTGCCGCTGCGAAGCAGCGGTGGGCCTAGCCCTACTAGTCTCAATCTCCA	10716
Sbjct	94572846	TATTAGTCTTTGCTGCCTGCGAGGCAGCAGTAGGCCTAGCCCTACTAGTTTCAATCTCCA	94572787
Query	10717	ACACATATGGCCTAGACTACGTACATAACCTAAACCTACTCCAATGCTAAAACCTAATCGT	10776
Sbjct	94572786	ACACATACGGCTTGACTACGCCATAACCTAAACCTACTCCAATGCTAAAACCTAATTAT	94572727
Query	10777	CCCAACAATTATATTACTACCACTGACATGACTT-TCCAAAAAACACATAATTTGAATCA	10835
Sbjct	94572726	TCCAACAATCATATTACTACCACTAACATGA-TTCTCAAAAAACATATAATTTGAATCA	94572668
Query	10836	ACACAACCACCCACAGCCTAATTATTAGCATCATCCCTCTACTATTTTTTAACCAAATCA	10895
Sbjct	94572667	ACACAACCACCCACAGCCTAATTATCAGCATTATCCCCCTACTATTTTTCAACCAGATCA	94572608
Query	10896	ACAACAACCTATTTAGCTGTTCCCCAACCTTTTCCTCCGACCCCTAACAAACCCCTCC	10955
Sbjct	94572607	ACAACAACCTATATAGCTATTCTCTATCCTTCTCCTCCGACCCCTAACGACCCCTTC	94572548

Query	10956	TAATACTAACTACCTGACTCCTACCCCTCACAATCATGGCAAGCCAACGCCACTTATCCA	11015
Sbjct	94572547	TAATACGGACAACCTGACTCCTACCCCTCATAATCATAGCAAGCCAACGCCACCTATTC	94572488
Query	11016	GTGAACCACTATCACGaaaaaaCTCTACCTCTCTATACTAATCTCCCTACAAATCTCCT	11075
Sbjct	94572487	ACGAACCCCTATCACGAAAAAACTCTACGTCTCTATACTAATCTTCCTCCAAAACCTCT	94572428
Query	11076	TAATTATAACATTCACAGCCACAGAACTAATCATATTTTATATCTTCTTCGAAACCACAC	11135
Sbjct	94572427	TAATTATAACATTCACAGCCACAGAACTAATTATATCTACATCTTCTTCGAAGCCACAC	94572368
Query	11136	TTATCCCCACCTTGGCTATCATCACCCGATGAGGCAACCAGCCAGAACGCCTGAACGCAG	11195
Sbjct	94572367	TTATCCCCACCCTAGCTATTATCACCCGATGAGGCAACCAAACGGAACGTCTAAACGCAG	94572308
Query	11196	GCACATACTTCTATTCTACACCCTAGTAGGCTCCCTTCCCCTACTCATCGCACTAATTT	11255
Sbjct	94572307	GCACATATTTCTATTTTTATACCCTAGTGGGCTCCCTCCCCTACTCATCGCATTAATTC	94572248
Query	11256	ACACTCACAACACCCTAGGCTCACTAAACATTCTACTACTCACTCTCACTGCCAAGAAC	11315
Sbjct	94572247	ACACACACAACACCCTGGGCTCACTAAATATTTTATTACTCACCCTTACTGCCAAGAGC	94572188
Query	11316	TATCAAACCTCTGAGCCAACAACCTTAATATGACTAGCTTACACAATAGCTTTTATAGTAA	11375
Sbjct	94572187	TATCAAACCTCTGAGCTAGTAACTTAATATGACTAGCATAACAATAGCTTTCATAGTAA	94572128

Query	11796	AAGGACTTCAAACCTCTACTCCCACCTAATAGCTTTTTGATGACTTCTAGCAAGCCTCGCTA	11855
Sbjct	94571707	AAGGACTTCAAACCTCTACTCCCACCTAATAGCCTTTTTGATGACTTCTGGCAAGCCTCGCCA	94571648
Query	11856	ACCTCGCCTTACCCCCACTATTAACCTACTGGGAGAACTC-TCTGTGCTAGTAACCACG	11914
Sbjct	94571647	ACCTCGCTTTGCCCCCACCATTAACCTACTAGGAGAACTCTTC-GTACTAGTGACCTCA	94571589
Query	11915	TTCTCCTGATCAAATATCACTCTCCTACTTACAGGACTCAACATACTAGTCACAGCCCTA	11974
Sbjct	94571588	TTCTCCTGATCAAACATCACCTCCTACTCACAGGACTTAACATACTAATCACAGCCCTA	94571529
Query	11975	TACTCCCTCTACATATTTACCACAACAATGGGGCTCACTCACCCACCACATTAACAAC	12034
Sbjct	94571528	TACTCCCTCTATATATTTACCACAACAATGAGGGCTCGCTCACACACCACATTAACAAC	94571469
Query	12035	ATAAAACCCTCA-TTCACACGAGAAAACACCCTCATGTTTCATACACCTATCCCCATTCT	12093
Sbjct	94571468	ATAAAACCCTCACTT-ACACGAGAAAACACTCTCATATTCATACACCTATCCCCATCCT	94571410
Query	12094	CCTCCTATCCCTCAACCCCGACATCATTACCGGGTTTT-CCTCTTGTAATATAGTTTAA	12152
Sbjct	94571409	CCTCCTATCCCTTAACCCTGATATCATTACC-GGTTTTACCTCCTGTAAATATAGTTTAA	94571351
Query	12153	CCAAAACATCAGATTGTGAATCTGACAACAGAGGCTTACGA-CCCCTTATTTACCGAGAA	12211
Sbjct	94571350	CCAAAACATCAGATTGTGAATCTGATAACAGAGGCTCAC-AGCCCCTTATTTACCGAGAA	94571292

Query	12212	AGCTCACAAGAAGCTGCTAACTCATGCCCCCATGTCTAACAACATGGCTTTCTCAACTTTT	12271
Sbjct	94571291	AGCTCATAAGAAGCTGCTAACTCATACTCCCATGTCTAACAACATGGCTTTCTCGACTTTT	94571232
Query	12272	AAAGGATAACAGCTATCCATTGGTCTTAGGCCCCAAAAATTTGGTGCAACTCCAAATAA	12331
Sbjct	94571231	AAAGGATAACAGCCATCCGTTGGTCTTAGGCCCCAAAAATTTGGTGCAACTCCAAATAA	94571172
Query	12332	AAGTAATAACCATGCACACTACTATAACCACCCTAACCCCTGACTTCCCTAATTCCCCCA	12391
Sbjct	94571171	AAGTAATAACCATGTATGCCACCATAACCATCCTAGCCCTAACTTCCTTAATTCCCCGA	94571112
Query	12392	TCCTTACCACCCTCGTTAACCCCTAACaaaaaaaaaCTCATACCCCATTATGTAAAATCCA	12451
Sbjct	94571111	TCATTGCCACCTTCATCAACCCTAACAAAAAGAGTTCATACCCCCTATGTAAAATCAA	94571052
Query	12452	TTGTGCGCATCCACCTTTATTATCAGTCTCTTCCCCACAACAATATTCATGTGCCTAGACC	12511
Sbjct	94571051	TTATTGCATCCGCCTTTATTATTAGCCTCCTCCCCACAACAATATTCATATGCCTAGACC	94570992
Query	12512	AAGAAGTTATTATCTCGAACTGACACTGAGCCACAACCCAAACAACCCAGCTCTCCCTAA	12571
Sbjct	94570991	AAGAAGTTATTATCTCAAAGCTGACACTGAGCAACAACCCAAACAATACAACCTCTCGCTAA	94570932
Query	12572	GCTTCAAAGTAGACTACTTCTCCATAATATTCATCCCTGTAGCATTGTTTCGTTACATGGT	12631
Sbjct	94570931	GCTTTAAAGTAGACTATTTCTCCATAATATTAATCCCTGTAGCACTATTCGTCACATGAT	94570872

Query	13469	TAGCA-TTAGCAGGAATACCTTTCTCCTCACAGGTTTCTACTCCAAAGACCACATCATCGAA	13527
Sbjct	94570034	TGGCACTT-GCAGGAATGCCCTTCTCCTCACGGGCTTCTATTCCATAGACCTCATCATCAA	94569976
Query	13528	ACCGCAAACATATCATACACAAACGCCTGAGCCCTATCTATTACTCTCATCGCTACCTCC	13587
Sbjct	94569975	ACCGCAAATATATCATACACCAACGCCTGAGCCCTATCTATTACTCTCATCGCCACTTCC	94569916
Query	13588	CTGACAAGCGCCTATAGCACTCGAATAATTCTTCTCACCCCTAACAGGTCAACCTCGCTTC	13647
Sbjct	94569915	CTAACAAGCGCCAATAGCACTCGAATAATTCTCCTCACCCCTAACAGGCCAACCTCGTTTC	94569856
Query	13648	CCCACCCTTACTAACATTAACGAAAATAACCCCCACCCTACTAAACCCCATTAACGCCTG	13707
Sbjct	94569855	CCAACCCTAACCAACATCAACGAAAACAACCCCTACCCTGCTAAGCCCCATCAAACGCCTA	94569796
Query	13708	GCAGCCGGAAGCCTATTTCGAGGATTTCTCATTACTAACAACATTTCCCCCGCATCC--C	13765
Sbjct	94569795	ACAATCGGAAGCCTATTTCGAGGATTTCTCATCACCAGCAACATTTTCCCACATCCATC	94569736
Query	13766	CCTTCCAAACAACAATCCCCCT-CTACCTAAAACCTCACAGCCCTCG-CTGTCACTTTCCT	13823
Sbjct	94569735	CC--CCAAATGACAATCCCCTTC-ACTTAAAACCTCACAGCCCTAGGCA-TCACCTTCTT	94569680
Query	13824	AGGACTTCTAACAGCCCTAGACCTCAACTACCTAACCAACAAACTTAAAAATAAAAATCCCC	13883
Sbjct	94569679	AGGACTTCTGACAGCCCTAGACCTCAACTACTTAACCAACAAACTCAAAAATAAAAAACCC	94569620

Table I.1.2 Detailed description of the updated NUMT.

Database information	Homo sapiens chromosome 1, GRCh37 primary reference assembly/ ref NC_000001.10/ NC_000001
mtDNA homology region	3911-9755
Chr. 1 region (NUMT)	564461-570304
% homology	98,52890866
Score	11122
Total length (mtDNA / NUMT alignment)	5846
nDNA length (Chr. 1)	5844
mtDNA length	5845
Total of conserved positions	5760
Total of identical positions	5760
Not conserved positions (NUMT)	564463, 564598, 564654, 564862, 564868, 565006, 565286, 565319, 565406, 565454, 565464, 565490, 565508, 565541, 565591, 565697, 565870, 565901, 565937, 565976, 566021, 566024, 566048, 566130, 566371, 566390, 566573, 566771, 566792, 566816, 566849, 566916, 566933, 566960, 567002, 567033, 567062, 567092, 567119, 567191, 567240, 567486, 567489, 567697, 567783, 567807, 567867, 568072, 568201, 568256, 568361, 568419, 568442, 568463, 568572, 568616, 568691, 568703, 568718, 568752, 568941, 569004, 569010, 569052, 569094, 569204, 569226, 569250, 569267, 569409, 569492, 569609, 569624, 569717, 569803, 569874, 569878, 569983, 570076, 570079, 570089, 570094, 570097, 570178.
Not conserved positions (mtDNA)	3913, 4048, 4104, 4312, 4318, 4456, 4736, 4769, 4856, 4904, 4914, 4940, 4958, 4991, 5041, 5147, 5320, 5351, 5387, 5426, 5471, 5474, 5498, 5580, 5821, 5840, 6023, 6221, 6242, 6266, 6299, 6366, 6383, 6410, 6452, 6483, 6512, 6542, 6569, 6641, 6935, 6938,

	7146, 7232, 7256, 7316, 7521, 7650, 7705, 7810, 7868, 7891, 7912, 8021, 8065, 8140, 8152, 8167, 8195, 8196, 8203, 8392, 8455, 8461, 8503, 8545, 8655, 8677, 8701, 8718, 8860, 8943, 9060, 9075, 9168, 9254, 9325, 9329, 9434, 9527, 9530, 9540, 9545, 9548, 9629.
Not identical positions (NUMT)	564463, 564598, 564654, 564862, 564868, 565006, 565286, 565319, 565406, 565454, 565464, 565490, 565508, 565541, 565591, 565697, 565870, 565901, 565937, 565976, 566021, 566024, 566048, 566130, 566371, 566390, 566573, 566771, 566792, 566816, 566849, 566916, 566933, 566960, 567002, 567033, 567062, 567092, 567119, 567191, 567240, 567486, 567489, 567697, 567783, 567807, 567867, 568072, 568201, 568256, 568361, 568419, 568442, 568463, 568572, 568616, 568691, 568703, 568718, 568752, 568941, 569004, 569010, 569052, 569094, 569204, 569226, 569250, 569267, 569409, 569492, 569609, 569624, 569717, 569803, 569874, 569878, 569983, 570076, 570079, 570089, 570094, 570097, 570178.
Not identical positions (mtDNA)	3913, 4048, 4104, 4312, 4318, 4456, 4736, 4769, 4856, 4904, 4914, 4940, 4958, 4991, 5041, 5147, 5320, 5351, 5387, 5426, 5471, 5474, 5498, 5580, 5821, 5840, 6023, 6221, 6242, 6266, 6299, 6366, 6383, 6410, 6452, 6483, 6512, 6542, 6569, 6641, 6935, 6938, 7146, 7232, 7256, 7316, 7521, 7650, 7705, 7810, 7868, 7891, 7912, 8021, 8065, 8140, 8152, 8167, 8195, 8196, 8203, 8392, 8455, 8461, 8503, 8545, 8655, 8677, 8701, 8718, 8860, 8943, 9060, 9075, 9168, 9254, 9325, 9329, 9434, 9527, 9530, 9540, 9545, 9548, 9629.
Identical positions (NUMT)	564461, 564462, 564464-564597, 564599-564653, 564655-564861,

	<p>564863-564867, 564869-565005, 565007-565285, 565287-565318, 565320-565405, 565407-565453, 565455-565463, 565465-565489, 565491-565507, 565509-565540, 565542-565590, 565592-565696, 565698-565869, 565871-565900, 565902-565936, 565938-565975, 565977-566020, 566022, 566023, 566025-566047, 566049-566129, 566131-566370, 566372-566389, 566391-566572, 566574-566770, 566772-566791, 566793-566815, 566817-566848, 566850-566915, 566917-566932, 566934-566959, 566961-567001, 567003-567032, 567034-567061, 567063-567091, 567093-567118, 567120-567190, 567192-567239, 567241-567485, 567487, 567488, 567490-567696, 567698-567782, 567784-567806, 567808-567866, 567868-568071, 568073-568200, 568202-568255, 568257-568360, 568362-568418, 568420-568441, 568443-568462, 568464-568571, 568573-568615, 568617-568690, 568692-568702, 568704-568717, 568719-568751, 568753-568940, 568942-569003, 569005-569009, 569011-569051, 569053-569093, 569095-569203, 569205-569225, 569227-569249, 569251-569266, 569268-569408, 569410-569491, 569493-569608, 569610-569623, 569625-569716, 569718-569802, 569804-569873, 569875-569877, 569879-569982, 569984-570075, 570077, 570078, 570080-570088, 570090-570093, 570095, 570096, 570098-570177, 570179-570304</p>
<p>Identical positions (mtDNA)</p>	<p>3911, 3912, 3914-4047, 4049-4103, 4105-4311, 4313-4317, 4319-4455, 4457-4735, 4737-4768, 4770-4855, 4857-4903, 4905-4913, 4915-4939, 4941-4957, 4959-4990, 4992-5040,</p>

	<p>5042-5146, 5148-5319, 5321-5350, 5352-5386, 5388-5425, 5427-5470, 5472, 5473, 5475-5497, 5499-5579, 5581-5820, 5822-5839, 5841-6022, 6024-6220, 6222-6241, 6243-6265, 6267-6298, 6300-6365, 6367-6382, 6384-6409, 6411-6451, 6453-6482, 6484-6511, 6513-6541, 6543-6568, 6570-6640, 6642-6934, 6936, 6937, 6939-7145, 7147-7231, 7233-7255, 7257-7315, 7317-7520, 7522-7649, 7651-7704, 7706-7809, 7811-7867, 7869-7890, 7892-7911, 7913-8020, 8022-8064, 8066-8139, 8141-8151, 8153-8166, 8168-8194, 8197-8202, 8204-8391, 8393-8454, 8456-8460, 8462-8502, 8504-8544, 8546-8654, 8656-8676, 8678-8700, 8702-8717, 8719-8859, 8861-8942, 8944-9059, 9061-9074, 9076-9167, 9169-9253, 9255-9324, 9326-9328, 9330-9433, 9435-9526, 9528, 9529, 9531-9539, 9541-9544, 9546, 9547, 9549-9628, 9630-9755</p>
<p>Conserved positions (NUMT)</p>	<p>564461, 564462, 564464-564597, 564599-564653, 564655-564861, 564863-564867, 564869-565005, 565007-565285, 565287-565318, 565320-565405, 565407-565453, 565455-565463, 565465-565489, 565491-565507, 565509-565540, 565542-565590, 565592-565696, 565698-565869, 565871-565900, 565902-565936, 565938-565975, 565977-566020, 566022, 566023, 566025-566047, 566049-566129, 566131-566370, 566372-566389, 566391-566572, 566574-566770, 566772-566791, 566793-566815, 566817-566848, 566850-566915, 566917-566932, 566934-566959, 566961-567001, 567003-567032, 567034-567061, 567063-567091, 567093-567118, 567120-567190, 567192-567239, 567241-567485, 567487, 567488, 567490-567696,</p>

	<p>567698-567782, 567784-567806, 567808-567866, 567868-568071, 568073-568200, 568202-568255, 568257-568360, 568362-568418, 568420-568441, 568443-568462, 568464-568571, 568573-568615, 568617-568690, 568692-568702, 568704-568717, 568719-568751, 568753-568940, 568942-569003, 569005-569009, 569011-569051, 569053-569093, 569095-569203, 569205-569225, 569227-569249, 569251-569266, 569268-569408, 569410-569491, 569493-569608, 569610-569623, 569625-569716, 569718-569802, 569804-569873, 569875-569877, 569879-569982, 569984-570075, 570077, 570078, 570080-570088, 570090-570093, 570095, 570096, 570098-570177, 570179-570304</p>
<p>Conserved positions (mtDNA)</p>	<p>3911, 3912, 3914-4047, 4049-4103, 4105-4311, 4313-4317, 4319-4455, 4457-4735, 4737-4768, 4770-4855, 4857-4903, 4905-4913, 4915-4939, 4941-4957, 4959-4990, 4992-5040, 5042-5146, 5148-5319, 5321-5350, 5352-5386, 5388-5425, 5427-5470, 5472, 5473, 5475-5497, 5499-5579, 5581-5820, 5822-5839, 5841-6022, 6024-6220, 6222-6241, 6243-6265, 6267-6298, 6300-6365, 6367-6382, 6384-6409, 6411-6451, 6453-6482, 6484-6511, 6513-6541, 6543-6568, 6570-6640, 6642-6934, 6936, 6937, 6939-7145, 7147-7231, 7233-7255, 7257-7315, 7317-7520, 7522-7649, 7651-7704, 7706-7809, 7811-7867, 7869-7890, 7892-7911, 7913-8020, 8022-8064, 8066-8139, 8141-8151, 8153-8166, 8168-8194, 8197-8202, 8204-8391, 8393-8454, 8456-8460, 8462-8502, 8504-8544, 8546-8654, 8656-8676, 8678-8700, 8702-8717, 8719-8859, 8861-8942, 8944-9059, 9061-9074, 9076-9167, 9169-9253,</p>

	9255-9324, 9326-9328, 9330-9433, 9435-9526, 9528, 9529, 9531-9539, 9541-9544, 9546, 9547, 9549-9628, 9630-9755
--	---

Table I.1.3 Alignment of Homo sapiens, five primates and the horse sequences.

BLAST (cutoff E-value of $1e-10$) was used to search in GenBank for the 400bp sequences flanking the region Human Chr1:564461-570304 (accession number CM000663). We obtained a common set of sequences from five species, belonging to the same accession numbers in relative close range, no farther apart than 900bp (e.g. Human Chr1:564161-564561 best hit Chimp NC_006468.2 Chr 1: 223983932-223984210; Human Chr1:570204-570604 best hit Chimp NC_006468.2 Chr: 223984204-223984501). We retrieved the sequences corresponding to the combined hit intervals (e.g. Chimp NC_006468.2 Chr 1: 223983932-223984501) and we aligned the human region Chr1:564161-570604 to them using DIALIGN2 (default setting) (Morgenstern 1999). The alignment was further used to infer a maximum likelihood tree of the 5 primates and the horse sequences with PAML (Yang 2007) (baseml, GTR substitution model, 8 Gamma categories for site-specific rates).

Human564350-570450 **tcccgtaactaattaaccctggcccaaccogtcactctactctaccatctttgcaggcac**
Pan_troglodytes -----
Pongo_abelii -----
Callithrix_jacchus -----
Macaca_mulatta -----
Equus_caballus -----

Human564350-570450 **actcatcacagcgtaagctogcactgattttttaccogagtaggcctagaaataaacat**
Pan_troglodytes -----
Pongo_abelii -----
Callithrix_jacchus -----
Macaca_mulatta -----
Equus_caballus -----

Human564350-570450 **gctagcttttattccagttctaaccaaaaaataaacctcogttccacagaagctgcat**
Pan_troglodytes -----
Pongo_abelii -----
Callithrix_jacchus -----
Macaca_mulatta -----
Equus_caballus -----

Human564350-570450 **caagtaatttcctcagcgaagcaaccgcatccataactcttaatagctatcctctcaa**
Pan_troglodytes -----
Pongo_abelii -----
Callithrix_jacchus -----
Macaca_mulatta -----
Equus_caballus -----

Human564350-570450 **caataactctccggacaatgaaccataaccaataaccaccaatcaatactcatcattaat**
Pan_troglodytes -----
Pongo_abelii -----
Callithrix_jacchus -----
Macaca_mulatta -----
Equus_caballus -----

Human564350-570450 **aatcataatggctatagcaataaaactaggaatagccccctttcactctgagctccaga**
Pan_troglodytes -----
Pongo_abelii -----
Callithrix_jacchus -----
Macaca_mulatta -----
Equus_caballus -----

Human564350-570450 **ggttaaccaaggcaccctctgacatccggcctgctcctctcacatgacaaaaactagc**
Pan_troglodytes -----
Pongo_abelii -----
Callithrix_jacchus -----
Macaca_mulatta -----
Equus_caballus -----

Human564350-570450 **ccccctcfaatcatataccaaaatttccctcattaaacgtaagccttctcctcactct**
Pan_troglodytes -----
Pongo_abelii -----
Callithrix_jacchus -----
Macaca_mulatta -----
Equus_caballus -----

Human564350-570450 **ttcaatcttatccatcatggcaggcagttgaggtggattaaaccaaaccaactacgcaa**
Pan_troglodytes -----
Pongo_abelii -----
Callithrix_jacchus -----
Macaca_mulatta -----
Equus_caballus -----

Human564350-570450 **aatcttagcactactcctcaattaccacataggatgaataacagcagttctaccgtacaa**
Pan_troglodytes -----
Pongo_abelii -----
Callithrix_jacchus -----
Macaca_mulatta -----
Equus_caballus -----

Human564350-570450 **ccctaacataaccattcttaatttaactatttatattcctaacactactaccgcatcct**
Pan_troglodytes -----
Pongo_abelii -----
Callithrix_jacchus -----
Macaca_mulatta -----
Equus_caballus -----

Human564350-570450 **actactcaacttaaaactccagcaccacaaccctactactatctcgcacctgaacaagct**
Pan_troglodytes -----
Pongo_abelii -----
Callithrix_jacchus -----
Macaca_mulatta -----
Equus_caballus -----

Human564350-570450 **aacatgactaacacccttaattccatccaccctcctctccctaggaggcctgccccgct**
Pan_troglodytes -----
Pongo_abelii -----
Callithrix_jacchus -----
Macaca_mulatta -----
Equus_caballus -----

Human564350-570450 **aaccggctttttgcccaaatgggccattatcgagaatttcacaaaaacaatagcctcat**
Pan_troglodytes -----
Pongo_abelii -----
Callithrix_jacchus -----
Macaca_mulatta -----
Equus_caballus -----

Human564350-570450 **catccccacatcatagccatcatcacccctccttaacctctacttctacctgcgctaat**
Pan_troglodytes -----
Pongo_abelii -----
Callithrix_jacchus -----
Macaca_mulatta -----
Equus_caballus -----

Human564350-570450 **ctactccacctcaatcacactactccctatatctaacacgtaaaaataaaatgacagtt**
Pan_troglodytes -----
Pongo_abelii -----
Callithrix_jacchus -----
Macaca_mulatta -----
Equus_caballus -----

Human564350-570450 **tgaacacacaaaaccacccccattcctccccacactcatcgcccttaccacactgctcct**
Pan_troglodytes -----
Pongo_abelii -----
Callithrix_jacchus -----
Macaca_mulatta -----
Equus_caballus -----

Human564350-570450 **acctatctccccttttatgctaaataattattagaaatttaggttaaaatacagaccaaga**
Pan_troglodytes -----
Pongo_abelii -----
Callithrix_jacchus -----
Macaca_mulatta -----
Equus_caballus -----

Human564350-570450 **gccttcaaagccctcagtaagttgcaatacttaattctgcaacagctaaggactgcaaa**
Pan_troglodytes -----
Pongo_abelii -----
Callithrix_jacchus -----
Macaca_mulatta -----
Equus_caballus -----

Human564350-570450 **accccactctgcatcaactgaaagcaaatcagccactttaattaagctaagcccttacta**
Pan_troglodytes -----
Pongo_abelii -----
Callithrix_jacchus -----
Macaca_mulatta -----
Equus_caballus -----

Human564350-570450 **gaccaatgggacttaaacccacaaacacttagttaacagctaaagcaccctaatcaactgg**
Pan_troglodytes -----
Pongo_abelii -----
Callithrix_jacchus -----
Macaca_mulatta -----
Equus_caballus -----

Human564350-570450 **cttcaatctacttctccgccgcccgggaaaaaggcgggagaagccccggcaggtttgaa**
Pan_troglodytes -----
Pongo_abelii -----
Callithrix_jacchus -----
Macaca_mulatta -----
Equus_caballus -----

Human564350-570450 gctgcttcttcgaaatttgcaattcaatatgaaaaacacctcagagctggtaaaaaagggc
Pan_troglodytes -----
Pongo_abelii -----
Callithrix_jacchus -----
Macaca_mulatta -----
Equus_caballus -----

Human564350-570450 ttaaccocctgtcttagatttacagtcocaaatgcttoactcagccattttaccoccccc
Pan_troglodytes -----
Pongo_abelii -----
Callithrix_jacchus -----
Macaca_mulatta -----
Equus_caballus -----

Human564350-570450 actgatgttcgcgacccgttgactattctctacaaaccacaagaacattggaacctata
Pan_troglodytes -----
Pongo_abelii -----
Callithrix_jacchus -----
Macaca_mulatta -----
Equus_caballus -----

Human564350-570450 cctattattcggcgcgatgagctggagtcctaggcacagctctaagcccttattogagc
Pan_troglodytes -----
Pongo_abelii -----
Callithrix_jacchus -----
Macaca_mulatta -----
Equus_caballus -----

Human564350-570450 cgaactgggccagccaggcaacctctaggtaacgaccacatctacaacgttatcgtcac
Pan_troglodytes -----
Pongo_abelii -----
Callithrix_jacchus -----
Macaca_mulatta -----
Equus_caballus -----

Human564350-570450 agcccatgcatcttgtaataatcttctcatagtaatacccatcataatcggaggctttgg
Pan_troglodytes -----
Pongo_abelii -----
Callithrix_jacchus -----
Macaca_mulatta -----
Equus_caballus -----

Human564350-570450 caactgactagttccccaaataatcggtgccccgatatggcgtttccccgataaaca
Pan_troglodytes -----
Pongo_abelii -----
Callithrix_jacchus -----
Macaca_mulatta -----
Equus_caballus -----

Human564350-570450 cataagctctgactcttaccocctctctcactcctgcttgcatctgctatagtgga
Pan_troglodytes -----
Pongo_abelii -----
Callithrix_jacchus -----
Macaca_mulatta -----
Equus_caballus -----

Human564350-570450 ggccggcgaggaaacaggttgaacagtctaccctccctggcagggaactactcccacc
Pan_troglodytes -----
Pongo_abelii -----
Callithrix_jacchus -----
Macaca_mulatta -----
Equus_caballus -----

Human564350-570450 tggagcctccgtagacctaacctctctccttacacctagcaggtatctcctctatctt
Pan_troglodytes -----
Pongo_abelii -----
Callithrix_jacchus -----
Macaca_mulatta -----
Equus_caballus -----

Human564350-570450 aggagccatcaatttctcacaacaattattaataaaaaccocctgccataaccaata
Pan_troglodytes -----
Pongo_abelii -----
Callithrix_jacchus -----
Macaca_mulatta -----
Equus_caballus -----

Human564350-570450 **ccaaa**cgcccc**ttt**cg**t**g**at**cc**g**tc**ct**aa**tc**acag**cag**t**ct**ta**ct**tc**ct**at**ct**
Pan_troglodytes -----
Pongo_abelii -----
Callithrix_jacchus -----
Macaca_mulatta -----
Equus_caballus -----

Human564350-570450 **cccag**tc**ct**ag**cc**g**ct**gg**cat**ca**ct**ata**ct**aa**cag**ac**gc**g**ta**ac**ct**ca**ac**ca**cc**o**ct**
Pan_troglodytes -----
Pongo_abelii -----
Callithrix_jacchus -----
Macaca_mulatta -----
Equus_caballus -----

Human564350-570450 **cttcg**ac**cc**ag**cc**g**g**ag**g**ag**g**ag**ac**cc**ca**tt**ct**ata**cc**aa**ca**cc**ct**att**ct**g**at**tt**tt**g**g**
Pan_troglodytes -----
Pongo_abelii -----
Callithrix_jacchus -----
Macaca_mulatta -----
Equus_caballus -----

Human564350-570450 **tc**cc**ct**ga**ag**tt**ta**t**tt**ct**at**cc**ta**cc**ag**g**ct**tg**ga**aa**ta**ct**cc**at**att**g**ta**ac
Pan_troglodytes -----
Pongo_abelii -----
Callithrix_jacchus -----
Macaca_mulatta -----
Equus_caballus -----

Human564350-570450 **tt**act**act**cc**gg**g**aaaa**aa**ga**cc**att**gg**ata**ca**tag**g**at**g**g**ct**g**ag**ct**at**g**at
Pan_troglodytes -----
Pongo_abelii -----
Callithrix_jacchus -----
Macaca_mulatta -----
Equus_caballus -----

Human564350-570450 **ca**att**gg**ct**cc**tag**gg**tt**at**cg**t**g**g**ag**ca**cc**ata**t**att**ta**cc**ag**tag**ga**at**ag**ac**g
Pan_troglodytes -----
Pongo_abelii -----
Callithrix_jacchus -----
Macaca_mulatta -----
Equus_caballus -----

Human564350-570450 **tag**ac**ac**ag**ac**at**tt**ca**cc**tc**gc**ta**cc**ata**at**ca**tc**gc**ta**cccc**ac**gg**ct**ca
Pan_troglodytes -----
Pongo_abelii -----
Callithrix_jacchus -----
Macaca_mulatta -----
Equus_caballus -----

Human564350-570450 **a**ag**ta**tt**ta**g**ct**g**act**cg**cc**ac**ct**cc**ac**g**ga**g**ca**at**at**g**aa**at**ga**t**ct**g**ct**g**c**ag**t**g**c**
Pan_troglodytes -----
Pongo_abelii -----
Callithrix_jacchus -----
Macaca_mulatta -----
Equus_caballus -----

Human564350-570450 **ct**g**ag**cc**ct**ag**g**att**tt**tt**tt**ct**tt**cc**gc**tag**g**tg**gc**g**act**g**gc**att**gt**att**ag**
Pan_troglodytes -----
Pongo_abelii -----
Callithrix_jacchus -----
Macaca_mulatta -----
Equus_caballus -----

Human564350-570450 **ca**a**act**ca**ct**ag**ac**at**cg**t**act**ac**gc**ac**gc**g**ta**ct**ac**g**tt**g**tag**ccc**act**tc**act**
Pan_troglodytes -----
Pongo_abelii -----
Callithrix_jacchus -----
Macaca_mulatta -----
Equus_caballus -----

Human564350-570450 **at**g**tc**ot**at**ca**at**ag**g**ag**ct**g**t**att**tg**cc**at**ca**tag**g**ag**g**ct**ca**tc**act**g**att**cccc**
Pan_troglodytes -----
Pongo_abelii -----
Callithrix_jacchus -----
Macaca_mulatta -----
Equus_caballus -----

Human564350-570450 **tattctcaggctacaccctagacccaaacctacgccaaaatccatttcgctatcatattca**
Pan_troglodytes -----
Pongo_abelii -----
Callithrix_jacchus -----
Macaca_mulatta -----
Equus_caballus -----

Human564350-570450 **tcggcgtaaatcctaactttctccacaacactttctcggcctatccgggaatgccccgac**
Pan_troglodytes -----
Pongo_abelii -----
Callithrix_jacchus -----
Macaca_mulatta -----
Equus_caballus -----

Human564350-570450 **gttactcggactatcccgatgcatacaccatgaaatatccatcatctgtaggctcat**
Pan_troglodytes -----
Pongo_abelii -----
Callithrix_jacchus -----
Macaca_mulatta -----
Equus_caballus -----

Human564350-570450 **tcatttctctaacagcagtaataattaattttcataatttgagaagccttcgcttoga**
Pan_troglodytes -----
Pongo_abelii -----
Callithrix_jacchus -----
Macaca_mulatta -----
Equus_caballus -----

Human564350-570450 **agcgaaaagtccctaagtagagaagaccctccataaacctggagtgactataggatgcc**
Pan_troglodytes -----
Pongo_abelii -----
Callithrix_jacchus -----
Macaca_mulatta -----
Equus_caballus -----

Human564350-570450 **ccccccctaccacacattcgaagaaccctatacataaaaatctagacaaaaaaggagg**
Pan_troglodytes -----
Pongo_abelii -----
Callithrix_jacchus -----
Macaca_mulatta -----
Equus_caballus -----

Human564350-570450 **aatcgaaacccccaaagctggttcaagccaaccccatggcctccatgactttttcaaaa**
Pan_troglodytes -----
Pongo_abelii -----
Callithrix_jacchus -----
Macaca_mulatta -----
Equus_caballus -----

Human564350-570450 **agatattagaaaaaccatttcaataactttgtcaaaagttaattataggctaaatcctata**
Pan_troglodytes -----
Pongo_abelii -----
Callithrix_jacchus -----
Macaca_mulatta -----
Equus_caballus -----

Human564350-570450 **tactttaatggcactgcagcgaagtaggtctacaagacgctacttcccctatcataga**
Pan_troglodytes -----
Pongo_abelii -----
Callithrix_jacchus -----
Macaca_mulatta -----
Equus_caballus -----

Human564350-570450 **agagcttatcatctttcatgatcagccctcaataatcttttcttatctgcttccctagt**
Pan_troglodytes -----
Pongo_abelii -----
Callithrix_jacchus -----
Macaca_mulatta -----
Equus_caballus -----

Human564350-570450 **ccgttacgcccttttctaacactcacaacaaaactaactaataactaacatctcagagc**
Pan_troglodytes -----
Pongo_abelii -----
Callithrix_jacchus -----
Macaca_mulatta -----
Equus_caballus -----

Human564350-570450 **tcaggaatagaaacgctcgaactatcctgcccgccatcctcctagtccttatcgcct**
Pan_troglodytes -----
Pongo_abelii -----
Callithrix_jacchus -----
Macaca_mulatta -----
Equus_caballus -----

Human564350-570450 **cccatccctacgcatcctttacataacagagaggccaacgatccctcctttaccatcaa**
Pan_troglodytes -----
Pongo_abelii -----
Callithrix_jacchus -----
Macaca_mulatta -----
Equus_caballus -----

Human564350-570450 **atcaattggccatcaatggtactgaacctcgaatacaccgactcggcggactaatctt**
Pan_troglodytes -----
Pongo_abelii -----
Callithrix_jacchus -----
Macaca_mulatta -----
Equus_caballus -----

Human564350-570450 **caactcctacatacttccccattatcctagaaccaggcgacctgogactccttgaact**
Pan_troglodytes -----
Pongo_abelii -----
Callithrix_jacchus -----
Macaca_mulatta -----
Equus_caballus -----

Human564350-570450 **tgcaatcgagtagtactcccggttgaagccccattcgtataataattacatcacaaga**
Pan_troglodytes -----
Pongo_abelii -----
Callithrix_jacchus -----
Macaca_mulatta -----
Equus_caballus -----

Human564350-570450 **cgctttacactcatgagctgtccccacattaggcttaaaacagatgcaattccggcag**
Pan_troglodytes -----
Pongo_abelii -----
Callithrix_jacchus -----
Macaca_mulatta -----
Equus_caballus -----

Human564350-570450 **cttaaaccaaaccaactttcactgtacacgaccaggggtatactcggccaatgctctga**
Pan_troglodytes -----
Pongo_abelii -----
Callithrix_jacchus -----
Macaca_mulatta -----
Equus_caballus -----

Human564350-570450 **aatctgtggagcaaacagttttatgccatcgtcctagaattaattccccaaaaatct**
Pan_troglodytes -----
Pongo_abelii -----
Callithrix_jacchus -----
Macaca_mulatta -----
Equus_caballus -----

Human564350-570450 **ttgaaatagggccgctatttaccctatagcaccctctacccctctagagcccactgt**
Pan_troglodytes -----
Pongo_abelii -----
Callithrix_jacchus -----
Macaca_mulatta -----
Equus_caballus -----

Human564350-570450 **aaagctaaccttagcattaacctttaagttaaagattaagagaaccaaccctctttaca**
Pan_troglodytes -----
Pongo_abelii -----
Callithrix_jacchus -----
Macaca_mulatta -----
Equus_caballus -----

Human564350-570450 **gtgaaatgccccactaaatactacgctatgcccccaataattccccatactcctta**
Pan_troglodytes -----
Pongo_abelii -----
Callithrix_jacchus -----
Macaca_mulatta -----
Equus_caballus -----

Human564350-570450	cactattcctcatcaccacaactaaaaatattaatacaaaattaccacotcctccctcac
Pan_troglodytes	-----
Pongo_abelii	-----
Callithrix_jacchus	-----
Macaca_mulatta	-----
Equus_caballus	-----
Human564350-570450	caagcccataaaaataaaaaactataacaaaccctgagaacccaaaatgaaogaaaatct
Pan_troglodytes	-----
Pongo_abelii	-----
Callithrix_jacchus	-----
Macaca_mulatta	-----
Equus_caballus	-----
Human564350-570450	gttcacttcattcattgccccacaatcctaggcctaccgcgcagtagctgatctct
Pan_troglodytes	-----
Pongo_abelii	-----
Callithrix_jacchus	-----
Macaca_mulatta	-----
Equus_caballus	-----
Human564350-570450	atttccctctattgtatccccacctccaaaatctcatcaacaaccgactaattaccac
Pan_troglodytes	-----
Pongo_abelii	-----
Callithrix_jacchus	-----
Macaca_mulatta	-----
Equus_caballus	-----
Human564350-570450	ccaacaatgactaatccaactaacctcaaaacaaatgatagccatacacaacactaaggg
Pan_troglodytes	-----
Pongo_abelii	-----
Callithrix_jacchus	-----
Macaca_mulatta	-----
Equus_caballus	-----
Human564350-570450	aggaacctgatctcttatactagtatccttaactctttttattgccacaactaacctct
Pan_troglodytes	-----
Pongo_abelii	-----
Callithrix_jacchus	-----
Macaca_mulatta	-----
Equus_caballus	-----
Human564350-570450	cggaactcctgcctcactcatttacaccaaccaccaactatctataaacctagccatggc
Pan_troglodytes	-----
Pongo_abelii	-----
Callithrix_jacchus	-----
Macaca_mulatta	-----
Equus_caballus	-----
Human564350-570450	catcccccttagagcgggcgagtgattataggctttcgctcctaaagattaaaaatgcct
Pan_troglodytes	-----
Pongo_abelii	-----
Callithrix_jacchus	-----
Macaca_mulatta	-----
Equus_caballus	-----
Human564350-570450	agcccaacttcttaccacaaggcacacctacacccttatccctatactagttattatoga
Pan_troglodytes	-----
Pongo_abelii	-----
Callithrix_jacchus	-----
Macaca_mulatta	-----
Equus_caballus	-----
Human564350-570450	aaccatcagcctactcattcaaccaatagccctggcctgtaogcctaaccgctaacattac
Pan_troglodytes	-----
Pongo_abelii	-----
Callithrix_jacchus	-----
Macaca_mulatta	-----
Equus_caballus	-----
Human564350-570450	tgcaggccacctactcctgcaacctaatggaagcgcacactagcaatatcaactattaa
Pan_troglodytes	-----
Pongo_abelii	-----
Callithrix_jacchus	-----
Macaca_mulatta	-----
Equus_caballus	-----

Human564350-570450 **ccttccctctacacttatcatcttcacaattctaatctactgactatcctagaaatcgc**
Pan_troglodytes -----
Pongo_abelii -----
Callithrix_jacchus -----
Macaca_mulatta -----
Equus_caballus -----

Human564350-570450 **tgtcgccttaatccaagcctacgtttttacacttctagtaagcctctacctgcacgacaa**
Pan_troglodytes -----
Pongo_abelii -----
Callithrix_jacchus -----
Macaca_mulatta -----
Equus_caballus -----

Human564350-570450 **cacataatgacccaccaatcacatgccatcatatagtaaaaccagccatggccccta**
Pan_troglodytes -----
Pongo_abelii -----
Callithrix_jacchus -----
Macaca_mulatta -----
Equus_caballus -----

Human564350-570450 **acaggggcccctctcagccctcctaaatgacctccggcctagccatgtgatttcacttcac**
Pan_troglodytes -----
Pongo_abelii -----
Callithrix_jacchus -----
Macaca_mulatta -----
Equus_caballus -----

Human564350-570450 **tccacaaccctcctcactactaggcctactaaccaacacactaaccatataccaatgatgg**
Pan_troglodytes -----
Pongo_abelii -----
Callithrix_jacchus -----
Macaca_mulatta -----
Equus_caballus -----

Human564350-570450 **cgcgatgtaacaagagaagcacatccaaggccaccacaccaccctgtccgaaaggcc**
Pan_troglodytes -----
Pongo_abelii -----
Callithrix_jacchus -----
Macaca_mulatta -----
Equus_caballus -----

Human564350-570450 **cttcgatcagggataatcctatttattacctcagaagttttttcttcgcaggatttttc**
Pan_troglodytes -----
Pongo_abelii -----
Callithrix_jacchus -----
Macaca_mulatta -----
Equus_caballus -----

Human564350-570450 **tgagccttttaccactccagcctagctcccccccccaactagggggacactggccccca**
Pan_troglodytes -----
Pongo_abelii -----
Callithrix_jacchus -----
Macaca_mulatta -----
Equus_caballus -----

Human564350-570450 **acaggcatcacccccgctaaatcccctagaagtcccactcctaaacacatcogtattactc**
Pan_troglodytes -----
Pongo_abelii -----
Callithrix_jacchus -----
Macaca_mulatta -----
Equus_caballus -----

Human564350-570450 **gcatcaggggtatcaatcacctgagctcaccatagctcfaatagaaaacaaccgaaaccaa**
Pan_troglodytes -----
Pongo_abelii -----
Callithrix_jacchus -----
Macaca_mulatta -----
Equus_caballus -----

Human564350-570450 **ataattcaagcactgcttattacaattttactgggtctctattttaccctctacaagcc**
Pan_troglodytes -----
Pongo_abelii -----
Callithrix_jacchus -----
Macaca_mulatta -----
Equus_caballus -----

```

Human564350-570450 tcagagtacttcgaggttaaAATA---TTAGATATTTCCCTGATACAGGGCTCAATC
Pan_troglodytes .....CA.....
Pongo_abelii .....
Callithrix_jacchus .....AGACA.....C.....G.....A.....A
Macaca_mulatta .....AGACA.....G.....
Equus_caballus .....G..AGAtccc.....A.....G..


Human564350-570450 TTTTCTTTTAAAGCAATATTTCTCAAAGTAC-----TTTCACAGA
Pan_troglodytes .....
Pongo_abelii .....A...
Callithrix_jacchus .....T.....a-TTTTTTCAAAGTAC.....
Macaca_mulatta .....acTTTTTCAAAGTACA.....
Equus_caballus .....AT.G....CT..C..A...-.....G..TG..

Human564350-570450 ACTTAAGTTTCATTAAGCAC TTCACTAAAAGAAAAGTCTGTGATCTAATAAATTGGAAA
Pan_troglodytes .....
Pongo_abelii .....T...T.....G...G..
Callithrix_jacchus .....TC..G.T.....C..A.....
Macaca_mulatta .....C..C..T.....C..G.A.....
Equus_caballus .....C.....CT..C.....C..Tc.....T.....C.G.G.....


Human564350-570450 ATA
Pan_troglodytes ...
Pongo_abelii ...
Callithrix_jacchus ...
Macaca_mulatta ...
Equus_caballus ..t

```


Figure I.3.1. Implication of mtDNA point heteroplasmies in the secondary structure of tRNAs, rRNAs and tertiary structure of COXI, COXII and CytB




tRNA
Lysine




Mutation 8307




tRNA
Lysine
entropy




Mutation 8307
entropy




tRNA
Lysine




Mutation 8307




tRNA
Lysine
entropy




Mutation 8307
entropy




tRNA
Arginine




Mutation 10427







tRNA Arginine
entropy






Mutation 10427
entropy













rRNA 12S





rRNA 12S
entropy











COXI




51 Aspartic acid (6054 mtDNA position)




51 Asparagine Mut (6054 mtDNA position)


COXII




38 Valine (7697 mtDNA position)




38 Isoleucine Mut (7697 mtDNA position)



cyt B



190 Alanine (15314 mtDNA position)



190 Threonine Mut (15314 mtDNA position)




Table I.3.2 Mutation report of complete mitochondrial DNA of 101 individuals. Point and length heteroplasmy are showed in bold. Sex and haplogroup is also reported.

Sample name	Sex	Haplogroup	Haplotype
Z19	male	J	73, 185, 228, 263, 295, 310, 310.1C, 462, 482, 489, Het Poly-C 568-573 , 750, 1438, 2706, 3010, 3107d, 3394, 4216, 4769, 7028, 8860, 10398, 11251, 11719, 12612, 13708, 14766, 14798, 15326, 15452A, 16069, 16126
Z237	female	K	73, 263, Het Poly-C 303-309 , 750, 761, 1438, 3107d, 4769, 6776, 8860, 15326, 16519
Snb85	male	H1	263, 315.1C, 750, 1438, 3010, 3107d, 4769, 6497, 7202, 8860, 15326, 16519
Z225	female	U	73, 94, 150, 263, 315.1C, 750, 1438, 1721, 2706, 3107d, 3197, 3221, 4639, 4769, Het 5306Y , 8860, 9097, 9477, 11467, 11653, 11719, 12308, 12372, 12634, 13617, 13630, 13637, 14182, 14766, 15326, 16148, 16261, 16390
Z153	female	pre*V	72, 195, 263, Het Poly-C 303-309 , 750, 1438, 2706, 3107d, 4769, 7028, 8860, 15110, 15326, 16298, 16301
Z8	male	J1b	73, 263, 295, 315.1C, 462, 489, 750, 1438, 1733, 2706, 3010, 3107d, 4216, 4769, 6719, 7028, 8269, 8860, 10398, 11251, 11719, 12612, 13708, 14766, 14927, 15326, 15452A, 16069, 16126, 16145, 16222, 16261
Z326	male	H3	146, 263, 315.1C, 572.2C, 750, 1438, 3107d, 4769, 6776, 8860, 12957, 13359, 15326, 16519
Z349	male	U5	152, 195, 263, 315.1C, 750, 1438, 3010, 3107d, 4769, 4820, 8596, 8860, 9986, 11002, 12061, 15326, 16519

Sample name	Sex	Haplogroup	Haplotype
Z115	male	H*	263, 292, Het Poly-C 303-309 , 750, 1438, 3107d, 4769, 8860, 15326, 16218, 16328A, 16362
Z218	female	T2	73, 207, 263, Het Poly-C 303-309 , 709, 750, 930, 1438, 1888, 2706, 3107d, 3398, 4216, 4769, 4917, 5147, 7028, 8697, 8860, 9181, 10463, 11251, 11719, 11812, 13368, 14766, 14905, 15326, 15452A, 15607, 15928, 16126, 16294, 16296, 16304, 16519
Z265	female	J1a	73, 150, 152, 195, 215, 263, 295, 310.1C, 315.1C, 319, 489, 513, 750, 1438, 2706, 3107d, 4216, 4769, 5899.1C, 7028, 7476, 7768, 7789, 8860, 10398, 10499, 11251, 11377, 11719, 12612, 13708, 13722, 14133, 14766, 15257, 15326, 15452A, 15596, 16069, 16126, 16145, 16231, 16261
Z249	male	I	73, 199, 204, 250, 263, 315.1C, Het Poly-C 568-573 , 750, 1438, 1719, 2706, 3107d, 4529T, 4769, 7028, 8251, 8519, 8860, 9090, 10034, 10238, 10398, 10819, 11719, 12501, 12705, 13780, 14766, 15043, 15326, 15924, 16129, 16223, 16304, 16391, 16519
Z269	female	J1b1	73, Het 152Y , 242, 263, 295, 315.1C, 462, 489, 524.1AC, 750, 1438, 2158, 2706, 3010, 3107d, 4216, 4769, 5460, 7028, 8269, 8557, 8860, 10398, 11251, 11719, 12007, 12612, 13708, 13879, 14766, 15326, 15452A, 16069, 16126, 16145, 16172, 16222, 16261
Z120	female	U5a	73, 150, 263, 315.1C, 750, 1438, 1721, 2706, 3107d, 3197, 4491, 4639, 4732, 4769, 6329, 6366, 7028, 7768, 8838, 8860, 9477, 11467, 11719, 12308, 12372, 12957, 13617, 13637, 13677, 14182, 14305, 14766, 15326, 16114A, 16192, 16270

Sample name	Sex	Haplogroup	Haplotype
Z223	female	H1	195, 263, Het Poly-C 303-309 , 523-524d, 750, 1438, 3010, 3107d, 3745, 4769, 5584C, Het 8603Y , 8860, 15326, 16519
Z138	female	H*	146, 263, 315.1C, 750, 1438, 3107d, 4769, 4793, 7028, 7768, 8860, 15326, 15409, 16519
Z62	male	U2	73, 217, 228, 263, 315.1C, 340, 508, 750, 1438, 1811, 2706, 3107d, 3720, 4769, 5390, 5426, 6045, 6152, 7028, 8860, 10876, 11467, 11719, 12308, 12372, 13020, 13734, 14766, 15326, 15907, 16051, 16129C, 16183C, 16193.1C, 16291, 16362, 16519
Z144	female	K	73, 263, 310.1C, 315.1C, 497, Length Het Poly AC 514-525 , 750, 1189, 1438, 1811, 2706, 3107d, 3480, 4769, 6260, 7028, 8860, 9055, 9698, 10398, 10550, 11467, 11719, 11840, 11944, 12308, 12372, 13740, 14167, 14766, 14798, 15326, 16224, 16311, 16519
Z217	female	U5a1	73, Het 152Y , 263, Het Poly-C 303-309 , 750, 1438, 2706, 3107d, 3197, 4769, 7028, 8860, 9477, 9667, 11467, 11719, 12308, 12372, 13617, 14766, 14793, 15218, 15326, 16172, 16192, 16256, 16270, 16362, 16399
Z90	female	H1	185, 263, Het Poly-C 303-309 , 750, 1438, Het 2887Y , 3010, 3107d, 4659, 4769, Length het 8289-8290CCCCCTCTA , 8860, 11215, 12810, 15326, 16209, 16519
Z63	female	H*	64, 263, 315.1C, 750, 1438, 3107d, 4769, 5237, 8860, 15326, 16145, 16519

Sample name	Sex	Haplogroup	Haplotype
Z248	male	U5a1a	73, 150, 263, 315.1C, 750, 1303, 1438, 3107d, 3192, 3197, 3591, 4592, 4769, Het 6054R , 7028, 8860, 9477, 11296, 11467, 11719, 11938, 12308, 12372, 12618, 13617, 14766, 14793, 15218, 15326, 16192, 16239, 16256, 16270, 16399
Z80	female	L1b	73, 152, 182, 185T, 189, 195, 247, 263, 315.1C, 357, 523d, 709, 710, 750, 769, 825A, 1018, 1738, 2352, 2706, 2758, 2768, 2885, 3107d, 3308, 3594, 3666, 3693, 4104, 4769, 5036, 5046, 5393, 5655, 6548, 6827, 6989, 7028, 7055, 7146, 7256, 7389, 7521, 7867, 8248, 8468, 8655, 8701, 8860, 9476, 9540, 10398, 10688, 10810, 10873, 11719, 12519, 12705, 13105, 13506, 13650, 13789, 13880A, 14178, 14203, 14560, 14766, 14769, 15115, 15326, 15479, 16126, 16187, 16189, 16223, 16264, 16270, 16278, 16293, 16311, 16362, 16400, 16519
Snb33	female	V	72, 263, Het Poly-C 303-309 , 750, 1438, 2706, 3107d, 4580, 4769, 7028, 8860, 12810, 12840, 15326, 15431, 15904, 16240, 16298
Z213	male	N1b	73, 152, 204, 263, 310.1C, 315.1C, 750, 1438, 1598, 2639, 2706, 3107d, 3921A, 4769, 4904, 4960, 5471, 7028, 8251, 8472, 8836, 8860, 9335, 9947, 10238, 10948G, 11362, 11719, 12501, 12705, 12822, 14766, 15326, 16145, 16176G, 16223, 16390, 16519
Z272	male	J	73, 185, 228, 263, 295, Het Poly-C 303-309 , 462, 482, 489, Het Poly-C 568-573 , 750, 1438, 2706, 3010, 3107d, 3394, 4216, 4769, 7028, 8860, 10398, 11251, 11719, 12612, 13708, 14766, 14798, 15326, 15452A, 16069, 16126
Z64	female	H3	263, 293, Het Poly-C 303-309 , 709, 750, 1438, 3107d, 4769, 6776, 8860, 9521, 12346, 15326, 15530, 16519

Sample name	Sex	Haplogroup	Haplotype
Z156	male	H1	263, 315.1C, 750, 1438, 3010, 3107d, 4769, 5100, 5460, 5746, 8860, 15326, 15928, 16166C, 16519
Z163	female	M1	73, 195, 263, Het Poly-C 303-309 , 489, 524.1AC, 709, 750, 813, 1438, 2706, 3107d, 4769, 6446, 6671, 6680, 7028, 8701, 8860, 9540, 10398, 10400, 10873, 11719, 12403, 12414, 12705, 12950C, 13637, 14110, 14766, 14783, 15043, 15301, 15326, 16093, 16129, 16148, 16183C, Het Poly-C 16184-16193 , 16249, 16311, 16519
Z172	female	pre*V	72, 195, 263, Het Poly-C 303-309 , 750, 1438, 2706, 3107d, 3263, 4769, 5567, 7028, 8860, 10410, 12662, 15326, 16298, 16519
Z188	female	J	73, 185, 188, 228, 263, 295, 315.1C, 462, 489, 750, 1438, 1555, 2706, 2963, 3010, 3107d, 4216, 4769, 7028, 8860, 10398, 11251, 11719, 12612, 13708, 14766, 14798, 15326, 15452A, 16069, 16126, 16519
Z340	male	H3	263, 315.1C, 750, 1438, 3107d, 4769, 6776, 8860, Het 9029R , 10754, 12308, 12372, 15326, 16519
Z71	male	U5a1a, U5b	73, 195, 263, 310.1C, Het Poly-C 568-573 , 750, 1438, 2706, 3027, 3107d, 3197, 3552, 4769, 4823, 5583, 7028, 8860, 9477, 11467, 11719, 12308, 12372, 13135, 13617, 14766, 14793, 15218, 15326, 15496, 16145, Het Poly-C 16184-16193 , 16311, 16399
Z141	male	H*	73, Het 189R , 195, 198, 204, 207, 263, Het Poly-C 303-309 , 709, 750, 1243, 1438, 2706, 3107d, 3505, 4659, 4769, 5046, 5460, 7028, 7864, 8251, 8860, 8994, 11674, 11719, 11947, 12414, 12705, 14766, 15326, Het 15496R , 15884C, 15930, 16223, 16292, 16346, 16519

Sample name	Sex	Haplogroup	Haplotype
Z66	female	T5	41, 73, 150, 263, 310.1C, 315.1C, Length Het 514-525 , 709, 750, 1438, 1888, 2706, 3107d, 4216, 4769, 4917, 7028, 8697, 8860, 10463, 11251, 11719, 11812, 13368, 14178, 14203, 14766, 14905, 15326, 15452A, 15607, 15928, 16126, 16153, 16294, 16519
Z125	female	J1b1	73, 242, 263, 295, 315.1C, 462, 489, 524.1AC, 750, 1438, 2158, 2706, 3010, 3107d, 4216, 4769, 5460, 7028, 8269, 8557, 8860, 10398, 11251, 11719, 12007, 12612, 13708, 13879, 14766, 15326, 15452A, 16069, 16126, 16145, 16172, 16222, 16261
Z99	male	T1	73, 263, Het Poly-C 303-309 , 709, 750, 1438, 1888, 2706, 3107d, 3867, 4216, 4769, 4917, 7028, 8697, 8860, 10376, 10463, 11251, 11719, 12633A, 13368, 14766, 14905, 15326, 15452A, 15607, 15928, 16126, 16163, 16186, 16189d, 16294, 16519
Snb9	male	K	73, 263, Het Poly-C 303-309 , 497, 524.1AC, 750, 1189, 1438, 2706, 3107d, 3480, 4769, 6260, 7028, 8860, 9055, 9698, 10398, 10550, 11299, 11467, 11485, 11719, 11840, 11944, 12308, 12372, 13740, 14167, 14766, 14798, 15326, 16224, 16311, 16519
Z187	female	U5a	73, 150, 152, 263, 315.1C, Het Poly-C 568-573 , 750, 1438, 2706, 3107d, 3197, 4769, 5004, 5656, 7028, 7768, 8860, 9477, 11467, 11719, 12308, 12372, 13617, 14182, 14766, 15326, 16192, 16270, 16519
Z253	female	H1	73, 263, 315.1C, 750, 1438, 3010, 3107d, 4769, 5039, 6365, 8860, 15326, 16162, Het 16189Y , 16209, 16519
Z201	female	H*	263, Het Poly-C 303-309 , 750, 1438, 2259, 3107d, 4745, 4769, 7337, 8860, 13326, 13680, 14872, 15326, 16365

Sample name	Sex	Haplogroup	Haplotype
Z298	male	U5	73, 150, 263, 310.1C, 315.1C, 456, 517T, 750, 1438, 1721, 2706, 2755, 3107d, 3197, 4769, 6242A, 7028, 7768, 8860, 11467, 11653, 11719, 12308, 12372, 12634, 13630, 13637, 14182, 14766, 15068, 15326, 15905, 16224, 16270, 16311, 16519
Z273	female	K	73, 263, 310.1C, 315.1C, 497, 524.1AC, 750, 1189, 1438, 1811, 2706, 3107d, 3480, Het 3729R , 4769, 6260, 7028, 8860, 9055, 9698, 10398, 10463, 10550, 11299, 11467, 11485, 11719, 11840, 11944, 12308, 12372, 13740, 14167, 14766, 14798, 15326, 16224, 16311, 16519
Snb37	female	U6a1	263, Het Poly-C 303-309 , 750, 1438, 3010, 3107d, 4769, 5665, 8860, 15326, 16519
Snb78	female	H3	263, Het Poly-C 303-309 , 750, 1438, 3107d, 4769, 5498, 6293, 6776, 8860, Het 13812Y , 15326, 16519
Z167	male	(pre-HV)1	60.1T, 64, 263, 315.1C, 451, 750, 1438, 2442, 2706, 3107d, 3275A, 3847, 4769, 7028, 8860, 9620, 11969, 13188, 14668, 14766, 14905, 15326, 16126, 16362
Z48	male	U5a1a	73, 152, 182, 185T, 189, 195, 247, 263, 315.1C, 357, 471, 524.1AC, 709, 750, Het 772R , 930, 1438, 1700, 1811, 2706, 3107d, 4025, 4164, 4769, 6503, 7028, 8860, 8938, 10343, 11467, 11719, 11812C, 11893, 12127, 12308, 12372, 14766, 14926, 15326, 16051, 16183C, Het Poly-C 16184-16193 , 16234, 16266, 16294, 16519, 16525

Sample name	Sex	Haplogroup	Haplotype
Z18	female	L2b	73, 146, 150, 152, 182, 183, 195, 198, 204, 263, Het Poly-C 303-309 , 750, 769, 1018, 1438, 1442, 1706, 2332, 2358, 2416, 2706, 3107d, 3594, 4104, 4158, 4370, 4767, 4769, 5027, 5331A, 5814, 6614, 6713, 6806, 7028, 7256, 7521, 7624A, 7670C, 8080, 8206, 8387, 8503, 8701, 8860, 9221, 9540, 10115, 10398, 10873, 11719, 11944, 12236, 12373, 12705, 12948, 13590, 13650, 14016, 14059, 14766, 15110, 15217, 15326, 16114A, 16129, 16213, 16223, 16278, 16390
Z87	male	U5b	73, 150, 152, 195, 263, 310, 310.1C, 315.1C, 750, 1438, 2234, 2706, 3107d, 3197, 4769, 5656, 7028, 7768, 8860, 9477, 11467, 11719, 12308, 12372, 13617, 14182, 14766, 15122, 15326, 16172, 16183C, Het Poly-C 16184-16193 , 16270, 16274, 16311, 16325, 16357, 16465, 16519
Snb22	male	pre*V	195, 263, 315.1C, 750, 1438, 2706, 3107d, 4769, 7028, 8860, 9180, 15326, 16153, Het 16293R , 16298
Z362	male	J	73, 185, 188, 228, 263, 295, 310.1C, 315.1C, 462, 489, 523d, 524d, 750, 1438, 2706, 3010, 3107d, 4216, 4769, 7028, 8860, 10398, 11251, 11719, 12612, 13708, 14766, 14798, 15326, 15452A, 16069, 16126, 16366, 16390, 16519
Z241	male	H3	Het 93R , 263, 315.1C, 750, 930, 1438, 2581, 3107d, 4769, 5471, 6776, 8860, 15326, 16129, 16519
Z176	male	H1	263, 310.1C, 315.1C, 750, 1438, 3010, 3107d, 4769, 4859, Het 8307R , 8860, 15326, Het 15908Y , 16188A, 16519

Sample name	Sex	Haplogroup	Haplotype
Z83	female	U2	73, 217, 228, 263, 315.1C, 340, 750, 1438, 1811, 2706, 3107d, 3720, 4769, 5390, 5426, 5510T, 6045, 6152, 7028, 8860, 10876, 11467, 11719, 12308, 12372, 13020, 13734, 14766, 15326, 15907, 16051, 16129C, 16183C, 16193.1C, 16291, 16362, 16519
Snb48	male	preHV	73, 146, 263, 315.1C, 750, 1438, 1811, 2217, 2706, 3107d, 3480, 4769, 5231, 7028, 8860, 9055, 9698, 9716, 10550, 11299, 11467, 11719, 11869A, 12308, 12372, 13135, Het 13590R , 14037, 14167, 14766, 14798, 15326, 16129, Het 16189Y , 16222, 16224, 16270, 16311, 16519
Z256	female	J2	73, 150, 152, 263, Het Poly-C 303-309 , 489, 750, 1438, 2101A, 2706, 3107d, 4216, 4769, 5633, 6216, 6893, 7028, 7476, 7859, 8860, 10172, 10398, 11251, 11719, 13708, 14766, 15257, 15326, 15452A, 15812, 16069, 16126, 16193, 16218, 16278, 16290
Z38	male	H3	204, 263, Het Poly-C 303-309 , Het 593Y , 750, 1438, 3107d, 4769, 6776, 8541, 8860, 15326, 16286, 16519
Z104	female	H1	150, 263, 315.1C, 750, 1438, 3010, 3107d, 4769, 5460, 7715, 8512, 8860, 14902, 15326, 16519
Z297	male	U5	263, 315.1C, 523d, 524d, 750, 1438, 3107d, 3992, 4024, 4769, 5004, 5514, 8860, 9011.1CA, 9123, 14365, 14582, 15326, 16311, 16319
Z131	male	T	263, 315.1C, 523d, 524d, 750, 1438, 3107d, 3992, 4024, 4769, 5004, 7581, 8860, 9011.1A, 9123, 12308, 12372, 12618, 14365, 14582, 15326, 15497, 15930

Sample name	Sex	Haplogroup	Haplotype
Z5	male	H*	152, 207, 263, 315.1C, 750, 1438, 2259, 3107d, 4745, 4769, 6221, 8860, 12501, 13680, 14872, 15326
Snb63	male	T3	73, 146, 152, 263, 279, Het Poly-C 303-309 , 709, 750, 1438, 1888, 2706, 3107d, 4216, 4769, 4917, 5187, 6261, 7028, 7873, 8652, 8697, 8860, 10822, 10999, 11251, 11719, 11812, 12952, 13368, 14233, 14766, 14905, 15119, 15326, 15452A, 15607, 15928, 16111, 16126, 16292, 16294, 16519
Z195	male	K	73, 152, 263, 310.1C, 315.1C, Length Het Poly AC 514-525 , 750, 1189, 1438, 1811, 2706, 3107d, 3480, 4769, 5913, 7028, 8860, 9055, 9698, 9962, 10196G, 10289, 10398, 10550, 11299, 11467, 11719, 11923, 12308, 12372, 13967, 14167, 14766, 14798, 15257, 15326, 15946, 16093, 16224, 16311, 16319, 16463
Z3	female	U5a	73, 150, 263, 310.1C, 315.1C, 750, 1438, 2706, 3105, 3107d, 3197, 3498, 4769, 5656, 6674, 7028, 7768, 8860, 8944, 9477, 11467, 11719, 12308, 12372, 13617, 14182, 14766, 15326, 15777, 16167, 16192, 16270, 16311, 16356
Z30	female	H1	263, 315.1C, 750, 1438, 3010, 3107d, 3394, 4769, 8512, 8860, 14458, 14902, 15326, 16519
Z229	female	H*	95C, 195, 263, Het Poly-C 303-309 , 750, 961G, 1438, 2626, 3107d, 4769, 8448, Het 8577R , 8860, 11179, 13759, 15326, 16311, 16320

Sample name	Sex	Haplogroup	Haplotype
Z59	male	U5	73, 150, 263, 310.1C, 315.1C, 750, 1438, 1721, 2231, 2706, 3107d, 3197, 3861, 4769, 7028, 7768, 8860, 9477, 11467, 11653, 11719, 12308, 12372, 12634, 13617, 13630, 13637, 14182, 14766, 15326, 15497, 15778, 16270, 16292, 16362
Snb6	female	K	73, 146, 263, Het Poly-C 303-309 , 750, 1438, 1811, 2217, 2706, 3107d, 3480, 4769, 5231, 7028, 8860, 9055, 9698, 9716, 10550, 11299, 11467, 11719, 11869A, 13135, 14037, 14167, 14766, 14798, 15326, 16129, 16222, 16224, 16270, 16311, 16519
Z128	male	V	72, 263, Het Poly-C 303-309 , 460, 750, 1438, 2706, 3107d, 4580, 4769, 7028, 8860, 15326, 15904, 16172, 16298, 16519
Z137	female	H3	152, 263, 315.1C, 750, 1438, 3107d, 4769, 6776, 8860, 9011.1A, 14350, 15326, 15885, 16299
Snb13	male	H1	263, Het Poly-C 303-309 , 750, 1438, 3010, 3107d, 4769, 6497, 7202, 8860, 15326, 15452A, 16519
Z49	male	U5a, U5b	73, 150, 195, 263, 315.1C, 750, 1438, 1822, 2706, 3107d, 3197, 3316, 4769, 5656, 5788, 7028, 7385, 7768, 8860, 9477, 10301, 10927, 11467, 11719, 13818, 14182, 14470, 14766, 15326, 16129, 16223, 16304, 16391, 16519
Snb74	male	H1	73, 263, 315.1C, 523d, 524d, 750, 1438, 3010, 3107d, 4769, 6647, 8844, 8860, 9746, 11827, 11863, 12591, 15326, 16519

Sample name	Sex	Haplogroup	Haplotype
Snb61	female	U	73, 150, 263, Het Poly-C 303-309 , 750, 896, 1438, 2706, 3107d, 3197, 4732, 4769, 7028, 7768, 8860, Het 9449Y , 9477, Het 11016R , 11467, 11719, 12308, 12372, 12972C, 13617, 13637, 14182, 14766, Het 15244R , 15326, 15511, 16192, 16311
Z12	male	pre*V	72, 195, 263, Het Poly-C 303-309 , 750, 1438, 2706, 3107d, 4769, 7028, 8860, 12618, 14179, 14766, 15110, 15326, 16298, 16301
Z75	male	J1	73, 146, 263, 295, Het Poly-C 303-309 , 462, 489, 750, 1438, 2706, 3010, 3107d, 4216, 4769, 5501, 7028, 8269, 8277, Lenght Het 8272-8278 , 8990, 10398, 11251, 11719, 12519, 12612, 13708, 14766, 15326, 15452A, 16069, 16126, 16145, 16162, Het Poly-C 16184-16193 , 16261, 16286
Z252	male	H3	263, Het Poly-C 303-309 , 709, 750, 1438, 3107d, 4769, 5585, 6776, 8854, 8860, 9287, 10535, 15326, 16209, 16519
Z22	male	H1	263, 315.1C, 750, 1438, 3010, 3107d, 4769, 6497, 7202, 8860, 9986, 15326, 16468, 16519
Snb38	male	H*	63, 315.1C, 750, 1438, 3107d, 3915, 4769, 8860, 8895A, 12811, 15326, 16129, 16519
Z24	male	R1	146, 263, Het Poly-C 303-309 , 750, 1438, 2706, 3107d, 4769, 5471, 7028, Het 7912R , 8380, 8860, 14560, 15326, 16256, 16278, 16311, 16519

Sample name	Sex	Haplogroup	Haplotype
Z247	female	J1	73, 146, 189, Het 234R , 242, 263, 295, 315.1C, 462, 489, 750, 1438, 2158, 2706, 3010, 3107d, 4216, 4769, 5460, 7028, 8269, 8557, 8860, 10398, 11251, 11719, 12007, 12612, 13708, 13879, 14470, 14766, 15326, 15452A, 16069, 16093, 16126, 16145, 16172, 16184, 16261
Snb3	female	HV	153, 263, 315.1C, 523d, 524d, 750, 1438, 2158, 2706, 3107d, 4231, 4745, 4769, 7903, 8860, 14470, 14872, 15326, 16519
Z108	female	H1	263, Het Poly-C 303-309 , 750, 1438, 3010, 3107d, 3951, 4769, 8860, 12341, 15323, 15326, 16519
Z330	male	H*	263, Het Poly-C 303-309 , 750, 1438, 3107d, 3915, 4769, 8860, 8895A, 15326, 15924, 16129, 16519
Z203	female	H1	185, 263, 315.1C, 750, 1438, 3010, 3107d, 4659, 4769, 8860, 11215, 12810, 15326, 16209, 16311, 16519
Snb27	female	H3	152, 263, 315.1C, 338, 383, 750, 1438, 3107d, 4769, 6776, 8860, 15326, 16259, 16274, 16292, 16294G, 16519
Z168	male	U	73, 146, 263, 310.1C, 315.1C, 750, 1438, 2706, 3107d, 3348, 4769, 5471, 7028, 7391, 7805, 8860, 11467, 11719, 11914, 12308, 12372, 12501, 12618, 13440, 15326, 15941, 16129, 16172, 16278

Sample name	Sex	Haplogroup	Haplotype
Z34	male	K	73, 195, 263, 315.1C, 497, 524.1AC, 750, 1189, 1438, 1811, 2706, 3107d, 3480, 4769, 5460, 5655, 7028, 7521, 8860, 9055, 9698, 10398, 10550, 11299, 11467, 11719, 11914, 12308, 12372, 14167, 14766, 14798, 15326, 16093, 16189, 16224, 16311, 16519
Z234	female	U5a1	73, 263, 310.1C, 315.1C, 750, 1438, 2706, 3107d, 3197, 4655, 4769, 7028, 8697, 8860, 9477, 11467, 11719, 12308, 12372, 13617, 13827, 13928C, 14766, 14793, 15326, 16114A, 16192, 16256, 16270, 16294, 16526
Z53	female	H1	263, Het Poly-C 303-309 , 750, 1438, 3010, 3107d, 4769, 6719, 8860, 11016, 15326, 16519
Z251	female	H*	152, 263, 315.1C, 750, 1438, 3107d, 4769, 4793, 5348, Het 7697R , 8860, 12702, 15326, 16519
Snb28	male	L1b	73, 152, 182, 185T, 189, 195, 247, 263, 315.1C, 357, 523d, 524d, 709, 710, 750, 769, 825A, 1018, 1738, 2706, 2758, 2768, 2885, 3107d, 3308, 3594, 3666, 3693, 4104, 4769, 5036, 5046, 5393, 5655, 6548, 6827, 6989, 7028, 7055, 7146, 7256, 7389, 7521, 7867, 8248, 8468, 8655, 8701, 8860, 9476, 9540, 10398, 10688, 10810, 10873, 11719, 12519, 12705, 13105, 13506, 13650, 13789, 13880A, 14178, 14203, 14560, 14766, 14769, 15115, 15326, 15479, 16126, 16187, 16189, 16223, 16264, 16270, 16278, 16293, 16311, 16362, 16400, 16519
Z287	male	V	72, 263, Het Poly-C 303-309 , 750, 1438, 2352, 2706, 3107d, 4580, 4769, 7028, 8860, 11151, 14988, 15326, 15904, 16298, 16399

Sample name	Sex	Haplogroup	Haplotype
Z161	female	H3	263, 293, 315.1C, 750, 1438, 3107d, 4769, 6776, 8860, 12346, 15326, 15530, 16519
Snb19	male	H1	263, 315.1C, 750, 1438, 3010, 3107d, 4769, 6497, 7202, 8764, 8860, 15326, Het 15986R , 16468, 16519
Z190	female	H1	152, 263, 315.1C, 750, Het Poly-C 956-965 , 1438, 3010, 3107d, 4769, 6237A, 8860, 15326, 16519
Z224	female	H3	263, Het Poly-C 303-309 , 750, 1438, 3107d, 4769, 6776, 8860, 15326, 16519
Snb5	male	J	73, 185, 188, 263, 295, 315.1C, 482, 489, 750, 1438, 2706, 3010, 3107d, 3394, 4216, 4769, 7028, 7184, 8860, 9180, 10398, 11251, 11719, 12612, 13708, 14766, 14798, 15326, 15452A, 16069, 16126, 16291
Z31	female	V	72, 263, Het Poly-C 303-309 , 750, 1438, 2706, 3107d, Het 4055Y , 4580, 4769, 6773, 7028, 8860, 15326, 15904, 15927, 16254, 16298
Z226	female	W	73, 189, 194, 195, 204, 207, 263, Het Poly-C 303-309 , 709, 750, 1243, 1406, 1438, 2706, 3107d, 3505, 4769, 5046, 5460, 7028, 8251, 8860, 8994, 11674, 11719, 11947, 12414, 12705, Het 12948R , 13263, 14766, 15326, 15784, 15883, 15884C, 16223, 16292, 16519
Z222	male	X	73, 150, 185, 188, 228, 263, 295, Het Poly-C 303-309 , 462, 489, 523d, 524d, 750, 1438, 2706, 3010, 3107d, 4216, 4769, 7028, 8860, 10398, 10463, 11251, 11719, 12612, 13708, 14766, 14798, 15326, 15452A, 16069, 16126, 16366, 16519

Table I.3.2. Complete results of each heteroplasmic position analyzed (map locus, position, sample name, heteroplasmy type, heteroplasmy origin, mean proportion of height peaks, distribution in population database, number of hits in mtDNA phylogeny (PhyloTree.org) and by Soares et al. (2009), probability of mutation and nucleotide and amino acid Conservation Index).

Map Locus	Position	Sample name	Het	CRS	Origin	Mean proportion height peaks	Distribution in population database	No. Hits phylogeny (PhyloTree.org)	No. Hits Soares et al. (2009)
CR ^a	93	Z241	G/a	A	Germinal	84.51G 15.49A	GAP:0.1, A:96.3, G:3.6	11	19
CR ^b	64	Ir28	T/c	C	n.a.	87T 13C	C:96.8, T:3.1, GAP:0.1	10	22
CR ^b	146	Ir17	T/c	T	n.a.	90T 10C	T:81.4, C:18.4, A:0.2, GAP:0.1	66	109
CR ^b	146	G65	T/c	T	n.a.	80T 20C	T:81.4, C:18.4, A:0.2, GAP:0.1	66	109
CR ^b	150	Arm17	C/t	C	n.a.	88C 12T	C:88.2, T:11.7, G:0.1, GAP:0.1	41	63
CR ^b	152	Ir11	T/c	T	n.a.	89T 11C	T:70.3, C:29.6, GAP:0.1	117	157
CR ^a	152	Z217	T/c	T	Germinal	66.74T 33.26C	GAP:0.1, C:29.6, T:70.3	117	157
CR ^a	152	Z269	T/c	T	Germinal	87T 13C	GAP:0.1, C:29.6, T:70.3	117	157
CR ^b	195	G67	T/c	T	n.a.	90T 10C	GAP:0.1, T:73.7, C:25.8, A:0.4	71	98
CR ^b	203	Az5	A/g	G	n.a.	66A 34G	G:99.7, A:0.3, GAP:0.1	2	6
CR ^b	204	Arm17	T/c	T	n.a.	89T 11C	T:93.4, C:6.5, A:0.1, GAP:0.1	23	43
CR ^a	234	Z247	G/a	A	Somatic	83.45G 16.55A	GAP:0.1, A:99.4, G:0.5	8	43
CR ^a	189	Z141	A/g	A	Somatic	85.145T 14.855C	GAP:0.1, A:91, C:1.8, G:7.1	19	31

Map Locus	Position	Sample name	Het	CRS	Origin	Mean proportion heighth peaks	Distribution in population database	No. Hits phylogeny (PhyloTree.org)	No. Hits Soares et al. (2009)
tRNA phe ^a	593	Z38	T/c	T	Germinal	91.77T 8.23C	C:0.6, T:99.4	4	11
12S ^a	772	Z48	A/g	A	Germinal	85.83A 14.17G	A:100	0	0
12S ^b	1552	Ir54	G/a	G	n.a.	87G 13A	G:100	0	0
16S ^a	2887	Z90	T/c	T	Germinal	91.95T 8.05C	T: 99.8, C:0.2	2	2
16S ^b	3014	Az10	G/t	G	n.a.	86G 14T	G:100	0	0
ND1 ^b	3492	Arm25	A/c	A	n.a.	65A 35C	A:100	0	1
ND1 ^b	3492	G20	A/c	A	n.a.	78A 22C	A:100	0	1
ND1 ^b	3532	Az14	A/g	A	n.a.	82A 18G	A:100	0	0
ND1 ^a	3729	Z273	A/g	A	Germinal	88.68A 11.32G	A:99.9, G:0.1	1	1
ND1 ^a	4055	Z31	T/c	T	Somatic	90.38T 9.62C	T:100	0	0
ND2 ^b	4991	Az4	G/a	G	n.a.	65G 35A	G:99.3, A:0.7	4	6
ND2 ^a	5306	Z225	C/t	C	Germinal	54.42C 45.58T	C:100	0	0
ND2 ^b	5460	Az7	A/g	G	n.a.	68A 32G	G:92.8, A:7.2	22	36
COX1 ^a	6054	Z248	G/a	G	Germinal	78.75G 21.25A	G:100	0	0
COX2 ^a	7697	Z251	A/g	G	Germinal	75.55A 24.45G	G:99.8, A:0.2	2	1

Map Locus	Position	Sample name	Het	CRS	Origin	Mean proportion heigh peaks	Distribution in population database	No. Hits phylogeny (PhyloTree.org)	No. Hits Soares et al. (2009)
COX2 ^b	7754	T186	A/g	G	n.a.	89A 11G	G:100	0	1
COX2 ^a	7912	Z24	A/g	G	Germinal	75.64A 24.36G	G:99.9, A:0.1	3	4
ATP6/ATP8 ^b	8551	Ir30	C/t	T	n.a.	54C 46T	T:99.9, C:0.1	0	4
ATP6 ^a	8603	Z223	T/c	T	Germinal	87.95T 12.05C	T:99.9, C:0.1	1	1
ATP6 ^a	8577	Z229	G/a	A	Germinal	59.51G 40.49A	A:99.8, G:0.2	0	3
ATP6 ^b	8743	Ir29	G/a	G	n.a.	68G 32A	G:99.9, A:0.1	0	1
ATP6 ^a	9029	Z340	G/a	A	n.a.	84.6G 15.4A	A:100	0	0
COX3 ^a	9449	Snb61	T/c	C	Germinal	16.26T 83.73C	C:98.6, T:1.4	4	6
ND3 ^b	10208	Ir10	C/t	T	n.a.	89C 11T	T:99.9, C:0.1	1	2
tRNA arg ^b	10427	Az39	G/a	G	n.a.	85G 15A	G:99.8, A:0.2	1	2
ND4 ^a	11016	Snb61	G/a	G	Germinal	82.82G 17.18A	G:99.3, A:0.7	8	9
ND4 ^b	11253	G1	C/t	T	n.a.	76C 24T	T:99.6, C:0.4	2	5

Map Locus	Position	Sample name	Het	CRS	Origin	Mean proportion heigh peaks	Distribution in population database	No. Hits phylogeny (PhyloTree.org)	No. Hits Soares et al. (2009)
ND4 ^b	11692	G38	A/c	C	n.a.	76A 24C	C:100	0	1
ND4 ^b	11809	G82	T/c	T	n.a.	78T 22C	T:99.8, C:0.2	1	0
ND5 ^b	12654	Arm37	A/g	A	n.a.	86A 14G	A:99.7, G:0.3	4	3
ND5 ^b	13368	Arm19	G/a	G	n.a.	54G 45A	G:96.5, A:3.5	8	8
ND5 ^a	13590	Snb48	G/a	G	Germinal	62.11G 37.89A	G:93.6, A:6.4	6	6
ND5 ^b	13604	Ir43	G/a	G	n.a.	90G 10A	G:100	0	0
ND5 ^a	13812	Snb78	T/c	T	Germinal	76.63T 23.37C	T:99.9, C:0.1	1	2
ND6 ^b	14527	G25	A/g	A	n.a.	89A 11G	A:99.9, G:0.1	1	3
ND6 ^b	14561	T9	A/g	A	n.a.	78A 22G	A:100	0	0
CytB ^b	14770	Az14	T/c	C	n.a.	55T 45C	C:99.9, T:0.1	1	1
CytB ^b	15046	T186	G/a	A	n.a.	74G 26A	A:99.9, G:0.1	0	1
CytB ^a	15244	Snb61	G/a	A	Germinal	71.74G 28.26A	A:98.5, G:1.5	7	16

Map Locus	Position	Sample name	Het	CRS	Origin	Mean proportion heighth peaks	Distribution in population database	No. Hits phylogeny (PhyloTree.org)	No. Hits Soares et al. (2009)
CytB ^b	15314	Arm20	G/a	G	n.a.	84G 14A	G:99.3, A:0.7	6	12
CytB ^a	15496	Z141	G/a	A	Somatic	86.21G 17.79A	A:99.9, G:0.1	1	2
tRNA thr ^a	15908	Z176	T/c	T	Germinal	73T 27C	T:99.9, C:0.1	1	2
tRNA pro ^a	15986	Snb19	G/a	G	Germinal	58.5G 41.5A	G:100	0	0
CR ^b	16093	Az49	C/t	T	n.a.	91C 8T	T:98.8, C:1.2	36	79
CR ^a	16189	Snb48	T/c	T	Germinal	91.31T 8.69C	GAP:0.1, A:0.1, C:59.6, T:40, G:0.2	66	90
CR ^a	16189	Z253	T/c	T	Germinal	88.75T 11.25C	GAP:0.1, A:0.1, C:59.6, T:40, G:0.2	66	90
CR ^b	16217	T30	C/t	T	n.a.	91C 9T	T:96.5, C:3.4, GAP:0.1	1	6
CR ^b	16223	G73	T/c	C	n.a.	89T 11C	T:51.9, C:48, GAP:0.1	22*	37
CR ^b	16223	Arm20	T/c	C	n.a.	89T 11C	T:51.9, C:48, GAP:0.1	22	37
CR ^a	16293	Snb22	A/g	A	Germinal	79A 21G	A:96.5, C:0.2, T:3, G:0.3	8	17
CR ^b	16362	G67	T/c	T	n.a.	87T 13C	T:77.6, C:22.3, A:0.1	48	67

^aHeteroplasmic positions detected in present study

^bHeteroplasmic positions reported by Li et al. (2010)

Position	Probability of mutation	Nucleotide Conservation Index (%)	Amino acid change	Aa Conservation Index (%)
93	1,78E-03	A:34.04 , C:6.38, G:29.79, T:29.79	-	-
64	2,06E-03	C:12.77 , G:8.51, T:78.72	-	-
146	1,02E-02	A:27.66, C:42.55, T:29.79	-	-
146	1,02E-02	A:27.66, C:42.55, T:29.79	-	-
150	5,90E-03	A:19.15, C:42.55 , G:27.66, T:10.64	-	-
152	1,47E-02	A:17.03, C:48.93, T:34.04	-	-
152	1,47E-02	A:17.03, C:48.93, T:34.04	-	-
152	1,47E-02	A:17.03, C:48.93, T:34.04	-	-
195	9,17E-03	A:31.91, C:38.30, G:8.51, T:21.28	-	-
203	5,62E-04	A:53.19, C:2.13, G:34.04 , T:10.64	-	-
204	4,03E-03	A:8.51, C:17.02, G:53.19, T:21.28	-	-
234	4,03E-03	GAP:8.51, A:76.60 , C:2.13, G:6.38, T:6.38	-	-
189	2,90E-03	GAP:2.13, A:57.44 , C:10.64, G:29.79	-	-

Position	Probability of mutation	Nucleotide Conservation Index (%)	Amino acid change	Aa Conservation Index (%)
593	1,03E-03	GAP:85.57, A:4.43, C:3.29, G:0.87, T:5.84	-	-
772	0,00E+00	GAP:58.46, A:17.79 , C:9.8, G:4.83, T:9.13	-	-
1552	0,00E+00	GAP:0.47, A:11.88, C:3.09, G:73.29 , T:11.28	-	-
3492	9,36E-05	A:44.77 , C:40.13, G:5.97, T:9.13	NS (Lys->Asn)	A:0.1, F:0.3, G:0.1, H:1.2, I:0.1, K:6.2 , L:1.5, P:0.1, Q:2.1, R:85.2, S:0.3, W:0.3, Y:2.7
3532	0,00E+00	A:85.23 , C:1.01, G:13.42, T:0.34	NS (Thr->Ala)	A:5.1, F:0.1, G:0.1, I:31.5, L:1.1, M:33, S:0.1, T:20.5 , V:8.5
3729	9,36E-05	A:47.99 , C:33.76, G:4.23, T:14.03	S (Ser)	S:100
4055	0,00E+00	GAP:1.07, A:27.52, C:42.42, G:2.82, T:26.17	NS (Leu->Pro)	GAP:0.3, A:7.7, C:0.5, D:0.8, E:0.3, F:2.7, G:1.1, H:7.5, I:2.7, K:0.2, L:16.4 , M:4.4, N:9.5, P:5.1, Q:1.8, R:0.1, S:11.5, T:17.9, V:0.6, W:0.1, Y:8.8
4991	5,62E-04	A:78.86, C:1.74, G:18.86 , T:0.54	S (Gln)	E:0.1, H:2.5, L:0.2, N:0.1, Q:97.2
5306	0,00E+00	A:31.61, C:51.68 , G:1.54, T:15.17	S (Pro)	A:79, F:0.1, G:0.4, I:0.2, L:0.2, M:0.1, P:15.9 , S:2.2, T:1.8, V:0.3
5460	3,37E-03	A:62.08, C:3.62, G:21.88 , T:12.42	NS (Ala->Thr)	A:5.5 , C:0.3, F:0.1, I:22.8, L:1.8, M:11, N:0.2, P:2.7, S:10.8, T:27.1, V:17.6, Y:0.2
6054	0,00E+00	GAP:0.2, A:0.07, G:99.66 , T:0.07	NS (Asp->Asn)	D:99.8 , G:0.1, N:0.1, Y:0.1
7697	9,36E-05	GAP:0.07, A:5.3, C:1.81, G:92.48 , T:0.34	NS (Val->Ile)	GAP:0.1, G:0.1, I:4.3, V:95.6

Position	Probability of mutation	Nucleotide Conservation Index (%)	Amino acid change	Aa Conservation Index (%)
7754	9,36E-05	GAP:0.07, A:5.97, C:0.13, G:93.83	NS(Asp->Asn)	GAP:0.1, D:92.9 , E:2.8, G:0.1, N:3.9, Q:0.1, S:0.1
7912	3,74E-04	GAP:0.07, A:65.91, C:1.34, G:32.08 , T:0.6	S (Glu)	GAP:0.1, D:0.1, E:99.7 , K:0.1, Q:0.1, V:0.1
8152	4,68E-04	GAP:0.07, A:52.15, C:20.27, G:4.83 , T:22.68	S (Pro)	GAP:0.1, A:0.4, H:0.1, L:0.1, N:0.2, P:95.1 , Q:0.1, S:0.9, T:1.8, V:1.3
8307	0,00E+00	GAP:22.89, A:63.29 , C:0.47, G:1.95, T:11.41	-	-
8551	3,74E-04	GAP:0.13, A:2.95, C:35.84, G:0.2, T:60.87 /A:2.01, C:84.77, G:0.54, T:12.68	S (His)	A:0.1, F:0.1, H:21.3 , I:15.7, L:53.6, M:4.3, N:0.1, Q:0.1, S:0.2, T:0.4, V:4.2/GAP:77.P418, H:4.2 , L:15.9, N:0.8, P:0.7, S:0.5, Y:0.2
8603	9,36E-05	A:0.4, C:3.89, G:0.2, T:95.5	NS (Phe->Ser)	GAP:0.1, A:1.6, C:0.1, D:0.1, F:28.7 , I:5.0, L:55.8, M:4.2, P:0.1, S:0.5, T:1.6, V:1.6, W:0.1, Y:0.4
8577	2,81E-04	GAP:0.4, A:11.28 , C:44.97, G:3.69, T:39.66	S (Leu)	GAP:0.4, A:0.3, F:0.8, I:64.4, L:17.4 , M:2.8, N:0.1, Q:0.6, T:1.0, V:12.2
8743	9,36E-05	A:67.05, C:1.74, G:27.72 , T:3.49	NS (Val->Met)	GAP:0.1, A:21.5, C:0.6, F:0.1, I:8.7, L:2.8, M:16.1, S:2.3, T:43, V:4.9
9029	0,00E+00	A:100	NS (His->Arg)	D:0.1, H:99.8 , Q:0.1, Y:0.1
9449	5,62E-04	A:0.2, C:56.85 , T:42.95	S (Tyr)	C:0.2, F:1.8, H:0.1, I:0.1, L:0.3, M:0.1, W:0.5, Y:97
10208	1,87E-04	A:39.06, C:34.03, G:2.48, T:24.43	S (Pro)	I:0.1, P:99.7 , Q:0.1, T:0.1
10427	1,87E-04	A:59.87, C:26.04, G:1.95 , T:12.15	-	-
11016	8,42E-04	A:47.79, C:40.2, G:0.74 , T:11.28	NS (Ser->Asn)	A:1.8, C:0.1, D:0.3, E:1.1, F:0.2, G:0.3, H:10.6, I:0.2, K:20.2, L:8.3, M:1.7, N:7.8, P:19.5, Q:6.5, R:0.3, S:10.6 , T:8.8, V:0.6, Y:1
11253	4,68E-04	GAP:0.07, C:5.03, G:0.07, T:94.83	NS(Ile->Thr))	A:0.1, F:0.2, I:7.8 , L:80.4, M:3, S:2.1, T:3, V:3.4

Position	Probability of mutation	Nucleotide Conservation Index (%)	Amino acid change	Aa Conservation Index (%)
11692	9,36E-05	GAP:0.07, A:48.46, C:16.91 , G:23.56, T:11.01	S (Gly)	A:0.3, G:99.5 , S:0.3
11809	0,00E+00	GAP:0.07, A:48.46, C:21.81, G:14.16, T:15.5	S (Thr)	A:3.9, C:0.1, F:0.1, G:0.2, I:8.8, K:0.3, L:6.9, M:36.8, N:2.6, P:9.1, S:2, T:21.8 , V:7.4, W:0.1
12654	2,81E-04	A:80.87 , C:0.54, G:18.39, T:0.2	S (Trp)	A:0.1, H:0.1, K:0.1, L:0.1, Q:0.8, S:0.6, W:97.9 , Y:0.4
12948	9,36E-05	GAP:0.81, A:17.38 , C:44.56, G:3.22, T:34.03	S(Leu)	GAP:1.6, A:9.4, C:0.8, D:0.1, E:1.1, F:0.4, G:0.1, H:1.3, I:4.6, L:35.5 , M:2.5, N:3, P:6.8, Q:3.5, S:9.4, T:17.9, V:1.4, Y:0.6
13368	7,49E-04	A:30.27, C:42.42, G:17.65 , T:9.66	S (Gly)	A:0.1, G:99.9
13590	5,62E-04	A:16.24, C:52.95, G:1.14 , T:29.66	S (Leu)	A:0.1, C:0.2, F:73.6, I:0.1, L:17.1 , M:8.9, T:0.1, V:0.1
13604	0,00E+00	A:0.54, C:6.04, G:93.42	NS (Ser->Asn)	G:0.1, N:0.5, S:95.3 , T:4.1
13812	1,87E-04	A:44.03, C:30.4, G:6.58, T:18.99	S (Ala)	A:19 , C:0.7, F:1.4, G:0.8, I:22.8, L:23.8, M:10.3, N:0.1, Q:0.1, S:2.2, T:13.8, V:4.7, Y:0.3
14527	2,81E-04	A:65.5 , C:13.15, G:10, T:11.34	S (Gly)	A:3.1, C:0.6, F:0.2, G:2.1 , H:0.4, I:0.3, L:0.4, M:0.1, N:0.1, P:9.5, Q:0.1, S:72.7, T:8.7, V:1.3, Y:0.3
14561	0,00E+00	A:77.25 , C:8.79, G:13.76, T:0.2	NS (Asp->Gly)	A:10.2, C:3.3, D:0.1 , F:8.2, G:4.1, I:3.9, L:12.3, M:11.6, S:3.9, T:0.7, V:41.6
14770	9,36E-05	A:0.27, C:83.42 , G:2.95, T:13.36	S (Asn)	GAP:0.2, E:0.1, H:93.2, I:0.1, K:0.1, L:0.1, M:0.3, N:3.2 , P:0.1, Q:2.1, R:0.1, S:0.1, T:0.1, V:0.1, X:0.1, Y:0.2
15046	9,36E-05	A:77.11 , C:8.12, G:8.05, T:6.71	S (Arg)	A:0.1, L:0.1, R:99.7 , W:0.1
15244	1,50E-03	A:27.72 , C:24.77, G:31.74, T:15.77	S (Gly)	G:99.9 , R:0.1

Position	Probability of mutation	Nucleotide Conservation Index (%)	Amino acid change	Aa Conservation Index (%)
15314	1,12E-03	A:18.66, C:4.56, G:71.07 , T:5.7	NS (Ala->Thr)	A:61.4 , F:0.2, I:5.3, L:7.7, M:4, S:3.7, T:9.9, V:7.9
15496	1,87E-04	A:66.98 , C:10, G:9.66, T:13.36	S (Leu)	GAP:0.1, F:2.6, L:96.7 , M:0.4, P:0.1, V:0.1, Y:0.1
15908	1,87E-04	GAP:1.81, A:80.94, C:0.2, G:0.27, T:16.78	-	-
15986	0,00E+00	GAP:0.13, A:50.34, C:0.13, G:49.4	-	-
16093	7,39E-03	GAP:4.3, A:21.3, C:4.3, G:6.4, T:63.8	-	-
16189	8,42E-03	GAP:2.13, A:19.15, C:40.42, G:8.51, T:29.79	-	-
16189	8,42E-03	GAP:2.13, A:19.15, C:40.42, G:8.51, T:29.79	-	-
16217	5,62E-04	GAP:14.89, A:10.63, C:25.53, G:6.38, T:42.55	-	-
16223	3,46E-03	GAP:8.51, A:23.40, C:44.68 , T:23.41	-	-
16223	3,46E-03	GAP:8.51, A:23.40, C:44.68 , T:23.41	-	-
16293	1,59E-03	A:51.06 , C:19.15, G:4.26, T:25.53	-	-
16362	6,27E-03	A:25.53, C:19.15, T:55.32	-	-

7.2 Annex 2



Part del resultat presentat en aquesta Tesi, han quedat recollits en les següents publicacions científiques:

Ramos, A; Santos, C; Alvarez, L; Nogués, R; Aluja, MP. Human mitochondrial DNA complete amplification and sequencing: a new validated primer set that prevents nuclear DNA sequences of mitochondrial origin co-amplification. Electrophoresis. 2009 May; 30(9):1587-1593.

Ramos, A; Santos, C; Barbena, E; Mateiu, L; Alvarez, L; Nogues, R; Aluja MP. Validated primer set that prevents nuclear DNA sequences of mitochondrial origin coamplification: A revision based on the New Human Genome Reference (GRCh37). Electrophoresis. 2011 Mar;32(6-7):782-3.

Ramos, A; Barbena, E; Matieu, L; González, MM; Mairal, Q; Lima, M; Montiel, R; Aluja, MP; Santos, C. Nuclear insertions of mitochondrial origin: data base updating and usefulness in cancer studies. Mitochondrion. 2011 Nov;11(6):946-53.

Amanda Ramos
Cristina Santos
Luis Alvarez
Ramon Nogués
Maria Pilar Aluja

Unitat d'Antropologia Biològica,
Departament BABVE, Universitat
Autònoma de Barcelona,
Cerdanyola del Vallès, Barcelona,
Spain

Received September 15, 2008
Revised November 11, 2008
Accepted November 13, 2008

Research Article

Human mitochondrial DNA complete amplification and sequencing: A new validated primer set that prevents nuclear DNA sequences of mitochondrial origin co-amplification

To date, there are no published primers to amplify the entire mitochondrial DNA (mtDNA) that completely prevent the amplification of nuclear DNA (nDNA) sequences of mitochondrial origin. The main goal of this work was to design, validate and describe a set of primers, to specifically amplify and sequence the complete human mtDNA, allowing the correct interpretation of mtDNA heteroplasmy in healthy and pathological samples. Validation was performed using two different approaches: (i) Basic Local Alignment Search Tool and (ii) amplification using isolated nDNA obtained from sperm cells by differential lyses. During the validation process, two mtDNA regions, with high similarity with nDNA, represent the major problematic areas for primer design. One of these could represent a non-published nuclear DNA sequence of mitochondrial origin. For two of the initially designed fragments, the amplification results reveal PCR artifacts that can be attributed to the poor quality of the DNA. After the validation, nine overlapping primer pairs to perform mtDNA amplification and 22 additional internal primers for mtDNA sequencing were obtained. These primers could be a useful tool in future projects that deal with mtDNA complete sequencing and heteroplasmy detection, since they represent a set of primers that have been tested for the non-amplification of nDNA.

Keywords:

Mitochondrial DNA / Nuclear DNA sequences of mitochondrial origin / Primer design
DOI 10.1002/elps.200800601



1 Introduction

It is now accepted that mitochondria descend from prokaryotic endosymbionts and that inter-organelle DNA transfer has been rearranging genetic material between the nucleus and mitochondria. Moreover, it seems that the transfer of DNA from mitochondria to the nucleus has contributed significantly to the evolution and function of

eukaryotic genomes (for a review see Leister [1]). Almost all the present-day mitochondrial DNA (mtDNA) transfers to the nucleus give rise to non-coding sequences, the so-called nuclear DNA sequences of mitochondrial origin (NUMTs). Human NUMT loci are evenly distributed within and among chromosomes [2–4], and up to 9857 bp of the human mtDNA can be found at a single nuclear locus [5]. However, only about a third of all NUMTs present in the human nuclear genome are due to insertions of mitochondrial sequences, the rest being originated as duplications of pre-existing NUMTs [6]. Moreover, a subset of human NUMTs is highly rearranged, comprising sequences derived from different regions of the organellar chromosome that have undergone inversions, deletions and duplications [3–5, 7].

A comparison of published compilations of NUMTs clearly shows significant discrepancies among data [8]. For example, in relatively recent studies, Ricchetti *et al.* [9], Mishmar *et al.* [10] and Hazkani-Covo and Dan Graur [11] identify 211, 247 and 452 NUMTs, respectively. According to Lascaro *et al.* [8] these discrepancies are due both to an unwise

Correspondence: Amanda Ramos, Unitat d'Antropologia Biològica, Departament Biologia Animal, Biologia Vegetal i Ecologia, Universitat Autònoma de Barcelona, 08193 Cerdanyola del Vallès, Barcelona, Spain
E-mail: amanda.ramos@campus.uab.cat
Fax: +34-935811321

Abbreviations: ABC, ammonium bicarbonate; BLAST, Basic Local Alignment Search Tool; mtDNA, mitochondrial DNA; nDNA, nuclear DNA; NUMT, nuclear DNA sequences of mitochondrial origin

application of Bioinformatic methods and to the use of a not yet correctly assembled nuclear genome. Thus, to optimize the quantification and location of NUMTs, the authors produced a consensus compilation of Human NUMTs – Reference Human Numt Sequences (RHNumtS)– by applying various bioinformatics and experimental approaches. This allows the identification of 190 human NUMTs that could constitute a valuable tool in the implementation of experimental designs of mtDNA amplification and sequencing.

The human mtDNA has been widely used in population genetics, phylogeographic and phylogenetic studies, because it presents a high copy number *per cell*, a compact organization, is maternally transmitted and provides an easy access to an orthologous set of genes with little or no recombination, with rapid evolution and that are selectively neutral [12, 13]. However, this traditional view has been challenged. Many works have been published pointing out: (i) the possibility of recombination of the mtDNA [14, 15]; (ii) the hypothesis that mtDNA frequency variation is due to natural selection [16–18] and (iii) that mitochondrial DNA heteroplasmy is not an exceptional condition related to mitochondrial disease [19–27].

The majority of population studies based on the mtDNA sequencing have focused on the control region, which constitutes less than 7% of the mitochondrial genome. However, the routinary study of the coding region has been performed for a long time to study the implication of mtDNA in diseases such as cancer [28]. Moreover, in the last years, the rapid development of automated DNA sequencing technology has permitted to study the complete mtDNA genome in a large number of healthy individuals [29–35]. Many of these studies, particularly those that deal with the study of mtDNA in pathological samples, have been severely criticized and a large number of manuscripts addressing errors related to the interpretation of mtDNA results (particularly mtDNA heteroplasmy) have been published [21, 36–42]. One of the critiques reported is that NUMTs are a potential source of contamination when PCR is used to study mtDNA [42]. Although this problem has previously been considered to be muted because of the high copy number of mtDNA over the corresponding nuclear loci, caution is warranted [42–44] since amplification of overlapping NUMTs paralogous to the mitochondrial genome indicates that co-amplification of nuclear mitochondrial pseudogenes is a real problem for accurate sequence interpretation, and particularly for the interpretation of mtDNA heteroplasmy [42, 44]. Parr *et al.* [44], in a study performed with p0 cells, suggested that among the factors that determine whether an NUMT will or not co-amplify with mtDNA, there are the region of the mtDNA targeted by the PCR and the number of copies of the NUMT. Moreover, samples of ancient DNA or a tissue with a reduced quantity of mtDNA copy number, in both physiological (sperm) and pathological states, also seem to be important factors that could determine the amplification of NUMTs [44, 45]. Although, Goios and co-workers [44, 45] stated that, in standard sequencing of samples used in a population

characterization [29, 30], the amplification of NUMTs does not constitute a real problem (since the mtDNA content of samples is much higher than the content of nuclear DNA (nDNA) and the detection of mtDNA heteroplasmy is not a priority), Yao *et al.* demonstrate that it can occur even when standard samples are used [42].

To date, primers to amplify the entire mtDNA have already been published [31, 34, 46], however, none of the published sets completely prevents the amplification of NUMTs. The main goal of this work was to design, validate and describe a set of primers to specifically amplify and sequence the complete human mtDNA, allowing the correct interpretation of mtDNA heteroplasmy in healthy and pathological samples.

2 Materials and methods

2.1 Primer design and validation

In order to analyze the whole mitochondrial genome, primers previously published [34] were tested and new ones were designed. The primer design was performed using the Lasergene 7.2 software, from the DNASTAR package, following the general criteria of primers design [47]. Particular attention was devoted to adjust, as much as possible, the melting temperatures (T_m) of all the primer pairs.

To discard co-amplifications of nDNA and mtDNA, PCR primers were submitted to the Basic Local Alignment Search Tool (BLAST) available in the National Center for Biotechnology Information (<http://www.ncbi.nlm.nih.gov/BLAST/>) [48]. BLAST finds regions of local similarity between sequences comparing nucleotide sequences with sequence databases and calculating the statistical significance of matches. In this work, the specific tool Basic BLAST, optimized for highly similar sequences (Megablast), was performed using the *Reference genomic sequence database for Homo sapiens* (refseq_genomic: Genomic sequences from National Center for Biotechnology Information Reference Sequence Project). A primer pair was discarded if both primers showed homology (expected number of chance matches in a random model – E-value – lower than 1) inside the same chromosome region.

After BLAST validation, primers were further tested in PCR experiments employing total DNA standard samples (see Section 2.2) and nDNA obtained from sperm cells. The nDNA isolation was performed by sperm differential lyses using the QIAmp DNA Investigator Kit (Qiagen) according to the manufacturer's specifications. To guarantee the complete mtDNA elimination, the initial washing step mentioned in QIAmp DNA Investigator Kit manual was repeated at least four times. Moreover, to ensure the integrity of nDNA, Y-chromosome STRs were amplified using AmpFlSTR[®] Y-filer[™] PCR kit (Applied Biosystems), under conditions recommended by the manufacturer and all the markers were correctly amplified.

Table 1. Validated primers to amplify the complete mtDNA in nine overlapping fragments. Melting temperatures (T_m) and annealing temperature (T_a) for each pair of primers are also presented

Fragment	Fragment length	Name	Sequence (5'–3')	Primers pair length (bp)	T_a	T_m
1	1822	14898for 151rev	tagccatgcactactaccaga ggatgagcaggaatcaagac	22	60	60.3
2	1758	16488for ^{a)} 1677rev ^{a)}	ctgtatccgacatctggtcct gtttagctcagagcggtcaagt	22	60	60.3
3	2543	1404for ^{a)} 3947rev	acttaagggtcgaaggtggatt tcgatgtgaagcctgagacta	22	57	58.4
4	3005	3734for 6739rev	aagtcaccctgaccatattcta gatatacatgctcagaccatacc	23	61	58.9
5	2709	6511for 9220rev	ctgtggcatcactactacta gattgtgggtcattatgtgtg	23	58	58.9
6	1738	8910for ^{a)} 10648rev	cttaccacaagggcacactaca ggcacaatattggtaagaggg	22	61	60.3
7	1866	10360for 12226rev	gtctggcctatgagtgactaca cagttcttgagcttctcgg	22	61	60.3
8	1853	11977for 13830rev	ctccctcatcattaccacaac aagtcctgaaagtgcagcga	24	63	59.3
9	1872	13477for ^{a)} 15349rev ^{a)}	gcaggaataccttctcacag gtgcaagaataggaggtggagt	23	63	60.6
				22	63	60.3

a) Oligonucleotides are from Torroni *et al.*, [34].

2.2 Total DNA extraction, amplification and sequencing of the entire mtDNA

Total DNA from blood samples was extracted using JETQUICK Blood DNA Spin Kit (Genomed) and isoamlic phenol-chloroform [49].

Optimized primers and PCR conditions for the mtDNA amplification are reported in Table 1. The PCR mix for each sample consisted of 50 pmol of each primer, 200 μ M of each dNTP, 2 mM of MgCl₂, 10 \times NH₄-based reaction buffer, 1 U of *Taq* DNA polymerase, and 30 ng of DNA in a final volume of 50 μ L. The PCRs were performed in a G-Storm GS1 thermocycler and the amplification program consisted of an initial denaturation step of 5 min, followed by 35 cycles of PCR (1 min at 94°C, 40 s at annealing temperature (T_a) and 2.5 min at 72°C), and a final extension step of 5 min at 72°C. The PCR amplification results were visualized by electrophoresis in agarose gels (2%).

PCR products were purified using the JETQUICK PCR Purification Spin Kit (Genomed) and the mtDNA was fully sequenced in both strands using 62 primers (Table 2). Sequence reactions were carried out using the sequencing kit BigDye Terminator v.3 (Applied Biosystems) according to the manufacturer's specifications and were run in an ABI 3130XL sequencer (Servei de Genòmica, Universitat Autònoma de Barcelona).

2.3 Cloning

PCR products that, in the optimization process, show consistently more than a one size product, were cloned into the pCR[®]4-TOPO[®] vector, using the TOPO TA Cloning[®]

Kit for Sequencing (Invitrogen). Ten clones were sequenced using the previously explained methodology.

3 Results

3.1 Primer design and validation

From the primers reported in the literature for the complete mtDNA amplification, we evaluated the 11 primer pairs published by Torroni *et al.* [34] since, compared with other works, the authors define a small number of fragments (see Table 2 in Torroni *et al.* [34]). These primers were tested using BLAST. After this analysis, four pairs of primers that show high similarity with nuclear regions were rejected.

The BLAST analysis allows detecting two major problematic regions for primer design. The first one, located between 3914 and 9074 mtDNA positions, presents a 98% similarity with a region within chromosome 1 (see BLAST results as online Supporting Information data); the second one encompasses the region located between 9582 and 14479 mtDNA positions and it shows a 88% similarity with a region within chromosome 5 (see BLAST results as online Supporting Information data). For these regions new primers were designed and verified until the selective amplification of mtDNA was obtained. The 3914–9074 region (Fig. 1) was split into two fragments (fragments 4 and 5 in Fig. 1); For each primer pair, one of the primers was designed outside the 3914–9074 region, preventing the amplification of the homologue region of chromosome 1. For the 9582–14479 region (Fig. 1), minimum of four fragments with \sim 2000 bp were necessary to completely amplify it. Thus, the previous strategy could only be applied

Table 2. Primers designed to sequencing the whole mtDNA after PCR amplification in nine overlapping fragments

Fragment	Name/sequence (5'–3')		
1	14898for tagccatgcactactaccagaga	15416for tacacaatcaaaagcgccttc	15966for agttttaactccaccattag
	151rev ggatgaggcaggaatcaaaagac	16281rev gttggtatcctagtggtgag	15825rev gtgaagtatagtagcgatgct
	16488for ctgtatccgacatctggttct	411for cggtatgcactttaacagtc	909for gattaaccaagtcataagaa
2	1677rev gtttagctcagagcgtcaagt	1159rev taagctgtgctcgtagtgt	638rev ggtgatgtgagccgtctaaa
	1404for acttaagggtcgaaggtgatt	2028for gatagaatcttagttcaact	2646for ggttcagctgtcttacttt
	3947rev tcgatgtgaagcctgagaacta	3382rev ttcttcggtaagcattagga	2801rev taatgcaggttggtagttaa
3	3734for aagtcaccctagccatcttcta	4346for gaaccatccctgagaatcca	5468for taccaaatctctccctacta
	6739rev gatatacatagctcagaccatacc	6154rev ggaactagtcagtgcctaaag	5571rev aagtattgcaactactgagg
	8910for cttaccacaaggcacacctaca	9393for cgagaaagcacatccaaggg	9874for taatatttcactttacatcca
4	10648rev ggcacaatattggctaagaggg	10154rev ttctatgtagccttgagtgt	9647rev agctcaggtgattgatactc
	10360for gtctggcctatgagtgactaca	10892for atcaacaacaacctatttagc	11461for actctaaaactgagccgcta
	12226rev cagttcttgtagctttctcgg	11673rev gtttgatgagaatgctgtt	11163rev cgggtgatgataccaaggtg
5	11977for ctccctctacatattaccacaac	12500for tgtgcttagaccaagaagtta	12988for ctagcagcagcaggcaaatca
	13830rev aagtcctaggaagtgacagcga	13297rev ggttgatgccgattgaacta	12763rev cgatgaacagttggaataggt
	13477for gcaggaataccttctcaccag	13950for ctatctaggcctcttaccgag	14440for atactcctcaatgaccatcgc
6	15349rev gtgcaagaataggaggtggagt	14838rev catcatcggagatgttgat	14325rev aactttaatagtgtaggaagc
	9220rev gattggtggctcattatgtgtg	8600rev agaatgatcagtagctcggcg	8000rev caacgtcaaggagtcgcaggt
	9220rev gattggtggctcattatgtgtg	8600rev agaatgatcagtagctcggcg	8000rev caacgtcaaggagtcgcaggt
7	9220rev gattggtggctcattatgtgtg	8600rev agaatgatcagtagctcggcg	8000rev caacgtcaaggagtcgcaggt
	9220rev gattggtggctcattatgtgtg	8600rev agaatgatcagtagctcggcg	8000rev caacgtcaaggagtcgcaggt
	9220rev gattggtggctcattatgtgtg	8600rev agaatgatcagtagctcggcg	8000rev caacgtcaaggagtcgcaggt
8	9220rev gattggtggctcattatgtgtg	8600rev agaatgatcagtagctcggcg	8000rev caacgtcaaggagtcgcaggt
	9220rev gattggtggctcattatgtgtg	8600rev agaatgatcagtagctcggcg	8000rev caacgtcaaggagtcgcaggt
	9220rev gattggtggctcattatgtgtg	8600rev agaatgatcagtagctcggcg	8000rev caacgtcaaggagtcgcaggt
9	9220rev gattggtggctcattatgtgtg	8600rev agaatgatcagtagctcggcg	8000rev caacgtcaaggagtcgcaggt
	9220rev gattggtggctcattatgtgtg	8600rev agaatgatcagtagctcggcg	8000rev caacgtcaaggagtcgcaggt
	9220rev gattggtggctcattatgtgtg	8600rev agaatgatcagtagctcggcg	8000rev caacgtcaaggagtcgcaggt

for flanking fragments (fragments 6 and 9 in Fig. 1), and the primers used to amplify the two fragments that were placed completely within the region (fragments 7 and 8 in Fig. 1) were designed in low-sequence similarity regions.

After BLAST validation, PCR optimization was performed using three samples of total DNA extracted using JETQUICK Blood DNA Spin Kit (Genomed). Surprisingly, the outcome of the amplifications of fragments between positions 12012–13828 and 3798–6739 resulted in more than one PCR product. However, a new amplification with a different sample isolated with isoamlic phenol-chloroform [49] was carried out and only one PCR fragment (with the expected size) was obtained (Fig. 2). These results allow to hypothesize that: (i) the observed additional bands correspond to deletions in mtDNA; (ii) the amplification of an NUMT not detected by BLAST analysis; (iii) the extraction method influences the DNA quality and by consequence the

PCR performance and specificity, resulting in unspecific amplification of nuclear or mtDNA. To test these hypotheses the fragment 12012–13828 was cloned into the pCR[®]4-TOPO[®] vector, using the TOPO TA Cloning[®] Kit for Sequencing (Invitrogen) and ten clones were sequenced. The resulting sequences were tested with BLAST showing a complete homology with mtDNA. A careful analysis reveals that the PCR forward primer hybridized with two close regions of mtDNA: the target region and another one that present several differences with the primer. Therefore, the amplification result is an artifact that can be attributed to the poor quality of DNA. For this reason, the forward primer was redesigned and tested again as previously described.

Finally, to discard co-amplifications of nDNA and mtDNA, which could not be deduced by BLAST analysis, PCR amplifications were performed using isolated nDNA obtained from sperm cells. The PCR primers were tested and no positive amplifications were observed.




Figure 1. Schematic representation of mtDNA. The nine overlapping fragments defined to PCR amplify the complete mtDNA genome are represented as well as the two nuclear regions with high homology with mtDNA.

3.2 PCR and sequencing primers to mtDNA analysis

For these primers, validated as previously explained, melting temperatures were adjusted as much as possible and the annealing temperatures were obtained by a PCR gradient being selected the highest temperature that shows positive amplification. In Table 1 PCR primers and annealing and melting temperatures to amplify the nine overlapping fragments that cover the entire mtDNA (Fig. 1) are reported. Some of the primers were previously published by Torroni *et al.* [34] and the remaining ones were designed for this study.

Since the size of fragments is of ~2000 bp, internal primers were designed to fully sequence both strands of each fragment. In Table 2 the sequence of the primers to sequence each fragment in both stands are shown. All the primers were tested to sequence three samples and a good efficiency of sequencing was obtained.

4 Discussion

The PCR amplification and sequencing of mtDNA is routinely used in many research fields; however, the interpretation of results, particularly of mtDNA heteroplasmy, could be complicated by the co-amplification of NUMTs [42, 44]. Therefore, an effort to design PCR primers that selectively amplify mtDNA must be performed. In this work we report a set of primers to amplify the whole mtDNA that were validated using the BLAST analysis and by the performance of PCR amplifications using nDNA isolated from sperm cells.

The BLAST search allowed the identification of two problematic regions in primer design (region 3914–9074 of the mtDNA present in chromosome 1 and region 9582–14479 present in chromosome 5). Region 3914–9074 was previously reported [8] as presenting a high sequence similarity with a region within chromosome 1, a result




Figure 2. Gel electrophoresis showing amplification results between positions 12012 and 13828 using blood samples extracted with different methods. (a) JETQUICK Blood DNA Spin Kit (Genomed); (b) isoamlic phenol-chloroform.

that is in accordance with our results. However, the presence of an NUMT in chromosome 5, which shows a high identity with the 9582–14479 region of the mtDNA, was not reported in previous studies; accordingly, this region could represent a non-reported NUMT and this deserves further investigation.

According to Goios *et al.* [45] the amplification of NUMTs can only be obtained when mtDNA is almost completely removed from the samples, such as those resulting from preferential semen lyses. Thus, to test the proposed set of primers for the selective amplification of mtDNA, we used a sperm sample that was submitted to DNA extraction using four steps of preferential lyses and for which Y-STRs were successfully amplified and no signs of amplification with the designed primers were detected. This result indicates that the proposed primers specifically amplify mtDNA and we can ensure that no NUMTs will be amplified if this set of nine pair primers is used.

The primers proposed amplification regions of about 2000 bp of mtDNA. As a consequence, in some samples (such as ancient and forensic ones) it would be almost impossible to obtain PCR amplifications with this set of primers. To overcome this problem, we suggest that additional primers within each fragment could be designed using a similar strategy to that applied for fragment 9582–14479, that is, locating primers in regions that show low homology with nDNA.

5 Concluding remarks

In conclusion, we report a set of primers that permit the selective amplification and sequencing of the whole mtDNA in nine overlapping fragments. These primers could be a useful tool in future projects that deal with mtDNA

complete sequencing since they represent the first published set of primers tested for the non-amplification of nDNA and therefore suitable for the screening of mtDNA heteroplasmy in both standard and pathological samples.

This work was supported by MEC (project: CGL2006 – 07374) and by the Instituto de estudios zamoranos Florián de Ocampo. We are indebted to all the sample donors and with the personal of the Provincial Hospital of Zamora “Rodríguez Chamorro”.

The authors have declared no conflict of interest.

6 References

- [1] Leister, D., *Trends Genet.* 2005, 21, 655–663.
- [2] Bensasson, D., Feldman, M. W., Petrov, D. A., *J. Mol. Evol.* 2003, 57, 343–354.
- [3] Moraes, C. T., Srivastava, S., Kirkinetzos, I., Oca-Cossio, J., van Waveren, C., Woischnick, M., Diaz, F., *Int. Rev. Neurobiol.* 2002, 53, 3–23.
- [4] Woischnick, M., Moraes, C. T., *Genome Res.* 2002, 12, 885–893.
- [5] Tourmen, Y., Baris, O., Dessen, P., Jacques, C., Malthiery, Y., Reynier, P., *Genomics* 2002, 80, 71–77.
- [6] Hazkani-Covo, E., Sorek, R., Graur, D., *J. Mol. Evol.* 2003, 56, 169–174.
- [7] Blanchard, J. L., Schmidt, G. W., *Mol. Biol. Evol.* 1996, 13, 537–548.
- [8] Lascaro, D., Castellana, S., Gasparre, G., Romeo, G., Saccone, C., Attimonelli, M., *BMC Genomics* 2008, 9, 267–280.
- [9] Ricchetti, M., Tekaia, F., Dujon, B., *PLoS Biol.* 2004, 2, 1313–1325.
- [10] Mishmar, D., Ruiz-Pesini, E., Brandon, M., Wallace, D. C., *Hum. Mutat.* 2004, 23, 125–133.
- [11] Hazkani-Covo, E., Graur, D., *Mol. Biol. Evol.* 2007, 24, 13–18.
- [12] Ballard, J. W. O., Rand, D. M., *Annu. Rev. Ecol. Evol. Syst.* 2005, 36, 621–642.
- [13] Rand, D. M., *Sci. Aging Knowledge Environ.* 2005, re5–13.
- [14] Kravtsov, Y., Schwartz, M., Brown, T. A., Ebralidse, K., Kunz, W. S., Clayton, D. A., Vissing, J. *et al.*, *Science* 2004, 304, 981.
- [15] Zsurka, G., Kravtsov, Y., Kudina, T., Kornblum, C., Elger, C. E., Khrapko, K., Kunz, W. S., *Nat. Genet.* 2005, 37, 873–877.
- [16] Mishmar, D., Ruiz-Pesini, E., Golik, P., Macaulay, V., Clark, A. G., Hosseini, S., Brandon, M. *et al.*, *Proc. Natl. Acad. Sci. USA* 2003, 100, 171–176.
- [17] Ruiz-Pesini, E., Mishmar, D., Brandon, M., Procaccio, V., Wallace, D. C., *Science* 2004, 303, 223–226.

- [18] Wallace, D. C., Ruiz-Pesini, E., Mishmar, D., *Cold Spring Harb. Symp. Quant. Biol.* 2003, **68**, 479–486.
- [19] Bendall, K. E., Macaulay, V. A., Baker, J. R., Sykes, B. C., *Am. J. Hum. Genet.* 1996, **59**, 1276–1287.
- [20] Bendall, K. E., Macaulay, V. A., Sykes, B. C., *Am. J. Hum. Genet.* 1997, **61**, 1303–1308.
- [21] Brandstatter, A., Sanger, T., Lutz-Bonengel, S., Parson, W., Beraud-Colomb, E., Wen, B., Kong, Q. P. *et al.*, *Electrophoresis* 2005, **26**, 3414–3429.
- [22] Grzybowski, T., Malyarchuk, B. A., Czarny, J., Miscicka-Sliwka, D., Kotzbach, R., *Electrophoresis* 2003, **24**, 1159–1165.
- [23] Monnat, Jr. R. J., Loeb, L. A., *Proc. Natl. Acad. Sci. USA* 1985, **82**, 2895–2899.
- [24] Santos, C., Montiel, R., Arruda, A., Alvarez, L., Aluja, M. P., Lima, M., *BMC Evol. Biol.* 2008, **8**, 167–179.
- [25] Santos, C., Montiel, R., Sierra, B., Bettencourt, C., Fernandez, E., Alvarez, L., Lima, M. *et al.*, *Mol. Biol. Evol.* 2005, **22**, 1490–1505.
- [26] Santos, C., Sierra, B., Alvarez, L., Ramos, A., Fernandez, E., Noguez, R., Aluja, M. P., *J. Mol. Evol.* 2008, **67**, 191–200.
- [27] Wilson, M. R., Polanskey, D., Replogle, J., DiZinno, J. A., Budowle, B., *Hum. Genet.* 1997, **100**, 167–171.
- [28] Santos, C., Martínez, M., Lima, M., Hao, Y.-J., Simoes, N., Montiel, R., *Curr. Top Med., Chem.* 2008, **8**, 1351–1366.
- [29] Abu-Amero, K. K., Larruga, J. M., Cabrera, V. M., Gonzalez, A. M., *BMC Evol. Biol.* 2008, **8**, 45–60.
- [30] Derenko, M., Malyarchuk, B., Grzybowski, T., Denisova, G., Dambueva, I., Perkova, M., Dorzhu, C. *et al.*, *Am. J. Hum. Genet.* 2007, **81**, 1025–1041.
- [31] Maca-Meyer, N., Gonzalez, A. M., Larruga, J. M., Flores, C., Cabrera, V. M., *BMC Genet.* 2001, **2**, 13–21.
- [32] Rajkumar, R., Banerjee, J., Gunturi, H. B., Trivedi, R., Kashyap, V. K., *BMC Evol. Biol.* 2005, **5**, 26–34.
- [33] Tanaka, M., Cabrera, V. M., Gonzalez, A. M., Larruga, J. M., Takeyasu, T., Fuku, N., Guo, L. J. *et al.*, *Genome Res.* 2004, **14**, 1832–1850.
- [34] Torroni, A., Rengo, C., Guida, V., Cruciani, F., Sellitto, D., Coppa, A., Calderon, F. L., Sellitto, D., Coppa, A., Calderon, F. L. *et al.*, *Am. J. Hum. Genet.* 2001, **69**, 1348–1356.
- [35] Volodko, N. V., Starikovskaya, E. B., Mazunin, I. O., Eltsov, N. P., Naidenko, P. V., Wallace, D. C., Sukernik, R. I. *Am. J. Hum. Genet.* 2008, **82**, 1084–1100.
- [36] Bandelt, H. J., Salas, A., Lutz-Bonengel, S., *Int. J. Legal Med.* 2004, **118**, 267–273.
- [37] Davis, J. I., Simmons, M. P., Stevenson, D. W., Wendel, J. F., *Syst. Biol.* 1998, **47**, 282–310.
- [38] Hirano, M., Shtilbans, A., Mayeux, R., Davidson, M. M., DiMauro, S., Knowles, J. A., Schon, E. A. *Proc. Natl. Acad. Sci. USA* 1997, **94**, 14894–14899.
- [39] Salas, A., Carracedo, A., Macaulay, V., Richards, M., Bandelt, H. J., *Biochem. Biophys. Res. Commun.* 2005, **335**, 891–899.
- [40] Salas, A., Quintans, B., Alvarez-Iglesias, V., *Methods Mol. Biol.* 2005, **297**, 197–208.
- [41] Yao, Y. G., Bravi, C. M., Bandelt, H. J., *Forensic Sci. Int.* 2004, **141**, 1–6.
- [42] Yao, Y. G., Kong, Q. P., Salas, A., Bandelt, H. J., *J. Med. Genet.* 2008, **45**, 769–772.
- [43] Parfait, B., Rustin, P., Munnich, A., Rotig, A., *Biochem. Biophys. Res. Commun.* 1998, **247**, 57–59.
- [44] Parr, R. L., Maki, J., Reguly, B., Dakubo, G. D., Aguirre, A., Wittrock, R., Robinson, K. *et al.*, *BMC Genomics* 2006, **7**, 185–198.
- [45] Goios, A., Prieto, L., Amorim, A., Pereira, L., *Int. J. Legal Med.* 2008, **122**, 341–345.
- [46] Wong, L. J., Liang, M. H., Kwon, H., Park, J., Bai, R. K., Tan, D. J., *Clin. Chem.* 2002, **48**, 1901–1912.
- [47] Roche Diagnostics GmbH, *PCR Applications Manual*, Mannheim 2006.
- [48] Altschul, S. F., Gish, W., Miller, W., Myers, E. W., Lipman, D. J., *J. Mol. Biol.* 1990, **215**, 403–410.
- [49] Sambrook, J., *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory, Cold Spring Harbor 2001.

Amanda Ramos¹
 Cristina Santos¹
 Elena Barbena¹
 Ligia Mateiu²
 Luis Alvarez^{1,3}
 Ramon Nogués¹
 Maria Pilar Aluja¹

¹Unitat d'Antropologia Biològica,
 Departament BABVE,
 Universitat Autònoma de
 Barcelona, Barcelona, Spain

²Department of Biology,
 University of Antwerp,
 Groenenborgerlaan, Antwerpen,
 Belgium

³IPATIMUP, Instituto de Patologia
 e Imunologia da Universidade
 do Porto, R. Dr. Roberto Frias,
 Porto, Portugal

Received November 1, 2010

Revised November 26, 2010

Accepted November 29, 2010

Short Communication

Validated primer set that prevents nuclear DNA sequences of mitochondrial origin co-amplification: A revision based on the New Human Genome Reference Sequence (GRCh37)

A new human genome reference sequence – GRCh37 – was recently generated and made available by the Genome Reference Consortium. Since the prior disposable human reference sequence – hg18 – was previously used for the mitochondrial DNA primer BLAST validation, a revision of those previously published primer pairs is required. Thus, the aim of this Short Communication is to perform an in silico BLAST test of the published disposable nine primer pairs using the new human reference sequence and to report the pertinent modifications. The new analysis showed that one of the tested primer pairs requires a revision. Therefore, a new validated primer pair, which specifically amplifies the mitochondrial region located between positions 6520 and 9184, is presented.

Keywords:

Mitochondrial DNA / Nuclear sequences of mitochondrial origin / Primer design
 DOI 10.1002/elps.201000583



Recently, a paper that deals with the complete amplification of Human mitochondrial DNA (mtDNA) was published in this journal [1]. The main goal of the mentioned work was to design, validate and describe a set of primers, to specifically amplify and sequence the complete human mtDNA, allowing the correct interpretation of mtDNA heteroplasmy in healthy and pathological samples. According to the authors, the interpretation of mtDNA data, particularly the presence of heteroplasmy, could be complicated due to the co-amplification of mtDNA and nuclear sequences of mitochondrial origin (NUMTs) [2, 3]. Therefore, an effort to design PCR primers that selectively amplify mtDNA was necessary. In accordance, Ramos et al. [1] proposed a set of nine primer pairs to amplify the whole mtDNA. Primers were validated, through the Basic Local Alignment Search Tool (BLAST) available in NCBI (National Center for

Biotechnology Information: <http://www.ncbi.nlm.nih.gov/BLAST/>) [4], and subsequently tested using a nuclear DNA (nDNA) sample.

In Ramos et al. [1], the human reference sequence hg18 was used in the in silico primer validation. However, a new human reference sequence – GRCh37 – was recently (February 2009) generated by the Genome Reference Consortium. Thus, the aim of this work is to test again with BLAST the previously published primers using the new human reference sequence and to report the pertinent modifications.

Accordingly to the latest human reference sequence update, one of the most problematic NUMTs for the primer design appears to be larger than earlier reported. This nuclear sequence is located in chromosome 1 and presents a 98% of homology with one-third of the mtDNA. This redefined NUMT (detailed and described as online Supporting Information S1) lays between positions 564 461 and 570 304 (in relation to the *Homo sapiens* chromosome 1, GRCh37 primary reference assembly – NC_000001), and presents a 98% homology with the region 3911–9755 of human mtDNA [5].

The new in silico analysis revealed that one of the nine previously described primer pairs, specifically the one designed to amplify the 2709-bp region of the mtDNA, located between positions 6511 and 9220 (fragment 5 in Table 1 of Ramos et al. [1]), lies on the redefined homologous region. Thus, an accidental co-amplification of mtDNA and nDNA could occur. The described NUMT

Correspondence: Amanda Ramos, Unitat d'Antropologia Biològica, Departament Biologia Animal, Biologia Vegetal i Ecologia, Universitat Autònoma de Barcelona, 08193 Cerdanyola del Vallès, Barcelona, Spain
E-mail: amanda.ramos@uab.cat
Fax: +34-935811321

Abbreviations: BLAST, Basic Local Alignment Search Tool; mtDNA, mitochondrial DNA; nDNA, nuclear DNA; NUMT, nuclear sequences of mitochondrial origin

Table 1. New validated primer pair to amplify the mtDNA region affected by the new updated NUMT is reported. Melting temperatures (T_m) are also presented

Fragment	Fragment length	Name	Sequence (5'–3')	Primers pair length (bp)	T_m
5	2664	6520for	tcactatactactaacagacc gc	23	58.9
		9184rev	gtagaggctactagaagt gtg	22	58.4

The primer base located in position 3' that differs from the sequence of chromosome 1 is shown in bold.

appears to be Human specific since it is present in *Homo sapiens* but it is not present in other primates (see alignment results as online Supporting Information S2). To date, its variability (presence/absence) in Human population is unknown, and we cannot discard the possibility of nDNA co-amplification at least in some individuals. For this reason, a new design, description and in silico validation (according to the methods presented in [1]) of the fragment 5 primer pair is presented.

The size of the redefined chromosome 1 NUMT does not allow locating a primer out of this region following a normal PCR amplification strategy. Consequently, a new approach to primer design was undertaken: (i) primers were relocated to areas with low degree of homology with chromosome 1 and (ii) the 3'-end of each primer were located in mismatch positions relatively to chromosome 1 sequence. Therefore, the possibility of co-amplification of nDNA and mtDNA is reduced. Optimized primer pair and PCR conditions for this concrete region of mtDNA are reported in Table 1. Internal sequence primers previously reported [1] are not affected and can still be used to sequence this region.

This work was supported by MEC (project: CGL2006–07374) and by Generalitat de Catalunya (Ref. 2009 SGR 566).

The authors have declared no conflict of interest.

References

- [1] Ramos, A., Santos, C., Alvarez, L., Nogues, R., Aluja, M. P., *Electrophoresis* 2009, 30, 1587–1593.
- [2] Yao, Y. G., Kong, Q. P., Salas, A., Bandelt, H. J., *J. Med. Genet.* 2008, 45, 769–772.
- [3] Parr, R. L., Maki, J., Reguly, B., Dakubo, G. D., Aguirre, A., Wittock, R., Robinson, K., Jakupciak, J. P., Thayer, R. E., *BMC Genomics* 2006, 7, 185.
- [4] Altschul, S. F., Gish, W., Miller, W., Myers, E. W., Lipman, D. J., *J. Mol. Biol.* 1990, 215, 403–410.
- [5] Andrews, R. M., Kubacka, I., Chinnery, P. F., Lightowlers, R. N., Turnbull, D. M., Howell, N., *Nat. Genet.* 1999, 23, 147.



Nuclear insertions of mitochondrial origin: Database updating and usefulness in cancer studies

Amanda Ramos ^a, Elena Barbena ^a, Ligia Mateiu ^b, María del Mar González ^a, Quim Mairal ^a, Manuela Lima ^{c,d}, Rafael Montiel ^e, Maria Pilar Aluja ^a, Cristina Santos ^{a,*}

^a Unitat d'Antropologia Biològica, Departament BABVE, Universitat Autònoma de Barcelona, 08193 Cerdanyola del Vallès, Barcelona, Spain

^b Laboratory for Molecular Plant Physiology and Biotechnology CGB, University of Antwerpen Groenenborgerlaan, 171 B-2020 Antwerpen, Belgium

^c IBMC – Institute for Molecular and Cellular Biology, University of Porto, Porto, Portugal

^d Center of Research in Natural Resources (CIRN), University of the Azores, Ponta Delgada, Portugal

^e Laboratorio Nacional de Genómica para la Biodiversidad, CINVESTAV-IPN, Irapuato, Mexico

ARTICLE INFO

Article history:

Received 10 June 2011

Received in revised form 10 August 2011

Accepted 26 August 2011

Available online 2 September 2011

Keywords:

NUMTs

Insertions

Heteroplasmy

Cancer

ABSTRACT

Nuclear insertions of mitochondrial origin (NUMTs) can be useful tools in evolution and population studies. However, due to their similarity to mitochondrial DNA (mtDNA), NUMTs may also be a source of contamination in mtDNA studies. The main goal of this work is to present a database of NUMTs, based on the latest version of the human genome—GRCh37 draft. A total of 755 insertions were identified. There are 33 paralogous sequences with over 80% sequence similarity and of a greater length than 500 bp. The non-identical positions between paralogous sequences are listed for the first time. As an application example, the described database is used to evaluate the impact of NUMT contamination in cancer studies. The evaluation reveals that 220 positions from 256 with zero hits in the current mtDNA phylogeny could in fact be traced to one or more nuclear insertions of mtDNA. This is due to they are located in non-identical positions between mtDNA and nuclear DNA (nDNA). After *in silico* primer validation of each revised cancer study, risk of co-amplification between mtDNA and nDNA was detected in some cases, whereas in others no risk of amplification was identified. This approach to cancer studies clearly proves the potential of our NUMT database as a valuable new tool to validate mtDNA mutations described in different contexts. Moreover, due to the amount of information provided for each nuclear insertion, this database should play an important role in designing evolutionary, phylogenetic and epidemiological studies.

© 2011 Elsevier B.V. and Mitochondria Research Society. All rights reserved.

1. Introduction

The evolution of eukaryotic cells is linked to the phenomena of endosymbiosis and it is widely accepted that DNA transfer occurs between the cellular organelles (mitochondria and chloroplasts) and the nucleus. The general evolutionary tendency is a reduction in the gene content of cellular organelles to avoid genetic redundancy (Kleine et al., 2009). Although the origin of this transfer is unknown (Blanchard and Lynch, 2000), it is accepted that it was an important evolutionary mechanism in the prokaryotic–eukaryotic transition and it appears that it was in the early endosymbiosis when this transfer was the most significant. DNA transfer from cellular organelle to the nucleus is a process that remains active (Hazkani-Covo et al., 2010; Hazkani-Covo and Graur, 2007; Ricchetti et al., 2004) and has

resulted in the formation of pseudogenes, known as NUMTs (nuclear insertions of mitochondrial origin) or NUPTs (nuclear insertions of chloroplast origin) depending on whether they are of mitochondrial or chloroplast origin (Leister, 2005). These insertions are non-uniformly distributed throughout the genomes and the patterns that enable prediction of the insertion position are currently unknown (Bensasson et al., 2001).

The most parsimonious explanation for the origin of specific NUMT integration is the non-homologous end joining (NHEJ) repair mechanism. NHEJ is the major mechanism of double-strand break repair (DSBR) in mammalian cells and during this process, NUMTs appear to prevent chromosomal deletions primarily through blunt-end repair (Hazkani-Covo and Covo, 2008).

De novo NUMT insertions have been described as being associated to diseases and to the aging process (Caro et al., 2010; Goldin et al., 2004; Turner et al., 2003). However, most reported NUMTs are polymorphic or fixed into the species.

Since the mutation rate is higher in mitochondrial DNA (mtDNA) than in nuclear DNA (nDNA), once an insertion is fixed, it undergoes a different evolutionary process to that of the original mtDNA sequence.

* Corresponding author at: Unitat d'Antropologia Biològica, Departament Biologia Animal, Biologia Vegetal i Ecologia, Universitat Autònoma de Barcelona, 08193 Cerdanyola del Vallès, Barcelona, Spain. Tel.: +34 935811503; fax: +34 935811321.

E-mail address: cristina.santos@uab.cat (C. Santos).

Thus, NUMTs are considered molecular fossils that provide information about the mtDNA ancestral state, allowing to root intra-specific mtDNA phylogenetic trees without needing an outgroup species. Moreover, they can be used as tools in the study of the evolutionary history of populations (Ricchetti et al., 2004; Thalmann et al., 2005; Turner et al., 2003) and in the establishment of molecular phylogenies (Hazkani-Covo, 2009; Hazkani-Covo and Graur, 2007; Jensen-Seaman et al., 2009).

Due to the similarity with mtDNA, NUMTs are a potential source of contamination in mtDNA studies based on PCR amplification (Parr et al., 2006b; Yao et al., 2008). Although this problem has previously been considered to be muted in consequence of the high copy number of mtDNA compared with the corresponding nuclear loci, caution is mandatory (Parfait et al., 1998) since amplification of NUMTs is a real problem for accurate sequence interpretation, and particularly for the interpretation of mtDNA heteroplasmy (Parr et al., 2006a, 2006b). Parr et al. (2006b), in a study performed with rho0 cells, suggested that one of the most important factors that determine whether a NUMT will or will not co-amplify with mtDNA are the region of the mtDNA targeted by the PCR and the number of NUMT copies. Moreover, samples of ancient DNA or any tissue with a low mtDNA copy number, in both normal and pathological states (such as, for example, tumor samples), also seem to be important factors that could determine the co-amplification of NUMTs (Goios et al., 2008; Parr et al., 2006b). Goios et al. (2008) stated that, in standard sequencing of samples used for population characterization, the amplification of NUMTs does not constitute a real problem, since the mtDNA content in samples is much higher than the nDNA content and the detection of mtDNA heteroplasmy is not a priority. Yao et al. (2008) demonstrated, nevertheless, that co-amplification of NUMTs can occur even when samples of a standard quality and amount are used.

From the analysis of several studies concerning the prevalence of NUMTs, a very different number of nuclear insertions of mitochondrial origin are reported. This discordance can be attributed to different factors: 1) after insertion of a NUMT, it becomes susceptible to suffering post-insertional processes, such as duplications, translocations, deletions, etc., that alter the initially inserted sequence (Hazkani-Covo et al., 2003, 2010); these post-insertional processes have not been equally considered in different studies; and 2) there are no unified criteria for the *in silico* detection of NUMTs. This lack of standardization affects both the selection of bioinformatic tools as well as the criteria for acceptance or not of the NUMT paralogous sequences (Lascaro et al., 2008). On the other hand, the existing NUMT compilations were based on a previous version of the Human Genome Reference Sequence, instead of the current version (GRCh37) and an update is required. This update would be useful for population and phylogenetic studies and the prevention of mtDNA and nDNA co-amplification.

The main goal of this study is to present a comprehensive database of NUMTs, based on the latest version of the human genome – GRCh37 draft. Moreover, as an application example, the described database is used to assess the impact of NUMT contamination on cancer studies.

2. Materials and methods

2.1. Updating of insertions of mitochondrial origin database

NUMT detection was performed *in silico*; the new version of the human genome draft (GRCh37) and the criteria for NUMTs detection proposed by Hazkani-Covo and Graur (2007) were used. The Basic Local Alignment Search Tool (BLAST), available from the NCBI (National Center for Biotechnology Information: <http://www.ncbi.nlm.nih.gov/BLAST/>) (Altschul et al., 1990), was used to identify regions of similarity between mitochondrial and nuclear genomes. The Human mtDNA Reference Sequence (NC_012920) was compared against the human RefSeq Genomic database at NCBI. The similar nucleotide sequences were found using the RemoteBlast package in Bioperl bundle (Stajich

et al., 2002) with the parameters set to restrict the search to human organism and the E-value of 10^{-3} (Hazkani-Covo and Graur, 2007). Moreover, regions with less than 20 bp were excluded. The BLAST report contains the basic information for each hit and the lists of the identical positions in the high scoring alignment pairs, both in the query and in the hit sequence. An *in-house* Perl script was written to further process this information. For each alignment pair, the array of sites listed in the query range was compared against the identical sites found. The same was carried out for positions in the hit range, and finally the sites of interest, namely the non-identical nucleotides, were extracted.

BLAST results were manually inspected to select only the hits obtained for the GRCh37 primary reference assembly and no post-insertional processes were taken into account.

2.2. Applications to cancer

MtDNA mutations previously described in cancer samples, and classified as having zero hits in the mtDNA phylogeny (that are therefore not polymorphic in human populations) by Santos et al. (2008) were used to evaluate the impact of NUMT contamination in cancer studies. First, mutations compiled by Santos et al. (2008) were re-evaluated using the updated mtDNA phylogeny – mit. Tree build 8 – (Van Oven and Kayser, 2009) and mutations that had one or more hits in the new phylogeny were not considered for subsequent analysis.

Mutations detected in cancer, with no hits in the mtDNA phylogeny, were then searched in the database of non-identical positions between the paralogous sequences. Furthermore, for those studies in which mutations coincided with non-identical positions between the paralogous sequences, an *in silico* validation of primers used in each study was performed. In brief, the PCR primers were submitted to BLAST. The specific Basic BLAST tool, optimized for highly similar sequences (Megablast), was performed using the Reference Genomic Sequence database for *Homo sapiens* (refseq_genomic: Genomic sequences from National Center for Biotechnology Information Reference Sequence Project). If both primers showed homology (expected number of chance matches in a random model – E-value – lower than 1) inside the same chromosome region they were selected as being susceptible to co-amplify mtDNA and nDNA.

3. Results

3.1. Database of nDNA sequences of mitochondrial origin based on the GRCh37 Human Genome Reference Sequence

The NUMT database based on the GRCh37 Human Genome Reference Sequence is reported in reported in Table I (Online Supplementary Material I). Additionally, a BLAST-searchable database of all NUMTs is also reported in Online Supplementary Material II.

Seven hundred and fifty-five insertions were found to be spread throughout the entire genome. For each insertion the following information is reported: location at the chromosome; length of the chromosome; access number; score and the E-value of the match; fraction and the percentage identity; number of gaps; total length of match (alignment mtDNA/nDNA); the effective length in nDNA and in the mtDNA; the number of identical positions; the region in the mtDNA and nDNA; and finally, matrix of the identical and non-identical positions in mtDNA and nDNA (Fig. 1).

The 755 insertions are distributed throughout the genome with variable frequencies and sizes for each chromosome (Table 1 and Fig. 2). A large number of insertions are observed in most chromosomes. There are only six chromosomes (14, 15, 16, 18, 20 and Y) that accumulate 15 or fewer insertions, representing less than 2% of the total insertions present in each.

There is a positive correlation between the number of insertions and chromosome size (Spearman correlation: 0.822 $p < 0.001$) (Fig. 3a). Chromosome 2, the second largest chromosome in relation to the entire




Fig. 2. Frequency and size (bp) of insertions for each chromosome.

The relationship between the size of the insertion and the percentage identity is shown in Table 3. Concerning the size of insertions, it appears that most refer to small insertions (Table 3 and Fig. 2) of less than 500 bp. Only 12.85% of the insertions have more than 1500 bp. The smallest insertions found are 39 bp long and are located on chromosomes 1 and 3. On the other hand, the largest insertion (14,836 bp) is located on chromosome 4 (Table I, Online Supplementary Material I).

About half of the small insertions have a percentage identity higher than 80% of the mitochondrial sequence (Table 3). As the size of the insertion increases, however, the proportion of insertions with a percentage identity equal to or higher than 80% decreases. There are 33 paralogous sequences with more than 500 bp, which present a similarity equal to or higher than 80% (Table 4). These sequences would represent the most problematic, in terms of mtDNA/nDNA co-amplification.

3.2. Applications to cancer

From the 271 mtDNA mutations previously described in cancer samples, and classified as having zero hits in the mtDNA phylogeny by Santos et al. (2008), 15 have one or more hits in the current phylogeny by van Oven and Kayser (2009) (mit. Tree build 8). From the 256 positions with zero hits in the current mtDNA phylogeny (Table II, Online Supplementary Material I), 220 could represent changes in one or more nuclear insertions of mtDNA (Table III of Online Supplementary Material I includes the 220 positions and their matches in non-identical positions in the insertions and the paralogous mtDNA sequences), since they are non-identical between mtDNA and nDNA. Accordingly at that point, only 36 positions can be considered as authentic mtDNA mutations, since they were not found as non-identical in any of the nuclear insertions reported in our study (positions signaled with * in Table II of Online Supplementary Material I).

The 220 positions that can represent false mtDNA mutations correspond to a total of 592 mutations described in the cancer studies, revised

in Santos et al. (2008). Of these, 186 mutations were once observed in different types of cancer and/or studies (Table II of Online Supplementary Material I and references therein). The mutations that occur more than once are mostly reported in the study of ovarian cancer by Aikhionbare et al. (2007). In this work, the D-loop and part of the coding region of mtDNA were characterized in 102 samples. The PCR reactions were performed with two primer pairs; after primer BLAST validation, the primer pair that amplifies the region located between positions 16,453–16,569 and 1–1693 reveals no risk of co-amplification. The *in silico* validation of the other primer pair, located between positions 7392 and 8921, reveals a risk of co-amplification between mtDNA and the region of chromosome 1 located between positions 46,578 and 48,102. However, in the NUMTs that can potentially be amplified by this primer set, the mtDNA mutations described by Aikhionbare et al. (2007) were not reported as non-identical positions in our NUMT database (Table III of Online Supplementary Material I).

With regard the remaining studies, in five we were unable to assess their primers (Liu et al., 2001; Lorenc et al., 2003; Parr et al., 2006a; Petros et al., 2005; Zhou et al., 2007), since PCR primers were not reported in the original manuscripts, and after requesting them from the authors no response was obtained.

In the study by Allegra et al. (2006), the primer pair which amplifies the 10,688–11,500 mtDNA region also co-amplifies nDNA; specifically, it amplifies the region 99,385,306–99,386,137 on chromosome 5. Moreover, position 11,203, reported as a mitochondrial mutation by Allegra et al. (2006), was reported as a non-identical position between mtDNA and the NUMT located on chromosome 5 in the region 99,381,642–99,390,749 (position signaled with † in Table III of Online Supplementary Material I).

In ten different studies (Aikhionbare et al., 2007; Allegra et al., 2006; Fliss et al., 2000; Hervouet and Godinot, 2006; Jin et al., 2007; Lievre et al., 2005; Mithani et al., 2007; Polyak et al., 1998; Tan et al., 2006) the primer *in silico* validation also revealed a risk of co-amplification




Fig. 3. Correlation between chromosome length and number of insertions (a), and correlation between chromosome and insertion length (b). Coefficient of determination (Sq r linear) for the two correlations is shown.

between mtDNA and nDNA. The twenty-seven positions described by the authors as mtDNA mutations, however, are not reported as non-identical position between mtDNA and the nuclear regions that might potentially be co-amplified.

Finally, 123 positions described in 15 studies (Aikhionbare et al., 2007; Fliss et al., 2000; Gasparre et al., 2007; Habano et al., 1999; Hervouet and Godinot, 2006; Jin et al., 2007; Jones et al., 2001; Kassaei et al., 2006; Lievre et al., 2005; Mithani et al., 2007; Nagy et al., 2003; Parrella et al., 2001; Polyak et al., 1998; Tan et al., 2006; Tzen et al., 2007) are more likely

to be authentic, since the primers used to amplify the regions that encompass such mutations did not suggest the possibility of nDNA co-amplification (positions signaled with ** in Table II of Online Supplementary Material I).

4. Discussion

In population and clinical genetics, as well as in the design of evolutionary, phylogenetic and epidemiological studies, it is important to

Table 2
Percentage identity for all chromosomes.

Chromosome	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	X	Y
Mean	78.76	80.20	79.42	81.24	82.02	80.77	77.67	77.88	78.22	78.31	78.27	83.40	80.61	80.40	79.23	77.37	81.69	84.61	72.92	81.43	75.82	75.74	76.05	79.00
Median	75.73	78.93	79.80	80.43	80.73	81.74	75.83	76.32	77.30	76.98	75.76	88	80.72	79.13	77.65	76.72	80.41	83.96	69.65	77.88	74.05	72.16	73.83	74.57
Minimum	64.71	65.04	68.14	68.71	66.35	64.69	68.46	67.77	68.02	69.08	66.46	67.79	65.41	73.55	71.83	68.26	68.54	74.08	63.50	69.49	65.59	65.67	64.82	70.15
Maximum	100	98.48	97.44	96.77	97.67	93.33	97.09	98.81	90.20	92	98.61	98.88	99.22	93.07	95.35	85.45	97.06	95.57	86.59	100	98.75	100	96.30	100
Percentiles	25	71.43	74.58	73.16	76.19	76.47	77.78	72.22	72.37	73.97	74.14	74.44	77.58	72.41	74.75	73.35	77.06	75.89	67.43	72.40	68.09	69.32	69.78	71.38
	50	75.73	78.93	79.80	80.43	80.73	81.74	75.83	76.32	77.30	76.98	75.76	88	80.72	79.13	77.65	76.72	80.41	83.96	77.88	74.04	72.16	73.83	74.57
	75	84.03	85.47	83.56	84.86	88.36	85	82.02	82.35	80.71	82.08	81.67	88	88.59	86.02	83.37	81.73	83.42	94.08	94.10	79.71	80.31	80.95	82.35

Table 3

Frequency and identity of insertions in relation to the size of insertion (bp).

Size (bp)	Identity		Total	Percentage
	≥80%	<80%		
<500	276	245	521	69.00
[500–1500]	21	116	137	18.15
[1500–2500]	5	43	48	6.36
[2500–4000]	3	21	24	3.18
≥4000	4	21	25	3.31
Total	309	446	755	100

have a complete overview of the total number of NUMTs, their location and variation. In this study, a NUMT database obtained using the latest version of the Human Genome – GRCh37 draft is reported. This is, to our knowledge, the first database that is based on this latest version of the human genome. Moreover, it is also the first where the non-identical positions between mtDNA and nDNA are listed for each NUMT.

In this study, 755 nuclear insertions of mtDNA origin were reported. A comparison of the total number of NUMTs in previously published works clearly shows significant discrepancies. The number of reported NUMTs ranges from 190 (Lascaro et al., 2008) to 1105 (Tourmen et al., 2002), with reports of 206 (Richly and Leister, 2004), 211 (Ricchetti et al., 2004), 247 (Mishmar et al., 2004), 452 (Hazkani-Covo and Graur, 2007), 612 (Woischnik and Moraes, 2002) and 871 (Hazkani-Covo et al., 2010) insertions. The reasons for such discrepancies have been discussed by others previously (Lascaro et al., 2008). According to Lascaro et al. (2008), the incautious usage of bioinformatics methods and the application of methods to an as yet not correctly assembled nuclear genome, are the main factors underlying the disagreement observed between studies. In this sense, the Human mtDNA Reference Sequence (NC_012920) was compared against the human RefSeq Genomic database at NCBI, using the RemoteBlast package in Bioperl bundle (Stajich et al., 2002) with the parameters set to restrict the search to the human organism and the E-value of 10^{-3} . Moreover, regions with less than 20 bp were excluded and only hits in the most recent version of the Human genome draft – GRCh37 primary reference assembly were considered.

Another factor that can induce differences in the number of reported insertions is whether or not the post-insertional processes were evaluated in order to differentiate original insertions from those that result from processes that alter the initially inserted sequence. In this study, post-insertional processes were not considered, since we aimed to obtain an accurate database with all the nuclear insertions and their specific variation (relatively to human mtDNA).

In accordance to other authors [for a review see Hazkani-Covo et al. (2010)], the reported frequency of insertions, as well as their length and distribution along the genome is variable. Most insertions have less than 500 bp. This agrees with the most parsimonious explanation for the origin of NUMT which assumes that mtDNA would be used as a “patch” in the double-strand break repair from non-homologous end joining repair mechanism (Hazkani-Covo et al., 2010; Hazkani-Covo and Covo, 2008; Leister, 2005).

As previously mentioned, due to the similarity with mtDNA, NUMTs are a potential source of contamination in mtDNA studies based on PCR amplification (Parr et al., 2006b; Yao et al., 2008). In this context, large insertions with a high percentage of identity with mtDNA would be particularly problematic. In fact, one of these insertions, located on chromosome 1, was previously reported to be a source of several errors and misinterpretations (Yao et al., 2008). We characterized the 33 large insertions (with more than 500 bp) that present a percentage identity greater than 80%. Its size makes it difficult to perform primer designs to prevent co-amplification between nuclear insertions and mtDNA (Ramos et al., 2009; Ramos et al., 2011).

This study reports for the first time all identical and non-identical positions between the NUMTs and the GRCh37 version of the nuclear

Table 4
Paralogous sequences with more than 500 bp and that present a similarity equal or higher than 80%.

Chromosome	% Identity	nDNA length	mtDNA length	mtDNA region	nDNA region
1	98.53	5844	5845	3911–9755	564,461–570,304
1	84.03	517	521	987–1507	142,792,601–142,793,117
1	83.87	518	521	987–1507	143,243,224–143,243,741
1	83.78	515	519	987–1505	143,344,679–143,345,193
2	84.03	516	521	987–1507	95,564,754–95,565,269
2	83.95	728	729	6270–6998	50,815,826–50,816,553
2	81.78	1350	1349	4854–6202	156,119,971–156,121,320
3	95.39	1323	1323	1396–2718	96,336,032–96,337,354
3	83.31	623	623	7151–7773	120,440,870–120,441,492
3	80.38	1621	1622	1418–3039	40,293,638–40,295,258
5	95.05	2114	2121	577–2697	79,945,841–79,947,954
5	94.06	5219	5219	10,269–15,487	134,258,999–134,264,217
5	88.36	9108	9067	6117–15,183	99,381,642–99,390,749
5	87.24	3463	3463	12,662–16,124	93,903,161–93,906,623
5	84.54	962	961	577–1537	123,096,499–123,097,460
6	90.70	527	527	2408–2934	62,284,008–62,284,534
7	83.66	2514	2517	577–3093	142,373,012–142,375,525
7	81.27	562	561	2740–3300	141,504,769–141,505,330
9	83.85	2517	2517	577–3093	33,656,612–33,659,128
10	84.62	533	533	8281–8813	101,817,140–101,817,672
11	94.24	2394	2396	577–2972	10,529,434–10,531,827
11	81.68	560	568	596–1163	87,524,440–87,524,999
14	93.07	1021	1024	5583–6606	32,953,304–32,954,324
17	96.17	653	653	6818–7470	51,183,094–51,183,746
17	83.42	10,477	10,536	577–11,112	22,021,365–22,031,841
17	81.73	621	619	2656–3274	19,504,577–19,505,197
17	80.57	1514	1521	577–2097	19,501,874–19,503,387
17	80.41	2206	2205	14,365–16,569	22,018,521–22,020,726
17	80.24	575	582	2084–2665	19,503,699–19,504,273
21	83.78	515	519	987–1505	9,735,524–9,736,038
X	93.68	554	554	10,606–11,159	125,606,714–125,607,267
X	93.07	749	750	6553–7302	125,605,687–125,606,435
Y	83.08	517	521	987–1507	13,290,151–13,290,667

genome and the mtDNA Reference Sequence. This information can be used as a tool in the authentication of mtDNA mutations reported in different fields. Notwithstanding, it is worth mentioning that, in this compilation, the variation of NUMTs was not considered since no studies of NUMT sequence variation had yet been performed to date. Moreover, the mtDNA variation was only taken into account for human mtDNA, although the original insertion could in fact represent mtDNA sequence from very different species.

The described NUMT database was used as a tool to assess the impact of NUMT contamination on cancer studies. Several authors detected innumerable deficiencies in the medical literature related to the analysis and interpretation of mtDNA data [Salas et al. (2005), Yao et al. (2004) among others]. Concerning cancer studies, Salas et al. (2005) showed the consequences of poor experimental design, both in the misinterpretation of the role of mtDNA in the complex tumoral process, as well as in the comparison of results. Also, Yao et al. (2004) showed that researchers may still ignore the possibility of a NUMT contribution when a seemingly novel mtDNA sequence is encountered. Using the NUMT database, we evaluated 256 mtDNA positions that were previously reported to be mutated in cancer samples and that present zero hits in the updated mtDNA phylogeny (Van Oven and Kayser, 2009). From those positions, 220 (identified in 21 studies) could represent changes in one or more nuclear insertions of mtDNA since they are non-identical between mtDNA and nDNA. Thus, we raise the hypothesis that these changes could represent nuclear variations instead of mtDNA variation. To test this hypothesis, we further validated *in silico* the primer pairs used in several original studies if they were accessible in the publication or if they were provided by the authors after request. After primer *in silico* validation, from a total of 16 works for which primers were available, only six studies (Habano et al., 1999; Jones et al., 2001; Kassaoui et al., 2006; Nagy et al., 2003; Parrella et al., 2001; Tzen et al., 2007) did not evidence the possibility of nDNA co-amplification. In the remaining studies (Table III of Online Supplementary Material I and references

therein), some of the positions reported are located in regions that could be the result of co-amplification. However, with the exception of position 11,203 reported by Allegra et al. (2006), these positions are not reported as non-identical between the potentially co-amplified mtDNA and nDNA regions. Even so, we must take into account the fact that the variability of NUMTs is unknown, and that the non-identical position database was generated using the mtDNA and nDNA Reference Sequences. Thus, the differences between mtDNA and nDNA reported in our database are surely underestimated and the above mentioned positions could be non-authentic mtDNA mutations. On the other hand, it is possible that these changes actually represent authentic mtDNA mutations; however, this hypothesis seems extremely difficult to test.

Using cancer studies as an example application, we aimed to highlight the applicability of the described NUMT database as a new tool to validate *in silico* mtDNA mutations described in different contexts; it is clear that there is a need to follow standardized protocols that avoid co-amplification between mitochondrial and nuclear paralogous sequences. Moreover, and due to the amount of information provided for each nuclear insertion, this database could be applied as a tool to design evolutionary, phylogenetic and epidemiological studies.

To our knowledge, this is the first work to report the non-identical positions between the mtDNA and nDNA. These positions are the basis for the application to cancer studies reported in this work, and knowledge of their distribution is useful for the authentication of mtDNA mutations reported in different kinds of study, especially those occurring in heteroplasmy.

Supplementary data associated with this article can be found, in the online version, at doi:10.1016/j.mito.2011.08.009.

Acknowledgments

This work was supported by MEC (project: CGL2009-08205) and by the Generalitat de Catalunya (Ref. 2009 SGR 566).

We are in debt with Dr. Czarnecka, Dr Liu and Dr. Maitra, the corresponding authors of cancer studies for supplying the information necessary for the analysis.

References

- Aikhionbare, F.O., Mehrabi, S., Kumaresan, K., Zavareh, M., Olatinwo, M., Odunsi, K., Partridge, E., 2007. Mitochondrial DNA sequence variants in epithelial ovarian tumor subtypes and stages. *J. Carcinog.* 6, 1.
- Allegra, E., Garozzo, A., Lombardo, N., De Clemente, M., Carey, T.E., 2006. Mutations and polymorphisms in mitochondrial DNA in head and neck cancer cell lines. *Acta Otorhinolaryngol. Ital.* 26, 185–190.
- Altschul, S.F., Gish, W., Miller, W., Myers, E.W., Lipman, D.J., 1990. Basic local alignment search tool. *J. Mol. Biol.* 215, 403–410.
- Bensasson, D., Zhang, D., Hartl, D.L., Hewitt, G.M., 2001. Mitochondrial pseudogenes: evolution's misplaced witnesses. *Trends Ecol. Evol.* 16, 314–321.
- Blanchard, J.L., Lynch, M., 2000. Organellar genes: why do they end up in the nucleus? *Trends Genet.* 16, 315–320.
- Caro, P., Gomez, J., Arduini, A., Gonzalez-Sanchez, M., Gonzalez-Garcia, M., Borrás, C., Vina, J., Puertas, M.J., Sastre, J., Barja, G., 2010. Mitochondrial DNA sequences are present inside nuclear DNA in rat tissues and increase with age. *Mitochondrion* 10, 479–486.
- Fliss, M.S., Usadel, H., Caballero, O.L., Wu, L., Buta, M.R., Eleff, S.M., Jen, J., Sidransky, D., 2000. Facile detection of mitochondrial DNA mutations in tumors and bodily fluids. *Science* 287, 2017–2019.
- Gasparre, G., Porcelli, A.M., Bonora, E., Pennisi, L.F., Toller, M., Iommarini, L., Ghelli, A., Moretti, M., Betts, C.M., Martinelli, G.N., Ceroni, A.R., Curcio, F., Carelli, V., Rugolo, M., Tallini, G., Romeo, G., 2007. Disruptive mitochondrial DNA mutations in complex I subunits are markers of oncogenic phenotype in thyroid tumors. *Proc. Natl. Acad. Sci. U.S.A.* 104, 9001–9006.
- Goios, A., Prieto, L., Amorim, A., Pereira, L., 2008. Specificity of mtDNA-directed PCR-influence of Nuclear MTDNA insertion (NUMT) contamination in routine samples and techniques. *Int. J. Legal Med.* 122, 341–345.
- Goldin, E., Stahl, S., Cooney, A.M., Kaneski, C.R., Gupta, S., Brady, R.O., Ellis, J.R., Schiffmann, R., 2004. Transfer of a mitochondrial DNA fragment to MCOLN1 causes an inherited case of mucopolidiosis IV. *Hum. Mutat.* 24, 460–465.
- Habano, W., Sugai, T., Yoshida, T., Nakamura, S., 1999. Mitochondrial gene mutation, but not large-scale deletion, is a feature of colorectal carcinomas with mitochondrial microsatellite instability. *Int. J. Cancer* 83, 625–629.
- Hazkani-Covo, E., 2009. Mitochondrial insertions into primate nuclear genomes suggest the use of numts as a tool for phylogeny. *Mol. Biol. Evol.* 26, 2175–2179.
- Hazkani-Covo, E., Covo, S., 2008. Numt-mediated double-strand break repair mitigates deletions during primate genome evolution. *PLoS Genet.* 4, e1000237.
- Hazkani-Covo, E., Graur, D., 2007. A comparative analysis of numt evolution in human and chimpanzee. *Mol. Biol. Evol.* 24, 13–18.
- Hazkani-Covo, E., Sorek, R., Graur, D., 2003. Evolutionary dynamics of large numts in the human genome: rarity of independent insertions and abundance of post-insertion duplications. *J. Mol. Evol.* 56, 169–174.
- Hazkani-Covo, E., Zeller, R.M., Martin, W., 2010. Molecular poltergeists: mitochondrial DNA copies (numts) in sequenced nuclear genomes. *PLoS Genet.* 6, e1000834.
- Hervouet, E., Godinot, C., 2006. Mitochondrial disorders in renal tumors. *Mitochondrion* 6, 105–117.
- Jensen-Seaman, M.I., Wildschutte, J.H., Soto-Caldere, I.D., Anthony, N.M., 2009. A comparative approach shows differences in patterns of numt insertion during hominoid evolution. *J. Mol. Evol.* 68.
- Jin, X., Zhang, J., Gao, Y., Ding, K., Wang, N., Zhou, D., Jen, J., Cheng, S., 2007. Relationship between mitochondrial DNA mutations and clinical characteristics in human lung cancer. *Mitochondrion* 7, 347–353.
- Jones, J.B., Song, J.J., Hempen, P.M., Parmigiani, G., Hruban, R.H., Kern, S.E., 2001. Detection of mitochondrial DNA mutations in pancreatic cancer offers a "mass"-ive advantage over detection of nuclear DNA mutations. *Cancer Res.* 61, 1299–1304.
- Kassaui, K., Habbe, N., Mullendore, M.E., Karikari, C.A., Maitra, A., Feldmann, G., 2006. Mitochondrial DNA mutations in pancreatic cancer. *Int. J. Gastrointest. Cancer* 37, 57–64.
- Kleine, T., Maier, U.G., Leister, D., 2009. DNA transfer from organelles to the nucleus: the idiosyncratic genetics of endosymbiosis. *Annu. Rev. Plant Biol.* 60, 115–138.
- Lascaro, D., Castellana, S., Gasparre, G., Romeo, G., Saccone, C., Attimonelli, M., 2008. The RHNumtS compilation: features and bioinformatics approaches to locate and quantify Human NumtS. *BMC Genomics* 9, 267.
- Leister, D., 2005. Origin, evolution and genetic effects of nuclear insertions of organelle DNA. *Trends Genet.* 21, 655–663.
- Lievre, A., Chapusot, C., Bouvier, A.M., Zinzindohoue, F., Piard, F., Roignot, P., Arrould, L., Beaune, P., Faivre, J., Laurent-Puig, P., 2005. Clinical value of mitochondrial mutations in colorectal cancer. *J. Clin. Oncol.* 23, 3517–3525.
- Liu, V.W., Shi, H.H., Cheung, A.N., Chiu, P.M., Leung, T.W., Nagley, P., Wong, L.C., Ngan, H.Y., 2001. High incidence of somatic mitochondrial DNA mutations in human ovarian carcinomas. *Cancer Res.* 61, 5998–6001.
- Lorenc, A., Bryk, J., Golik, P., Kuprynczyk, J., Ostrowski, J., Pronicki, M., Semczuk, A., Szolkowska, M., Bartnik, E., 2003. Homoplasmic MELAS A3243G mtDNA mutation in a colon cancer sample. *Mitochondrion* 3, 119–124.
- Mishmar, D., Ruiz-Pesini, E., Brandon, M., Wallace, D.C., 2004. Mitochondrial DNA-like sequences in the nucleus (NUMTs): insights into our African origins and the mechanism of foreign DNA integration. *Hum. Mutat.* 23, 125–133.
- Mithani, S.K., Taube, J.M., Zhou, S., Smith, I.M., Koch, W.M., Westra, W.H., Califano, J.A., 2007. Mitochondrial mutations are a late event in the progression of head and neck squamous cell cancer. *Clin. Cancer Res.* 13, 4331–4335.
- Nagy, A., Wilhelm, M., Kovacs, G., 2003. Mutations of mtDNA in renal cell tumours arising in end-stage renal disease. *J. Pathol.* 199, 237–242.
- Parfait, B., Rustin, P., Munnich, A., Rotig, A., 1998. Co-amplification of nuclear pseudogenes and assessment of heteroplasmy of mitochondrial DNA mutations. *Biochem. Biophys. Res. Commun.* 247, 57–59.
- Parr, R.L., Dakubo, G.D., Crandall, K.A., Maki, J., Reguly, B., Aguirre, A., Wittock, R., Robinson, K., Alexander, J.S., Birch-Machin, M.A., Abdel-Malak, M., Froberg, M.K., Diamandis, E.P., Thayer, R.E., 2006a. Somatic mitochondrial DNA mutations in prostate cancer and normal appearing adjacent glands in comparison to age-matched prostate samples without malignant histology. *J. Mol. Diagn.* 8, 312–319.
- Parr, R.L., Maki, J., Reguly, B., Dakubo, G.D., Aguirre, A., Wittock, R., Robinson, K., Jakupciak, J.P., Thayer, R.E., 2006b. The pseudo-mitochondrial genome influences mistakes in heteroplasmy interpretation. *BMC Genomics* 7, 185.
- Parrella, P., Xiao, Y., Fliss, M., Sanchez-Céspedes, M., Mazzarelli, P., Rinaldi, M., Nicol, T., Gabrielson, E., Cuomo, C., Cohen, D., Pandit, S., Spencer, M., Rabitti, C., Fazio, V.M., Sidransky, D., 2001. Detection of mitochondrial DNA mutations in primary breast cancer and fine-needle aspirates. *Cancer Res.* 61, 7623–7626.
- Petros, J.A., Baumann, A.K., Ruiz-Pesini, E., Amin, M.B., Sun, C.Q., Hall, J., Lim, S., Issa, M. M., Flanders, W.D., Hosseini, S.H., Marshall, F.F., Wallace, D.C., 2005. mtDNA mutations increase tumorigenicity in prostate cancer. *Proc. Natl. Acad. Sci. U.S.A.* 102, 719–724.
- Polyak, K., Li, Y., Zhu, H., Lengauer, C., Willson, J.K., Markowitz, S.D., Trush, M.A., Kinzler, K.W., Vogelstein, B., 1998. Somatic mutations of the mitochondrial genome in human colorectal tumours. *Nat. Genet.* 20, 291–293.
- Ramos, A., Santos, C., Alvarez, L., Nogués, R., Aluja, M.P., 2009. Human mitochondrial DNA complete amplification and sequencing: a new validated primer set that prevents nuclear DNA sequences of mitochondrial origin co-amplification. *Electrophoresis* 30, 1–7.
- Ramos, A., Santos, C., Barba, E., Mateu, L., Alvarez, L., Nogués, R., Aluja, M.P., 2011. Validated primer set that prevents nuclear DNA sequences of mitochondrial origin co-amplification: a revision based on the New Human Genome Reference Sequence (GRCh37). *Electrophoresis* 32, 782–783.
- Ricchetti, M., Tekcia, F., Dujon, B., 2004. Continued colonization of the human genome by mitochondrial DNA. *PLoS Biol.* 2, E273.
- Richly, E., Leister, D., 2004. NUMTs in sequenced eukaryotic genomes. *Mol. Biol. Evol.* 21, 1081–1084.
- Salas, A., Carracedo, A., Macaulay, V., Richards, M., Bandelt, H.J., 2005. A practical guide to mitochondrial DNA error prevention in clinical, forensic, and population genetics. *Biochem. Biophys. Res. Commun.* 335, 891–899.
- Santos, C., Martínez, M., Lima, M., Hao, Y.-J., Simoes, N., Montiel, R., 2008. Mitochondrial DNA mutations in cancer: a review. *Curr. Top. Med. Chem.* 8, 1351–1366.
- Stajich, J., Block, D., Boulez, K., Brenner, S., Chervitz, S., Dagdigan, C., Fuellen, G., Gilbert, J., Korf, I., Lapp, H., Levshvaloi, H., Matsalla, C., Mungall, C., Osborne, B., Pocock, M., Schattner, P., Senger, M., Stein, L., Stupka, E., Wilkinson, M., Birney, E., 2002. The BioPerl toolkit: Perl modules for the life sciences. *Genome Res.* 12, 1611–1618.
- Tan, D.J., Chang, J., Liu, L.L., Bai, R.K., Wang, Y.F., Yeh, K.T., Wong, L.J., 2006. Significance of somatic mutations and content alteration of mitochondrial DNA in esophageal cancer. *BMC Cancer* 6, 93.
- Thalmann, O., Serre, D., Hofreiter, M., Lukas, D., Eriksson, J., Vigilant, L., 2005. Nuclear insertions help and hinder inference of the evolutionary history of gorilla mtDNA. *Mol. Ecol.* 14, 179–188.
- Tourmen, Y., Baris, O., Dessen, P., Jacques, C., Malthiery, Y., Reynier, P., 2002. Structure and chromosomal distribution of human mitochondrial pseudogenes. *Genomics* 80, 71–77.
- Turner, C., Killoran, C., Thomas, N.S.T., Rosenberg, M., Chuzhanova, N.A., Johnston, J., Kemel, Y., Cooper, D.N., Biesecker, L.G., 2003. Human genetic disease caused by *de novo* mitochondrial-nuclear DNA transfer. *Hum. Genet.* 112, 303–309 (112, 303–309).
- Zhen, C.Y., Mau, B.L., Wu, T.Y., 2007. ND4 mutation in transitional cell carcinoma: does mitochondrial mutation occur before tumorigenesis? *Mitochondrion* 7, 273–278.
- Van Oven, M., Kayser, M., 2009. Updated comprehensive phylogenetic tree of global human mitochondrial DNA variation. *Hum. Mutat.* 30, E386–E394.
- Woischnik, M., Moraes, C.T., 2002. Pattern of organization of human mitochondrial pseudogenes in the nuclear genome. *Genome Res.* 12, 885–893.
- Yao, Y.G., Bravi, C.M., Bandelt, H.J., 2004. A call for mtDNA data quality control in forensic science. *Forensic Sci. Int.* 141, 1–6.
- Yao, Y.G., Kong, Q.P., Salas, A., Bandelt, H.J., 2008. Pseudomitochondrial genome haunts disease studies. *J. Med. Genet.* 45, 769–772.
- Zhou, S., Kachhap, S., Sun, W., Wu, G., Chuang, A., Poeta, L., Grumbine, L., Mithani, S.K., Chatterjee, A., Koch, W., Westra, W.H., Maitra, A., Glazer, C., Carducci, M., Sidransky, D., McFate, T., Verma, A., Califano, J.A., 2007. Frequency and phenotypic implications of mitochondrial DNA mutations in human squamous cell cancers of the head and neck. *Proc. Natl. Acad. Sci. U.S.A.* 104, 7540–7545.